{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [],
   "source": [
    "import xmltodict\n",
    "import string"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [],
   "source": [
    "filename = \"/home/santi/workspace/data/pubmed/pubmedsample18n0001.xml\"\n",
    "with open(filename,\"r\") as fp:\n",
    "    data = xmltodict.parse(fp.read())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [],
   "source": [
    "printable = set(string.printable)\n",
    "def get_data(input_file):\n",
    "    with open(input_file,\"r\") as fp:\n",
    "        data = xmltodict.parse(fp.read())\n",
    "    return data\n",
    "\n",
    "def get_text(input_data):\n",
    "    text= \"\"\n",
    "    if isinstance(input_data,dict):\n",
    "        for key in input_data.keys():\n",
    "            text += get_text(input_data[key]) \n",
    "    elif isinstance(input_data,list):\n",
    "        for item in input_data:\n",
    "            text += get_text(item)\n",
    "    elif isinstance(input_data,str):\n",
    "        return input_data+\" \"\n",
    "    elif input_data:\n",
    "        out_text = filter(lambda x: x in printable,input_data)\n",
    "        return out_text+\" \"\n",
    "    else:\n",
    "        return \"\"\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "MEDLINE NLM 1 973217 1976 12 03 2002 11 13 Print Print 0095-3814 Print 3 1 1976 Fall Topics in health care financing Top Health Care Financ Hospital debt management and cost reimbursement. 69-81 Y Y Blume F R FR eng D016428 Journal Article United States Top Health Care Financ 7509107 0095-3814 IM D000066 N Accounting D004469 Y Economics, Hospital D006739 Y Hospital Administration D014481 N Geographic United States pubmed 1976 1 1 medline 1976 1 1 0 1 entrez 1976 1 1 0 0 ppublish pubmed 973217\n"
     ]
    }
   ],
   "source": [
    "print(get_text(data[\"PubmedArticleSet\"][\"PubmedArticle\"][0]).strip())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_list = [data,data]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "from dask.distributed import Client"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "distributed.nanny - WARNING - Worker process still alive after 47 seconds, killing\n",
      "distributed.nanny - WARNING - Worker process 21176 was killed by signal 15\n"
     ]
    }
   ],
   "source": [
    "client = Client('10.1.10.108:8786')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_list = client.map(get_data,[filename,filename,filename])\n",
    "data_list = client.gather(data_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [],
   "source": [
    "text_data = client.map(get_text,data_list)\n",
    "final_text_data = client.gather(text_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(final_text_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "u'MEDLINE NLM 1 973217 1976 12 03 2002 11 13 Print Print 0095-3814 Print 3 1 1976 Fall Topics in health care financing Top Health Care Financ Hospital debt management and cost reimbursement. 69-81 Y Y Blume F R FR eng D016428 Journal Article United States Top Health Care Financ 7509107 0095-3814 IM D000066 N Accounting D004469 Y Economics, Hospital D006739 Y Hospital Administration D014481 N Geographic United States pubmed 1976 1 1 medline 1976 1 1 0 1 entrez 1976 1 1 0 0 ppublish pubmed 973217 MEDLINE NLM 1 1669026 1993 11 15 2008 11 21 Print Print 0377-8231 Print Anniv No Pt 1 1991 Bulletin et memoires de l\\'Academie royale de medecine de Belgique Bull. Mem. Acad. R. Med. Belg. [150th Anniversary Celebration of the Royal Academy of Medicine of Belgium. Part 1. Bruxelles, 26-28 September 1991]. 1-191 fre D016423 Congresses D016424 Overall D019477 Portraits Clbration du CL Anniversaire de l\\'Acadmie Royal de Mdecine de Belgique. Premire partie. Bruxelles, 26-28 septembre 1991. Belgium Bull Mem Acad R Med Belg 7608462 0377-8231 IM D000047 Y Academies and Institutes D001530 N Geographic Belgium pubmed 1991 1 1 medline 1991 1 1 0 1 entrez 1991 1 1 0 0 ppublish pubmed 1669026 MEDLINE NLM 1 1875346 1991 09 25 2013 11 21 Print Print 0022-2623 Print 34 8 1991 Aug Journal of medicinal chemistry J. Med. Chem. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives. 2489-95 Modification of the hexahydronaphthalene ring 5-position in simvastatin 2a via oxygenation and oxa replacement afforded two series of derivatives which were evaluated in vitro for inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and acutely in vivo for oral effectiveness as inhibitors of cholesterogenesis in the rat. Of the compounds selected for further biological evaluation, the 6 beta-methyl-5-oxa 10 and 5 alpha-hydroxy 16 derivatives of 3,4,4a,5-tetrahydro 2a, as well as, the 6 beta-epimer 14 of 16 proved orally active as hypocholesterolemic agents in cholestyramine-primed dogs. Subsequent acute oral metabolism studies in dogs demonstrated that compounds 14 and 16 evoke lower peak plasma drug activity and area-under-the-curve values than does compound 10 and led to the selection of 14 and 16 for toxicological evaluation. N Y Duggan M E ME Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486. Y Alberts A W AW Y Bostedor R R Y Chao Y S YS Y Germershausen J I JI Y Gilfillan J L JL Y Halczenko W W Y Hartman G D GD Y Hunt V V Y Imagire J S JS eng D016428 Journal Article United States J Med Chem 9716531 0022-2623 0 C070477 6-(2-(8-(2,2-dimethylbutyryl)oxy)-2,6-dimethyl-5-hydroxy-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one 0 D000085 Acetates 0 D000924 Anticholesteremic Agents 0 D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors 97C5T2UQ7J D002784 Cholesterol 9LHU78OQFD D008148 Lovastatin AGG2FN16EV D019821 Simvastatin S88TT14065 D010100 Oxygen IM D000085 N Acetates Q000378 N metabolism D000818 N Animals D000924 N Anticholesteremic Agents Q000138 Y chemical synthesis Q000493 N pharmacokinetics Q000494 N pharmacology D055598 N Chemical Phenomena D002621 N Chemistry D002784 N Cholesterol Q000096 N biosynthesis D004285 N Dogs D019161 Y Hydroxymethylglutaryl-CoA Reductase Inhibitors D007700 N Kinetics D008148 N Lovastatin Q000031 Y analogs & derivatives Q000138 N chemical synthesis Q000737 N chemistry Q000493 N pharmacokinetics Q000494 N pharmacology D008297 N Male D008968 N Molecular Conformation D015394 N Molecular Structure D010100 Y Oxygen D051381 N Rats D019821 N Simvastatin D013329 N Structure-Activity Relationship pubmed 1991 8 1 medline 1991 8 1 0 1 entrez 1991 8 1 0 0 ppublish pubmed 1875346 MEDLINE NLM 1 5757641 1970 03 22 2003 11 14 Print Print 15 1968 Trudy Instituta fiziologii, Akademiia nauk Gruzinskoi SSR Tr Inst Fiz Akad Nauk Gruz Ssr [The effect of immediate stimulation of the hippocampus on reflex reactions in animals]. 86-96 Y Y Tevzadze V G VG geo D016428 Journal Article O vliianii neposredstvennogo razdrazheniia gippokampa na reflektornye reaktsii zhivotnykh. Georgia (Republic) Tr Inst Fiz Akad Nauk Gruz Ssr 7507618 IM D000818 N Animals D004285 N Dogs D004558 N Electric Stimulation D006624 N Hippocampus Q000502 Y physiology D012018 Y Reflex pubmed 1968 1 1 medline 1968 1 1 0 1 entrez 1968 1 1 0 0 ppublish pubmed 5757641 MEDLINE NLM 1 3549656 1987 05 15 2014 11 20 Print Print 0021-8820 Print 40 1 1987 Jan The Journal of antibiotics J. Antibiot. Semisynthetic beta-lactam antibiotics. III. Effect on antibacterial activity and comt-susceptibility of chlorine-introduction into the catechol nucleus of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic acid. 22-8 The resistance of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic acid (1a) to metabolism by catechol-O-methyl-transferase (COMT) was increased by introduction of the chlorine atom into the catechol moiety. Penicillins (1b-1d) having one or two chlorine atoms at the positions adjacent to the hydroxyl group were found to have greater stability to COMT. This resulted in greater efficiency in vivo in experimental Pseudomonas aeruginosa and Escherichia coli infections. In vitro activities were essentially unchanged. Y Y Ohi N N Y Aoki B B Y Kuroki T T Y Matsumoto M M Y Kojima K K Y Nehashi T T eng D003160 Comparative Study D016428 Journal Article Japan J Antibiot (Tokyo) 0151115 0021-8820 0 D000900 Anti-Bacterial Agents 0 D065098 Catechol O-Methyltransferase Inhibitors 0 D007202 Indicators and Reagents 0 D010406 Penicillins 0 D047090 beta-Lactams 88852-54-4 C052009 6-(2-(3-(5-chloro-3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido)-2-phenylacetamido)penicillanic acid 92773-65-4 C052008 6-(2-(3-(2-chloro-3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido)-2-phenylacetamido)penicillanic acid 92773-66-5 C052007 6-(2-(3-(2,5-dichloro-3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido)-2-phenylacetamido)penicillanic acid IM D000818 N Animals D000900 N Anti-Bacterial Agents Q000138 Y chemical synthesis Q000494 N pharmacology D001419 N Bacteria Q000187 N drug effects D065098 Y Catechol O-Methyltransferase Inhibitors D004927 N Escherichia coli Infections Q000188 N drug therapy D007202 N Indicators and Reagents D008297 N Male D051379 N Mice D008815 N Mice, Inbred Strains D008826 N Microbial Sensitivity Tests D010406 N Penicillins Q000138 Y chemical synthesis Q000494 N pharmacology Q000627 N therapeutic use D011552 N Pseudomonas Infections Q000188 N drug therapy D013329 N Structure-Activity Relationship D047090 N beta-Lactams pubmed 1987 1 1 medline 1987 1 1 0 1 entrez 1987 1 1 0 0 ppublish pubmed 3549656 MEDLINE NLM 1 8119288 1994 04 01 2016 10 17 Print Print 0014-2956 Print 220 1 1994 Feb 15 European journal of biochemistry Eur. J. Biochem. Purification and characterisation of a water-soluble ferrochelatase from Bacillus subtilis. 201-8 Bacillus subtilis ferrochelatase is encoded by the hemH gene of the hemEHY gene cluster and catalyses the incorporation of Fe2+ into protoporphyrin IX. B. subtilis ferrochelatase produced in Escherichia coli was purified. It was found to be a monomeric, water-soluble enzyme of molecular mass 35 kDa which in addition to Fe2+ can incorporate Zn2+ and Cu2+ into protoporphyrin IX. Chemical modification experiments indicated that the single cysteine residue in the ferrochelatase is required for enzyme activity although it is not a conserved residue compared to other ferrochelatases. In growing B. subtilis, the ferrochelatase constitutes approximately 0.05% (by mass) of the total cell protein, which corresponds to some 600 ferrochelatase molecules/cell. The turnover number of isolated ferrochelatase, 18-29 min-1, was found to be consistent with the rate of haem synthesis in exponentially growing cells (0.2 mol haem formed/min/mol enzyme). It is concluded that the B. subtilis ferrochelatase has enzymic properties which are similar to those of other characterised ferrochelatases of known primary structure, i.e. ferrochelatases of the mitochondrial inner membrane of yeast and mammalian cells. However, in contrast to these enzymes the B. subtilis enzyme is a water-soluble protein and should be more amenable to structural analysis. Y Y Hansson M M Department of Microbiology, Lund University, Sweden. Y Hederstedt L L eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t England Eur J Biochem 0107600 0014-2956 059QF0KO0R D014867 Water EC 4.99.1.1 D005294 Ferrochelatase IM hemE hemH hemY D000595 N Amino Acid Sequence D001412 N Bacillus subtilis Q000201 Y enzymology Q000235 N genetics D002384 N Catalysis D003001 N Cloning, Molecular D004926 N Escherichia coli Q000201 N enzymology Q000235 N genetics D005294 N Ferrochelatase Q000235 N genetics Q000302 Y isolation & purification Q000378 N metabolism D017353 N Gene Deletion D005798 N Genes, Bacterial D007700 N Kinetics D008969 N Molecular Sequence Data D008970 N Molecular Weight D012995 N Solubility D014867 N Water pubmed 1994 2 15 medline 1994 2 15 0 1 entrez 1994 2 15 0 0 ppublish pubmed 8119288 MEDLINE NLM 1 8219565 1993 12 08 2016 11 23 Print Print 1051-0443 Print 4 5 1993 Sep-Oct Journal of vascular and interventional radiology : JVIR J Vasc Interv Radiol Transcatheter manipulation of asymmetrically opened titanium Greenfield filters. 687-90 PURPOSE OBJECTIVE The problem of asymmetric opening of the modified hook titanium Greenfield inferior vena cava filter necessitating transcatheter manipulation was evaluated in a retrospective study. PATIENTS AND METHODS METHODS Titanium Greenfield filters were placed in 166 patients over a 36-month period. The radiographic reports of all patients were reviewed to identify cases in which the filter failed to open symmetrically after deployment and catheter or wire manipulation of the filter was performed. The reports and angiograms from these patients were reviewed with respect to the circumstances surrounding filter placement and methods to achieve more symmetric opening. RESULTS RESULTS Transcatheter manipulation of asymmetrically opened filters was performed in 15 of 166 cases (9%). In 12 of these patients, acceptable and uneventful opening of the filter was achieved with a guide wire, pigtail catheter, or occlusion balloon catheter. In one case manipulation only partly improved orientation of the limbs, while in another case successful manipulation was complicated by distal migration. In the final case, the asymmetric filter covered only part of the lumen of the vena cava despite manipulations and a second filter was placed for optimal caval interruption. No specific cause for incomplete expansion was identified in any case. CONCLUSION CONCLUSIONS Marked asymmetry in opening of the modified hook titanium Greenfield filter that warrants manipulation occurs infrequently, but recognition and proper management may be important to ensure optimal caval interruption. Y Y Moore B S BS Department of Radiology, University of California at San Diego 92103. Y Valji K K Y Roberts A C AC Y Bookstein J J JJ eng D016428 Journal Article United States J Vasc Interv Radiol 9203369 1051-0443 D1JT611TNE D014025 Titanium IM CommentIn J Vasc Interv Radiol. 1994 May-Jun;5(3):526-7 1 8054760 CommentIn J Vasc Interv Radiol. 1993 Sep-Oct;4(5):617-20 1 8219555 CommentIn J Vasc Interv Radiol. 1994 May-Jun;5(3):528-32 1 8054761 D002405 Y Catheterization, Central Venous D006801 N Humans D011859 N Radiography D014025 N Titanium D016306 Y Vena Cava Filters D014682 N Vena Cava, Inferior Q000000981 N diagnostic imaging pubmed 1993 9 1 medline 1993 9 1 0 1 entrez 1993 9 1 0 0 ppublish pubmed 8219565 MEDLINE NLM 1 8655018 1996 07 30 2017 03 03 Print Print 0017-0011 Print 67 1 1996 Jan Ginekologia polska Ginekol. Pol. [Effect of fetal and neonatal growth on the occurrence of some diseases in adults]. 34-6 The findings of many authors show that reduced fetal growth is followed by increased mortality from cardiovascular disease in adult life. They are further evidence that cardiovascular disease originates, among other risk factors, through programming of the bodies structure and metabolism during fetal and early post-natal life. Wrong maternal nutrition may have an important influence on programming. Y Y Jendryczko A A Katedry i Zakadu Chemii i Analizy Lekw, AM w Katowicach. Y Poreba R R pol D004740 English Abstract D016428 Journal Article D016441 Retracted Publication D016454 Review Wpyw przebiegu rozwoju podu i noworodka na ujawnienie sie niektrych chorb okresu dorosego. Poland Ginekol Pol 0374641 0017-0011 IM CommentIn Ginekol Pol. 1998 Jul;69(7):561 1 9867475 RetractionIn Ginekol Pol. 1998 Jul;69(7):559-60 1 9867474 D000328 N Adult D002318 N Cardiovascular Diseases Q000209 N etiology Q000401 Y mortality D002657 N Child Development Q000502 Y physiology D005314 N Embryonic and Fetal Development Q000502 Y physiology D005317 N Fetal Growth Retardation Q000150 N complications Q000503 Y physiopathology D006801 N Humans D007231 N Infant, Newborn D009747 N Nutritional Physiological Phenomena D012307 N Risk Factors D015996 N Survival Rate 11 pubmed 1996 1 1 medline 1996 1 1 0 1 entrez 1996 1 1 0 0 ppublish pubmed 8655018 MEDLINE NLM 1 8863847 1996 11 25 2014 11 20 Print Print 0026-895X Print 50 4 1996 Oct Molecular pharmacology Mol. Pharmacol. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells. 1000-9 The mitogenic effect of extracellular ATP was examined in cultured rat aortic smooth muscle cells (VSMCs). ATP, 2-methylthio-ATP, and ADP stimulated [3H]thymidine and [3H]leucine incorporation and cell growth. AMP, adenosine, UTP, and P2x agonists showed little of these effects. Reactive blue 2, a P2Y purinoceptor antagonist, was effective in suppressing the mitogenic effect of ATP and 2-methylthio-ATP, indicating that extracellular ATP-induced VSMC proliferation is mediated by P2Y purinoceptors. The P2Y purinoceptor activation was coupled to a pertussis toxin (PTX)-insensitive G protein (Gq) and triggered phosphoinositide hydrolysis with subsequent activation of protein kinase C (PKC), Raf-1, and mitogen-activated protein kinase (MAPK) in VSMCs. In response to ATP, both 42-and 44-kDa MAPKs were activated, and tyrosine was phosphorylated. Western blot analysis using PKC isozyme-specific antibodies indicated that VSMCs express PKC-alpha, PKC-delta, and PKC-zeta. A complete down-regulation of PKC-alpha and PKC-delta was seen after 24-hr treatment with 12-O-tetradecanoylphorbol-13-acetate. When cells were pretreated with 12-O-tetradecanoyl-phorbol-13-acetate for 24 hr and subsequently challenged with ATP, Raf-1 activation and 42-kDa as well as 44-kDa MAPK tyrosine phosphorylation failed to be induced. These results demonstrate that ATP-induced Raf-1 and MAPK activations involve the activation of PKC-alpha and PKC-delta. P2Y purinoceptor stimulation with ATP also caused accumulation of c-fos and c-myc mRNAs. Both Reactive blue 2 and staurosporine significantly blocked this increase by ATP. In conclusion, the mitogenic effect of ATP seemed to be triggered by activation of the Gq protein-coupled P2Y purinoceptor that led to the formation of inositol trisphosphate and activation of PKC. PKC and, in turn, Raf-1 and MAPK were then activated, leading eventually to DNA synthesis and cell proliferation. Y Y Yu S M SM Department of Pharmacology, Chang Gung College of Medicine and Technology, Kwei-San, Tao-Yuan, Taiwan. smyu@cguaplo.cgu.edu Y Chen S F SF Y Lau Y T YT Y Yang C M CM Y Chen J C JC eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t D016441 Retracted Publication United States Mol Pharmacol 0035623 0026-895X 0 D011518 Proto-Oncogene Proteins 0 D012333 RNA, Messenger 0 D018048 Receptors, Purinergic P2 0 D014157 Transcription Factors 10028-17-8 D014316 Tritium 8L70Q75FXE D000255 Adenosine Triphosphate 9007-49-2 D004247 DNA EC 2.7.11.1 D017346 Protein-Serine-Threonine Kinases EC 2.7.11.1 D019908 Proto-Oncogene Proteins c-raf EC 2.7.11.13 D011493 Protein Kinase C EC 2.7.11.17 D017871 Calcium-Calmodulin-Dependent Protein Kinases EC 3.6.1.- D019204 GTP-Binding Proteins GMW67QNF9C D007930 Leucine VC2W18DGKR D013936 Thymidine IM ErratumIn Mol Pharmacol 1997 Mar;51(3):533 RetractionIn Wu D, Yang CM, Lau YT, Chen JC. Mol Pharmacol. 1998 Feb;53(2):346 1 9499167 D000255 N Adenosine Triphosphate Q000494 Y pharmacology D000818 N Animals D001011 N Aorta Q000166 N cytology Q000187 N drug effects Q000378 N metabolism D017871 N Calcium-Calmodulin-Dependent Protein Kinases Q000378 N metabolism D002452 N Cell Count D002455 N Cell Division Q000187 N drug effects D002478 N Cells, Cultured D004247 N DNA Q000096 N biosynthesis D004789 N Enzyme Activation D005110 N Extracellular Space Q000378 N metabolism D019204 N GTP-Binding Proteins Q000378 N metabolism Q000502 N physiology D066298 N In Vitro Techniques D007930 N Leucine Q000378 N metabolism D009131 N Muscle, Smooth, Vascular Q000166 Y cytology Q000187 Y drug effects Q000378 N metabolism D011493 N Protein Kinase C Q000378 N metabolism D017346 N Protein-Serine-Threonine Kinases Q000378 N metabolism D011518 N Proto-Oncogene Proteins Q000378 N metabolism D019908 N Proto-Oncogene Proteins c-raf D012333 N RNA, Messenger Q000378 N metabolism D051381 N Rats D017207 N Rats, Sprague-Dawley D018048 N Receptors, Purinergic P2 Q000502 N physiology D015398 N Signal Transduction Q000502 N physiology D013268 N Stimulation, Chemical D013936 N Thymidine Q000378 N metabolism D014157 N Transcription Factors Q000096 N biosynthesis D014316 N Tritium pubmed 1996 10 1 medline 1996 10 1 0 1 entrez 1996 10 1 0 0 ppublish pubmed 8863847 MEDLINE NLM 1 9110943 1996 10 23 2011 11 17 Print Print 1059-2725 Print Doc No 200-201 1996 Jul 30 The Online journal of current clinical trials Online J Curr Clin Trials Conservative management of mechanical neck disorders. A systematic overview and meta-analysis. [34457 words; 185 paragraphs] OBJECTIVE OBJECTIVE This overview reports the efficacy of conservative treatments (drug therapy, manual therapy, patient education, physical medicine modalities) in reducing pain in adults with mechanical neck disorders. METHODS METHODS Computerized bibliographic database searches from 1985 to December 1993, information requests from authors, and bibliography screenings were used to identify published and unpublished research. Applying strict criteria, two investigators independently reviewed the blinded articles. Each selected trial was evaluated independently for methodologic quality. RESULTS RESULTS Twenty-four randomized controlled trials (RCTs) and eight before-after studies met our selection criteria. Twenty RCTs rated moderately strong or better in terms of methodologic quality. Five trials using manual therapy in combination with other treatments were clinically similar, were statistically not heterogeneous (p = 0.98), and were combined to yield an effect size of -0.6 (95% CI: -0.9, -0.4), equivalent to a 16 point improvement on a 100 point pain scale. Four RCTs using physical medicine modalities were combined using the inverse chi-square method: two using electromagnetic therapy produced a significant reduction in pain (p < 0.01); and two using laser therapy did not differ significantly from a placebo (p = 0.63). Little or no scientific evidence exists for other therapies, including such commonly used treatments as medication, rest and exercise. CONCLUSIONS CONCLUSIONS Within the limits of methodologic quality, the best available evidence supports the use of manual therapies in combination with other treatments for short-term relief of neck pain. There is some support for the use of electromagnetic therapy and against the use of laser therapy. In general, other interventions have not been studied in enough detail adequately to assess efficacy or effectiveness. This overview provides the foundation for an evidence-based approach to practice. More robust design and methodology should be used in future research, in particular, the use of valid and reliable outcomes measures. Y Y Gross A R AR Chedoke-McMaster Hospitals & Schools of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada. Y Aker P D PD Y Goldsmith C H CH Y Peloso P P eng D016428 Journal Article D017418 Meta-Analysis D013485 Research Support, Non-U.S. Gov\\'t United States Online J Curr Clin Trials 9300367A 1059-2725 IM D015670 N Acupuncture Therapy D000328 N Adult D002684 N Chiropractic D016206 N Databases, Bibliographic D006801 N Humans D008349 N Manipulation, Orthopedic D019838 Y Neck Injuries D010146 N Pain Q000188 N drug therapy Q000534 N rehabilitation D059408 Y Pain Management D010353 N Patient Education as Topic D026741 Y Physical Therapy Modalities D016032 N Randomized Controlled Trials as Topic D015203 N Reproducibility of Results D014947 N Wounds and Injuries Q000188 N drug therapy Q000534 N rehabilitation Q000628 N therapy pubmed 1996 7 30 medline 1996 7 30 0 1 entrez 1996 7 30 0 0 ppublish pubmed 9110943 MEDLINE NLM 1 8941094 1997 01 02 2016 11 24 Print Print 0009-7322 Print 94 11 1996 Dec 01 Circulation Circulation Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. 2712-9 BACKGROUND BACKGROUND To date, late redistribution after resting 201Tl injection has not been evaluated. In addition, the concordance between resting 201Tl imaging and dobutamine echocardiography in identifying viable myocardium has not been assessed. METHODS AND RESULTS RESULTS Forty patients with coronary artery disease underwent rest-4-hour-24-hour 201Tl tomography and dobutamine echocardiography (5 to 10 micrograms.kg-1.min-1). Late redistribution occurred in 46 (21%) of 219 persistent defects at 4 hours. Systolic function and contractile reserve were similar among persistent defects at 4 hours with and without late redistribution. Contractile reserve was more frequent in segments with normal 201Tl uptake (59%), completely reversible defects (53%), or mild to moderate defects at 4 hours (56%) compared with severe defects (14%; P < .02 versus all). Of 105 hypokinetic segments, 99 (94%) were viable by 201Tl, and 88 (84%) showed contractile reserve. In contrast, of 155 akinetic segments, 119 (77%) were viable by 201Tl, but only 34 (22%) had contractile reserve. Concordance between 201Tl and dobutamine was 82% in hypokinetic segments but 43% in akinetic segments. In 109 revascularized segments, positive accuracy for functional recovery was 72% for 201Tl and 92% for dobutamine, whereas negative accuracy was 100% and 65%, respectively. Sensitivity was 100% for 201Tl and 79% for dobutamine. CONCLUSIONS CONCLUSIONS Late redistribution occurs in one fifth of persistent defects at 4 hours, and it does not correlate to systolic function or contractile reserve. Dobutamine and 201Tl yield concordant information in the majority of hypokinetic segments, whereas concordance is low in akinetic segments. Dobutamine demonstrates higher positive accuracy and sensitivity in predicting recovery of dysfunctional myocardium, whereas 201Tl shows higher negative predictive accuracy but reduced positive accuracy. Y Y Perrone-Filardi P P Division of Cardiology, Federico II University Medical School, Naples, Italy. Y Pace L L Y Prastaro M M Y Squame F F Y Betocchi S S Y Soricelli A A Y Piscione F F Y Indolfi C C Y Crisci T T Y Salvatore M M Y Chiariello M M eng D016428 Journal Article United States Circulation 0147763 0009-7322 0 D013794 Thallium Radioisotopes 3S12J47372 D004280 Dobutamine AIM IM CommentIn Circulation. 1996 Dec 1;94(11):2685-8 1 8941087 CommentIn Circulation. 1996 Dec 1;94(11):2674-80 1 8941085 CommentIn Circulation. 1996 Dec 1;94(11):2681-4 1 8941086 CommentIn Circulation. 1997 Oct 21;96(8):2740-2 1 9355926 D000368 N Aged D002470 N Cell Survival D002908 N Chronic Disease D002940 N Circadian Rhythm D003327 N Coronary Disease Q000000981 Y diagnostic imaging Q000503 N physiopathology D004280 Y Dobutamine D004452 Y Echocardiography D005500 N Follow-Up Studies D006321 N Heart Q000000981 Y diagnostic imaging D006801 N Humans D008297 N Male D008875 N Middle Aged D009200 N Myocardial Contraction D009204 N Myocardial Revascularization D011877 N Radionuclide Imaging D012146 N Rest D013599 N Systole D013794 Y Thallium Radioisotopes Q000493 N pharmacokinetics D013997 N Time Factors D018487 N Ventricular Dysfunction, Left Q000000981 N diagnostic imaging Q000628 N therapy pubmed 1996 12 1 medline 1996 12 1 0 1 entrez 1996 12 1 0 0 ppublish pubmed 8941094 MEDLINE NLM 1 9394824 1998 01 02 2006 11 15 Print Print 0014-2980 Print 27 11 1997 Nov European journal of immunology Eur. J. Immunol. Hypermutation, diversity and dissemination of human intestinal lamina propria plasma cells. 2959-64 In this work we have microdissected lamina propria plasma cells and used polymerase chain reaction and sequencing to investigate immunoglobulin (Ig) gene rearrangements and mutations in human intestine. In addition, specific primers were designed for individual Ig gene rearrangements to analyze the distribution of related B cell and plasma cell clones at different sites along the bowel. Confirming our earlier work, intestinal IgVH genes were highly mutated in plasma cells from older individuals (> 30 years). IgVH genes were significantly less mutated in samples taken from patients aged 11-30 years, and there were fewer mutations again in samples from young children (< 11 years). In age-matched specimens the number of mutations was equivalent in the duodenum and colon. Using complementarity-determining region 3 primers to amplify specific Ig gene rearrangements, evidence was also found for the existence of related lamina propria plasma cells along the small bowel and colon, although these were quite scarce. In addition, analysis of the numbers of related clones in a random sampling from discrete areas of lamina propria indicates that the local population is diverse. These results suggest that the highly mutated IgVH genes in adult intestinal plasma cells are a consequence of chronic antigen exposure with age. Duodenal plasma cells are as highly mutated as colonic plasma cells, despite the fact that the upper bowel has no indigenous microbial flora (the stimulus for intestinal plasma cells). They also show that the plasma cell population is diverse and can be widely disseminated along the bowel. Y Y Dunn-Walters D K DK Department of Histopathology, UMDS, London, Great Britain. Y Boursier L L Y Spencer J J eng N GENBANK Z93128 Z93129 Z93130 Z93131 Z93132 Z93133 Z93134 Z93135 Z93136 Z93137 Z93138 Z93139 Z93140 Z93141 Z93142 Z93143 Z93144 Z93145 Z93146 Z93147 Z93148 Z93149 Z93150 Z93151 Z93152 Z93153 Z93154 Z93155 Z93156 Z93157 D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Germany Eur J Immunol 1273201 0014-2980 0 D007143 Immunoglobulin Heavy Chains 0 D007135 Immunoglobulin Variable Region IM D000293 N Adolescent D000328 N Adult D000368 N Aged D000369 N Aged, 80 and over D000375 N Aging Q000235 N genetics Q000276 N immunology D001483 N Base Sequence D002648 N Child D003106 N Colon Q000276 N immunology Q000378 N metabolism D004386 N Duodenum Q000276 N immunology Q000378 N metabolism D015321 N Gene Rearrangement Q000276 N immunology D005803 N Genes, Immunoglobulin D006801 N Humans D007143 N Immunoglobulin Heavy Chains Q000235 N genetics D007135 N Immunoglobulin Variable Region Q000235 N genetics D007223 N Infant D007413 N Intestinal Mucosa Q000166 Y cytology Q000276 Y immunology D008875 N Middle Aged D008969 N Molecular Sequence Data D009154 Y Mutation D009928 N Organ Specificity Q000235 N genetics Q000276 N immunology D010950 N Plasma Cells Q000276 Y immunology Q000378 Y metabolism pubmed 1997 12 12 medline 1997 12 12 0 1 entrez 1997 12 12 0 0 ppublish pubmed 9394824 doi 10.1002/eji.1830271131 MEDLINE NLM 1 9482442 1998 03 18 2016 11 24 Print Print 0140-6736 Print 351 9101 1998 Feb 14 Lancet (London, England) Lancet A woman with nodules in her lungs. 494 Y Y Jrvelinen H H Department of Medicine, Turku University Central Hospital, Finland. Y Vainionp H H Y Kuopio T T Y Lehtonen A A eng D002363 Case Reports D016428 Journal Article England Lancet 2985213R 0140-6736 0 D011208 Powders 7631-86-9 D012822 Silicon Dioxide AIM IM ErratumIn Lancet 1998 Jun 27;351(9120):1968 ErratumIn Lancet 1998 Mar 7;351(9104):760 D000368 N Aged D005260 N Female D006801 N Humans D009324 N Naturopathy D011208 N Powders D011859 N Radiography D012822 N Silicon Dioxide Q000008 Y administration & dosage D012829 N Silicosis Q000000981 Y diagnostic imaging Q000209 Y etiology pubmed 1998 3 3 medline 1998 3 3 0 1 entrez 1998 3 3 0 0 ppublish pubmed 9482442 pii S0140673697104913 MEDLINE NLM 1 9505772 1998 03 24 2004 11 17 Print Print 0007-0912 Print 80 1 1998 Jan British journal of anaesthesia Br J Anaesth Myocardial ischaemia after coronary artery bypass grafting: early vs late extubation. 20-5 The technique of early extubation after coronary artery bypass grafting is increasing in popularity, but its safety and effect on myocardial ischaemia remain to be established. In a randomized, prospective study, patients undergoing routine elective coronary artery bypass grafting were managed with either early or late tracheal extubation. The incidence and severity of electrocardiographic myocardial ischaemia were compared. Data were analysed from 85 patients (43 early extubation; 42 late extubation). Median time to extubation was 110 min in the early extubation patients and 757 min in the late extubation patients. After correction for randomization bias, there were no significant differences between groups in ischaemic burden, maximal ST-segment deviation, incidence of ischaemia and area under the ST deviation-time curve (integral of ST deviation and time). Similarly, there were no differences between groups in postoperative creatine kinase MB-isoenzyme concentrations and duration of stay in the ICU or hospital. Therefore, this study provides evidence for the safety of early extubation after routine coronary artery bypass grafting. Y Y Berry P D PD Cardiothoracic Centre Liverpool-NHS Trust. Y Thomas S D SD Y Mahon S P SP Y Jackson M M Y Fox M A MA Y Fabri B B Y Weir W I WI Y Russell G N GN eng D016430 Clinical Trial D016428 Journal Article D016449 Randomized Controlled Trial England Br J Anaesth 0372541 0007-0912 IM ErratumIn Br J Anaesth 1998 Apr;80(4):572 ErratumIn Br J Anaesth 1998 Jul;81(1):111 D000328 N Adult D000368 N Aged D001026 N Coronary Artery Bypass Q000009 Y adverse effects D004562 N Electrocardiography D005260 N Female D006801 N Humans D007442 N Intubation, Intratracheal Q000379 Y methods D008297 N Male D008875 N Middle Aged D017202 N Myocardial Ischemia Q000209 Y etiology D011182 N Postoperative Care Q000379 Y methods D011184 N Postoperative Period D011446 N Prospective Studies D016896 N Treatment Outcome pubmed 1998 3 20 medline 1998 3 20 0 1 entrez 1998 3 20 0 0 ppublish pubmed 9505772 MEDLINE NLM 1 9575322 1998 05 12 2007 11 15 Print Print 0002-838X Print 57 8 1998 Apr 15 American family physician Am Fam Physician Lumbar spine stenosis: a common cause of back and leg pain. 1825-34, 1839-40 Lumbar spine stenosis most commonly affects the middle-aged and elderly population. Entrapment of the cauda equina roots by hypertrophy of the osseous and soft tissue structures surrounding the lumbar spinal canal is often associated with incapacitating pain in the back and lower extremities, difficulty ambulating, leg paresthesias and weakness and, in severe cases, bowel or bladder disturbances. The characteristic syndrome associated with lumbar stenosis is termed neurogenic intermittent claudication. This condition must be differentiated from true claudication, which is caused by atherosclerosis of the pelvofemoral vessels. Although many conditions may be associated with lumbar canal stenosis, most cases are idiopathic. Imaging of the lumbar spine performed with computed tomography or magnetic resonance imaging often demonstrates narrowing of the lumbar canal with compression of the cauda equina nerve roots by thickened posterior vertebral elements, facet joints, marginal osteophytes or soft tissue structures such as the ligamentum flavum or herniated discs. Treatment for symptomatic lumbar stenosis is usually surgical decompression. Medical treatment alternatives, such as bed rest, pain management and physical therapy, should be reserved for use in debilitated patients or patients whose surgical risk is prohibitive as a result of concomitant medical conditions. Y Y Alvarez J A JA University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio, USA. Y Hardy R H RH Jr eng D016428 Journal Article D016454 Review United States Am Fam Physician 1272646 0002-838X AIM IM CommentIn Am Fam Physician. 1999 Jan 15;59(2):280, 283-4 1 9930124 D003937 N Diagnosis, Differential D006801 N Humans D017116 N Low Back Pain Q000209 Y etiology D008161 N Lumbosacral Region D010146 N Pain Q000209 Y etiology D010353 N Patient Education as Topic D013130 N Spinal Stenosis Q000150 Y complications Q000175 Y diagnosis Q000503 N physiopathology Q000628 N therapy D013664 N Teaching Materials 13 pubmed 1998 5 12 2 2 medline 2001 3 28 10 1 entrez 1998 5 12 2 2 ppublish pubmed 9575322 MEDLINE NLM 1 9627170 1998 08 25 2016 10 20 Print Print 1435-2443 Print 383 1 1998 Mar Langenbeck\\'s archives of surgery Langenbecks Arch Surg Outcome of patients with sepsis and septic shock after ICU treatment. 44-8 OBJECTIVE OBJECTIVE Today, sepsis syndrome is the leading cause of death in adult, non-coronary intensive care units (ICUs) and is of great clinical importance. The purpose of this review was to evaluate recent prospective studies concerning the short- and long-term prognosis of patients suffering from systemic inflammatory-response syndrome (SIRS), sepsis, severe sepsis and septic shock. It has been shown in multicentre prospective surveys that 1% and 0.3% of all patients admitted to hospitals suffer, respectively, from bacteraemia alone and bacteraemia with severe sepsis. This rate increases, of course, when only admissions to the ICUs are considered: the above-mentioned rates increase then by a factor of 8 and 30, respectively. Thus, approximately 10% of patients in the ICU suffer from sepsis, 6% from severe sepsis and 2-3% from septic shock. SIRS occurs more frequently and its occurrence ranges from 40% to 70% of all patients admitted to ICUs. Thereby, 40-70% suffering from SIRS progress to a more severe septic-disease state. The overall prognosis is still poor, despite the recent advances in ICU treatment. The mortality rate of SIRS ranges from 6% to 7% and in septic shock amounts to over 50%. In particular, abdominal sepsis exhibits the highest mortality rate with 72%. The long-term prognosis is equally poor; only approximately 30% survived the first year after hospital admission. CONCLUSION CONCLUSIONS The prognosis of sepsis and septic shock remains poor, despite the advances in ICU treatment. Although prognostic factors have been identified for some patients, groups have not yet been able to identify the immediate or long-term prognosis for the majority of these septic patients. Y Y Schoenberg M H MH Department of General Surgery, University of Ulm, Germany. Y Weiss M M Y Radermacher P P eng D016428 Journal Article D016454 Review Germany Langenbecks Arch Surg 9808285 1435-2443 IM D000328 N Adult D016470 N Bacteremia Q000401 Y mortality Q000628 N therapy D002423 N Cause of Death D003422 Y Critical Care D005260 N Female D006801 N Humans D008297 N Male D011379 N Prognosis D011446 N Prospective Studies D012772 N Shock, Septic Q000401 Y mortality Q000628 N therapy D013530 N Surgical Wound Infection Q000401 Y mortality Q000628 N therapy D015996 N Survival Rate D018746 N Systemic Inflammatory Response Syndrome Q000401 Y mortality Q000628 N therapy 21 pubmed 1998 6 17 medline 1998 6 17 0 1 entrez 1998 6 17 0 0 ppublish pubmed 9627170 MEDLINE NLM 1 9634358 1998 06 18 2004 03 31 Print Print 0022-1899 Print 177 6 1998 Jun The Journal of infectious diseases J. Infect. Dis. Retraction: A rabbit model for human cytomeglovirus--induced chorioretinal disease (J Infect Dis 1993;168:336-44). 1778 Y Y Dunkel E C EC Y Scheer D I DI Y Zhu Q Q Y Whitley R J RJ Y Schaffer P A PA Y Pavan-Langston D D N Whitely R J RJ eng D016440 Retraction of Publication United States J Infect Dis 0413675 0022-1899 AIM IM ErratumIn J Infect Dis 1998 Aug;178(2):601 Whitely RJ [corrected to Whitley RJ] RetractionOf Dunkel EC, de Freitas D, Scheer DI, Siegel ML, Zhu Q, Whitley RJ, Schaffer PA, Pavan-Langston D. J Infect Dis. 1993 Aug;168(2):336-44 1 8393056 pubmed 1998 6 20 medline 1998 6 20 0 1 entrez 1998 6 20 0 0 ppublish pubmed 9634358 MEDLINE NLM 1 9626910 1998 08 12 2015 11 19 Print Print 0047-1828 Print 62 5 1998 May Japanese circulation journal Jpn. Circ. J. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. 389-91 As a collaborative research project of the Committees for the Study of Idiopathic Cardiomyopathy, a questionnaire was sent out to 19 medical institutions in Japan in order to examine the possible association between hepatitis C virus (HCV) infection and cardiomyopathies. Hepatitis C virus antibody was found in 74 of 697 patients (10.6%) with hypertrophic cardiomyopathy (mean age, 57.7 years) and in 42 of 663 patients (6.3%) with dilated cardiomyopathy (mean age, 56.5 years); these prevalences were significantly higher than that found in volunteer blood donors in Japan (2.4%, 50-59 years of age, each p<0.0001). The prevalence was significantly higher in patients suffering from hypertrophic cardiomyopathy as opposed to those with dilated cardiomyopathy (p<0.01). The presence of HCV antibody was detected in 650 of 11,967 patients (5.4%) patients seeking care in 5 academic hospitals. Various cardiac abnormalities were found among these patients, arrhythmias being the most frequent. These observations suggest that HCV infection is an important cause of a variety of otherwise unexplained heart diseases. N Y Matsumori A A Kyoto University, Japan. Y Ohashi N N Y Hasegawa K K Y Sasayama S S Y Eto T T Y Imaizumi T T Y Izumi T T Y Kawamura K K Y Kawana M M Y Kimura A A Y Kitabatake A A Y Matsuzaki M M Y Nagai R R Y Tanaka H H Y Hiroe M M Y Hori M M Y Inoko H H Y Seko Y Y Y Sekiguchi M M Y Shimotohno K K Y Sugishita Y Y Y Takeda N N Y Takihara K K Y Tanaka M M Y Yokoyama M M eng D016428 Journal Article D016448 Multicenter Study D013485 Research Support, Non-U.S. Gov\\'t Japan Jpn Circ J 7806868 0047-1828 0 D018937 Hepatitis C Antibodies IM D009202 N Cardiomyopathies Q000453 N epidemiology Q000209 N etiology Q000821 N virology D006321 N Heart Q000821 N virology D006331 N Heart Diseases Q000453 Y epidemiology Q000209 N etiology Q000821 Y virology D016174 N Hepacivirus Q000276 N immunology D006526 N Hepatitis C Q000150 Y complications D018937 N Hepatitis C Antibodies Q000097 N blood D006801 N Humans D007564 N Geographic Japan Q000453 N epidemiology D008875 N Middle Aged D009206 N Myocardium Q000276 N immunology Q000473 N pathology D015995 N Prevalence D011795 N Surveys and Questionnaires pubmed 1998 6 17 medline 1998 6 17 0 1 entrez 1998 6 17 0 0 ppublish pubmed 9626910 MEDLINE NLM 1 9861576 1999 03 29 2013 11 21 Print Print 0268-1315 Print 13 6 1998 Nov International clinical psychopharmacology Int Clin Psychopharmacol Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients. 263-7 Selective serotonin reuptake inhibitors (SSRIs) are the \\'new\\' drugs of first choice for the treatment of depression in the older patient. Systematic studies on the effects of SSRIs on cardiac function are scarce, despite the high prevalence of cardiac disorders in the older depressed patient. This is a study which systematically assessed cardiac function by echocardiography in middle-aged and elderly depressed patients treated with SSRI. In a double-blind randomized trial, 20 patients were assigned to receive fluvoxamine 100 mg/day [DOSAGE ERROR CORRECTED] or fluoxetine 20 mg/day [DOSAGE ERROR CORRECTED] for 6 weeks. Cardiac function was assessed by left ventricle ejection fraction, aortic flow integral and early or passive/late or active mitral inflow, and electrocardiography. Neither SSRI significantly affected cardiac function. Compared with patients without a history of myocardial infarction and/or hypertension, patients with such a history showed a significant improvement in left ventricular ejection fraction. Despite our small study sample, these data indicate that both fluoxetine and fluvoxamine do not affect cardiac function adversely. Y Y Strik J J JJ Department of Psychiatry, Maastricht University Hospital, The Netherlands. Y Honig A A Y Lousberg R R Y Cheriex E C EC Y Van Praag H M HM eng D016430 Clinical Trial D003160 Comparative Study D016428 Journal Article D016449 Randomized Controlled Trial England Int Clin Psychopharmacol 8609061 0268-1315 0 D017367 Serotonin Uptake Inhibitors 01K63SUP8D D005473 Fluoxetine O4L1XPO44W D016666 Fluvoxamine IM ErratumIn Int Clin Psychopharmacol 1999 Mar;14(2):138 Dosage error in published abstract; MEDLINE/PubMed abstract corrected D000368 N Aged D000369 N Aged, 80 and over D002318 N Cardiovascular Diseases Q000139 Y chemically induced Q000503 N physiopathology D003866 N Depressive Disorder Q000150 Y complications Q000188 N drug therapy D004311 N Double-Blind Method D004452 N Echocardiography D004562 N Electrocardiography Q000187 N drug effects D005260 N Female D005473 N Fluoxetine Q000009 Y adverse effects Q000627 N therapeutic use D016666 N Fluvoxamine Q000009 Y adverse effects Q000627 N therapeutic use D006801 N Humans D008297 N Male D008875 N Middle Aged D017367 N Serotonin Uptake Inhibitors Q000009 Y adverse effects Q000627 N therapeutic use pubmed 1998 12 23 medline 1998 12 23 0 1 entrez 1998 12 23 0 0 ppublish pubmed 9861576 MEDLINE NLM 1 9929727 1999 04 28 2017 11 16 Print Print 0300-2896 Print 34 11 1998 Dec Archivos de bronconeumologia Arch. Bronconeumol. [Tobacco control in children, adolescents and young people: knowledge, prevention and action]. 564 Y Y de Granda Orive J I JI Y Pea Miguel T T Y Morato Arniz A A spa D016422 Letter Comment La lucha contra el tabaco en los nios, adolescentes y jvenes: conocimiento, prevencin y actuacin. Spain Arch Bronconeumol 0354720 0300-2896 IM CommentOn Arch Bronconeumol. 1998 Apr;34(4):199-203 1 9611655 D000293 N Adolescent D000328 N Adult D002648 N Child D005260 N Female D007722 N Health Knowledge, Attitudes, Practice D006801 N Humans D008297 N Male D000074606 Y Smoking Prevention pubmed 1999 2 4 medline 1999 2 4 0 1 entrez 1999 2 4 0 0 ppublish pubmed 9929727 MEDLINE NLM 1 9885794 1999 03 29 2015 03 11 Print Print 0893-133X Print 20 2 1999 Feb Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Neuropsychopharmacology Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis. 141-9 Systemic injections of cholecystokinin (CCK), a \"gut-brain\" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. However, clinical trials of CCK agonists in schizophrenia patients showed mixed results. To re-examine the antipsychotic potential of CCK-based treatments, we examined systemic injections of CCK analogs in an animal model with strong face and construct validity for sensorimotor-gating deficits seen in schizophrenia patients and with strong predictive validity for antipsychotic drug activity. Prepulse inhibition (PPI) occurs when a weak acoustic lead stimulus (\"prepulse\") inhibits the startle response to a sudden loud sound (\"pulse\"). PPI is significantly reduced in schizophrenia patients and rats treated with dopamine agonists. Antipsychotics reverse decreased PPI in rats to a degree highly correlated with their clinical efficacy. Subcutaneous (s.c.) injections of caerulein (10 micrograms/kg) a mixed CCKA/B agonist, partially reversed amphetamine-induced reduction of PPI; whereas, s.c. haloperidol (0.5 mg/kg) totally reversed amphetamine-induced disruption of PPI. Caerulein\\'s effect on PPI was blocked by pretreatment with a CCKA antagonist (devazepide) but not a CCKB antagonist (L-365,260). CCK-4, a preferential CCKB agonist, had no significant effect on PPI. These results suggest that caerulein produces a weak neuroleptic-like effect on PPI that is mediated by stimulation of CCKA receptors. Possible circuities in this effect are discussed. In a separate experiment, s.c. caerulein produced to a more potent neuroleptic-like profile on amphetamine-induced hyperlocomotion, suggesting that selection of preclinical paradigms may be important in evaluating the antipsychotic potential of CCK-based treatments. Y Y Feifel D D Department of Psychiatry, University of California, San Diego, La Jolla 92093-8620, USA. Y Reza T T Y Robeck S S eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t England Neuropsychopharmacology 8904907 0893-133X 0 D014150 Antipsychotic Agents 0 D005765 Gastrointestinal Agents 0 D011949 Receptors, Cholecystokinin 0OL293AV80 D013758 Tetragastrin 888Y08971B D002108 Ceruletide 9011-97-6 D002766 Cholecystokinin J6292F8L3D D006220 Haloperidol IM D000818 N Animals D014150 N Antipsychotic Agents Q000008 N administration & dosage Q000627 Y therapeutic use D001522 N Behavior, Animal Q000187 N drug effects D002108 N Ceruletide Q000627 Y therapeutic use D002766 N Cholecystokinin Q000502 Y physiology D005765 N Gastrointestinal Agents Q000627 Y therapeutic use D006220 N Haloperidol Q000008 N administration & dosage Q000627 N therapeutic use D007279 N Injections, Subcutaneous D008297 N Male D009043 N Motor Activity Q000187 N drug effects D011618 N Psychotic Disorders Q000188 Y drug therapy Q000523 N psychology D051381 N Rats D017207 N Rats, Sprague-Dawley D011949 N Receptors, Cholecystokinin Q000037 N antagonists & inhibitors Q000187 N drug effects D013216 N Reflex, Startle Q000187 N drug effects D013758 N Tetragastrin Q000037 N antagonists & inhibitors Q000494 N pharmacology pubmed 1999 1 14 medline 1999 1 14 0 1 entrez 1999 1 14 0 0 ppublish pubmed 9885794 pii S0893-133X(98)00041-4 doi 10.1016/S0893-133X(98)00041-4 MEDLINE NLM 1 10078868 1999 06 09 2005 11 17 Print Print 0041-0101 Print 37 2 1999 Feb Toxicon : official journal of the International Society on Toxinology Toxicon Bibliography of toxinology. 399-404 eng D016417 Bibliography England Toxicon 1307333 0041-0101 0 D014118 Toxins, Biological IM D014118 Y Toxins, Biological pubmed 1999 3 17 medline 1999 3 17 0 1 entrez 1999 3 17 0 0 ppublish pubmed 10078868 MEDLINE NLM 1 10083987 1999 05 11 2004 11 17 Print Print 0832-610X Print 46 2 1999 Feb Canadian journal of anaesthesia = Journal canadien d\\'anesthesie Can J Anaesth Complete airway obstruction. 99-104 Y Y Crosby E T ET eng fre D016420 Comment D016421 Editorial United States Can J Anaesth 8701709 0832-610X 0 D000779 Anesthetics, Local IM CommentOn Can J Anaesth. 1999 Feb;46(2):176-8 1 10083999 D000402 N Airway Obstruction Q000209 Y etiology Q000601 N surgery D000776 N Anesthesiology Q000193 N education D000779 N Anesthetics, Local Q000008 N administration & dosage D002574 N Cervical Vertebrae Q000293 N injuries D016292 N Conscious Sedation Q000009 N adverse effects Q000379 N methods D006801 N Humans D007442 N Intubation, Intratracheal Q000009 Y adverse effects Q000295 N instrumentation Q000379 N methods D020704 N Laryngoscopes D007828 N Laryngoscopy Q000009 N adverse effects Q000379 N methods D014139 N Tracheostomy pubmed 1999 3 20 medline 1999 3 20 0 1 entrez 1999 3 20 0 0 ppublish pubmed 10083987 doi 10.1007/BF03012541 MEDLINE NLM 1 10101342 1999 04 15 2016 11 24 Print Print 0733-8627 Print 17 1 1999 Feb Emergency medicine clinics of North America Emerg. Med. Clin. North Am. Evaluation of the patient with extremity trauma: an evidence based approach. 77-95, viii This article reviews relevant literature to provide evidence based guidelines for the evaluation of patients with extremity trauma in the emergency department. The development of clinical decision rules for extremity trauma in the ankle and knee, and guidelines for obtaining postreduction radiographs of shoulder dislocations and nursemaid\\'s elbows are discussed. Y Y Kaufman D D Division of Emergency Medicine, Northwestern University Medical School, Chicago, Illinois, USA. Y Leung J J eng D016428 Journal Article United States Emerg Med Clin North Am 8219565 0733-8627 IM D016512 N Ankle Injuries Q000000981 N diagnostic imaging Q000209 N etiology Q000628 N therapy D003661 N Decision Support Techniques D004630 Y Emergencies D005121 N Extremities Q000000981 N diagnostic imaging Q000293 Y injuries D050723 N Fractures, Bone Q000000981 N diagnostic imaging Q000209 N etiology Q000628 N therapy D006801 N Humans D007718 N Knee Injuries Q000000981 N diagnostic imaging Q000209 N etiology Q000628 N therapy D017410 N Practice Guidelines as Topic D011859 N Radiography D012783 N Shoulder Dislocation Q000000981 N diagnostic imaging Q000209 N etiology Q000628 N therapy pubmed 1999 4 2 medline 1999 4 2 0 1 entrez 1999 4 2 0 0 ppublish pubmed 10101342 MEDLINE NLM 1 10168751 1997 08 28 2006 11 15 Print Print 0168-8510 Print 40 3 1997 Jun Health policy (Amsterdam, Netherlands) Health Policy Health technology assessment: decentralized and fragmented in the US compared to other countries. 177-98 This paper presents the results of the first comprehensive international survey to catalogue health technology assessment (HTA) activities. By 1995, there were formal HTA programs in 24 countries established mostly in the late 1980s and early 1990s. European countries generally have one or two federal or provincial HTA programs each, Canada has an extensive network of federal and regional organizations coordinated by a central body and the US has 53 HTA organizations, the vast majority of which are in the private sector. While the commitment of the US government to HTA has been erratic, the private sector has been witness to an expansion of HTA activities by insurance companies, hospitals, medical/device manufacturers, consulting firms and health professional societies. In contrast to other developed countries, the current state of technology assessment in the US is decentralized, fragmented and duplicative. We conclude by discussing the importance of a US HTA agency at the national level. Y Y Perry S S Medical Technology and Practice Patterns Institute, WHO Collaborating Center on Health Technology Assessment, Washington, DC 20007, USA. Y Thamer M M eng D003160 Comparative Study D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Ireland Health Policy 8409431 0168-8510 H RepublishedIn Health Policy 1997 Dec;42(3):269-90 D002170 N Geographic Canada D004059 N Diffusion of Innovation D005060 N Geographic Europe D019538 Y Health Care Surveys D006291 N Health Policy D007255 N Information Services D017149 N Private Sector D013673 N Technology Assessment, Biomedical Q000331 N legislation & jurisprudence Q000379 N methods Q000458 Y organization & administration Q000706 N statistics & numerical data D014481 N Geographic United States D014491 N United States Office of Technology Assessment pubmed 1997 5 7 medline 1997 5 7 0 1 entrez 1997 5 7 0 0 ppublish pubmed 10168751 pii S016885109700897X MEDLINE NLM 1 10097079 1999 05 12 2016 10 19 Print Print 0027-8424 Print 96 7 1999 Mar 30 Proceedings of the National Academy of Sciences of the United States of America Proc. Natl. Acad. Sci. U.S.A. Thermal adaptation analyzed by comparison of protein sequences from mesophilic and extremely thermophilic Methanococcus species. 3578-83 The genome sequence of the extremely thermophilic archaeon Methanococcus jannaschii provides a wealth of data on proteins from a thermophile. In this paper, sequences of 115 proteins from M. jannaschii are compared with their homologs from mesophilic Methanococcus species. Although the growth temperatures of the mesophiles are about 50 degrees C below that of M. jannaschii, their genomic G+C contents are nearly identical. The properties most correlated with the proteins of the thermophile include higher residue volume, higher residue hydrophobicity, more charged amino acids (especially Glu, Arg, and Lys), and fewer uncharged polar residues (Ser, Thr, Asn, and Gln). These are recurring themes, with all trends applying to 83-92% of the proteins for which complete sequences were available. Nearly all of the amino acid replacements most significantly correlated with the temperature change are the same relatively conservative changes observed in all proteins, but in the case of the mesophile/thermophile comparison there is a directional bias. We identify 26 specific pairs of amino acids with a statistically significant (P < 0.01) preferred direction of replacement. Y Y Haney P J PJ Department of Microbiology, University of Illinois, B103 Chemical and Life Sciences Laboratory, 601 South Goodwin Avenue, Urbana, IL 61801, USA. Y Badger J H JH Y Buldak G L GL Y Reich C I CI Y Woese C R CR Y Olsen G J GJ eng N GENBANK AF078607 AF078608 AF078609 AF078610 AF078611 AF078612 AF078613 AF078614 AF078615 AF078616 AF078617 AF078618 AF078619 AF078620 AF078621 AF078622 AF078623 AF078624 AF078625 AF078626 AF078627 AF078628 AF078629 AF078630 AF078631 AF078632 AF078633 AF078634 AF078635 AF078636 Y T32 GM007283 GM NIGMS NIH HHS United States GM07283 GM NIGMS NIH HHS United States D003160 Comparative Study D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. D013487 Research Support, U.S. Gov\\'t, P.H.S. United States Proc Natl Acad Sci U S A 7505876 0027-8424 0 D001426 Bacterial Proteins IM S Cites J Theor Biol. 1967 Aug;16(2):187-211 1 6048539 Cites Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2056-60 1 9482837 Cites J Theor Biol. 1973 Jun;39(3):645-51 1 4354159 Cites Science. 1974 Sep 6;185(4154):862-4 1 4843792 Cites J Theor Biol. 1975 Mar;50(1):167-83 1 1127956 Cites Nature. 1975 May 15;255(5505):256-9 1 1143325 Cites Biochemistry. 1979 Dec 11;18(25):5698-703 1 518863 Cites Eur J Biochem. 1980 Jul;108(2):581-6 1 7408869 Cites J Biochem. 1980 Dec;88(6):1895-8 1 7462208 Cites J Mol Biol. 1982 May 5;157(1):105-32 1 7108955 Cites Eur J Biochem. 1982 Nov 15;128(2-3):565-75 1 7151796 Cites Proc Natl Acad Sci U S A. 1986 Nov;83(21):8069-72 1 3464944 Cites J Biol Chem. 1988 Mar 5;263(7):3086-91 1 3257756 Cites J Mol Biol. 1988 Feb 5;199(3):525-37 1 3127592 Cites Nature. 1988 Dec 15;336(6200):651-6 1 3200317 Cites Adv Protein Chem. 1988;39:191-234 1 3072868 Cites J Mol Biol. 1989 Mar 20;206(2):397-406 1 2716053 Cites Proteins. 1989;5(1):22-37 1 2664764 Cites Biochemistry. 1989 Sep 5;28(18):7205-13 1 2684274 Cites Science. 1990 Mar 16;247(4948):1306-10 1 2315699 Cites Biochemistry. 1990 Mar 6;29(9):2403-8 1 2337607 Cites Biochemistry. 1990 Aug 7;29(31):7133-55 1 2207096 Cites J Mol Biol. 1990 Oct 5;215(3):403-10 1 2231712 Cites Biochemistry. 1991 Jan 15;30(2):589-94 1 1988046 Cites Biochemistry. 1991 Jul 23;30(29):7142-53 1 1854726 Cites Crit Rev Biochem Mol Biol. 1991;26(1):1-52 1 1678690 Cites Proc Natl Acad Sci U S A. 1992 May 1;89(9):3751-5 1 1570293 Cites Nat Genet. 1993 Mar;3(3):266-72 1 8485583 Cites J Mol Biol. 1994 Dec 2;244(3):332-50 1 7966343 Cites J Mol Biol. 1995 Mar 3;246(4):511-21 1 7877172 Cites Eur J Biochem. 1995 May 1;229(3):688-95 1 7758464 Cites Appl Environ Microbiol. 1995 Jul;61(7):2762-4 1 7618889 Cites J Bacteriol. 1996 Feb;178(3):723-7 1 8550506 Cites Structure. 1995 Nov 15;3(11):1147-58 1 8591026 Cites Nucleic Acids Res. 1996 Jan 1;24(1):1-5 1 8594554 Cites Biochemistry. 1996 Feb 27;35(8):2597-609 1 8611563 Cites Protein Eng. 1995 Aug;8(8):779-89 1 8637847 Cites Protein Eng. 1996 Jan;9(1):27-36 1 9053899 Cites Science. 1996 Aug 23;273(5278):1058-73 1 8688087 Cites Proteins. 1997 May;28(1):117-30 1 9144797 Cites J Mol Biol. 1997 Jun 20;269(4):631-43 1 9217266 Cites Gene. 1997 Dec 31;205(1-2):309-16 1 9461405 Cites J Theor Biol. 1968 Nov;21(2):170-201 1 5700434 D000064 N Acclimatization D000595 N Amino Acid Sequence D019943 N Amino Acid Substitution D001426 N Bacterial Proteins Q000737 Y chemistry Q000235 N genetics D017017 N Methanococcus Q000235 Y genetics Q000378 Y metabolism D008969 N Molecular Sequence Data D011487 N Protein Conformation D013045 N Species Specificity D013696 N Temperature NLM PMC22336 NASA N NASA Discipline Exobiology N Non-NASA Center Y Woese C R CR U IL, Urbana pubmed 1999 3 31 medline 1999 3 31 0 1 entrez 1999 3 31 0 0 ppublish pubmed 10097079 pmc PMC22336 MEDLINE NLM 1 10192114 1999 06 01 2007 01 29 Print Print 0031-7144 Print 54 3 1999 Mar Die Pharmazie Pharmazie Antimicrobial activity of some Nepalese medicinal plants. 232-4 Y Y Rajbhandari M M Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany. Y Schpke T T eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Germany Pharmazie 9800766 0031-7144 0 D000900 Anti-Bacterial Agents 0 D010936 Plant Extracts IM D000900 N Anti-Bacterial Agents Q000302 Y isolation & purification Q000494 N pharmacology D006094 N Gram-Positive Bacteria Q000187 N drug effects D008826 N Microbial Sensitivity Tests D009390 N Geographic Nepal D010936 N Plant Extracts Q000494 N pharmacology D010946 N Plants, Medicinal Q000737 Y chemistry pubmed 1999 4 7 medline 1999 4 7 0 1 entrez 1999 4 7 0 0 ppublish pubmed 10192114 MEDLINE NLM 1 10192115 1999 06 01 2013 11 21 Print Print 0031-7144 Print 54 3 1999 Mar Die Pharmazie Pharmazie Different kinetics of hydroquinone depletion in various medicinal plant tissue cultures producing arbutin. 234-5 Y Y Jahodr L L Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University, Hradec Krlov, Czech Republic. Y Duskov J J Y Polsek M M Y Papugov P P eng D016428 Journal Article Germany Pharmazie 9800766 0031-7144 0 D006873 Hydroquinones C5INA23HXF D001104 Arbutin IM D001104 N Arbutin Q000032 N analysis Q000096 Y biosynthesis D046508 N Culture Techniques D017022 N Flow Injection Analysis D006873 N Hydroquinones Q000032 N analysis Q000737 Y chemistry D007700 N Kinetics D010946 N Plants, Medicinal Q000378 Y metabolism pubmed 1999 4 7 medline 1999 4 7 0 1 entrez 1999 4 7 0 0 ppublish pubmed 10192115 MEDLINE NLM 1 10188493 1999 04 13 2016 11 24 Print Print 1354-5760 Print 5 8 1998 Dec-1999 Jan Nursing management (Harrow, London, England : 1994) Nurs Manag (Harrow) Women\\'s health osteopathy: an alternative view. 6-9 Y Y Hyne J J eng D016428 Journal Article England Nurs Manag (Harrow) 9433248 1354-5760 N D005260 N Female D006801 N Humans D010021 N Osteopathic Medicine Q000379 Y methods D013222 N State Medicine D006113 N United Kingdom D016387 Y Women\\'s Health pubmed 1999 4 3 medline 1999 4 3 0 1 entrez 1999 4 3 0 0 ppublish pubmed 10188493 MEDLINE NLM 1 10331748 1999 06 01 2009 11 11 Print Print 0031-9023 Print 79 5 1999 May Physical therapy Phys Ther Looking for the Forrest. 454-5 Y Y Rothstein J M JM eng D016421 Editorial United States Phys Ther 0022623 0031-9023 AIM IM D004645 Y Empathy D006801 N Humans D019359 N Knowledge D026741 N Physical Therapy Modalities D011369 Y Professional-Patient Relations D012922 Y Social Change D014754 N Violence Q000523 Y psychology pubmed 1999 5 20 medline 1999 5 20 0 1 entrez 1999 5 20 0 0 ppublish pubmed 10331748 MEDLINE NLM 1 10331749 1999 06 01 2009 11 11 Print Print 0031-9023 Print 79 5 1999 May Physical therapy Phys Ther Effects of side lying on lung function in older individuals. 456-66 BACKGROUND AND PURPOSE OBJECTIVE Body positioning exerts a strong effect on pulmonary function, but its effect on other components of the oxygen transport pathway are less well understood, especially the effects of side-lying positions. This study investigated the interrelationships between side-lying positions and indexes of lung function such as spirometry, alveolar diffusing capacity, and inhomogeneity of ventilation in older individuals. SUBJECTS AND METHODS METHODS Nineteen nonsmoking subjects (mean age=62.8 years, SD=6.8, range=50-74) with no history of cardiac or pulmonary disease were tested over 2 sessions. The test positions were sitting and left side lying in one session and sitting and right side lying in the other session. In each of the positions, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), single-breath pulmonary diffusing capacity (DLCO/VA), and the slope of phase III (DN2%/L) of the single-breath nitrogen washout test to determine inhomogeneity of ventilation were measured. RESULTS RESULTS Compared with measurements obtained in the sitting position, FVC and FEV1 were decreased equally in the side-lying positions, but no change was observed in DLCO/VA or DN2%/L. CONCLUSION AND DISCUSSION CONCLUSIONS Side-lying positions resulted in decreases in FVC and FEV1, which is consistent with the well-documented effects of the supine position. These findings further support the need for prescriptive rather than routine body positioning of patients with risks of cardiopulmonary compromise and the need to use upright positions in which lung volumes and capacities are maximized. Y Y Manning F F Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Y Dean E E Y Ross J J Y Abboud R T RT eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States Phys Ther 0022623 0031-9023 AIM IM S D000368 N Aged Q000502 Y physiology D001944 N Breath Tests D005260 N Female D005541 N Forced Expiratory Volume Q000502 Y physiology D006331 N Heart Diseases Q000517 N prevention & control D006801 N Humans D008171 N Lung Diseases Q000517 N prevention & control D008297 N Male D008875 N Middle Aged D011187 N Posture Q000502 Y physiology D011237 N Predictive Value of Tests D011653 N Pulmonary Diffusing Capacity Q000502 Y physiology D013147 N Spirometry D014797 N Vital Capacity Q000502 Y physiology pubmed 1999 5 20 medline 1999 5 20 0 1 entrez 1999 5 20 0 0 ppublish pubmed 10331749 MEDLINE NLM 1 10389168 1999 07 15 2016 10 20 Print Print 0869-8139 Print 85 1 1999 Jan Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova Ross Fiziol Zh Im I M Sechenova [Ethanol modifies the ion selectivity of sodium channels in the rat sensory neurons]. 110-8 Ethanol was shown to decrease the reversal potential of tetrodotoxin-resistant (TTXr) and TTX-sensitive channels in short-term culture of the dorsal root ganglion cells. The ethanol led to alterations in ionic selectivity of the TTXr channels (its shifting from the X-th Eisenmann selectivity sequence to the XI-th one). The data obtained suggest that the findings were due to selectivity filter modification because of disturbed hydrogen bounds in the channel macromolecule. Y Y Krylov B V BV I. P. Pavlov Institute of Physiology, Russian Acad. Sci., St. Petersburg, Russia. Y Vilin Iu Iu IuIu Y Katina I E IE Y Podzorova S A SA rus D004740 English Abstract D016428 Journal Article Etanol modifitsiruet ionnuiu izbiratel\\'nost\\' natrievykh kanalov sensornykh neronov krysy. Russia (Federation) Ross Fiziol Zh Im I M Sechenova 9715665 0869-8139 0 D002412 Cations 0 D015222 Sodium Channels 3K9958V90M D000431 Ethanol 4368-28-9 D013779 Tetrodotoxin IM D000818 N Animals D002412 N Cations Q000378 Y metabolism D002478 N Cells, Cultured D000431 N Ethanol Q000494 Y pharmacology D005727 N Ganglia, Spinal Q000166 N cytology D015640 N Ion Channel Gating D009475 N Neurons, Afferent Q000187 Y drug effects Q000378 N metabolism D018408 N Patch-Clamp Techniques D051381 N Rats D017208 N Rats, Wistar D015222 N Sodium Channels Q000187 Y drug effects D013779 N Tetrodotoxin Q000494 N pharmacology pubmed 1999 7 2 medline 1999 7 2 0 1 entrez 1999 7 2 0 0 ppublish pubmed 10389168 MEDLINE NLM 1 10540283 1999 12 17 2006 11 15 Print Print 0950-382X Print 34 1 1999 Oct Molecular microbiology Mol. Microbiol. Transcription regulation of the nir gene cluster encoding nitrite reductase of Paracoccus denitrificans involves NNR and NirI, a novel type of membrane protein. 24-36 The nirIX gene cluster of Paracoccus denitrificans is located between the nir and nor gene clusters encoding nitrite and nitric oxide reductases respectively. The NirI sequence corresponds to that of a membrane-bound protein with six transmembrane helices, a large periplasmic domain and cysteine-rich cytoplasmic domains that resemble the binding sites of [4Fe-4S] clusters in many ferredoxin-like proteins. NirX is soluble and apparently located in the periplasm, as judged by the predicted signal sequence. NirI and NirX are homologues of NosR and NosX, proteins involved in regulation of the expression of the nos gene cluster encoding nitrous oxide reductase in Pseudomonas stutzeri and Sinorhizobium meliloti. Analysis of a NirI-deficient mutant strain revealed that NirI is involved in transcription activation of the nir gene cluster in response to oxygen limitation and the presence of N-oxides. The NirX-deficient mutant transiently accumulated nitrite in the growth medium, but it had a final growth yield similar to that of the wild type. Transcription of the nirIX gene cluster itself was controlled by NNR, a member of the family of FNR-like transcriptional activators. An NNR binding sequence is located in the middle of the intergenic region between the nirI and nirS genes with its centre located at position -41.5 relative to the transcription start sites of both genes. Attempts to complement the NirI mutation via cloning of the nirIX gene cluster on a broad-host-range vector were unsuccessful, the ability to express nitrite reductase being restored only when the nirIX gene cluster was reintegrated into the chromosome of the NirI-deficient mutant via homologous recombination in such a way that the wild-type nirI gene was present directly upstream of the nir operon. Y Y Saunders N F NF Department of Molecular Cell Physiology, Faculty of Biology, BioCentrum Amsterdam, Vrije Universiteit, De Boelelaan 1087, NL-1081 HV Amsterdam, The Netherlands. Y Houben E N EN Y Koefoed S S Y de Weert S S Y Reijnders W N WN Y Westerhoff H V HV Y De Boer A P AP Y Van Spanning R J RJ eng Y GENBANK AF005358 U47133 U94899 PDB P33943 D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t England Mol Microbiol 8712028 0950-382X 0 D001426 Bacterial Proteins 0 D004268 DNA-Binding Proteins 0 D008565 Membrane Proteins 0 C120062 NNR protein, Paracoccus denitrificans 0 C401644 NirI protein, Paracoccus denitrificans 0 C401643 NirX protein, Paracoccus denitrificans 0 D014157 Transcription Factors EC 1.7.- D009572 Nitrite Reductases IM D000595 N Amino Acid Sequence D001426 Y Bacterial Proteins D001483 N Base Sequence D004268 Y DNA-Binding Proteins D015964 N Gene Expression Regulation, Bacterial D005816 N Genetic Complementation Test D008565 N Membrane Proteins Q000737 N chemistry Q000235 Y genetics Q000378 N metabolism D008969 N Molecular Sequence Data D005810 N Multigene Family D009154 N Mutation D009572 N Nitrite Reductases Q000235 Y genetics Q000378 N metabolism D010231 N Paracoccus denitrificans Q000235 Y genetics Q000378 N metabolism D017433 N Protein Structure, Secondary D017386 N Sequence Homology, Amino Acid D014157 N Transcription Factors Q000235 Y genetics Q000378 N metabolism D014158 Y Transcription, Genetic pubmed 1999 12 14 medline 1999 12 14 0 1 entrez 1999 12 14 0 0 ppublish pubmed 10540283 pii mmi1563 MEDLINE NLM 1 10854512 2000 06 29 2004 11 17 Print-Electronic Electronic 1432-2218 Internet 14 1 2000 Jan Surgical endoscopy Surg Endosc Inflammatory fibroid polyp of the duodenum. 86 Duodenal inflammatory fibroid polyps (IFP) are extemely rare lesions indistinguishable from submucosal tumors by endoscopic inspection alone. Like gastric inflammatory fibroid polyps, they can be managed by endoscopic polypectomy or mucosectomy. However, preoperative diagnosis of this benign lesion is difficult. Here we present a case of duodenal IFP causing gastrointestinal bleeding that was evaluated by endoscopic ultrasound before surgical removal. On endosonography, the duodenal IFP appeared as a coarsely heterogeneous isoechoic and hypoechoic mass circumscribed by a distinct margin and arising from the third layer of the duodenal wall. The endosonographic appearance of this lesion was in marked contrast to that previously reported for gastric IFPs, which have tended to appear as hypoechoic homogeneous lesions with indistinct margins. Endosonographic evaluation of suspected IFPs before endoscopic or surgical treatment is useful. However, the endosonographic appearances of duodenal and gastric IFPs may be significantly different, possibly because of differences in the makeup of the duodenal and gastric walls. Y Y Soon M S MS Division of Gastroenterology, ChangHua Christian Medical Center, ChangHua, Taiwan. Y Lin O S OS eng D002363 Case Reports D016428 Journal Article Electronic 1999 11 25 Germany Surg Endosc 8806653 0930-2794 IM D004379 N Duodenal Neoplasms Q000150 Y complications Q000473 N pathology Q000601 N surgery D004382 N Duodenitis Q000209 Y etiology Q000473 N pathology Q000601 N surgery D016099 N Endoscopy, Gastrointestinal D019160 N Endosonography D005260 N Female D005350 N Fibroma Q000473 N pathology Q000601 N surgery D005753 N Gastric Mucosa Q000473 N pathology D006471 N Gastrointestinal Hemorrhage Q000209 N etiology Q000473 N pathology Q000601 N surgery D006801 N Humans D007417 N Intestinal Polyps Q000150 Y complications Q000473 N pathology Q000601 N surgery D008875 N Middle Aged received 1999 07 22 accepted 1999 08 10 pubmed 2000 6 16 medline 2000 7 6 entrez 2000 6 16 0 0 ppublish pubmed 10854512 doi 10.1007/s004649901204 MEDLINE NLM 1 10737756 2000 04 13 2013 11 21 Print Print 0022-2623 Print 43 6 2000 Mar 23 Journal of medicinal chemistry J. Med. Chem. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. 1234-41 The regioselective dibenzylphosphorylation of 2 followed by catalytic reduction in the presence of N-methyl-D-glucamine afforded 2-(S)-(1-(R)-(3, 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(5-(2- phosphoryl-3-oxo-4H,-1,2,4-triazolo)methylmorpholine, bis(N-methyl-D-glucamine) salt, 11. Incubation of 11 in rat, dog, and human plasma and in human hepatic subcellular fractions in vitro indicated that conversion to 2 would be expected to occur in vivo most readily in humans during hepatic circulation. Conversion of 11 to 2 occurred rapidly in vivo in the rat and dog with the levels of 11 being undetectable within 5 min after 1 and 8 mg/kg doses iv in the rat and within 15 min after 0.5, 2, and 32 mg/kg doses iv in the dog. Compound 11 has a 10-fold lower affinity for the human NK-1 receptor as compared to 2, but it is functionally equivalent to 2 in preclinical models of NK-1-mediated inflammation in the guinea pig and cisplatin-induced emesis in the ferret, indicating that 11 acts as a prodrug of 2. Based in part on these data, 11 was identified as a novel, water-soluble prodrug of the clinical candidate 2 suitable for intravenous administration in humans. Y Y Hale J J JJ Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, and Merck, Sharp & Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, U.K. jeffrey_hale@merck.com Y Mills S G SG Y MacCoss M M Y Dorn C P CP Y Finke P E PE Y Budhu R J RJ Y Reamer R A RA Y Huskey S E SE Y Luffer-Atlas D D Y Dean B J BJ Y McGowan E M EM Y Feeney W P WP Y Chiu S H SH Y Cascieri M A MA Y Chicchi G G GG Y Kurtz M M MM Y Sadowski S S Y Ber E E Y Tattersall F D FD Y Rupniak N M NM Y Williams A R AR Y Rycroft W W Y Hargreaves R R Y Metzger J M JM Y MacIntyre D E DE eng D016428 Journal Article United States J Med Chem 9716531 0022-2623 0 C406348 2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluoro)phenyl-4-(5-(2-phosphoryl-3-oxo-4H,-1,2,4-triazolo))methylmorpholine, bis(N-methylglucamine) salt 0 D000080 Acetals 0 D000894 Anti-Inflammatory Agents, Non-Steroidal 0 D000932 Antiemetics 0 D000970 Antineoplastic Agents 0 D009025 Morpholines 0 D064729 Neurokinin-1 Receptor Antagonists 0 D011355 Prodrugs 059QF0KO0R D014867 Water 1NF15YR6UY C114556 aprepitant Q20Q21Q62J D002945 Cisplatin IM D000080 N Acetals Q000138 Y chemical synthesis Q000737 N chemistry Q000378 Y metabolism Q000494 N pharmacology D000818 N Animals D000894 N Anti-Inflammatory Agents, Non-Steroidal Q000138 Y chemical synthesis Q000737 N chemistry Q000378 N metabolism Q000494 N pharmacology D000932 N Antiemetics Q000138 Y chemical synthesis Q000737 N chemistry Q000378 N metabolism Q000494 N pharmacology D000970 N Antineoplastic Agents D002945 N Cisplatin D004285 N Dogs D004353 N Drug Evaluation, Preclinical D005289 N Ferrets D006168 N Guinea Pigs D006801 N Humans D009025 N Morpholines Q000138 Y chemical synthesis Q000737 N chemistry Q000378 Y metabolism Q000494 N pharmacology D064729 Y Neurokinin-1 Receptor Antagonists D011355 N Prodrugs Q000138 Y chemical synthesis Q000737 N chemistry Q000378 N metabolism Q000494 N pharmacology D051381 N Rats D012995 N Solubility D013237 N Stereoisomerism D013329 N Structure-Activity Relationship D014839 N Vomiting Q000139 N chemically induced Q000188 N drug therapy D014867 N Water pubmed 2000 3 29 9 0 medline 2000 4 15 9 0 entrez 2000 3 29 9 0 ppublish pubmed 10737756 pii jm990617v MEDLINE NLM 1 10612833 2000 01 20 2012 07 11 Print Electronic 1098-1004 Internet 15 1 2000 Jan Human mutation Hum. Mutat. Erratum: analysis of DNA elements that modulate myosin VIIa expression in humans. 114-5 Usher syndromeIb (USH1B), an autosomal recessive disorder caused by mutations in myosin VIIa (MYO7A), is characterized by congenital profound hearing loss, vestibular abnormalities and retinitis pigmentosa. Promoter elements in the 5 kb upstream of the translation start were identified using adult retinal pigment epithelium cells (ARPE-19) as a model system. A 160 bp minimal promoter within the first intron was active in ARPE-19 cells, but not in HeLa cells that do not express MYO7A. A 100 bp sequence, 5\\' of the first exon, and repeated with 90% homology within the first intron, appeared to modulate expression in both cell lines. Segments containing these elements were screened by heteroduplex analysis. No heteroduplexes were detected in the minimal promoter, suggesting that this sequence is conserved. A -2568 A>T transversion in the 5\\' 100 bp repeat, eliminating a CCAAT element, was found only in USH1B patients. However, in all 5 families, -2568 A>T was in cis with the same missense mutation in the myosin VIIa tail (Arg1240Gln), and 4 of the 5 families were Dutch. These observations suggest either 1) linkage disequilibrium or 2)that a combination of a promoter mutation with a less active myosin VIIa protein results in USH1B. Copyright 2000 Wiley-Liss, Inc. Y Y Orten D J DJ Center for Hereditary Communication Disorders, Boys Town National Research Hospital Omaha, NE, USA. ortend@boystown.org Y Weston M D MD Y Kelley P M PM Y Cremers C W CW Y Wagenaar M M Y Jacobson S G SG Y Kimberling W J WJ eng N DC00677 DC NIDCD NIH HHS United States DC00982 DC NIDCD NIH HHS United States DC03351 DC NIDCD NIH HHS United States D016439 Corrected and Republished Article D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t D013487 Research Support, U.S. Gov\\'t, P.H.S. United States Hum Mutat 9215429 1059-7794 EC 3.6.4.1 D009218 Myosins EC 3.6.4.1 C096109 myosin VIIa EC 3.6.4.2 D004398 Dyneins IM RepublishedFrom Hum Mutat. 1999 Oct;14(4):354 1 10502787 D019943 N Amino Acid Substitution D002460 N Cell Line D004398 N Dyneins D005786 Y Gene Expression Regulation D006367 N HeLa Cells D006319 N Hearing Loss, Sensorineural Q000235 Y genetics Q000378 N metabolism D006801 N Humans D015810 N Linkage Disequilibrium D020125 N Mutation, Missense D009218 N Myosins Q000096 N biosynthesis Q000235 Y genetics D010375 N Pedigree D010857 N Pigment Epithelium of Eye Q000378 N metabolism D016133 N Polymerase Chain Reaction D012150 N Polymorphism, Restriction Fragment Length D011401 Y Promoter Regions, Genetic D012174 N Retinitis Pigmentosa Q000235 Y genetics Q000378 N metabolism D013577 N Syndrome D015837 N Vestibular Diseases Q000235 Y genetics Q000378 N metabolism pubmed 1999 12 29 medline 1999 12 29 0 1 entrez 1999 12 29 0 0 ppublish pubmed 10612833 pii 10.1002/(SICI)1098-1004(200001)15:1<114::AID-HUMU21>3.0.CO;2-4 doi 10.1002/(SICI)1098-1004(200001)15:1<114::AID-HUMU21>3.0.CO;2-4 MEDLINE NLM 1 10972993 2000 09 26 2008 11 21 Print Print 0899-1987 Print 28 4 2000 Aug Molecular carcinogenesis Mol. Carcinog. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. 236-46 Germline mutations of BRCA1 and BRCA2 predispose to hereditary breast, ovarian, and possibly prostate cancer, yet structural mutations in these genes are infrequent in sporadic cancer cases. To better define the involvement of these genes in sporadic cancers, we characterized expression levels of BRCA1 and BRCA2 transcripts in cancer cell lines derived from neoplasms of the ovary, prostate, and breast and compared them with those expressed in primary cultures of normal epithelial cells established from these organs. We observed upregulation of BRCA1 and/or BRCA2 expression in six of seven ovarian cancer cell lines (OVCA420, OVCA429, OVCA432, ALST, DOV13, and SKOV3) when compared with levels found in normal ovary surface epithelial cells. Furthermore, five cancerous or immortalized prostatic epithelial cell lines (BPH-1, TSU-Pr1, LNCaP, PC-3, and DU145) also expressed higher levels of BRCA1 and/or BRCA2 mRNA than did primary cultures of normal prostatic epithelial cells. In contrast, only the estrogen receptor-positive MCF-7 cell line overexpressed these messages, whereas the estrogen receptor-negative breast cancer cell lines Hs578T, MDA-MB-231, and MDA-MB-468 showed no change in expression levels when compared with normal breast epithelial cells. In addition, expanding on our recent identification of a novel BRCA2 transcript variant carrying an in-frame exon 12 deletion (BRCA2 delta 12), we report increased expression of this variant in several ovarian, prostate, and mammary cancer cell lines (OVCA420, OVCA433, ALST, DOV13, SKOV3, TSU-Pr1, DU145, and MDA-MB-468). Most notably, high levels of BRCA2 delta 12 mRNA were detected in an estrogen receptor-positive breast cancer cell line, MCF-7, and in an androgen-independent prostate cancer cell line, DU-145. Interestingly, the wild-type BRCA2 transcript was barely detectable in DU145, which could be used as a model system for future investigations on BRCA2 delta 12 function. Taken together, our data suggest disruption of BRCA1 and/or BRCA2 gene expression in certain epithelial cancer cell lines of the ovary, prostate, and breast. Because wild-type BRCA1 and BRCA2 gene products increase during cell-cycle progression and are believed to exert growth-inhibitory action, enhanced expression of these genes in cancer cells may represent a negative feedback mechanism for curbing proliferation in fast-growing cells. At present, the functionality of BRCA2 delta 12 remains elusive. Copyright 2000 Wiley-Liss, Inc. Y Y Rauh-Adelmann C C Department of Biology, Tufts University, Medford, Massachusetts, USA. Y Lau K M KM Y Sabeti N N Y Long J P JP Y Mok S C SC Y Ho S M SM eng N C69453 PHS HHS United States CA15576 CA NCI NIH HHS United States CA62269 CA NCI NIH HHS United States D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t D013487 Research Support, U.S. Gov\\'t, P.H.S. United States Mol Carcinog 8811105 0899-1987 0 D019313 BRCA1 Protein 0 D024682 BRCA2 Protein 0 D009363 Neoplasm Proteins 0 D012333 RNA, Messenger 0 D014157 Transcription Factors IM D019313 N BRCA1 Protein Q000235 Y genetics D024682 N BRCA2 Protein D001940 N Breast Q000378 N metabolism D001943 N Breast Neoplasms Q000235 Y genetics D002460 N Cell Line D004847 N Epithelial Cells Q000378 N metabolism D005091 N Exons D005260 N Female D015972 N Gene Expression Regulation, Neoplastic D019398 Y Genes, BRCA1 D014644 N Genetic Variation D006801 N Humans D008297 N Male D009363 N Neoplasm Proteins Q000235 Y genetics D010051 N Ovarian Neoplasms Q000235 Y genetics D011471 N Prostatic Neoplasms Q000235 Y genetics D012333 N RNA, Messenger Q000235 N genetics D017384 N Sequence Deletion D014157 N Transcription Factors Q000235 Y genetics D014158 Y Transcription, Genetic D014407 N Tumor Cells, Cultured pubmed 2000 9 6 11 0 medline 2000 9 30 11 1 entrez 2000 9 6 11 0 ppublish pubmed 10972993 pii 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H MEDLINE NLM 1 11025314 2001 01 05 2006 11 15 Print Print 0108-2701 Print 56 ( Pt 10) 2000 Oct Acta crystallographica. Section C, Crystal structure communications Acta Crystallogr C Multicentre hydrogen bonds in a 2:1 arylsulfonylimidazolone hydrochloride salt. 1247-50 The title compound, (S)-(+)-4-[5-(2-oxo-4, 5-dihydroimidazol-1-ylsulfonyl)indolin-1 -ylcarbonyl ]anilinium chloride (S)-(+)-1-[1-(4-aminobenzoyl)indoline-5- sulfonyl]-4-phenyl-4, 5-dihydroimidazol-2-one, C(24)H(23)N(4)O(4)S(+).Cl(-). C(24)H(22)N(4)O(4)S, crystallizes in space group C2 from a CH(3)OH/CH(2)Cl(2) solution. In the crystal structure, there are two different conformers with their terminal C(6) aromatic rings mutually oriented at angles of 67.69 (14) and 61.16 (15) degrees. The distances of the terminal N atoms (of the two conformers) from the chloride ion are 3.110 (4) and 3.502 (4) A. There are eight distinct hydrogen bonds, i.e. four N-H...Cl, three N-H...O and one N-H...N, with one N-H group involved in a bifurcated hydrogen bond with two acceptors sharing the H atom. C-H...O contacts assist in the overall hydrogen-bonding process. Y Y Park K L KL College of Pharmacy, Chungnam National University, Taejeon 305-764, Korea. parki@cnu.ac.kr. Y Moon B G BG Y Jung S H SH Y Kim J G JG Y Suh I H IH eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States Acta Crystallogr C 8305826 0108-2701 0 C417516 1-(1-(4-aminobenzoyl)indoline-5-sulfonyl)-4-phenyl-4,5-dihydroimidazol-2-one 0 D000970 Antineoplastic Agents 0 D007093 Imidazoles 0 D013450 Sulfones IM D000970 N Antineoplastic Agents Q000737 Y chemistry D018360 N Crystallography, X-Ray D006860 N Hydrogen Bonding D007093 N Imidazoles Q000737 Y chemistry D008958 N Models, Molecular D008968 N Molecular Conformation D013237 N Stereoisomerism D013450 N Sulfones Q000737 Y chemistry received 2000 05 17 accepted 2000 07 03 pubmed 2000 10 12 11 0 medline 2001 2 28 10 1 entrez 2000 10 12 11 0 ppublish pubmed 11025314 pii S0108270100009495 MEDLINE NLM 1 11034741 2001 08 02 2013 06 28 Print Electronic 1469-493X Internet 4 2000 The Cochrane database of systematic reviews Cochrane Database Syst Rev Parent-training programmes for improving maternal psychosocial health. CD002020 BACKGROUND BACKGROUND The prevalence of mental health problems in women is 1:3 and such problems tend to be persistent. There is evidence from a range of studies to suggest that a number of factors relating to maternal psychosocial health can have a significant effect on the mother-infant relationship, and that this can have consequences for the psychological health of the child. It is now thought that parenting programmes may have an important role to play in the improvement of maternal psychosocial health. OBJECTIVES OBJECTIVE The objective of this review is to address whether group-based parenting programmes are effective in improving maternal psychosocial health including anxiety, depression and self-esteem. SEARCH STRATEGY METHODS A range of biomedical, social science, educational and general reference electronic databases were searched including MEDLINE, EMBASE CINAHL, PsychLIT, ERIC, ASSIA, Sociofile and the Social Science Citation Index. Other sources of information included the Cochrane Library (SPECTR, CENTRAL), and the National Research Register (NRR). SELECTION CRITERIA METHODS Only randomised controlled trials were included in which participants had been randomly allocated to an experimental and a control group, the latter being either a waiting-list, no-treatment or a placebo control group. Studies had to include at least one group-based parenting programme, and one standardised instrument measuring maternal psychosocial health. DATA COLLECTION AND ANALYSIS METHODS A systematic critical appraisal of all included studies was undertaken using the Journal of the American Medical Association (JAMA) published criteria. The data were summarised using effect sizes but were not combined in a meta-analysis due to the small number of studies within each group and the presence of significant heterogeneity. MAIN RESULTS RESULTS A total of 22 studies were included in the review but only 17 provided sufficient data to calculate effect sizes. These 17 studies reported on a total of 59 outcomes including depression, anxiety, stress, self-esteem, social competence, social support, guilt, mood, automatic thoughts, dyadic adjustment, psychiatric morbidity, irrationality, anger and aggression, mood, attitude, personality, and beliefs. Approximately 22% of the outcomes measured suggested significant differences favouring the intervention group. A further 40% showed differences favouring the intervention group but which failed to achieve conventional levels of statistical significance, in some cases due to the small numbers that were used. Approximately 38% of outcomes suggested no evidence of effectiveness. REVIEWER\\'S CONCLUSIONS CONCLUSIONS It is suggested that parenting programmes can make a significant contribution to the improvement of psychosocial health in mothers. While the critical appraisal suggests some variability in the quality of the included studies, it is concluded that there is sufficient evidence to support their use with diverse groups of parents. However, it is also suggested that some caution should be exercised before the results are generalised to parents irrespective of the level of pathology present, and that further research is still required. Y Y Barlow J J Health Services Research Unit, University of Oxford, Institute of Health Sciences, Old Road, Oxford, UK, OX3 7LF. esther.coren@dphpc.ox.ac.uk Y Coren E E eng D016428 Journal Article D016454 Review England Cochrane Database Syst Rev 100909747 1361-6137 IM UpdateIn Cochrane Database Syst Rev. 2001;(2):CD002020 1 11406024 D001007 N Anxiety Q000628 N therapy D003863 N Depression Q000628 N therapy D005260 N Female D006801 N Humans D008425 N Maternal Behavior Q000523 Y psychology D009034 Y Mother-Child Relations D016487 Y Parenting D015397 Y Program Evaluation D016032 N Randomized Controlled Trials as Topic D012649 N Self Concept 99 pubmed 2000 10 18 11 0 medline 2001 8 3 10 1 entrez 2000 10 18 11 0 ppublish pubmed 11034741 pii CD002020 doi 10.1002/14651858.CD002020 PubMed-not-MEDLINE NLM 1 11056631 2016 03 08 2000 12 01 Print Print 0031-9007 Print 85 19 2000 Nov 06 Physical review letters Phys. Rev. Lett. Dislocated epitaxial islands. 4088-91 Dislocation networks observed in CoSi (2) islands grown epitaxially on Si are compared with the results of dislocation-dynamics calculations. The calculations make use of the fact that image forces play a relatively minor role compared to line tension forces and dislocation-dislocation interactions. Remarkable agreement is achieved, demonstrating that this approach can be applied more generally to study dislocations in other mesostructures. Y Y Liu X H XH IBM Watson Research Center, P.O. Box 218, Yorktown Heights, New York 10598, USA. Y Ross F M FM Y Schwarz K W KW eng D016428 Journal Article United States Phys Rev Lett 0401141 0031-9007 received 2000 07 17 pubmed 2000 11 1 11 0 medline 2000 11 1 11 1 entrez 2000 11 1 11 0 ppublish pubmed 11056631 doi 10.1103/PhysRevLett.85.4088 MEDLINE NLM 1 11238657 2001 05 17 2013 11 21 Print Print 0022-1767 Print 166 6 2001 Mar 15 Journal of immunology (Baltimore, Md. : 1950) J. Immunol. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. 4083-91 Increasing evidence suggests that a continuous release of histamine from mast cells occurs in the airways of asthmatic patients and that histamine may modulate functions of other inflammatory cells such as macrophages. In the present study histamine (10(-9)-10(-6) M) increased in a concentration-dependent fashion the basal release of beta-glucuronidase (EC(50) = 8.2 +/- 3.5 x 10(-9) M) and IL-6 (EC(50) = 9.3 +/- 2.9 x 10(-8) M) from human lung macrophages. Enhancement of beta-glucuronidase release induced by histamine was evident after 30 min and peaked at 90 min, whereas that of IL-6 required 2-6 h of incubation. These effects were reproduced by the H(1) agonist (6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)heptane carboxamide but not by the H(2) agonist dimaprit. Furthermore, histamine induced a concentration-dependent increase of intracellular Ca(2+) concentrations ([Ca(2+)](i)) that followed three types of response, one characterized by a rapid increase, a second in which [Ca(2+)](i) displays a slow but progressive increase, and a third characterized by an oscillatory pattern. Histamine-induced beta-glucuronidase and IL-6 release and [Ca(2+)](i) elevation were inhibited by the selective H(1) antagonist fexofenadine (10(-7)-10(-4) M), but not by the H(2) antagonist ranitidine. Inhibition of histamine-induced beta-glucuronidase and IL-6 release by fexofenadine was concentration dependent and displayed the characteristics of a competitive antagonism (K(d) = 89 nM). These data demonstrate that histamine induces exocytosis and IL-6 production from human macrophages by activating H(1) receptor and by increasing [Ca(2+)](i) and they suggest that histamine may play a relevant role in the long-term sustainment of allergic inflammation in the airways. Y Y Triggiani M M Division of Clinical Immunology and Allergy, University of Naples Federico II, Naples, Italy. triggian@unina.it Y Gentile M M Y Secondo A A Y Granata F F Y Oriente A A Y Taglialatela M M Y Annunziato L L Y Marone G G eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States J Immunol 2985117R 0022-1767 0 D017442 Histamine Agonists 0 D006634 Histamine H1 Antagonists 0 D006635 Histamine H2 Antagonists 0 D015850 Interleukin-6 0 D012333 RNA, Messenger 0 D011969 Receptors, Histamine H1 0 D014052 Toluidines 103827-15-2 C081972 6-((2-(4-imidazolyl)ethyl)amino)heptanoic acid 4-toluidide 820484N8I3 D006632 Histamine EC 3.2.1.31 D005966 Glucuronidase SY7Q814VUP D002118 Calcium ZZQ699148P D017259 Dimaprit AIM IM D002118 N Calcium Q000378 N metabolism Q000502 N physiology D003600 N Cytosol Q000378 N metabolism D017259 N Dimaprit Q000494 N pharmacology D004306 N Dose-Response Relationship, Immunologic D005089 N Exocytosis Q000276 Y immunology D005966 N Glucuronidase Q000557 N secretion D006632 N Histamine Q000031 Y analogs & derivatives Q000494 N pharmacology Q000502 Y physiology D017442 N Histamine Agonists Q000494 N pharmacology D006634 N Histamine H1 Antagonists Q000494 N pharmacology D006635 N Histamine H2 Antagonists Q000494 N pharmacology D006801 N Humans D015850 N Interleukin-6 Q000096 Y biosynthesis Q000235 N genetics Q000557 N secretion D008168 N Lung Q000166 N cytology Q000201 N enzymology Q000276 Y immunology Q000378 Y metabolism D016676 N Macrophages, Alveolar Q000201 N enzymology Q000276 N immunology Q000378 Y metabolism Q000557 N secretion D012333 N RNA, Messenger Q000096 N biosynthesis D011969 N Receptors, Histamine H1 Q000378 Y metabolism D014052 N Toluidines Q000494 N pharmacology D015854 N Up-Regulation Q000276 N immunology pubmed 2001 3 10 10 0 medline 2001 5 18 10 1 entrez 2001 3 10 10 0 ppublish pubmed 11238657 MEDLINE NLM 1 11279676 2001 12 07 2014 11 20 Print Electronic 1469-493X Internet 1 2001 The Cochrane database of systematic reviews Cochrane Database Syst Rev Elective versus selective caesarean section for delivery of the small baby. CD000078 BACKGROUND BACKGROUND Elective caesarean delivery for women in preterm labour might reduce the chances of fetal or neonatal death, but it might also increase the risk of maternal morbidity. OBJECTIVES OBJECTIVE To assess the effects of a policy of elective caesarean delivery versus selective caesarean delivery for women in preterm labour. SEARCH STRATEGY METHODS The Cochrane Pregnancy and Childbirth Group trials register was searched. Date of last search: September 2000. SELECTION CRITERIA METHODS Randomised trials comparing a policy of elective caesarean delivery versus expectant management with recourse to caesarean section. DATA COLLECTION AND ANALYSIS METHODS One reviewer assessed eligibility and trial quality, and both contributed to the update. MAIN RESULTS RESULTS Six studies involving 122 women were included. All trials reported recruiting difficulties. No significant differences between elective and selective policies for caesarean delivery were found for fetal, neonatal or maternal outcomes. REVIEWER\\'S CONCLUSIONS CONCLUSIONS There is not enough evidence to evaluate the use of a policy for elective caesarean delivery for small babies. Randomised trials in this area are likely to continue to experience recruitment problems. However, it still may be possible to investigate elective caesarean delivery in preterm babies with cephalic presentations. Y Y Grant A A Health Services Research Unit, The Polwarth Building, Foresterhill, Aberdeen, UK, AB9 2ZD. a.grant@abdn.ac.uk Y Glazener C M CM eng D016428 Journal Article D016454 Review England Cochrane Database Syst Rev 100909747 1361-6137 IM UpdateIn Cochrane Database Syst Rev. 2001;(2):CD000078 1 11405950 UpdateOf Cochrane Database Syst Rev. 2000;(2):CD000078 1 10796117 D002585 Y Cesarean Section D017558 Y Elective Surgical Procedures D005260 N Female D006801 N Humans D007231 N Infant, Newborn D007234 N Infant, Premature D007752 Y Obstetric Labor, Premature D011247 N Pregnancy D016032 N Randomized Controlled Trials as Topic 21 pubmed 2001 5 2 10 0 medline 2002 1 5 10 1 entrez 2001 5 2 10 0 ppublish pubmed 11279676 pii CD000078 doi 10.1002/14651858.CD000078 MEDLINE NLM 1 11243089 2001 05 17 2006 11 15 Print Print 0019-557X Print 43 1 1999 Jan-Mar Indian journal of public health Indian J Public Health Nutritional status of pavement dweller children of Calcutta City. 49-54 Pavement dwelling is likely to aggravate malnutrition among its residents due to extreme poverty, lack of dwelling and access to food and their exposure to polluted environment. Paucity of information about nutritional status of street children compared to that among urban slum dwellers, squatters or rural/tribal population is quite evident. The present study revealed the magnitude of Protein Energy Malnutrition (PEM) and few associated factors among a sample of 435 underfives belonging to pavement dweller families and selected randomly from clusters of such families, from each of the five geographical sectors of Calcutta city. Overall prevalence of PEM was found almost similar (about 70%) to that among other \\'urban poor\\' children viz. slum dwellers etc., but about 16% of them were found severely undernourished (Grade III & V of IAP classification of PEM). About 35% and 70% of street dweller children had wasting and stunting respectively. Severe PEM (Grade III & IV) was more prevalent among 12-23 months old, girl child, those belonged to illiterate parents and housewife mothers rather than wage earners. It also did increase with increase of birth rate of decrease of birth interval. Y Y Ray S K SK Department of Community Medicine, Medical College, Calcutta. Y Mishra R R Y Biswas R R Y Kumar S S Y Halder A A Y Chatterjee T T eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t India Indian J Public Health 0400673 0019-557X IM J D002675 N Child, Preschool D016000 N Cluster Analysis D003430 N Cross-Sectional Studies D004522 N Educational Status D005260 N Female D006801 N Humans D007194 N Geographic India Q000453 N epidemiology D007223 N Infant D008297 N Male D009752 Y Nutritional Status D011203 N Poverty D011287 N Prejudice D015995 N Prevalence D011502 N Protein-Energy Malnutrition Q000453 Y epidemiology PIP 143717 POP 00288124 PIP eng This document presents a cross-sectional survey concerning the magnitude of protein energy malnutrition (PEM) and its associated factors among 435 under-5 pavement-dwelling children in Calcutta. Results revealed that 69.43% were undernourished and that 16% of them were suffering from severe malnutrition (grade III and IV of the Indian Academy of Pediatrics criteria for PEM). The 24-35 month age group had the highest prevalence of malnutrition (82.93%) followed by the 36-47 and 12-23 month age groups with prevalences of 76.19% and 74.03%, respectively. Prevalence of severe grade malnutrition was noted to be three times higher in females (24.76%) than males (8.45%), and among families it increased in direct proportion to birth rate and inverse proportion to birth interval. Moreover, children of illiterate parents and nonworking mothers had a higher incidence of severe PEM. Simple measures such as exclusive breast-feeding and timely complementary feeding as well as measures directed toward birth spacing and limiting family size should be implemented to solve the problem of malnutrition. PIP N Age Factors N Asia Y Child Y Child Nutrition N Demographic Factors N Developing Countries N Diseases N Geographic Factors N Health Y Homeless Persons N India Y Malnutrition N Nutrition N Nutrition Disorders N Population N Population Characteristics N Research Methodology Y Research Report N Residence Characteristics N Sampling Studies N Southern Asia N Spatial Distribution N Studies Y Surveys Y Urban Population N Youth PIP TJ: INDIAN JOURNAL OF PUBLIC HEALTH. pubmed 2001 3 13 10 0 medline 2001 5 18 10 1 entrez 2001 3 13 10 0 ppublish pubmed 11243089 MEDLINE NLM 1 11428848 2001 09 27 2007 11 15 Print Print 0195-668X Print 22 13 2001 Jul European heart journal Eur. Heart J. Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. 1074-81 Y Y Hauer R N RN Heart Lung Center Utrecht, University Medical Center, The Netherlands. Y Aliot E E Y Block M M Y Capucci A A Y Lderitz B B Y Santini M M Y Vardas P E PE Y European Society of Cardiology. Working Group on Arrhythmias and Working Group on Cardiac Pacing eng D016431 Guideline D016428 Journal Article D017065 Practice Guideline England Eur Heart J 8006263 0195-668X IM D001145 N Arrhythmias, Cardiac Q000209 N etiology Q000628 Y therapy D019571 N Arrhythmogenic Right Ventricular Dysplasia Q000628 N therapy D002311 N Cardiomyopathy, Dilated Q000628 N therapy D002312 N Cardiomyopathy, Hypertrophic Q000628 N therapy D003327 N Coronary Disease Q000628 N therapy D016757 N Death, Sudden, Cardiac Q000517 Y prevention & control D017147 Y Defibrillators, Implantable D006349 N Heart Valve Diseases Q000628 N therapy D006801 N Humans D008133 N Long QT Syndrome Q000628 N therapy D014693 N Ventricular Fibrillation Q000628 N therapy pubmed 2001 6 29 10 0 medline 2001 9 28 10 1 entrez 2001 6 29 10 0 ppublish pubmed 11428848 doi 10.1053/euhj.2001.2584 pii S0195668X01925849 PubMed-not-MEDLINE NLM 1 11431089 2005 06 08 2004 04 20 Print Print 0924-7947 Print 7 2001 Archives of gerontology and geriatrics. Supplement Arch Gerontol Geriatr Suppl An investigation on behavioral problems in centenarians. 375-8 Y Y Tafaro L L Department of Aging Science, Policlinico Umberto I, University La Sapienza, Roma, Italy. Y Cicconetti P P Y Martella S S Y Tedeschi G G Y Zannino G G Y Troisi G G Y Pastena I I Y Fioravanti M M Y Marigliano V V eng D016428 Journal Article Ireland Arch Gerontol Geriatr Suppl 8911786 0924-7947 pubmed 2001 6 30 10 0 medline 2001 6 30 10 1 entrez 2001 6 30 10 0 ppublish pubmed 11431089 pii S0167494301001649 MEDLINE NLM 1 11406024 2002 02 28 2013 06 28 Print Electronic 1469-493X Internet 2 2001 The Cochrane database of systematic reviews Cochrane Database Syst Rev Parent-training programmes for improving maternal psychosocial health. CD002020 BACKGROUND BACKGROUND Mental health problems are common, and there is evidence from a range of studies to suggest that a number of factors relating to maternal psychosocial health can have a significant effect on the mother-infant relationship, and that this can have consequences for both the short and long-term psychological health of the child. The use of parenting programmes is increasing in the UK and evidence of their effectiveness in improving outcomes for mothers is now required. OBJECTIVES OBJECTIVE The objective of this review is to address whether group-based parenting programmes are effective in improving maternal psychosocial health including anxiety, depression, and self-esteem. SEARCH STRATEGY METHODS A range of biomedical, social science, educational and general reference electronic databases were searched including MEDLINE, EMBASE CINAHL, PsychLIT, ERIC, ASSIA, Sociofile and the Social Science Citation Index. Other sources of information included the Cochrane Library (SPECTR, CENTRAL), and the National Research Register (NRR). SELECTION CRITERIA METHODS Only randomised controlled trials were included in which participants had been randomly allocated to an experimental and a control group, the latter being either a waiting-list, no-treatment or a placebo control group. Studies had to include at least one group-based parenting programme, and one standardised instrument measuring maternal psychosocial health. DATA COLLECTION AND ANALYSIS METHODS A systematic critical appraisal of all included studies was undertaken using a modified version of the Journal of the American Medical Association (JAMA) published criteria. The treatment effect for each outcome in each study was standardised by dividing the mean difference in post-intervention scores for the intervention and treatment group, by the pooled standard deviation, to produce an effect size. Where appropriate the results were then combined in a meta-analysis using a fixed-effect model, and 95% confidence intervals were used to assess the significance of the findings. MAIN RESULTS RESULTS A total of 23 studies were included in the review but only 17 provided sufficient data to calculate effect sizes. The 17 studies provided a total of 59 assessments of outcome on a range of aspects of psychosocial functioning including depression, anxiety, stress, self-esteem, social competence, social support, guilt, mood, automatic thoughts, dyadic adjustment, psychiatric morbidity, irrationality, anger and aggression, mood, attitude, personality, and beliefs. There was only sufficient data, however, on five outcomes (depression; anxiety/stress; self-esteem; social support; and relationship with spouse/marital adjustment) to combine the results in a meta-analysis. The meta-analyses show statistically significant results favouring the intervention group as regards depression; anxiety/stress; self-esteem; and relationship with spouse/marital adjustment. The meta-analysis of the social support data, however, showed no evidence of effectiveness. These results suggest that parenting programmes, irrespective of the type (or content) of programme, can be effective in improving important aspects of maternal psycho-social functioning. Of the data summarising the effectiveness of the different types of parenting programmes, which it was not possible to combine in a meta-analysis, approximately 22% of the outcomes measured, showed significant differences between the intervention group and the control group. A further 40% showed medium to large non-significant differences favouring the intervention group. Approximately one-third of outcomes showed small non-significant differences or no evidence of effectiveness. A meta-analysis of the follow-up data on three outcomes was also conducted - depression, self-esteem and relationship with spouse/marital adjustment. The results show that there was a continued improvement in self-esteem, depression and marital adjustment at follow-up, although the latter two findings were not statistically significant. REVIEWER\\'S CONCLUSIONS CONCLUSIONS It is suggested that parenting programmes can make a significant contribution to short-term psychosocial health in mothers, and that the limited follow-up data available suggest that these are maintained over time. However, the overall paucity of long-term follow-up data points to the need for further evidence concerning the long-term effectiveness of parenting programmes on maternal mental health. Furthermore, it is suggested that some caution should be exercised before the results are generalised to parents irrespective of the level of pathology present, and that further research is still required. Y Y Barlow J J Health Services Research Unit, University of Oxford, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. esther.coren@public-health.oxford.ac.uk Y Coren E E eng D016428 Journal Article D016454 Review England Cochrane Database Syst Rev 100909747 1361-6137 IM UpdateIn Cochrane Database Syst Rev. 2004;(1):CD002020 1 14973981 UpdateOf Cochrane Database Syst Rev. 2000;(4):CD002020 1 11034741 D001007 N Anxiety Q000628 N therapy D003863 N Depression Q000628 N therapy D005260 N Female D006801 N Humans D008425 N Maternal Behavior Q000523 Y psychology D008429 N Maternal Welfare D009034 Y Mother-Child Relations D016487 Y Parenting D015397 Y Program Evaluation D016032 N Randomized Controlled Trials as Topic D012649 N Self Concept 100 pubmed 2001 6 19 10 0 medline 2002 3 1 10 1 entrez 2001 6 19 10 0 ppublish pubmed 11406024 pii CD002020 doi 10.1002/14651858.CD002020 MEDLINE NLM 1 11441930 2001 07 19 2015 11 19 Print Print 0284-186X Print 40 2-3 2001 Acta oncologica (Stockholm, Sweden) Acta Oncol Assessment of quality of life during chemotherapy. 175-84 Increasingly more aggressive chemotherapy together with expected small differences between treatments with respect to objective endpoints has heightened awareness about the importance of addressing how patients experience and value the impact that treatment has had on their overall life situation. Assessment of a patient\\'s quality of life (QoL) is now conceptually viewed as an important complement to traditional objective evaluation measures. It was therefore considered important to review the basis for the assessment of this endpoint when The Swedish Council of Technology Assessment in Health Care (SBU) performed a systematic overview of chemotherapy effects in several tumour types. The group came to the following conclusions: QoL assessments, mostly by patient self-reporting in questionnaires, have come increasingly into use during the past decade. A number of general, cancer-specific and cancer diagnosis-specific instruments have been developed. There is at present little need for development of new cancer instruments, although specific treatment modalities and tumour types may need new additional modules. A predefined hypothesis should determine the instrument to be used. Since the selection of a QoL instrument in a specific study influences both the results and the conclusions, it is essential to carefully select the instrument or instruments that have the greatest likelihood of identifying relevant differences between treatment alternatives. Interpretation of QoL data is more difficult than interpretation of objective endpoints such as survival time, objective response rates or toxicity. Despite these difficulties, QoL analyses have provided new insights into the advantages and disadvantages of various treatments not provided by traditional end-points. Some palliative treatments seemingly increase patients\\' QoL despite side-effects or the lack of, or marginal, increases in survival. When using potentially curative chemotherapy, it is not a matter of when the treatment should be started, but rather when it should be concluded. When using less active chemotherapy, the expected small therapeutic gains must be weighed against the QoL costs of using the therapy: does the toxicity and/or the inconvenience of the proposed treatment justify the expected gain? When it is found that the strain on the patient is greater than the effects of the cancer, treatment must be discontinued. It is not possible to determine whether or not the advantages of palliative chemotherapy are worth their costs without knowledge about patients\\' personal values regarding the influence on factors of relevance for QoL. The mostly used QoL questionnaires do not consider individual preferences, which therefore need to be addressed in the dialogue with the patient. QoL assessment is clearly in need of further methodological improvement before this endpoint can be regarded as fully established with respect to ability to provide unequivocally useful data in clinical trials. The multitude of questionnaires, missing data, lack of pre-study hypotheses of relevant differences between treatments and data multiplicity giving a risk for chance findings are examples of serious methodological problems. Patient response-shifts over time further complicate the interpretation of the data. Thus, QoL data, also from seemingly well-performed clinical trials, have to be interpreted cautiously. The international development during recent years has aimed at creating increased standardization of QoL measures. This has created greater possibilities to compare results from different trials. Hopefully, this also implies that it will be possible to draw firmer conclusions from QoL measurements in recently completed or ongoing trials than has been the case previously. QoL assessments are resource demanding even when short standardized questionnaires are used. Since cancer patients also generally give priority to anticancer effects over toxicity and convenience, QoL assessments in clinical trials are motivated mainly in study settings comparing treatments without expected major differences of outcome in objective endpoints. Y Y Gunnars B B Department of Oncology, University Hospital, Lund, Sweden. Y Nygren P P Y Glimelius B B Y SBU-group. Swedish Council of Technology Assessment in Health Care eng D016428 Journal Article D016454 Review England Acta Oncol 8709065 0284-186X 0 D000970 Antineoplastic Agents IM D000970 N Antineoplastic Agents Q000009 N adverse effects Q000627 Y therapeutic use D023381 N Endpoint Determination D006801 N Humans D009369 N Neoplasms Q000188 Y drug therapy D017063 N Outcome Assessment (Health Care) D010166 N Palliative Care D017060 N Patient Satisfaction D011788 Y Quality of Life D011795 N Surveys and Questionnaires 112 pubmed 2001 7 10 10 0 medline 2001 7 20 10 1 entrez 2001 7 10 10 0 ppublish pubmed 11441930 MEDLINE NLM 1 11442735 2001 10 04 2013 11 21 Print Print 0303-6979 Print 28 8 2001 Aug Journal of clinical periodontology J. Clin. Periodontol. Utilisation of locally delivered doxycycline in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 treatment approaches. 753-61 AIM OBJECTIVE In the present 6-month multicentre trial, the outcome of 2 different approaches to non-surgical treatment of chronic periodontitis, both involving the use of a locally delivered controlled-release doxycycline, was evaluated. MATERIAL AND METHODS METHODS 105 adult patients with moderately advanced chronic periodontitis from 3 centres participated in the trial. Each patient had to present with at least 8 periodontal sites in 2 jaw quadrants with a probing pocket depth (PPD) of > or =5 mm and bleeding following pocket probing (BoP), out of which at least 2 sites had to be > or =7 mm and a further 2 sites > or =6 mm. Following a baseline examination, including assessments of plaque, PPD, clinical attachment level (CAL) and BoP, careful instruction in oral hygiene was given. The patients were then randomly assigned to one of two treatment groups: scaling/root planing (SRP) with local analgesia or debridement (supra- and subgingival ultrasonic instrumentation without analgesia). The \"SRP\" group received a single episode of full-mouth supra-/subgingival scaling and root planing under local analgesia. In addition, at a 3-month recall visit, a full-mouth supra-/subgingival debridement using ultrasonic instrumentation was provided. This was followed by subgingival application of an 8.5% w/w doxycycline polymer at sites with a remaining PPD of > or =5 mm. The patients of the \"debridement\" group were initially subjected to a 45-minute full-mouth debridement with the use of an ultrasonic instrument and without administration of local analgesia, and followed by application of doxycycline in sites with a PPD of > or =5 mm. At month 3, sites with a remaining PPD of > or =5 mm were subjected to scaling and root planing. Clinical re-examinations were performed at 3 and 6 months. RESULTS RESULTS At 3 months, the proportion of sites showing PPD of < or =4 mm was significantly higher in the \"debridement\" group than in the \"SRP\" group (58% versus 50%; p<0.05). The CAL gain at 3 months amounted to 0.8 mm in the \"debridement\" group and 0.5 mm in the \"SRP\" group (p=0.064). The proportion of sites demonstrating a clinically significant CAL gain (> or =2 mm) was higher in the \"debridement\" group than in the \"SRP\" group (38% versus 30%; p<0.05). At the 6-month examination, no statistically significant differences in PPD or CAL were found between the two treatment groups. BoP was significantly lower for the \"debridement\" group than for the \"SRP\" group (p<0.001) both at 3- and 6 months. The mean total treatment time (baseline and 3-month) for the \"SRP\" patients was 3:11 h, compared to 2:00 h for the patients in the \"debridement\" group (p<0.001). CONCLUSION CONCLUSIONS The results indicate that simplified subgingival instrumentation combined with local application of doxycycline in deep periodontal sites can be considered as a justified approach for non-surgical treatment of chronic periodontitis. Y Y Wennstrm J L JL Department of Periodontology, Institute of Odontology, Gteborg University, SE 405 30 Gteborg, Sweden. wennstrom@odontologi.gu.se Y Newman H N HN Y MacNeill S R SR Y Killoy W J WJ Y Griffiths G S GS Y Gillam D G DG Y Krok L L Y Needleman I G IG Y Weiss G G Y Garrett S S eng fre ger D016430 Clinical Trial D016428 Journal Article D016448 Multicenter Study D016449 Randomized Controlled Trial D013485 Research Support, Non-U.S. Gov\\'t United States J Clin Periodontol 0425123 0303-6979 0 D000900 Anti-Bacterial Agents N12000U13O D004318 Doxycycline D IM D000328 N Adult D000368 N Aged D000900 N Anti-Bacterial Agents Q000008 Y administration & dosage D002908 N Chronic Disease D002985 N Clinical Protocols D003362 N Cost-Benefit Analysis D003646 N Debridement D012534 N Dental Scaling Q000379 Y methods D004318 N Doxycycline Q000008 Y administration & dosage Q000031 N analogs & derivatives D004339 N Drug Compounding D005260 N Female D005884 N Gingival Hemorrhage Q000209 N etiology D006801 N Humans D008297 N Male D008875 N Middle Aged D010514 N Periodontal Pocket Q000473 N pathology D010518 N Periodontitis Q000150 N complications Q000188 N drug therapy Q000473 N pathology Q000628 Y therapy D011446 N Prospective Studies D016745 N Root Planing Q000379 N methods D016037 N Single-Blind Method D016896 N Treatment Outcome pubmed 2001 7 10 10 0 medline 2001 10 5 10 1 entrez 2001 7 10 10 0 ppublish pubmed 11442735 pii cpe280806 MEDLINE NLM 1 11237011 2001 03 22 2016 10 25 Print Print 0028-0836 Print 409 6822 2001 Feb 15 Nature Nature Initial sequencing and analysis of the human genome. 860-921 The human genome holds an extraordinary trove of information about human development, physiology, medicine and evolution. Here we report the results of an international collaboration to produce and make freely available a draft sequence of the human genome. We also present an initial analysis of the data, describing some of the insights that can be gleaned from the sequence. Y Y Lander E S ES Whitehead Institute for Biomedical Research, Center for Genome Research, Cambridge, MA 02142, USA. lander@genome.wi.mit.edu Y Linton L M LM Y Birren B B Y Nusbaum C C Y Zody M C MC Y Baldwin J J Y Devon K K Y Dewar K K Y Doyle M M Y FitzHugh W W Y Funke R R Y Gage D D Y Harris K K Y Heaford A A Y Howland J J Y Kann L L Y Lehoczky J J Y LeVine R R Y McEwan P P Y McKernan K K Y Meldrim J J Y Mesirov J P JP Y Miranda C C Y Morris W W Y Naylor J J Y Raymond C C Y Rosetti M M Y Santos R R Y Sheridan A A Y Sougnez C C Y Stange-Thomann Y Y Y Stojanovic N N Y Subramanian A A Y Wyman D D Y Rogers J J Y Sulston J J Y Ainscough R R Y Beck S S Y Bentley D D Y Burton J J Y Clee C C Y Carter N N Y Coulson A A Y Deadman R R Y Deloukas P P Y Dunham A A Y Dunham I I Y Durbin R R Y French L L Y Grafham D D Y Gregory S S Y Hubbard T T Y Humphray S S Y Hunt A A Y Jones M M Y Lloyd C C Y McMurray A A Y Matthews L L Y Mercer S S Y Milne S S Y Mullikin J C JC Y Mungall A A Y Plumb R R Y Ross M M Y Shownkeen R R Y Sims S S Y Waterston R H RH Y Wilson R K RK Y Hillier L W LW Y McPherson J D JD Y Marra M A MA Y Mardis E R ER Y Fulton L A LA Y Chinwalla A T AT Y Pepin K H KH Y Gish W R WR Y Chissoe S L SL Y Wendl M C MC Y Delehaunty K D KD Y Miner T L TL Y Delehaunty A A Y Kramer J B JB Y Cook L L LL Y Fulton R S RS Y Johnson D L DL Y Minx P J PJ Y Clifton S W SW Y Hawkins T T Y Branscomb E E Y Predki P P Y Richardson P P Y Wenning S S Y Slezak T T Y Doggett N N Y Cheng J F JF Y Olsen A A Y Lucas S S Y Elkin C C Y Uberbacher E E Y Frazier M M Y Gibbs R A RA Y Muzny D M DM Y Scherer S E SE Y Bouck J B JB Y Sodergren E J EJ Y Worley K C KC Y Rives C M CM Y Gorrell J H JH Y Metzker M L ML Y Naylor S L SL Y Kucherlapati R S RS Y Nelson D L DL Y Weinstock G M GM Y Sakaki Y Y Y Fujiyama A A Y Hattori M M Y Yada T T Y Toyoda A A Y Itoh T T Y Kawagoe C C Y Watanabe H H Y Totoki Y Y Y Taylor T T Y Weissenbach J J Y Heilig R R Y Saurin W W Y Artiguenave F F Y Brottier P P Y Bruls T T Y Pelletier E E Y Robert C C Y Wincker P P Y Smith D R DR Y Doucette-Stamm L L Y Rubenfield M M Y Weinstock K K Y Lee H M HM Y Dubois J J Y Rosenthal A A Y Platzer M M Y Nyakatura G G Y Taudien S S Y Rump A A Y Yang H H Y Yu J J Y Wang J J Y Huang G G Y Gu J J Y Hood L L Y Rowen L L Y Madan A A Y Qin S S Y Davis R W RW Y Federspiel N A NA Y Abola A P AP Y Proctor M J MJ Y Myers R M RM Y Schmutz J J Y Dickson M M Y Grimwood J J Y Cox D R DR Y Olson M V MV Y Kaul R R Y Raymond C C Y Shimizu N N Y Kawasaki K K Y Minoshima S S Y Evans G A GA Y Athanasiou M M Y Schultz R R Y Roe B A BA Y Chen F F Y Pan H H Y Ramser J J Y Lehrach H H Y Reinhardt R R Y McCombie W R WR Y de la Bastide M M Y Dedhia N N Y Blcker H H Y Hornischer K K Y Nordsiek G G Y Agarwala R R Y Aravind L L Y Bailey J A JA Y Bateman A A Y Batzoglou S S Y Birney E E Y Bork P P Y Brown D G DG Y Burge C B CB Y Cerutti L L Y Chen H C HC Y Church D D Y Clamp M M Y Copley R R RR Y Doerks T T Y Eddy S R SR Y Eichler E E EE Y Furey T S TS Y Galagan J J Y Gilbert J G JG Y Harmon C C Y Hayashizaki Y Y Y Haussler D D Y Hermjakob H H Y Hokamp K K Y Jang W W Y Johnson L S LS Y Jones T A TA Y Kasif S S Y Kaspryzk A A Y Kennedy S S Y Kent W J WJ Y Kitts P P Y Koonin E V EV Y Korf I I Y Kulp D D Y Lancet D D Y Lowe T M TM Y McLysaght A A Y Mikkelsen T T Y Moran J V JV Y Mulder N N Y Pollara V J VJ Y Ponting C P CP Y Schuler G G Y Schultz J J Y Slater G G Y Smit A F AF Y Stupka E E Y Szustakowki J J Y Thierry-Mieg D D Y Thierry-Mieg J J Y Wagner L L Y Wallis J J Y Wheeler R R Y Williams A A Y Wolf Y I YI Y Wolfe K H KH Y Yang S P SP Y Yeh R F RF Y Collins F F Y Guyer M S MS Y Peterson J J Y Felsenfeld A A Y Wetterstrand K A KA Y Patrinos A A Y Morgan M J MJ Y de Jong P P Y Catanese J J JJ Y Osoegawa K K Y Shizuya H H Y Choi S S Y Chen Y J YJ Y Szustakowki J J Y International Human Genome Sequencing Consortium eng Y U54 HG003273 HG NHGRI NIH HHS United States D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. D013487 Research Support, U.S. Gov\\'t, P.H.S. England Nature 0410462 0028-0836 0 D004251 DNA Transposable Elements 0 D011506 Proteins 0 D020543 Proteome 63231-63-0 D012313 RNA IM CommentIn Nature. 2001 Feb 15;409(6822):814-6 1 11236992 CommentIn Nature. 2001 Feb 15;409(6822):820-1 1 11236995 CommentIn Nature. 2001 Feb 15;409(6822):818-20 1 11236994 CommentIn Nature. 2001 Feb 15;409(6822):822-3 1 11236997 CommentIn Nature. 2001 Oct 18;413(6857):660 1 11606985 ErratumIn Nature 2001 Jun 7;411(6838):720 Szustakowki, J [corrected to Szustakowski, J] ErratumIn Nature 2001 Aug 2;412(6846):565 D000818 N Animals D002874 N Chromosome Mapping D017124 N Conserved Sequence D018899 N CpG Islands D004251 N DNA Transposable Elements D016208 N Databases, Factual D004345 N Drug Industry D019143 N Evolution, Molecular D005544 N Forecasting D020862 N GC Rich Sequence D020440 N Gene Duplication D005796 N Genes D030342 N Genetic Diseases, Inborn D005826 N Genetics, Medical D015894 Y Genome, Human D016045 Y Human Genome Project D006801 N Humans D009154 N Mutation D017149 N Private Sector D011506 N Proteins Q000235 N genetics D020543 N Proteome D017150 N Public Sector D012313 N RNA Q000235 N genetics D012091 N Repetitive Sequences, Nucleic Acid D017422 Y Sequence Analysis, DNA Q000379 N methods D013045 N Species Specificity pubmed 2001 3 10 10 0 medline 2001 3 27 10 1 entrez 2001 3 10 10 0 ppublish pubmed 11237011 doi 10.1038/35057062 MEDLINE NLM 1 11488864 2001 10 25 2013 11 21 Print Print 0905-7161 Print 12 4 2001 Aug Clinical oral implants research Clin Oral Implants Res Early endosseous integration enhanced by dual acid etching of titanium: a torque removal study in the rabbit. 350-7 Textured implant surfaces are thought to enhance endosseous integration. Torque removal forces have been used as a biomechanical measure of anchorage, or endosseous integration, in which the greater forces required to remove implants may be interpreted as an increase in the strength of bony integration. The purpose of this study was to compare the torque resistance to removal of screw-shaped titanium implants having a dual acid-etched surface (Osseotite) with implants having either a machined surface, or a titanium plasma spray surface that exhibited a significantly more complex surface topography. Three custom screw-shaped implant types - machined, dual acid-etched (DAE), and titanium plasma sprayed (TPS) - were used in this study. Each implant surface was characterized by scanning electron microscopy and optical profilometry. One DAE implant was placed into each distal femur of eighteen adult New Zealand White rabbits along with one of the other implant types. Thus, each rabbit received two DAE implants and one each of the machined, or TPS, implants. All implants measured 3.25 mm in diameter x 4.00 mm in length without holes, grooves or slots to resist rotation. Eighteen rabbits were used for reverse torque measurements. Groups of six rabbits were sacrificed following one, two and three month healing periods. Implants were removed by reverse torque rotation with a digital torque-measuring device. Three implants with the machined surface preparation failed to achieve endosseous integration. All other implants were anchored by bone. Mean torque values for machined, DAE and TPS implants at one, two and three months were 6.00+/-0.64 N-cm, 9.07+/-0.67 N-cm and 6.73+/-0.95 N-cm; 21.86+/-1.37 N-cm, 27.63+/-3.41 N-cm and 27.40+/-3.89 N-cm; and 27.48+/-1.61 N-cm, 44.28+/-4.53 N-cm and 59.23+/-3.88 N-cm, respectively. Clearly, at the earliest time point the stability of DAE implants was comparable to that of TPS implants, while that of the machined implants was an order of magnitude lower. The TPS implants increased resistance to reverse torque removal over the three-month period. The results of this study confirm our previous results that demonstrated enhanced bony anchorage to dual acid-etched implants as compared to machined implants. Furthermore, the present results indicate that dual acid etching of titanium enhances early endosseous integration to a level which is comparable to that achieved by the topographically more complex TPS surfaces. Y Y Klokkevold P R PR Division of Associated Specialties, Section of Periodontics, UCLA School of Dentistry, Los Angeles, CA 90095, USA. pklok@ucla.edu Y Johnson P P Y Dadgostari S S Y Caputo A A Y Davies J E JE Y Nishimura R D RD eng fre ger D003160 Comparative Study D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Denmark Clin Oral Implants Res 9105713 0905-7161 0 D020099 Coated Materials, Biocompatible 0 D015921 Dental Implants 0 D013464 Sulfuric Acids D1JT611TNE D014025 Titanium O40UQP6WCF C033158 sulfuric acid QTT17582CB D006851 Hydrochloric Acid D D000704 N Analysis of Variance D000818 N Animals D020099 N Coated Materials, Biocompatible D003758 N Dental Implantation, Endosseous D015921 Y Dental Implants D003775 N Dental Polishing D017267 Y Dental Prosthesis Design D020878 N Device Removal D005269 N Femur D006851 N Hydrochloric Acid D020007 Y Implants, Experimental D008669 N Metallurgy D016348 Y Osseointegration D011817 N Rabbits D013464 N Sulfuric Acids D013499 N Surface Properties D014025 Y Titanium D019415 N Torque pubmed 2001 8 8 10 0 medline 2001 10 26 10 1 entrez 2001 8 8 10 0 ppublish pubmed 11488864 pii clr120409 MEDLINE NLM 1 11473127 2001 11 01 2013 11 21 Print-Electronic Print 0021-9258 Print 276 39 2001 Sep 28 The Journal of biological chemistry J. Biol. Chem. Evidence that ligand and metal ion binding to integrin alpha 4beta 1 are regulated through a coupled equilibrium. 36520-9 We have used the highly selective alpha(4)beta(1) inhibitor 2S-[(1-benzenesulfonyl-pyrrolidine-2S-carbonyl)-amino]-4-[4-methyl-2S-(methyl-[2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl]-amino)-pentanoylamino]-butyric acid (BIO7662) as a model ligand to study alpha(4)beta(1) integrin-ligand interactions on Jurkat cells. Binding of [(35)S]BIO7662 to Jurkat cells was dependent on the presence of divalent cations and could be blocked by treatment with an excess of unlabeled inhibitor or with EDTA. K(D) values for the binding of BIO7662 to Mn(2+)-activated alpha(4)beta(1) and to the nonactivated state of the integrin that exists in 1 mm Mg(2+), 1 mm Ca(2+) were <10 pm, indicating that it has a high affinity for both activated and nonactivated integrin. No binding was observed on alpha(4)beta(1) negative cells. Through an analysis of the metal ion dependences of ligand binding, several unexpected findings about alpha(4)beta(1) function were made. First, we observed that Ca(2+) binding to alpha(4)beta(1) was stimulated by the addition of BIO7662. From solution binding studies on purified alpha(4)beta(1), two types of Ca(2+)-binding sites were identified, one dependent upon and the other independent of BIO7662 binding. Second, we observed that the metal ion dependence of ligand binding was affected by the affinity of the ligand for alpha(4)beta(1). ED(50) values for the metal ion dependence of the binding of BIO7762 and the binding of a lower affinity ligand, BIO1211, differed by 2-fold for Mn(2+), 30-fold for Mg(2+), and >1000-fold for Ca(2+). Low Ca(2+) (ED(50) = 5-10 microm) stimulated the binding of BIO7662 to alpha(4)beta(1). The effects of microm Ca(2+) closely resembled the effects of Mn(2+) on alpha(4)beta(1) function. Third, we observed that the rate of BIO7662 binding was dependent on the metal ion concentration and that the ED(50) for the metal ion dependence of BIO7662 binding was affected by the concentration of the BIO7662. These studies point to an even more complex interplay between metal ion and ligand binding than previously appreciated and provide evidence for a three-component coupled equilibrium model for metal ion-dependent binding of ligands to alpha(4)beta(1). Y Y Chen L L LL Biogen, Inc., Cambridge, Massachusetts 02142, USA. Y Whitty A A Y Scott D D Y Lee W C WC Y Cornebise M M Y Adams S P SP Y Petter R C RC Y Lobb R R RR Y Pepinsky R B RB eng D016428 Journal Article Electronic 2001 07 25 United States J Biol Chem 2985121R 0021-9258 0 C438014 2-((1-benzenesulfonylpyrrolidine-2-carbonyl)amino)-4-(4-methyl-2-(methyl-(2-(4-(3-o-tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid 0 D001565 Benzoates 0 D002412 Cations 0 D004151 Dipeptides 0 D039041 Integrin alpha4beta1 0 D016023 Integrins 0 D007477 Ions 0 D008024 Ligands 0 D010671 Phenylurea Compounds 0 D016201 Receptors, Lymphocyte Homing 42Z2K6ZL8P D008345 Manganese 9G34HU7RV0 D004492 Edetic Acid I38ZP9992A D008274 Magnesium SY7Q814VUP D002118 Calcium IM D001565 N Benzoates Q000494 N pharmacology D002118 N Calcium Q000378 N metabolism Q000494 N pharmacology D002412 N Cations D004151 N Dipeptides Q000494 N pharmacology D004305 N Dose-Response Relationship, Drug D004492 N Edetic Acid Q000494 N pharmacology D006801 N Humans D039041 N Integrin alpha4beta1 D016023 N Integrins Q000037 N antagonists & inhibitors Q000737 Y chemistry Q000378 Y metabolism D007477 Y Ions D019169 N Jurkat Cells D007700 N Kinetics D008024 Y Ligands D008274 N Magnesium Q000494 N pharmacology D008345 N Manganese Q000494 N pharmacology D008956 N Models, Chemical D010671 N Phenylurea Compounds Q000494 N pharmacology D011485 N Protein Binding D016201 N Receptors, Lymphocyte Homing Q000037 N antagonists & inhibitors Q000737 Y chemistry Q000378 Y metabolism D013997 N Time Factors pubmed 2001 7 27 10 0 medline 2001 11 3 10 1 entrez 2001 7 27 10 0 ppublish pubmed 11473127 doi 10.1074/jbc.M106216200 pii M106216200 MEDLINE NLM 1 11488868 2001 10 25 2012 11 15 Print Print 0905-7161 Print 12 4 2001 Aug Clinical oral implants research Clin Oral Implants Res Histology of human alveolar bone regeneration with a porous tricalcium phosphate. A report of two cases. 379-84 Porous beta-phase tricalcium phosphate particles (pTCP) (Cerasorb) were used in two patients to restore or augment alveolar bone prior to the placement of dental implants. In one patient, pTCP was used to fill a large alveolar defect in the posterior mandible after the removal of a residual cyst, and in another patient to augment the sinus floor. Biopsies were taken at the time of implant placement, 9.5 and 8 months after grafting, respectively, and processed for hard tissue histology. Goldner-stained histological sections showed considerable replacement of the bone substitute by bone and bone marrow. In the 9.5 months biopsy of the mandible, 34% of the biopsy consisted of mineralised bone tissue and 29% of remaining pTCP, while the biopsy at 8 months after sinus floor augmentation consisted of 20% mineralised bone and 44% remaining pTCP. Bone and osteoid were lying in close contact with the remaining pTCP and were also seen within the micropores of the grafted particles. Tartrate resistant-acid phosphatase (TRAP) multinuclear cells, presumably osteoclasts, were found surrounding, within and in close contact with the pTCP particles, suggesting active resorption of the bone substitute. Remodelling of immature woven bone into mature lamellar bone was also found. No histological signs of inflammation were detected. The limited data presented from these two cases suggest that this graft material, possibly by virtue of its porosity and chemical nature, may be a suitable bone substitute that can biodegrade and be replaced by new mineralising bone tissue. Y Y Zerbo I R IR Department of Oral Cell Biology, ACTA, Vrije Universiteit, Vander Boechorststraat 7, 1081 BT Amsterdam, Netherlands. IR.Zerbo.Ocb.ACTA@med.vu.nl Y Bronckers A L AL Y de Lange G L GL Y van Beek G J GJ Y Burger E H EH eng D002363 Case Reports D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Denmark Clin Oral Implants Res 9105713 0905-7161 0 D018786 Bone Substitutes 0 D002130 Calcium Phosphates 0 C485817 beta-tricalcium phosphate K4C08XP666 C018392 tricalcium phosphate D D020341 N Absorbable Implants D000368 N Aged D000540 N Alveolar Ridge Augmentation Q000379 N methods D001861 N Bone Regeneration Q000187 Y drug effects D018786 N Bone Substitutes Q000494 Y pharmacology D002130 N Calcium Phosphates Q000494 Y pharmacology D006801 N Humans D008297 N Male D008334 N Mandible Q000601 N surgery D008443 N Maxillary Sinus Q000601 N surgery D008875 N Middle Aged D013516 Y Oral Surgical Procedures, Preprosthetic D016062 N Porosity pubmed 2001 8 8 10 0 medline 2001 10 26 10 1 entrez 2001 8 8 10 0 ppublish pubmed 11488868 pii clr120413 MEDLINE NLM 1 11520209 2001 09 27 2013 11 21 Print Print 0022-2623 Print 44 18 2001 Aug 30 Journal of medicinal chemistry J. Med. Chem. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. 3001-13 This paper describes the synthesis of a series of azo compounds able to deliver 5-aminosalicylic acid (5-ASA) and a potent platelet activating factor (PAF) antagonist in a colon-specific manner for the purpose of treating ulcerative colitis. We found it possible to add an amino group on the aromatic moiety of our reported 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives or on British Biotech compounds BB-882 and BB-823 maintaining a high level of activity as PAF antagonist. A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats. Through attachment of 49c to the 5-ASA via azo functionality we obtained UR-12746 (70). Pharmacokinetics experiments with [14C]-70 allow us to reach the following conclusions, critical in the design of these new prodrugs of 5-ASA. Neither the whole molecule 70 nor the carrier 49c were absorbed after oral administration of [14C]-70 in rat as was demonstrated by the absence of plasma levels of radioactivity and the high recovery of it in feces. Effective cleavage of azo bond (84%) by microflora in the colon is achieved. These facts ensure high topical concentrations of 5-ASA and 49c in the colon. Additionally, 70 exhibited a potent anticolitic effect in the trinitrobenzenesulfonic acid-induced colitis model in the rat. This profile suggests that UR-12746 (70) provides an attractive new approach to the treatment of ulcerative colitis. Y Y Carceller E E Research Center, J. Uriach & Ca.S.A., Deg Bah 59-67, 08026 Barcelona, Spain. chem-carceller@uriach.com Y Salas J J Y Merlos M M Y Giral M M Y Ferrando R R Y Escamilla I I Y Ramis J J Y Garca-Rafanell J J Y Forn J J eng D016428 Journal Article United States J Med Chem 9716531 0022-2623 0 C435198 1-((1-(3-(4-aminophenyl)-3-phenylpropenoyl)-4-piperidyl)methyl)-1H-2-methylimidazo(4,5-c)pyridine 0 D000588 Amines 0 D000636 Aminosalicylic Acids 0 D000894 Anti-Inflammatory Agents, Non-Steroidal 0 D001372 Aza Compounds 0 D001391 Azo Compounds 0 D007093 Imidazoles 0 D010972 Platelet Activating Factor 0 D011355 Prodrugs 0 D011725 Pyridines 0 C419382 UR 12746 4Q81I59GXC D019804 Mesalamine 8T3HQG2ZC4 D014302 Trinitrobenzenesulfonic Acid IM D000588 N Amines Q000138 N chemical synthesis Q000737 N chemistry Q000494 N pharmacology D000636 N Aminosalicylic Acids D000818 N Animals D000894 N Anti-Inflammatory Agents, Non-Steroidal Q000138 Y chemical synthesis Q000737 N chemistry Q000493 N pharmacokinetics Q000494 N pharmacology D001372 N Aza Compounds Q000138 Y chemical synthesis Q000737 N chemistry Q000494 N pharmacology D001391 N Azo Compounds Q000138 Y chemical synthesis Q000737 N chemistry Q000493 N pharmacokinetics Q000494 N pharmacology D003093 N Colitis, Ulcerative Q000139 N chemically induced Q000188 N drug therapy D004353 N Drug Evaluation, Preclinical D005260 N Female D007022 N Hypotension Q000188 N drug therapy D007093 N Imidazoles Q000138 Y chemical synthesis Q000737 N chemistry Q000494 N pharmacology D008297 N Male D019804 N Mesalamine Q000138 Y chemical synthesis Q000737 Y chemistry Q000494 N pharmacology D010972 N Platelet Activating Factor Q000037 Y antagonists & inhibitors D010974 N Platelet Aggregation Q000187 N drug effects D011355 N Prodrugs Q000138 Y chemical synthesis Q000737 N chemistry Q000493 N pharmacokinetics Q000494 N pharmacology D011725 N Pyridines Q000138 Y chemical synthesis Q000737 N chemistry Q000494 N pharmacology D051381 N Rats D017207 N Rats, Sprague-Dawley D017208 N Rats, Wistar D013237 N Stereoisomerism D013329 N Structure-Activity Relationship D014302 N Trinitrobenzenesulfonic Acid pubmed 2001 8 25 10 0 medline 2001 9 28 10 1 entrez 2001 8 25 10 0 ppublish pubmed 11520209 pii jm010852p MEDLINE NLM 1 11525160 2001 08 30 2004 11 17 Print Print 0250-5525 Print 124 2000 Schweizerische medizinische Wochenschrift. Supplementum Schweiz Med Wochenschr Suppl 32nd Annual meeting of the Swiss Society of Nephrology. Lausanne, 14-15 December 2000. Abstracts. 1S-20S eng fre ger D016423 Congresses D016424 Overall Switzerland Schweiz Med Wochenschr Suppl 7708316 0250-5525 IM D000818 N Animals D006801 N Humans D007674 Y Kidney Diseases D009398 Y Nephrology pubmed 2001 8 30 10 0 medline 2001 8 31 10 1 entrez 2001 8 30 10 0 ppublish pubmed 11525160 MEDLINE NLM 1 11524736 2001 12 12 2016 11 24 Print Electronic 1098-1004 Internet 18 3 2001 Sep Human mutation Hum. Mutat. Detection of six novel FBN1 mutations in British patients affected by Marfan syndrome. 251 Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular matrix, is due to mutations in fibrillin-1 (FBN1) gene. Investigations carried out in the last decade, unveiled the unpredictability of the site of the mutation, which could be anywhere in the gene. FBN1 mutations have been reported in a spectrum of diseases related to MFS, with no clear evidence for a phenotype-genotype correlation. In this paper we analysed 10 British patients affected by MFS and we were able to characterise five novel missense mutations (C474W, C1402Y, G1987R, C2153Y, G2536R), one novel frameshift mutation (7926delC), one already described mutation (P1424A) and one FBN1 variant (P1148A) classified as a polymorphism in the Asian population. Four out of the five novel missense mutations involved either cysteines or an amino acid conserved in the domain structure. The mutation yield in this study is calculated at 80.0% (8/10), thus indicating that SSCA is a reliable and cost-effective technique for the screening of such a large gene. Our results suggest that this method is reliable to search for FBN1 mutations and that FBN1 screening could be a helpful tool to confirm and possibly anticipate the clinical diagnosis in familial cases. Hum Mutat 18:251, 2001. Copyright 2001 Wiley-Liss, Inc. Y Y Comeglio P P Department of Cardiological Sciences, St. George\\'s Hospital Medical School, London, UK. p.comeglio@sghms.ac.uk Y Evans A L AL Y Brice G W GW Y Child A H AH eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States Hum Mutat 9215429 1059-7794 0 C000605722 FBN1 protein, human 0 D000071838 Fibrillin-1 0 D000071837 Fibrillins 0 D008840 Microfilament Proteins IM RepublishedIn Hum Mutat. 2001 Dec;18(6):546-7 1 11748851 D000328 N Adult D001483 N Base Sequence D002675 N Child, Preschool D005260 N Female D000071838 N Fibrillin-1 D000071837 N Fibrillins D016368 N Frameshift Mutation D006801 N Humans D008297 N Male D008382 N Marfan Syndrome Q000235 Y genetics D008840 N Microfilament Proteins Q000235 Y genetics D008875 N Middle Aged D009154 N Mutation D020125 N Mutation, Missense D017384 N Sequence Deletion D006113 N United Kingdom pubmed 2001 8 29 10 0 medline 2002 1 5 10 1 entrez 2001 8 29 10 0 ppublish pubmed 11524736 pii 10.1002/humu.1181 doi 10.1002/humu.1181 MEDLINE NASA 1 11537092 1995 06 16 2017 08 16 Print Print 0033-183X Print 163 1991 Protoplasma Protoplasma Cytoplasmic calcium levels in protoplasts from the cap and elongation zone of maize roots. 181-8 Calcium has been implicated as a key component in the signal transduction process of root gravitropism. We measured cytoplasmic free calcium in protoplasts isolated from the elongation zone and cap of primary roots of light-grown, vertically oriented seedlings of Zea mays L. Protoplasts were loaded with the penta-potassium salts of fura-2 and indo-1 by incubation in acidic solutions of these calcium indicators. Loading increased with decreasing pH but the pH dependence was stronger for indo-1 than for fura-2. In the case of fura-2, loading was enhanced only at the lowest pH (4.5) tested. Dyes loaded in this manner were distributed predominantly in the cytoplasm as indicated by fluorescence patterns. As an alternative method of loading, protoplasts were incubated with the acetoxymethylesters of fura-2 and indo-1. Protoplasts loaded by this method exhibited fluorescence both in the cytoplasm and in association with various organelles. Cytoplasmic calcium levels measured using spectrofluorometry, were found to be 160 +/- 40 nM and 257 +/- 27 nM, respectively, in populations of protoplasts from the root cap and elongation zone. Cytoplasmic free calcium did not increase upon addition of calcium to the incubation medium, indicating that the passive permeability to calcium was low. Y Y Kiss H G HG Department of Plant Biology, Ohio State University, Columbus. Y Evans M L ML Y Johnson J D JD eng Y DMB 8608673 MB BHP HRSA HHS United States D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. Austria Protoplasma 9806853 0033-183X 0 D005456 Fluorescent Dyes 0 D007211 Indoles N18RMK75W1 C048960 indo-1 SY7Q814VUP D002118 Calcium TSN3DL106G D016257 Fura-2 S Cites Plant Physiol. 1990;92:792-6 1 11537998 Cites Plant Physiol. 1988;87:803-5 1 11537876 Cites Plant Physiol. 1989;89:875-8 1 11537451 Cites Stain Technol. 1985 Mar;60(2):69-79 1 2580370 Cites Plant Physiol. 1983 Dec;73(4):874-6 1 16663333 Cites Plant Physiol. 1982 Nov;70(5):1391-5 1 16662685 Cites Plant Physiol. 1989 Aug;90(4):1271-4 1 16666921 Cites Planta. 1984;160:536-43 1 11540830 Cites Plant Physiol. 1988;86:885-9 1 11538239 Cites Plant Physiol. 1990 Jul;93(3):841-5 1 16667590 Cites Science. 1983 Jun 24;220(4604):1375-6 1 17730651 Cites CRC Crit Rev Plant Sci. 1987;6(1):47-103 1 11540070 Cites J Biol Chem. 1985 Mar 25;260(6):3440-50 1 3838314 Cites Plant Physiol. 1989 Jun;90(2):482-91 1 16666797 Cites Planta. 1988 Dec;174(4):495-9 1 24221565 Cites Anal Biochem. 1985 May 1;146(2):349-52 1 3927770 Cites Sci Am. 1986 Dec;255(6):112-9 1 11536593 Cites Cell Calcium. 1987 Dec;8(6):455-72 1 3435914 Cites Plant Physiol. 1981 Aug;68(2):435-8 1 16661931 Cites Plant Physiol. 1984 Oct;76(2):342-6 1 16663844 Cites Nature. 1990 Jun 7;345:528-30 1 11540625 D002118 N Calcium Q000032 Y analysis Q000502 Y physiology D003593 N Cytoplasm Q000737 Y chemistry D005456 N Fluorescent Dyes D016257 N Fura-2 D018522 N Gravitropism Q000502 N physiology D018466 N Gravity Sensing Q000502 N physiology D007211 N Indoles D018518 N Plant Root Cap Q000166 N cytology Q000254 N growth & development Q000502 N physiology D018517 N Plant Roots Q000166 N cytology Q000254 Y growth & development Q000502 N physiology D011523 N Protoplasts Q000737 Y chemistry Q000502 N physiology D015398 N Signal Transduction D003313 N Zea mays Q000166 N cytology Q000254 N growth & development Q000502 N physiology NASA 00015446 NASA N NASA Discipline Number 40-50 N NASA Discipline Plant Biology N NASA Program Space Biology N Non-NASA Center Y Evans M L ML Ohio St U, Columbus, Dept Physiological Chemistry NASA Grant numbers: NAGW 297 pubmed 1991 1 1 0 0 medline 2001 9 11 10 1 entrez 1991 1 1 0 0 ppublish pubmed 11537092 MEDLINE NASA 1 11540070 1995 12 11 2013 11 21 Print Print 0735-2689 Print 6 1 1987 Critical reviews in plant sciences CRC Crit Rev Plant Sci Calcium messenger system in plants. 47-103 Y Y Poovaiah B W BW Department of Horticulture, Washington State University, Pullman, USA. Y Reddy A S AS eng Y DCB-8502215 DC NIDCD NIH HHS United States D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. D013487 Research Support, U.S. Gov\\'t, P.H.S. D016454 Review United States CRC Crit Rev Plant Sci 9889759 0735-2689 0 D002135 Calcium-Binding Proteins 0 D002147 Calmodulin 0 D010937 Plant Growth Regulators EC 2.7.11.17 D017871 Calcium-Calmodulin-Dependent Protein Kinases SY7Q814VUP D002118 Calcium S D000595 N Amino Acid Sequence D002118 N Calcium Q000502 Y physiology D002135 N Calcium-Binding Proteins Q000502 N physiology D017871 N Calcium-Calmodulin-Dependent Protein Kinases Q000378 N metabolism D002147 N Calmodulin Q000378 N metabolism D018506 Y Gene Expression Regulation, Plant D018522 N Gravitropism Q000502 N physiology D008969 N Molecular Sequence Data D059828 N Plant Cells D010937 N Plant Growth Regulators Q000378 N metabolism D018521 Y Plant Physiological Phenomena D010944 N Plants Q000235 Y genetics D015290 Y Second Messenger Systems D015398 N Signal Transduction Q000502 N physiology 363 NASA 00012050 NASA eng The purpose of this review is to delineate the ubiquitous and pivotal role of Ca2+ in diverse physiological processes. Emphasis will be given to the role of Ca2+ in stimulus-response coupling. In addition to reviewing the present status of research, our intention is to critically evaluate the existing data and describe the newly developing areas of Ca2+ research in plants. NASA N NASA Discipline Number 40-30 N NASA Discipline Plant Biology N NASA Program Space Biology N Non-NASA Center Y Poovaiah B W BW WA St U, Pullman, Dept Horticulture NASA Grant numbers: NAG-10-0032 pubmed 1987 1 1 0 0 medline 2001 9 11 10 1 entrez 1987 1 1 0 0 ppublish pubmed 11540070 doi 10.1080/07352688709382247 MEDLINE NLM 1 11543891 2001 09 27 2011 11 17 Print Print 0198-8859 Print 62 9 2001 Sep Human immunology Hum. Immunol. The origin of Palestinians and their genetic relatedness with other Mediterranean populations. 889-900 The genetic profile of Palestinians has, for the first time, been studied by using human leukocyte antigen (HLA) gene variability and haplotypes. The comparison with other Mediterranean populations by using neighbor-joining dendrograms and correspondence analyses reveal that Palestinians are genetically very close to Jews and other Middle East populations, including Turks (Anatolians), Lebanese, Egyptians, Armenians, and Iranians. Archaeologic and genetic data support that both Jews and Palestinians came from the ancient Canaanites, who extensively mixed with Egyptians, Mesopotamian, and Anatolian peoples in ancient times. Thus, Palestinian-Jewish rivalry is based in cultural and religious, but not in genetic, differences. The relatively close relatedness of both Jews and Palestinians to western Mediterranean populations reflects the continuous circum-Mediterranean cultural and gene flow that have occurred in prehistoric and historic times. This flow overtly contradicts the demic diffusion model of western Mediterranean populations substitution by agriculturalists coming from the Middle East in the Mesolithic-Neolithic transition. Y Y Arnaiz-Villena A A Department of Immunology and Molecular Biology, H. 12 de Octubre, Universidad Complutense, Madrid, Spain. aarnaiz@eucmax.sim.ucm.es Y Elaiwa N N Y Silvera C C Y Rostom A A Y Moscoso J J Y Gmez-Casado E E Y Allende L L Y Varela P P Y Martnez-Laso J J eng D003160 Comparative Study D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t D016441 Retracted Publication United States Hum Immunol 8010936 0198-8859 0 D006680 HLA Antigens 0 D015234 HLA-A Antigens 0 D015235 HLA-B Antigens 0 D006683 HLA-DQ Antigens 0 D059866 HLA-DQ beta-Chains 0 C069051 HLA-DQB1 antigen 0 D006684 HLA-DR Antigens 0 D059811 HLA-DRB1 Chains IM CommentIn Hum Immunol. 2001 Oct;62(10):1064 1 11600211 RetractionIn Suciu-Foca N, Lewis R. Hum Immunol. 2001 Oct;62(10):1063 1 11600210 D000483 N Alleles D018912 N Arabs Q000235 N genetics D005787 N Gene Frequency D006115 N Geographic Greece Q000208 N ethnology D006680 N HLA Antigens Q000235 Y genetics D015234 N HLA-A Antigens Q000235 N genetics D015235 N HLA-B Antigens Q000235 N genetics D006683 N HLA-DQ Antigens D059866 N HLA-DQ beta-Chains D006684 N HLA-DR Antigens Q000235 N genetics D059811 N HLA-DRB1 Chains D006239 N Haplotypes Q000235 N genetics D006801 N Humans D007514 N Islam D007557 N Geographic Israel D007585 N Jews Q000235 N genetics D015810 N Linkage Disequilibrium D019083 N Geographic Mediterranean Region D008877 N Geographic Middle East D010802 N Phylogeny D011110 N Polymorphism, Genetic Q000235 N genetics pubmed 2001 9 7 10 0 medline 2001 9 28 10 1 entrez 2001 9 7 10 0 ppublish pubmed 11543891 pii S0198885901002889 PubMed-not-MEDLINE NLM 1 11567133 2001 10 04 2007 03 19 Print Print 0036-8075 Print 293 5538 2001 Sep 21 Science (New York, N.Y.) Science Changes in seismic anisotropy after volcanic eruptions: evidence from Mount Ruapehu. 2231-3 The eruptions of andesite volcanoes are explosively catastrophic and notoriously difficult to predict. Yet changes in shear waveforms observed after an eruption of Mount Ruapehu, New Zealand, suggest that forces generated by such volcanoes are powerful and dynamic enough to locally overprint the regional stress regime, which suggests a new method of monitoring volcanoes for future eruptions. These results show a change in shear-wave polarization with time and are interpreted as being due to a localized stress regime caused by the volcano, with a release in pressure after the eruption. Y Y Miller V V Institute of Geophysics, Victoria University of Wellington, Wellington, New Zealand. Y Savage M M eng D016428 Journal Article United States Science 0404511 0036-8075 pubmed 2001 9 22 10 0 medline 2001 9 22 10 1 entrez 2001 9 22 10 0 ppublish pubmed 11567133 doi 10.1126/science.1063463 pii 293/5538/2231 MEDLINE NLM 1 11562649 2002 02 22 2014 11 20 Print Print 0891-5245 Print 15 5 2001 Sep-Oct Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners J Pediatr Health Care Educating parents about normal stool pattern changes in infants. 269-74 Y Y Arias A A Pediatric Nurse Practitioner Program at Ohio State University College of Nursing, Columbus, USA. Y Bennison J J Y Justus K K Y Thurman D D eng D016428 Journal Article D016454 Review United States J Pediatr Health Care 8709735 0891-5245 N SummaryForPatientsIn J Pediatr Health Care. 2001 Sep-Oct;15(5):270-1 1 11858131 D000293 N Adolescent D002648 N Child D002675 N Child, Preschool D003258 N Consumer Behavior D003672 Y Defecation D005243 Y Feces Q000737 N chemistry D006266 N Health Education Q000379 Y methods D006801 N Humans D007223 N Infant D007231 N Infant, Newborn D009820 N Geographic Ohio D016487 Y Parenting 13 pubmed 2001 9 20 10 0 medline 2002 2 23 10 1 entrez 2001 9 20 10 0 ppublish pubmed 11562649 pii S0891-5245(01)91970-4 doi 10.1067/mph.2000.118432 MEDLINE NLM 1 11580607 2001 10 25 2006 11 15 Print-Electronic Print 0031-9007 Print 87 13 2001 Sep 24 Physical review letters Phys. Rev. Lett. Maximal height scaling of kinetically growing surfaces. 136101 The scaling properties of the maximal height of a growing self-affine surface with a lateral extent L are considered. In the late-time regime its value measured relative to the evolving average height scales like the roughness: h*(L) approximately L alpha. For large values its distribution obeys logP(h*(L)) approximately (-)A(h*(L)/L(alpha))(a). In the early-time regime where the roughness grows as t(beta), we find h*(L) approximately t(beta)[lnL-(beta/alpha)lnt+C](1/b), where either b = a or b is the corresponding exponent of the velocity distribution. These properties are derived from scaling and extreme-value arguments. They are corroborated by numerical simulations and supported by exact results for surfaces in 1D with the asymptotic behavior of a Brownian path. Y Y Raychaudhuri S S Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA. Y Cranston M M Y Przybyla C C Y Shapir Y Y eng D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. Electronic 2001 09 05 United States Phys Rev Lett 0401141 0031-9007 IM D001419 N Bacteria Q000254 N growth & development D003460 N Crystallization D007700 N Kinetics D008962 Y Models, Theoretical D013499 N Surface Properties received 2001 05 07 pubmed 2001 10 3 10 0 medline 2001 10 26 10 1 entrez 2001 10 3 10 0 ppublish pubmed 11580607 doi 10.1103/PhysRevLett.87.136101 MEDLINE NASA 1 11583040 2001 10 04 2006 11 15 Print Print 0084-6597 Print 28 2000 Annual review of earth and planetary sciences Annu Rev Earth Planet Sci Understanding oblique impacts from experiments, observations, and modeling. 141-67 Natural impacts in which the projectile strikes the target vertically are virtually nonexistent. Nevertheless, our inherent drive to simplify nature often causes us to suppose most impacts are nearly vertical. Recent theoretical, observational, and experimental work is improving this situation, but even with the current wealth of studies on impact cratering, the effect of impact angle on the final crater is not well understood. Although craters\\' rims may appear circular down to low impact angles, the distribution of ejecta around the crater is more sensitive to the angle of impact and currently serves as the best guide to obliquity of impacts. Experimental studies established that crater dimensions depend only on the vertical component of the impact velocity. The shock wave generated by the impact weakens with decreasing impact angle. As a result, melting and vaporization depend on impact angle; however, these processes do not seem to depend on the vertical component of the velocity alone. Finally, obliquity influences the fate of the projectile: in particular, the amount and velocity of ricochet are a strong function of impact angle. Y Y Pierazzo E E Lunar and Planetary Lab., University of Arizona, Tucson, 84721, USA. betty@lpl.arizona.edu Y Melosh H J HJ eng D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. D016454 Review United States Annu Rev Earth Planet Sci 100971465 0084-6597 S D003198 N Computer Simulation D019419 Y Evolution, Planetary D006112 N Gravitation D019110 Y Meteoroids D008962 Y Models, Theoretical D016081 N Moon D016083 Y Planets 96 NASA 00026602 NASA N NASA Discipline Exobiology N Non-NASA Center Y Melosh H J HJ U AZ, Tucson NASA Grant numbers: NAGW-5159, NAGW-428. pubmed 2001 10 5 10 0 medline 2001 10 5 10 1 entrez 2001 10 5 10 0 ppublish pubmed 11583040 doi 10.1146/annurev.earth.28.1.141 MEDLINE NLM 1 11600210 2001 10 25 2001 10 15 Print Print 0198-8859 Print 62 10 2001 Oct Human immunology Hum. Immunol. Editorial. Anthropology and genetic markers. 1063 Y Y Suciu-Foca N N Y Lewis R R eng D016440 Retraction of Publication United States Hum Immunol 8010936 0198-8859 IM RetractionOf Arnaiz-Villena A, Elaiwa N, Silvera C, Rostom A, Moscoso J, Gmez-Casado E, Allende L, Varela P, Martnez-Laso J. Hum Immunol. 2001 Sep;62(9):889-900 1 11543891 pubmed 2001 10 16 10 0 medline 2001 10 16 10 1 entrez 2001 10 16 10 0 ppublish pubmed 11600210 pii S0198885901003500 MEDLINE NLM 1 11600211 2001 10 25 2004 11 17 Print Print 0198-8859 Print 62 10 2001 Oct Human immunology Hum. Immunol. Letter from the ASHI president and council. 1064 Y Y Tyan D B DB eng D016420 Comment D016422 Letter United States Hum Immunol 8010936 0198-8859 IM CommentOn Hum Immunol. 2001 Sep;62(9):889-900 1 11543891 D004992 Y Ethics, Medical D006648 Y Histocompatibility D006801 N Humans D007125 Y Immunogenetics D011643 Y Publishing D012955 N Societies, Medical D014481 N Geographic United States pubmed 2001 10 16 10 0 medline 2001 10 26 10 1 entrez 2001 10 16 10 0 ppublish pubmed 11600211 pii S0198-8859(01)00357-3 MEDLINE HMD 1 11612527 1991 03 18 2014 11 20 Print Print 0032-4728 Print 44 3 1990 Nov Population studies Popul Stud (Camb) On the origins of the United States Government\\'s international population policy. 385-99 Y Y Donaldson P J PJ eng D016456 Historical Article D016428 Journal Article England Popul Stud (Camb) 0376427 0032-4728 E Q QO D003710 Y Demography D014943 Y Global Health D049711 N History, Modern 1601- D011057 Y Politics D013223 N Statistics as Topic Q000266 Y history D014481 N Geographic United States NRCBL 36117 KIE N Agency for International Development N Genetics and Reproduction KIE 50 fn. KIE KIE Bib: population control pubmed 1990 11 1 0 0 medline 2001 10 31 10 1 entrez 1990 11 1 0 0 ppublish pubmed 11612527 doi 10.1080/0032472031000144816 MEDLINE HMD 1 11620107 1988 11 16 2016 10 21 Print Print 0511-0726 Print 24 1984 A.A.G. bijdragen A A G Bijdr Demographic transition in the Netherlands: a statisticsl analysis of regional differences in the level and development of the birth rate and of fertility, 1850-1890. 1-57 Y Y Boonstra O W OW Y van der Woude A M AM eng D016456 Historical Article D016428 Journal Article Netherlands A A G Bijdr 100966038 0511-0726 Q QO D003710 Y Demography D049711 N History, Modern 1601- D009426 N Geographic Netherlands D013223 N Statistics as Topic Q000266 Y history pubmed 1984 1 1 0 0 medline 2001 10 31 10 1 entrez 1984 1 1 0 0 ppublish pubmed 11620107 MEDLINE HMD 1 11675721 1976 07 01 2016 11 23 Print Print 0024-2160 Print 2 2 1974 Jun The Library Library (Lond) Thomas Dover\\'s \"Ancient physician\\'s legacy\". 228 Y Y Payne L M LM eng D019215 Biography D016456 Historical Article D016428 Journal Article England Library (Lond) 100969413 0024-2160 Q QO D001634 Y Bibliography as Topic D049711 N History, Modern 1601- D011327 N Printing Q000266 Y history D006113 N United Kingdom Dover T T pubmed 1974 6 1 0 0 medline 2001 10 31 10 1 entrez 1974 6 1 0 0 ppublish pubmed 11675721 MEDLINE KIE 1 11686167 1990 10 17 2016 11 23 Print Print 8756-2057 Print 25-26 1990 Jan-Apr Reporter on human reproduction and the law Report Hum Reprod Law The dilemma of the Webster decision: deconstitutionalizing the trimester system. 276-92 Y Y Kindregan Charles P CP eng D016428 Journal Article United States Report Hum Reprod Law 100971950 8756-2057 E D000025 N Abortion, Eugenic D000028 Y Abortion, Induced D000032 N Abortion, Therapeutic D033421 N Beginning of Human Life D002961 N Civil Rights D005314 Y Embryonic and Fetal Development D005328 Y Fetal Viability D005333 N Fetus D033161 Y Government Regulation D006664 N History D006801 N Humans D007391 N International Cooperation D038622 N Internationality D007603 Y Jurisprudence D007878 Y Legislation as Topic D019369 N Life D011247 N Pregnancy D037841 N Pregnant Women D018907 N Privacy D012067 N Religion D012926 Y Social Control, Formal D013219 Y State Government D035521 Y Supreme Court Decisions D006113 N United Kingdom D014481 N United States KIE 31521 KIE N Abortion Act 1967 (Great Britain) N Genetics and Reproduction N Legal Approach Y Roe v. Wade Y Webster v. Reproductive Health Services KIE 63 fn. KIE KIE BoB Subject Heading: abortion/legal aspects pubmed 1990 1 1 0 0 medline 2001 11 2 10 1 entrez 1990 1 1 0 0 ppublish pubmed 11686167 MEDLINE KIE 1 11686176 1982 01 01 2007 11 15 Print Print 0094-6133 Print 1979 Jan-Feb Malpractice digest Malpract Dig How physicians may minimize their chances of becoming involved in an informed consent claim. 1-2 Y Y Bower John J JJ eng D016428 Journal Article United States Malpract Dig 9879884 0094-6133 E D032962 N Consent Forms D006801 N Humans D007258 Y Informed Consent D007603 Y Jurisprudence D008318 N Malpractice D011996 N Records as Topic KIE 12517 KIE KIE BoB Subject Heading: INFORMED CONSENT pubmed 1979 1 1 0 0 medline 2001 11 2 10 1 entrez 1979 1 1 0 0 ppublish pubmed 11686176 MEDLINE NLM 1 11694165 2001 12 28 2016 10 17 Print Print 0098-7484 Print 286 17 2001 Nov 07 JAMA JAMA msJAMA: Breast reconstruction: one woman\\'s choice. 2163 Y Y Bily L L eng D016428 Journal Article United States JAMA 7501160 0098-7484 AIM IM D001828 Y Body Image D003657 Y Decision Making D005260 N Female D006801 N Humans D016462 N Mammaplasty Q000379 N methods Q000523 Y psychology D008408 N Mastectomy Q000523 Y psychology pubmed 2001 11 22 10 0 medline 2002 1 5 10 1 entrez 2001 11 22 10 0 ppublish pubmed 11694165 pii jms1107-7 MEDLINE NLM 1 11704686 2001 12 28 2011 11 17 Print-Electronic Print 0028-4793 Print 345 22 2001 Nov 29 The New England journal of medicine N. Engl. J. Med. Recognition and management of anthrax--an update. 1621-6 Y Y Swartz M N MN Department of Medicine, Massachusetts General Hospital, Boston 02114-2696, USA. eng D016428 Journal Article D016454 Review Electronic 2001 11 06 United States N Engl J Med 0255562 0028-4793 0 D022122 Anthrax Vaccines 0 D010406 Penicillins AIM IM CommentIn N Engl J Med. 2002 Mar 21;346(12):943-5; author reply 943-5 1 11911136 CommentIn N Engl J Med. 2002 Mar 21;346(12):943-5; author reply 943-5 1 11911138 CommentIn N Engl J Med. 2002 Mar 21;346(12):943-5; author reply 943-5 1 11907299 CommentIn N Engl J Med. 2002 Mar 21;346(12):943-5; discusson 943-5 1 11911137 ErratumIn N Engl J Med 2002 Feb 21;346(8):634 D000881 Y Anthrax Q000175 N diagnosis Q000188 N drug therapy Q000453 N epidemiology Q000517 N prevention & control D022122 N Anthrax Vaccines D019072 N Antibiotic Prophylaxis D001408 N Bacillus anthracis Q000472 N pathogenicity D023482 N Bioterrorism D019411 N Clinical Laboratory Techniques D003937 N Diagnosis, Differential D005767 N Gastrointestinal Diseases Q000175 N diagnosis Q000382 N microbiology D006801 N Humans D017053 N Infection Control Q000379 N methods D016920 N Meningitis, Bacterial Q000175 N diagnosis Q000382 N microbiology D010406 N Penicillins Q000627 N therapeutic use D012141 N Respiratory Tract Infections Q000175 N diagnosis Q000188 N drug therapy Q000382 Y microbiology D017192 N Skin Diseases, Bacterial Q000175 N diagnosis Q000382 Y microbiology D013171 N Spores, Bacterial D014774 N Virulence 11 pubmed 2001 11 13 10 0 medline 2002 1 5 10 1 entrez 2001 11 13 10 0 ppublish pubmed 11704686 doi 10.1056/NEJMra012892 pii NEJMra012892 MEDLINE NLM 1 11731716 2002 02 28 2005 11 16 Print Print 0031-7012 Print 64 1 2002 Jan Pharmacology Pharmacology Progress in the search for ideal drugs. 1-7 The search for ideal drugs to improve patient care requires applications of modern scientific methods to both discovery and development. Using these modern methods, the pharmaceutical industry with strong academic and government collaboration has introduced in the last 25 years many new drugs that approach the ideal. After reviewing Bjrnsson\\'s classification of drug action and the notion of contributory causality, this commentary defines an ideal drug from the perspectives of pharmacodynamics, pharmacokinetics, and therapeutics. Examples of new drugs for hypertension, heart disease, stroke, osteoporosis, asthma, ulcer, and migraine headaches are described. Finally, the profound implications of progress in developing ideal drugs not only for the patient but also for the academic, educational, and regulatory establishments are briefly reviewed. Copyright 2002 S. Karger AG, Basel Y Y Spector Reynold R Department of Medicine, Robert Wood Johnson Medical School, Piscataway, NJ, USA. eng D016428 Journal Article D016454 Review Switzerland Pharmacology 0152016 0031-7012 0 D004364 Pharmaceutical Preparations IM D004345 N Drug Industry D004358 N Drug Therapy Q000639 Y trends D006801 N Humans D004364 N Pharmaceutical Preparations Q000145 Y classification D010599 Y Pharmacokinetics D010600 Y Pharmacology 25 pubmed 2001 12 4 10 0 medline 2002 3 1 10 1 entrez 2001 12 4 10 0 ppublish pubmed 11731716 pii pha64001 MEDLINE NLM 1 11748851 2002 03 07 2016 11 24 Print Electronic 1098-1004 Internet 18 6 2001 Dec Human mutation Hum. Mutat. Erratum: Detection of six novel FBN1 mutations in British patients affected by Marfan syndrome. 546-7 Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular matrix, is due to mutations in fibrillin-1 (FBN1) gene. Investigations carried out in the last decade, unveiled the unpredictability of the site of the mutation, which could be anywhere in the gene. FBN1 mutations have been reported in a spectrum of diseases related to MFS, with no clear evidence for a phenotype-genotype correlation. In this paper we analysed 10 British patients affected by MFS and we were able to characterise five novel missense mutations (C474W, C1402Y, G1987R, C2153Y, G2536R), one novel frameshift mutation (7926delC), one already described mutation (P1424A) and one FBN1 variant (P1148A) classified as a polymorphism in the Asian population. Four out of the five novel missense mutations involved either cysteines or an amino acid conserved in the domain structure. The mutation yield in this study is calculated at 80.0% (8/10), thus indicating that SSCA is a reliable and cost-effective technique for the screening of such a large gene. Our results suggest that this method is reliable to search for FBN1 mutations and that FBN1 screening could be a helpful tool to confirm and possibly anticipate the clinical diagnosis in familial cases. Copyright 2001 Wiley-Liss, Inc. Y Y Comeglio P P Department of Cardiological Sciences, St. George\\'s Hospital Medical School, London, UK. p.comeglio@sghms.ac.uk Y Evans A L AL Y Brice G W GW Y Child A H AH eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Corrected and Republished Article United States Hum Mutat 9215429 1059-7794 0 C000605722 FBN1 protein, human 0 D000071838 Fibrillin-1 0 D000071837 Fibrillins 0 D008840 Microfilament Proteins 9007-49-2 D004247 DNA IM RepublishedFrom Hum Mutat. 2001 Sep;18(3):251 1 11524736 D000328 N Adult D001483 N Base Sequence D002675 N Child, Preschool D004247 N DNA Q000737 N chemistry Q000235 N genetics D004252 N DNA Mutational Analysis D005260 N Female D000071838 N Fibrillin-1 D000071837 N Fibrillins D016368 N Frameshift Mutation D006801 N Humans D008297 N Male D008382 N Marfan Syndrome Q000235 Y genetics Q000473 N pathology D008840 N Microfilament Proteins Q000235 Y genetics D008875 N Middle Aged D009154 N Mutation D020125 N Mutation, Missense D011110 N Polymorphism, Genetic D018807 N Polymorphism, Single-Stranded Conformational D006113 N United Kingdom pubmed 2001 12 19 10 0 medline 2002 3 8 10 1 entrez 2001 12 19 10 0 ppublish pubmed 11748851 pii 10.1002/humu.1235 doi 10.1002/humu.1235 MEDLINE NLM 1 11748856 2002 03 07 2016 11 24 Print Electronic 1098-1004 Internet 18 6 2001 Dec Human mutation Hum. Mutat. Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer families from Spain. 549 Germline mutations in the MLH1 and MSH2 genes, account for the majority of HNPCC families. We have screened such families from Spain by using DGGE analysis and subsequent direct sequencing techniques. In eight families we identified six novel MLH1 and two novel MSH2 mutations comprising one frame shift mutation (c.1420 del C), two missense mutations (L622H and R687W), two splice site mutations (c.1990-1 G>A and c.453+2 T>C and one nonsense mutation (K329X) in the MLH1 gene as well as two frame shift mutations (c.1979-1980 del AT and c.1704-1705 del AG) in the MSH2 gene. Our analysis contributes to the further characterization of the mutational spectrum of MLH1 and MSH2 genes in HNPCC families. Copyright 2001 Wiley-Liss, Inc. Y Y Godino J J Laboratory of Molecular Oncology, San Carlos University Hospital, 28040 Madrid, Spain. Y de La Hoya M M Y Diaz-Rubio E E Y Benito M M Y Calds T T eng Y OMIM 114500 120435 120436 600258 600259 600678 D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States Hum Mutat 9215429 1059-7794 0 D048868 Adaptor Proteins, Signal Transducing 0 D002352 Carrier Proteins 0 D004268 DNA-Binding Proteins 0 C501486 MLH1 protein, human 0 D009363 Neoplasm Proteins 0 D009687 Nuclear Proteins 0 D011518 Proto-Oncogene Proteins 9007-49-2 D004247 DNA EC 3.6.1.3 C497172 MSH2 protein, human EC 3.6.1.3 D000070957 MutL Protein Homolog 1 EC 3.6.1.3 D051718 MutS Homolog 2 Protein IM D048868 N Adaptor Proteins, Signal Transducing D002352 N Carrier Proteins D003123 N Colorectal Neoplasms, Hereditary Nonpolyposis Q000235 Y genetics D004247 N DNA Q000737 N chemistry Q000235 N genetics D004252 N DNA Mutational Analysis D004268 Y DNA-Binding Proteins D005192 N Family Health D005260 N Female D018095 Y Germ-Line Mutation D006801 N Humans D008297 N Male D000070957 N MutL Protein Homolog 1 D051718 N MutS Homolog 2 Protein D009363 N Neoplasm Proteins Q000235 Y genetics D009687 N Nuclear Proteins D011518 N Proto-Oncogene Proteins Q000235 Y genetics D013030 N Spain pubmed 2001 12 19 10 0 medline 2002 3 8 10 1 entrez 2001 12 19 10 0 ppublish pubmed 11748856 pii 10.1002/humu.1240 doi 10.1002/humu.1240 MEDLINE NLM 1 11831940 2002 02 25 2015 04 17 Print Print 0003-9950 Print 120 2 2002 Feb Archives of ophthalmology (Chicago, Ill. : 1960) Arch. Ophthalmol. Republication of color figures. 234-7 Y Y Dushku Nicholas N Y John Molykutty K MK Y Schultz Gregory S GS Y Reid Ted W TW eng D016420 Comment D016422 Letter United States Arch Ophthalmol 7706534 0003-9950 EC 3.4.24.- D020782 Matrix Metalloproteinases AIM IM CommentOn Arch Ophthalmol. 2001 May;119(5):695-706 1 11346397 D004847 N Epithelial Cells Q000201 Y enzymology Q000473 N pathology D005347 N Fibroblasts Q000201 N enzymology Q000473 N pathology D006801 N Humans D007124 N Immunoenzyme Techniques D016850 N Limbus Corneae Q000473 Y pathology D020782 N Matrix Metalloproteinases Q000378 Y metabolism D011625 N Pterygium Q000201 Y enzymology Q000473 N pathology pubmed 2002 2 28 10 0 medline 2002 2 28 10 1 entrez 2002 2 28 10 0 ppublish pubmed 11831940 pii elt0202-4 MEDLINE NLM 1 11838066 2002 02 25 2014 11 20 Print Print 0023-7205 Print 99 3 2002 Jan 17 Lakartidningen Lakartidningen [Unequal distribution of health resources. Research is not supported with consideration to the global significance of the diseases]. 148-9 Y Y Milerad Josef J josef.milerad@lakartidningen.se swe D019215 Biography D016456 Historical Article D016428 Journal Article D019477 Portraits Ojmn frdelning av hlsoresurser. Forskningspengar satsas inte i proportion till sjukdomars globala betydelse. Sweden Lakartidningen 0027707 0023-7205 IM D014943 Y Global Health D015276 N Health Care Rationing D049673 N History, 20th Century D006801 N Humans D009613 Y Nobel Prize D012109 Y Research Support as Topic Q000191 N economics Q000458 N organization & administration D013548 N Geographic Sweden D014481 N Geographic United States Varmus Harold H pubmed 2002 2 13 10 0 medline 2002 2 28 10 1 entrez 2002 2 13 10 0 ppublish pubmed 11838066 MEDLINE NLM 1 11858625 2002 03 06 2004 11 17 Print Print 0002-838X Print 65 3 2002 Feb 01 American family physician Am Fam Physician Information from your family doctor. Exercise for the elderly. 427-8 eng D016428 Journal Article D029282 Patient Education Handout United States Am Fam Physician 1272646 0002-838X AIM IM OriginalReportIn Am Fam Physician. 2002 Feb 1;65(3):419-26 1 11858624 D000368 N Aged D015444 Y Exercise D005194 N Family Practice D006293 Y Health Promotion D006801 N Humans pubmed 2002 2 23 10 0 medline 2002 3 7 10 1 entrez 2002 2 23 10 0 ppublish pubmed 11858625 MEDLINE NASA 1 11858276 2002 03 28 2008 11 21 Print Print 0094-5765 Print 48 5-12 2001 Mar-Jun Acta astronautica Acta Astronaut Phase 1 research program overview. 845-51 The Phase 1 research program was unprecedented in its scope and ambitious in its objectives. The National Aeronautics and Space Administration committed to conducting a multidisciplinary long-duration research program on a platform whose capabilities were not well known, not to mention belonging to another country. For the United States, it provided the first opportunity to conduct research in a long-duration space flight environment since the Skylab program in the 1970\\'s. Multiple technical as well as cultural challenges were successfully overcome through the dedicated efforts of a relatively small cadre of individuals. The program developed processes to successfully plan, train for and execute research in a long-duration environment, with significant differences identified from short-duration space flight science operations. Between August 1994 and June 1998, thousands of kilograms of research hardware was prepared and launched to Mir, and thousands of kilograms of hardware and data products were returned to Earth. More than 150 Principal Investigators from eight countries were involved in the program in seven major research disciplines: Advanced Technology; Earth Sciences; Fundamental Biology; Human Life Sciences; International Space Station Risk Mitigation; Microgravity; and Space Sciences. Approximately 75 long-duration investigations were completed on Mir, with additional investigations performed on the Shuttle flights that docked with Mir. The flight phase included the participation of seven US astronauts and 20 Russian cosmonauts. The successful completion of the Phase 1 research program not only resulted in high quality science return but also in numerous lessons learned to make the ISS experience more productive. The cooperation developed during the program was instrumental in its success. c2001 AIAA. Published by Elsevier Science Ltd. Y Y Uri J J JJ NASA Johnson Space Center, Houston, TX, USA. Y Lebedev O N ON eng D016428 Journal Article England Acta Astronaut 9890631 0094-5765 S D001690 N Biological Science Disciplines D004867 N Equipment Design D018559 N Exobiology D005118 N Extraterrestrial Environment D006801 N Humans D007391 Y International Cooperation D015397 Y Program Evaluation D012106 N Research Q000295 N instrumentation Q000458 Y organization & administration D012426 N Geographic Russia D013026 N Space Flight Q000295 N instrumentation Q000458 Y organization & administration Q000639 N trends D018531 N Spacecraft D014586 N Geographic USSR D014481 N Geographic United States D018557 N United States National Aeronautics and Space Administration Q000458 Y organization & administration D014893 Y Weightlessness NASA 00027286 Flight Experiment Mir Project STS Shuttle Project long duration manned short duration pubmed 2002 2 23 10 0 medline 2002 3 29 10 1 entrez 2002 2 23 10 0 ppublish pubmed 11858276 MEDLINE NLM 1 11869993 2002 03 22 2016 10 20 Print Print 1052-1577 Print 27 4 2002 Feb Harvard health letter Harv Health Lett By the way doctor... I\\'m 72 and was recently told that I am losing a bit of my sight because of macular degeneration. My doctor assured me that it was progressing very slowly, but also said there wasn\\'t really anything to do about it. But I read that zinc or vitamins might help. Should I be taking them? 8 Y Y Lee Thomas H TH eng D016428 Journal Article United States Harv Health Lett 9425764 1052-1577 0 D000975 Antioxidants 0 D014815 Vitamins J41CSQ7QDS D015032 Zinc K D000368 N Aged D000975 N Antioxidants Q000627 Y therapeutic use D004359 N Drug Therapy, Combination D006801 N Humans D008268 N Macular Degeneration Q000517 Y prevention & control D014815 N Vitamins Q000627 Y therapeutic use D015032 N Zinc Q000627 Y therapeutic use pubmed 2002 3 1 10 0 medline 2002 3 23 10 1 entrez 2002 3 1 10 0 ppublish pubmed 11869993 pii L0202i MEDLINE NASA 1 11876201 2002 03 22 2016 11 24 Print Print 1069-9422 Print 5 3 1998 Life support & biosphere science : international journal of earth space Life Support Biosph Sci Consumer acceptance of vegetarian sweet potato products intended for space missions. 339-46 Sweet potato is one of the crops selected for NASA\\'s Advanced Life Support Program for potential long-duration lunar/Mars missions. This article presents recipes of products made from sweet potato and determines the consumer acceptability of products containing from 6% to 20% sweet potato on a dry weight basis. These products were developed for use in nutritious and palatable meals for future space explorers. Sensory evaluation (appearance/color, aroma, texture, flavor/taste, and overall acceptability) studies were conducted to determine the consumer acceptability of vegetarian products made with sweet potato using panelists at NASA/Johnson Space Center in Houston, TX. None of these products including the controls, contained any ingredient of animal origin with the exception of sweet potato pie. A 9-point hedonic scale (9 being like extremely and 1 being dislike extremely) was used to evaluate 10 products and compare them to similar commercially available products used as controls. The products tested were pancakes, waffles, tortillas, bread, pie, pound cake, pasta, vegetable patties, doughnuts, and pretzels. All of the products were either liked moderately or liked slightly with the exception of the sweet potato vegetable patties, which were neither liked nor disliked. Mean comparisons of sensory scores of sweet potato recipes and their controls were accomplished by using the Student t-test. Because of their nutritional adequacy and consumer acceptability, these products are being recommended to NASA\\'s Advanced Life Support Program for inclusion in a vegetarian menu plan designed for lunar/Mars space missions. Y Y Wilson C D CD Center for Food and Environmental Systems for Human Exploration of Space, George Washington Carver Agricultural Experiment Station, Tuskegee University, Tuskegee, AL 36088, USA. Y Pace R D RD Y Bromfield E E Y Jones G G Y Lu J Y JY eng D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. United States Life Support Biosph Sci 9431217 1069-9422 S D014676 N Diet, Vegetarian Q000523 Y psychology D018504 N Ecological Systems, Closed D005069 N Evaluation Studies as Topic D005247 N Feeding Behavior Q000523 N psychology D005518 N Food Preferences Q000523 Y psychology D005524 N Food Technology D006801 N Humans D027723 Y Ipomoea batatas D008021 N Life Support Systems D008612 Y Menu Planning D009753 N Nutritive Value D013026 Y Space Flight D014481 N United States D018557 N United States National Aeronautics and Space Administration D014893 N Weightlessness NASA 00027330 NASA N NASA Discipline Life Support Systems N Non-NASA Center Y Mortley D G DG Tuskegee U, AL NASA Grant numbers: NCC 9-51, ALX-FS-2. pubmed 2002 3 6 10 0 medline 2002 3 23 10 1 entrez 2002 3 6 10 0 ppublish pubmed 11876201 MEDLINE NLM 1 11885531 2002 04 08 2006 11 15 Print Print 0028-2200 Print 99 7 1992 Jul Nederlands tijdschrift voor tandheelkunde Ned Tijdschr Tandheelkd [Microbiological diagnostics in periodontal treatment]. 245-6 Periodontal diseases are bacterial infections. The rationale for the use of microbiological diagnostics in periodontal treatment of severe periodontitis patients is discussed as well as the use of adjunct antimicrobial therapy for the elimination of specific bacterial species. Y Y de Graaff J J Uit de vakgroep Orale Microbiologie van het Academisch Centrum Tandheelkunde Amsterdam (ACTA). Y van Winkelhoff A J AJ dut D004740 English Abstract D016428 Journal Article D016454 Review Microbiologische diagnostiek in de paradontologie. Netherlands Ned Tijdschr Tandheelkd 0400771 0028-2200 0 D000900 Anti-Bacterial Agents D D000193 N Actinomycetales Infections Q000188 N drug therapy D000900 N Anti-Bacterial Agents Q000627 Y therapeutic use D006801 N Humans D006920 N Hygiene D010510 N Periodontal Diseases Q000175 Y diagnosis Q000188 N drug therapy Q000382 Y microbiology D010518 N Periodontitis Q000175 N diagnosis Q000188 N drug therapy Q000382 N microbiology D012307 N Risk Factors 6 pubmed 1992 7 1 0 0 medline 2002 4 9 10 1 entrez 1992 7 1 0 0 ppublish pubmed 11885531 MEDLINE NLM 1 11892742 2002 03 18 2009 07 23 Print Print 0012-1606 Print 242 2 2002 Feb 15 Developmental biology Dev. Biol. The major subacrosomal occupant of bull spermatozoa is a novel histone H2B variant associated with the forming acrosome during spermiogenesis. 376-87 Recent studies on the structural composition of mammalian sperm heads have shown a congregate of unidentified proteins occupying the periphery of the mammalian sperm nucleus, forming a layer of condensed cytosol. These proteins are the perinuclear theca (PT) and can be categorized into SDS-soluble and SDS-insoluble components. The present study focused on identifying the major SDS-insoluble PT protein, which we localized to the subacrosomal layer of bovine spermatozoa and cloned by immunoscreening a bull testicular cDNA library. The isolated clones encode a protein of 122 amino acids that bears 67% similarity with histone H2B and contains a predicted histone fold motif. The novel amino terminus of the protein contains a potential bipartite nuclear targeting sequence. Hence, we identified this prominent subacrosomal component as a novel H2B variant, SubH2Bv. Northern blot analyses of SubH2Bv mRNA expression showed that it is testis-specific and is also present in murid testes. Immunocytochemical analysis showed SubH2Bv intimately associates, temporally and spatially, with acrosome formation. While the molecular features of SubH2Bv are common to nuclear proteins, it is never seen developmentally within the nucleus of the spermatid. Considering its developmental and molecular characteristics, we have postulated roles of SubH2Bv in acrosome assembly and acrosome-nuclear docking. Copyright 2001 Academic Press. Y Y Aul Ritu B RB Department of Anatomy and Cell Biology, Queen\\'s University, Kingston, Ontario, Canada, K7L 3N6. Y Oko Richard J RJ eng D016439 Corrected and Republished Article D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States Dev Biol 0372762 0012-1606 0 D018076 DNA, Complementary 0 D006657 Histones 0 D012333 RNA, Messenger 63231-63-0 D012313 RNA IM RepublishedFrom Dev Biol. 2001 Nov 15;239(2):376-87 1 11784042 D000177 N Acrosome Q000737 Y chemistry Q000378 N metabolism Q000648 N ultrastructure D020816 N Amino Acid Motifs D000595 N Amino Acid Sequence D000818 N Animals D001483 N Base Sequence D015152 N Blotting, Northern D015153 N Blotting, Western D002417 N Cattle D018076 N DNA, Complementary Q000378 N metabolism D004591 N Electrophoresis, Polyacrylamide Gel D006657 N Histones Q000737 Y chemistry D015151 N Immunoblotting D007150 N Immunohistochemistry D008297 N Male D051379 N Mice D008969 N Molecular Sequence Data D012313 N RNA Q000378 N metabolism D012333 N RNA, Messenger Q000378 N metabolism D051381 N Rats D020133 N Reverse Transcriptase Polymerase Chain Reaction D012670 N Seminiferous Epithelium Q000378 N metabolism D017386 N Sequence Homology, Amino Acid D013091 N Spermatogenesis D013094 N Spermatozoa Q000737 N chemistry D013737 N Testis Q000378 N metabolism pubmed 2002 3 15 10 0 medline 2002 3 19 10 1 entrez 2002 3 15 10 0 ppublish pubmed 11892742 MEDLINE NLM 1 11916658 2002 04 15 2016 11 24 Print Print 1070-910X Print 9 7 2002 Mar Harvard women\\'s health watch Harv Womens Health Watch By the way, doctor. A few months ago, I was surprised to read that a new study has raised a question about the value of screening mammograms. Is that true? I thought the importance of having such mammograms was well-established. I\\'m 52 and have been getting annual mammograms for 10 years. Should I stop? 8 Y Y Robb-Nicholson Celeste C eng D016428 Journal Article United States Harv Womens Health Watch 9423147 1070-910X K D001943 N Breast Neoplasms Q000000981 N diagnostic imaging Q000401 Y mortality D002986 N Clinical Trials as Topic Q000592 Y standards D005260 N Female D006801 N Humans D008327 Y Mammography D008875 N Middle Aged D010353 N Patient Education as Topic D012107 N Research Design pubmed 2002 3 28 10 0 medline 2002 4 16 10 1 entrez 2002 3 28 10 0 ppublish pubmed 11916658 pii W0302f MEDLINE NLM 1 11953811 2002 05 24 2017 10 10 Print Electronic 1432-2218 Internet 16 5 2002 May Surgical endoscopy Surg Endosc Disruptive visions: surgeon responsibility during the era of change. 733-4 Y Y Satava R M RM eng D016421 Editorial Germany Surg Endosc 8806653 0930-2794 IM Cites Surg Endosc. 2000 May;14(5):417-8 1 10858462 D020811 Y Biomedical Technology D003132 N Commerce Q000639 N trends D003695 N Delivery of Health Care Q000639 N trends D013502 N General Surgery Q000592 N standards Q000639 Y trends D006301 N Health Services Needs and Demand Q000639 N trends D006801 N Humans pubmed 2002 4 16 10 0 medline 2002 5 25 10 1 entrez 2002 4 16 10 0 ppublish pubmed 11953811 doi 10.1007/s00464-002-0005-2 MEDLINE NLM 1 11966386 2002 05 02 2016 10 17 Print Print 0098-7484 Print 287 16 2002 Apr 24 JAMA JAMA The 2001 Bethesda System: terminology for reporting results of cervical cytology. 2114-9 OBJECTIVES OBJECTIVE The Bethesda 2001 Workshop was convened to evaluate and update the 1991 Bethesda System terminology for reporting the results of cervical cytology. A primary objective was to develop a new approach to broaden participation in the consensus process. PARTICIPANTS METHODS Forum groups composed of 6 to 10 individuals were responsible for developing recommendations for discussion at the workshop. Each forum group included at least 1 cytopathologist, cytotechnologist, clinician, and international representative to ensure a broad range of views and interests. More than 400 cytopathologists, cytotechnologists, histopathologists, family practitioners, gynecologists, public health physicians, epidemiologists, patient advocates, and attorneys participated in the workshop, which was convened by the National Cancer Institute and cosponsored by 44 professional societies. More than 20 countries were represented. EVIDENCE METHODS Literature review, expert opinion, and input from an Internet bulletin board were all considered in developing recommendations. The strength of evidence of the scientific data was considered of paramount importance. CONSENSUS PROCESS METHODS Bethesda 2001 was a year-long iterative review process. An Internet bulletin board was used for discussion of issues and drafts of recommendations. More than 1000 comments were posted to the bulletin board over the course of 6 months. The Bethesda Workshop, held April 30-May 2, 2001, was open to the public. Postworkshop recommendations were posted on the bulletin board for a last round of critical review prior to finalizing the terminology. CONCLUSIONS CONCLUSIONS Bethesda 2001 was developed with broad participation in the consensus process. The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology. Y Y Solomon Diane D EPN Room 2130, 6130 Executive Blvd, Bethesda, MD 20892, USA. ds87v@nih.gov Y Davey Diane D Y Kurman Robert R Y Moriarty Ann A Y O\\'Connor Dennis D Y Prey Marianne M Y Raab Stephen S Y Sherman Mark M Y Wilbur David D Y Wright Thomas T Jr Y Young Nancy N Y Forum Group Members Y Bethesda 2001 Workshop eng D016446 Consensus Development Conference D016447 Consensus Development Conference, NIH D016431 Guideline D016428 Journal Article D016454 Review United States JAMA 7501160 0098-7484 AIM IM CommentIn JAMA. 2002 Apr 24;287(16):2140-1 1 11966390 D018290 N Cervical Intraepithelial Neoplasia Q000145 N classification Q000473 Y pathology D005260 N Female D006801 N Humans D007753 N Laboratories Q000592 N standards D011786 N Quality Control D009626 N Terminology as Topic D002578 N Uterine Cervical Dysplasia Q000145 N classification Q000473 Y pathology D002583 N Uterine Cervical Neoplasms Q000175 N diagnosis Q000473 Y pathology D014626 N Vaginal Smears Q000145 N classification Q000592 Y standards 28 pubmed 2002 4 23 10 0 medline 2002 5 3 10 1 entrez 2002 4 23 10 0 ppublish pubmed 11966386 pii jst10014 MEDLINE NASA 1 12038483 2002 07 26 2013 11 21 Print Print 0273-1177 Print 26 12 2000 Advances in space research : the official journal of the Committee on Space Research (COSPAR) Adv Space Res Planetary protection issues for Mars sample acquisition flight projects. 1911-6 The planned NASA sample acquisition flight missions to Mars pose several interesting planetary protection issues. In addition to the usual forward contamination procedures for the adequate protection of Mars for the sake of future missions, there are reasons to ensure that the sample is not contaminated by terrestrial microbes from the acquisition mission. Recent recommendations by the Space Studies Board (SSB) of the National Research Council (United States), would indicate that the scientific integrity of the sample is a planetary protection concern (SSB, 1997). Also, as a practical matter, a contaminated sample would interfere with the process for its release from quarantine after return for distribution to the interested scientists. These matters are discussed in terms of the first planned acquisition mission. c2001 COSPAR Published by Elsevier Science Ltd. All rights reserved. Y Y Barengoltz J B JB Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA. eng D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. England Adv Space Res 9878935 0273-1177 BBX060AN9V D006861 Hydrogen Peroxide S D003264 Y Containment of Biohazards D004783 N Environmental Microbiology D005118 N Extraterrestrial Environment D006358 N Hot Temperature D006861 N Hydrogen Peroxide D018535 Y Mars D013026 N Space Flight Q000592 Y standards D018531 N Spacecraft D013048 Y Specimen Handling D013242 N Sterilization Q000379 N methods D014481 N Geographic United States D018557 N United States National Aeronautics and Space Administration Q000592 Y standards NASA 00027913 NASA N NASA Center JPL N NASA Discipline Exobiology Y Barengoltz J B JB JPL pubmed 2002 6 1 10 0 medline 2002 7 27 10 1 entrez 2002 6 1 10 0 ppublish pubmed 12038483 MEDLINE NLM 1 12101218 2002 08 12 2006 11 15 Print-Electronic Print 0021-9258 Print 277 28 2002 Jul 12 The Journal of biological chemistry J. Biol. Chem. Interaction between FtsZ and FtsW of Mycobacterium tuberculosis. 24983-7 The recruitment of FtsZ to the septum and its subsequent interaction with other cell division proteins in a spatially and temporally controlled manner are the keys to bacterial cell division. In the present study, we have tested the hypothesis that FtsZ and FtsW of Mycobacterium tuberculosis could be binding partners. Using gel renaturation, pull-down, and solid-phase assays, we confirm that FtsZ and FtsW interact through their C-terminal tails, which carry extensions absent in their Escherichia coli counterparts. Crucial to these interactions is the cluster of aspartate residues Asp(367) to Asp(370) of FtsZ, which most likely interact with a cluster of positively charged residues in the C-terminal tail of FtsW. Mutations of the aspartate residues 367-370 showed that changing three aspartate residues to alanine resulted in complete loss of interaction. This is the first demonstration of the direct interaction between FtsZ and FtsW. We speculate that this interaction between FtsZ and FtsW could serve to anchor FtsZ to the membrane and link septum formation to peptidoglycan synthesis in M. tuberculosis. The findings assume particular significance in view of the global efforts to explore new targets in M. tuberculosis for chemotherapeutic intervention. Y Y Datta Pratik P Department of Chemistry, Bose Institute, 93/1 Acharya Prafulla Chandra Road, Kolkata 700009, India. Y Dasgupta Arunava A Y Bhakta Sanjib S Y Basu Joyoti J eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Electronic 2002 05 06 United States J Biol Chem 2985121R 0021-9258 0 D001426 Bacterial Proteins 0 D003598 Cytoskeletal Proteins 0 D017931 DNA Primers 0 C071525 FtsZ protein, Bacteria 0 D008565 Membrane Proteins 125724-13-2 C061684 FtsW protein, Bacteria IM D000595 N Amino Acid Sequence D001426 N Bacterial Proteins Q000737 N chemistry Q000378 Y metabolism D001483 N Base Sequence D003598 Y Cytoskeletal Proteins D017931 N DNA Primers D008565 Y Membrane Proteins D008969 N Molecular Sequence Data D009169 N Mycobacterium tuberculosis Q000378 Y metabolism D011485 N Protein Binding pubmed 2002 7 9 10 0 medline 2002 8 13 10 1 entrez 2002 7 9 10 0 ppublish pubmed 12101218 doi 10.1074/jbc.M203847200 pii M203847200 MEDLINE KIE 1 12159900 2002 08 22 2013 06 07 Print Print 0362-4331 Print 2002 Jul 02 The New York times on the Web N Y Times Web Weighing medical ethics for many years to come: a conversation with Harold Shapiro. Interview by Howard Markel. F6 Y Y Shapiro Harold H eng D017203 Interview D018431 Newspaper Article United States N Y Times Web 9877126 0362-4331 E D026683 N Advisory Committees D026688 Y Bioethical Issues D035843 N Biomedical Research D001709 N Biotechnology D019976 N Cloning, Organism D016265 N Conflict of Interest D033041 N Embryo Research D004622 N Embryo, Mammalian Q000166 N cytology D005380 N Financing, Government D006292 N Health Priorities D006805 N Human Experimentation D006801 N Humans D012109 N Research Support as Topic D013234 N Stem Cells D014481 N Geographic United States KIE 103061 NRCBL VF 2.1 KIE N Bioethics and Professional Ethics N National Bioethics Advisory Commission N Popular Approach/Source KIE KIE Bib: bioethics pubmed 2002 8 6 10 0 medline 2002 8 23 10 1 entrez 2002 8 6 10 0 ppublish pubmed 12159900 MEDLINE KIE 1 12174865 2002 08 21 2004 11 17 Print Print 1145-0762 Print 11 2 2000 Jun Journal international de bioethique = International journal of bioethics J Int Bioethique Physicians\\' attitudes towards medical ethics issues in Turkey. 57-67 Y Y Pelin S S SS Dept. of Deontology, Faculty of Medicine, University of Ankara, Tip. Fak. Dekanligi, Morfoloji Terleskesi, Anakara, Sihhiye - 06100 Turkey. Y Arda B B eng D016428 Journal Article France J Int Bioethique 9015754 1145-0762 E D000028 N Abortion, Induced D032761 N Animal Experimentation D000818 N Animals D001291 Y Attitude of Health Personnel D026688 Y Bioethical Issues D035843 N Biomedical Research D000529 N Complementary Therapies D003219 N Confidentiality D003625 N Data Collection D004992 Y Ethics, Medical D032984 N Ethics, Research D005065 N Euthanasia D006801 N Humans D010817 N Physician-Patient Relations D010820 Y Physicians Q000523 N psychology D011287 N Prejudice D027724 N Reproductive Techniques, Assisted D014342 N Truth Disclosure D014421 N Geographic Turkey KIE 102894 KIE N Bioethics and Professional Ethics N Empirical Approach KIE Pelin, Serap Sahinoglu; Arda, Berna KIE KIE Bib: bioethics; medical ethics pubmed 2002 8 15 10 0 medline 2002 8 22 10 1 entrez 2002 8 15 10 0 ppublish pubmed 12174865 MEDLINE NLM 1 12145319 2002 09 16 2013 11 21 Print-Electronic Print 0021-9258 Print 277 31 2002 Aug 02 The Journal of biological chemistry J. Biol. Chem. Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. 28271-9 The regulation of SNARE complex assembly likely plays an important role in governing the specificity as well as the timing of membrane fusion. Here we identify a novel brain-enriched protein, amisyn, with a tomosyn- and VAMP-like coiled-coil-forming domain that binds specifically to syntaxin 1a and syntaxin 4 both in vitro and in vivo, as assessed by co-immunoprecipitation from rat brain. Amisyn is mostly cytosolic, but a fraction co-sediments with membranes. The amisyn coil domain can form SNARE complexes of greater thermostability than can VAMP2 with syntaxin 1a and SNAP-25 in vitro, but it lacks a transmembrane anchor and so cannot act as a v-SNARE in this complex. The amisyn coil domain prevents the SNAP-25 C-terminally mediated rescue of botulinum neurotoxin E inhibition of norepinephrine exocytosis in permeabilized PC12 cells to a greater extent than it prevents the regular exocytosis of these vesicles. We propose that amisyn forms nonfusogenic complexes with syntaxin 1a and SNAP-25, holding them in a conformation ready for VAMP2 to replace it to mediate the membrane fusion event, thereby contributing to the regulation of SNARE complex formation. Y Y Scales Suzie J SJ Howard Hughes Medical Institute, Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305-5345, USA. Y Hesser Boris A BA Y Masuda Esteban S ES Y Scheller Richard H RH eng Y GENBANK AF391153 D016428 Journal Article Electronic 2002 05 24 United States J Biol Chem 2985121R 0021-9258 0 D002352 Carrier Proteins 0 D008565 Membrane Proteins 0 D009419 Nerve Tissue Proteins 0 D050765 Qa-SNARE Proteins 0 D011993 Recombinant Fusion Proteins 0 C494208 SNAP25 protein, human 0 D050600 SNARE Proteins 0 C494212 STX1A protein, human 0 C465215 STXBP6 protein, human 0 C494210 Snap25 protein, rat 0 C494213 Stx1a protein, rat 0 D050825 Synaptosomal-Associated Protein 25 0 D050827 Syntaxin 1 0 D033921 Vesicular Transport Proteins EC 2.5.1.18 D005982 Glutathione Transferase X4W3ENH1CV D009638 Norepinephrine IM D000595 N Amino Acid Sequence D000818 N Animals D001665 N Binding Sites D002352 N Carrier Proteins Q000737 N chemistry Q000235 N genetics Q000502 Y physiology D005089 N Exocytosis D005982 N Glutathione Transferase Q000235 N genetics D006367 N HeLa Cells D006801 N Humans D007700 N Kinetics D008565 N Membrane Proteins Q000737 N chemistry Q000378 Y metabolism Q000502 Y physiology D008969 N Molecular Sequence Data D009419 N Nerve Tissue Proteins Q000737 N chemistry Q000378 N metabolism D009638 N Norepinephrine Q000037 N antagonists & inhibitors Q000557 N secretion D016716 N PC12 Cells D010673 N Pheochromocytoma D017433 N Protein Structure, Secondary D050765 N Qa-SNARE Proteins D051381 N Rats D011993 N Recombinant Fusion Proteins Q000378 N metabolism D050600 N SNARE Proteins D016415 N Sequence Alignment D017386 N Sequence Homology, Amino Acid D050825 N Synaptosomal-Associated Protein 25 D050827 N Syntaxin 1 D013816 N Thermodynamics D033921 Y Vesicular Transport Proteins pubmed 2002 7 30 10 0 medline 2002 9 17 10 1 entrez 2002 7 30 10 0 ppublish pubmed 12145319 doi 10.1074/jbc.M204929200 pii M204929200 MEDLINE NASA 1 12192682 2002 09 09 2006 11 15 Print Print 0018-9251 Print 35 3 1999 Jul IEEE transactions on aerospace and electronic systems IEEE Trans Aerosp Electron Syst Intelligent control of a planning system for astronaut training. 1055-70 This work intends to design, analyze and solve, from the systems control perspective, a complex, dynamic, and multiconstrained planning system for generating training plans for crew members of the NASA-led International Space Station. Various intelligent planning systems have been developed within the framework of artificial intelligence. These planning systems generally lack a rigorous mathematical formalism to allow a reliable and flexible methodology for their design, modeling, and performance analysis in a dynamical, time-critical, and multiconstrained environment. Formulating the planning problem in the domain of discrete-event systems under a unified framework such that it can be modeled, designed, and analyzed as a control system will provide a self-contained theory for such planning systems. This will also provide a means to certify various planning systems for operations in the dynamical and complex environments in space. The work presented here completes the design, development, and analysis of an intricate, large-scale, and representative mathematical formulation for intelligent control of a real planning system for Space Station crew training. This planning system has been tested and used at NASA-Johnson Space Center. Y Y Ortiz J J Johnson Space Center, USA. Y Chen G G eng D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. United States IEEE Trans Aerosp Electron Syst 9876802 0018-9251 S D000465 N Algorithms D001185 Y Artificial Intelligence D018480 N Astronauts Q000193 Y education D006801 N Humans D007318 Y Inservice Training D013026 N Space Flight Q000193 Y education D018531 N Spacecraft D013597 N Systems Analysis D017748 N Time Management D014481 N Geographic United States D018557 N United States National Aeronautics and Space Administration NASA 00028138 NASA Grant numbers: DAAG55-98-1-0198. pubmed 2002 8 24 10 0 medline 2002 9 11 10 1 entrez 2002 8 24 10 0 ppublish pubmed 12192682 MEDLINE PIP 1 12179763 1991 12 03 2015 09 01 Print Print 1226-0282 Print 10 2 1990 Dec Pogon sahoe nonjip = Journal of population, health, and social welfare Bogeon sahoe nonjib Recent changes in the population control policy and its future directions in Korea. 152-73 Y Y Cho N H NH Y Seo M H MH Y Tan B A BA eng D016428 Journal Article Korea (South) Bogeon sahoe nonjib 9422396 1226-0282 J D000328 N Adult D000367 N Age Factors D000368 Y Aged D001208 N Geographic Asia D001723 Y Birth Rate D003247 N Conservation of Natural Resources D003267 Y Contraception D003695 N Delivery of Health Care D003710 N Demography D003858 Y Dependency (Psychology) D003906 N Developing Countries D004467 Y Economics D004651 Y Employment D004777 N Environment D005193 N Family Planning Services D005202 N Geographic Far East D005298 N Fertility D006262 N Health D006280 N Health Manpower D006285 Y Health Planning D006296 N Health Services D007723 N Geographic Korea D008430 Y Maternal-Child Health Centers D009934 N Organization and Administration D011153 N Population D011154 N Population Characteristics D011156 N Population Density D011157 Y Population Dynamics D011158 Y Population Growth D011320 N Primary Health Care D015397 Y Program Evaluation D011640 Y Public Policy D017150 Y Public Sector D012106 Y Research D012946 Y Social Welfare D012959 Y Socioeconomic Factors D013245 Y Sterilization, Reproductive PIP 067656 POP 00204408 PIP eng The total fertility rate (TFR) in Korea decreased from 6.0 to 1.6 over the period 1960-87. A national family planning program and socioeconomic development have played roles in this decline. Should this most recent TFR prevail, the nation\\'s population will increase to 50.2 million by 2020, shifting to negative growth thereafter. Demographic aging and labor shortages will ensue. Future population policy should consider Korea\\'s socioeconomic conditions and its burgeoning population in relation to the available land area, and aim to maintain a minimum positive population growth rate. In this context, this paper considers future population policy directions for Korea, acknowledging that its strategies and objectives must change. Postponing reaching the goal of zero population growth rate is suggested to allow a moderate population infusion of economically active individuals. These people will help facilitate greater economic development and work to improve the quality of life in Korea. Strengthened family planning/maternal-child health programs which encourage and support temporary contraceptive methods instead of sterilization will help to achieve this goal. Improving qualitative program aspects should be the center of attention in these programs. The paper also calls upon the Korea Institute for Health and Social Affairs to strengthen its research and evaluation capabilities. PIP N Adult N Age Factors Y Aged N Asia N Birth Rate N Carrying Capacity N Contraception Y Contraceptive Methods N Delivery Of Health Care Y Demographic Aging N Demographic Factors Y Demographic Transition Y Dependency Burden N Developing Countries N Eastern Asia Y Economic Development N Economic Factors N Environment N Family Planning Y Family Planning Programs N Fertility N Fertility Measurements N Fertility Rate N Health N Health Services N Human Resources N Korea Y Labor Force N Macroeconomic Factors Y Maternal-child Health Services N Microeconomic Factors N Natural Resources N Organization And Administration N Policy N Population N Population Characteristics Y Population Decrease N Population Dynamics Y Population Growth Y Population Policy Y Population Pressure N Population Size N Primary Health Care Y Program Evaluation N Programs Y Public Sector Y Research Methodology N Social Policy Y Social Welfare Y Socioeconomic Factors Y Sterilization, Sexual Y Total Fertility Rate--changes Y Zero Population Growth PIP TJ: JOURNAL OF POPULATION, HEALTH AND SOCIAL WELFARE pubmed 1990 12 1 0 0 medline 2002 10 9 4 0 entrez 1990 12 1 0 0 ppublish pubmed 12179763 MEDLINE NLM 1 12211241 2002 09 13 2007 03 19 Print Electronic 1095-9203 Internet 297 5586 2002 Aug 30 Science (New York, N.Y.) Science Mycobacterium leprae and demyelination. 1475-6; author reply 1475-6 Y Y Ottenhoff Tom H M TH eng D016420 Comment D016422 Letter United States Science 0404511 0036-8075 IM CommentOn Science. 2002 May 3;296(5569):927-31 1 11988579 D001422 N Bacterial Adhesion D003711 N Demyelinating Diseases Q000276 N immunology Q000382 Y microbiology Q000473 N pathology D006801 N Humans D007918 N Leprosy Q000276 N immunology Q000382 Y microbiology Q000473 N pathology D009166 N Mycobacterium leprae Q000472 Y pathogenicity Q000502 N physiology D012583 N Schwann Cells Q000382 N microbiology pubmed 2002 9 5 10 0 medline 2002 9 14 10 1 entrez 2002 9 5 10 0 ppublish pubmed 12211241 MEDLINE KIE 1 12211266 2002 09 25 2004 11 17 Print Print 1054-6863 Print 12 1 2002 Mar Kennedy Institute of Ethics journal Kennedy Inst Ethics J Public policy and the sale of human organs. 47-64 Gill and Sade, in the preceding article in this issue of the Kennedy Institute of Ethics Journal, argue that living individuals should be free from legal constraints against selling their organs. The present commentary responds to several of their claims. It explains why an analogy between kidneys and blood fails; why, as a matter of public policy, we prohibit the sale of human solid organs, yet allow the sale of blood; and why their attack on Kant\\'s putative argument against the sale of human body parts is misplaced. Finally, it rejects the claim that the state is entitled to interfere with the actions of individuals only if such actions would harm others. We draw certain lines grounded in what Rawls has termed \"public reason\" beyond which we do not give effect to the autonomous self-regarding decisions of individuals. Public resistance to the sale of human body parts, no matter how voluntary or well informed, is grounded in the conviction that such a practice would diminish human dignity and our sense of solidarity. A system of organ donation, in contrast, conveys our respect for persons and honors our common humanity. Y Y Cohen Cynthia B CB Kennedy Institute of Ethics, Georgetown University, Washington, DC, USA. eng D016428 Journal Article United States Kennedy Inst Ethics J 9109135 1054-6863 E D001782 Y Blood Donors D032821 N Commodification D026689 Y Ethical Analysis D005249 Y Fees and Charges D018594 N Human Body D006801 N Humans D007668 Y Kidney D016030 N Kidney Transplantation Q000191 N economics D019520 Y Living Donors D011640 Y Public Policy D009927 N Tissue and Organ Procurement Q000191 Y economics D014481 N Geographic United States KIE 103573 KIE N Analytical Approach N Health Care and Public Health KIE 24 refs. 4 fn. KIE KIE Bib: blood donation; organ and tissue donation pubmed 2002 9 5 10 0 medline 2002 9 26 6 0 entrez 2002 9 5 10 0 ppublish pubmed 12211266 MEDLINE HMD 1 12219757 2002 09 13 2016 11 24 Print Print 1225-505X Print 10 1 2001 Jun Ui sahak Uisahak Development of neurophysiology in the early twentieth century: Charles Scott Sherrington and The Integrative action of the nervous system. 1-21 Y Y Kim O J OJ Department of the Medical History and Medical Humanities, Seoul National University College of Medicine. eng D019215 Biography D016456 Historical Article D016428 Journal Article Korea (South) Uisahak 9605018 1225-505X Q D001877 N Books Q000266 Y history D049672 N History, 19th Century D049673 N History, 20th Century D009482 N Neurophysiology Q000266 Y history D006113 N United Kingdom Sherrington C S CS pubmed 2002 9 11 10 0 medline 2002 9 14 10 1 entrez 2002 9 11 10 0 ppublish pubmed 12219757 MEDLINE HMD 1 12227380 2002 09 13 2004 11 17 Print Print 0269-8897 Print 15 1 2002 Mar Science in context Sci Context Paracelsus, Paracelsianism, and the secularization of the worldview. 9-27 This paper examines Paracelsus and Paracelsianism in the light of the ideas of Max Weber concerning the social consequences of the Reformation, with special reference to his theories of Entzauberung and secularization. He linked these tendencies both to the rise of capitalism and the growth of experimental science. The detailed case study of Paracelsus\\' account of diseases linked with saints, in common with his interpretation of many other conditions, demonstrates that he self-consciously extended the boundaries of medicine and eroded the role of magic and witchcraft associated with the church. On the other hand, Paracelsus adopted the Neoplatonic worldview, was immersed in popular magic, and evolved a system of medicine that self-consciously revolved around magic. These factors seem to place a distinct limit on his role in the demystification of knowledge. However, the magic of Paracelsus entailed a decisive break with the entrenched elitist and esoteric tradition of the occultists and hermeticists. It is argued that this reconstructed magic re-establishes the credentials of Paracelsus as a significant contributor to the disenchantment and secularization of the worldview. Y Y Webster Charles C All Souls College, Oxford. eng D019215 Biography D016456 Historical Article D016428 Journal Article England Sci Context 8904113 0269-8897 Q D005060 N Geographic Europe D049670 N History, 17th Century D049673 N History, 20th Century D049692 N History, Early Modern 1451-1600 D008273 N Magic Q000266 Y history D008511 Y Medicine D010684 N Philosophy Q000266 Y history D012068 Y Religion and Medicine D012585 N Sciatica Q000266 Y history Paracelsus Weber Max M pubmed 2002 9 14 10 0 medline 2002 9 14 10 1 entrez 2002 9 14 10 0 ppublish pubmed 12227380 MEDLINE NLM 1 12230384 2002 09 25 2005 11 17 Print Electronic 1539-3704 Internet 137 6 2002 Sep 17 Annals of internal medicine Ann. Intern. Med. Summaries for patients. Screening for osteoporosis: recommendations from the U.S. Preventive Services Task Force. I59 eng D016428 Journal Article D029282 Patient Education Handout United States Ann Intern Med 0372351 0003-4819 AIM IM OriginalReportIn Ann Intern Med. 2002 Sep 17;137(6):526-8 1 12230355 OriginalReportIn Ann Intern Med. 2002 Sep 17;137(6):529-41 1 12230356 D000368 N Aged D015519 N Bone Density D019317 Y Evidence-Based Medicine D005260 N Female D050723 N Fractures, Bone Q000209 N etiology Q000517 N prevention & control D006801 N Humans D008403 Y Mass Screening D008875 N Middle Aged D015663 N Osteoporosis, Postmenopausal Q000150 N complications Q000175 Y diagnosis Q000628 N therapy D012307 N Risk Factors D014481 N Geographic United States pubmed 2002 9 17 10 0 medline 2002 9 26 6 0 entrez 2002 9 17 10 0 ppublish pubmed 12230384 pii 200209170-00006 MEDLINE NLM 1 12230355 2002 09 25 2005 11 17 Print Electronic 1539-3704 Internet 137 6 2002 Sep 17 Annals of internal medicine Ann. Intern. Med. Screening for osteoporosis in postmenopausal women: recommendations and rationale. 526-8 Y Y U.S. Preventive Services Task Force eng D016431 Guideline D016428 Journal Article D017065 Practice Guideline United States Ann Intern Med 0372351 0003-4819 AIM IM CommentIn Ann Intern Med. 2003 Apr 15;138(8):689; author reply 389-90 1 12693905 SummaryForPatientsIn Ann Intern Med. 2002 Sep 17;137(6):I59 1 12230384 D000367 N Age Factors D000368 N Aged D005260 N Female D050723 N Fractures, Bone Q000209 N etiology Q000517 N prevention & control D006801 N Humans D008403 Y Mass Screening D008875 N Middle Aged D015663 N Osteoporosis, Postmenopausal Q000150 N complications Q000175 Y diagnosis D012307 N Risk Factors pubmed 2002 9 17 10 0 medline 2002 9 26 6 0 entrez 2002 9 17 10 0 ppublish pubmed 12230355 pii 200209170-00014 MEDLINE PIP 1 12349809 2000 12 06 2007 11 15 Print Print 0251-7329 Print 37 2 2000 UN chronicle UN Chron Gender and globalization. A century in retrospect. 69-70 Y Y Chinkin C C eng D016428 Journal Article United States UN Chron 8305532 0251-7329 J D004467 N Economics D005069 Y Evaluation Studies as Topic D007398 Y Interpersonal Relations D012922 Y Social Change D012959 N Socioeconomic Factors D014933 Y Women\\'s Rights PIP 152034 POP 00297373 PIP eng In the past, power structures of the nation-State have been organized around patriarchal assumptions, granting men monopoly over power, authority, and wealth. A number of structures have been erected to achieve this imbalance, which have disguised its inequity by making it appear as natural and universal. However, with globalization, this centralization of power within the Sovereign State has been fragmented. Although globalization opens up new spaces by weakening the nation-State, subsequently making possible the undermining of traditional gender hierarchies and devising new bases for gender relations, the reality that the State is no longer the sole institution that can define identity and belonging within it has denied women the space to assert their own claims to gendered self-determination. In this regard, globalization has impacted upon gender relations in complex and contradictory ways. This paper discusses such impacts of globalization on gender relations. Overall, it has become apparent that forms of inequality still exist regardless of a State\\'s prevailing political ideology. Their manifestations may differ, but the reality of women\\'s subordination remains constant. PIP Y Critique N Economic Factors N Gender Issues Y Gender Relations Y Social Change N Socioeconomic Factors Y Women\\'s Status Y World PIP TJ: UN CHRONICLE pubmed 2002 9 28 4 0 medline 2002 10 9 4 0 entrez 2002 9 28 4 0 ppublish pubmed 12349809 MEDLINE NLM 1 12369570 2003 02 21 2013 09 26 Print Print 8750-7587 Print 93 4 2002 Oct Journal of applied physiology (Bethesda, Md. : 1985) J. Appl. Physiol. Human unilateral lower limb suspension as a model for spaceflight effects on skeletal muscle. 1563-5; author reply 1565-6 Y Y Adams Gregory R GR eng D016420 Comment D016422 Letter United States J Appl Physiol (1985) 8502536 0161-7567 IM S CommentOn J Appl Physiol (1985). 2002 Jul;93(1):354-60 1 12070225 D001510 Y Bed Rest D006801 N Humans D007103 Y Immobilization D007866 Y Leg D018485 N Muscle Fibers, Skeletal Q000502 Y physiology D018482 N Muscle, Skeletal Q000502 Y physiology D013026 Y Space Flight D016474 Y Weight-Bearing NASA N NASA Discipline Musculoskeletal N Non-NASA Center Flight Experiment STS-78 Shuttle Project manned short duration Y Adams G R GR U CA, Irvine Y Fitts R H RH Vanderbilt U, Nashville, TN pubmed 2002 10 9 4 0 medline 2003 2 22 4 0 entrez 2002 10 9 4 0 ppublish pubmed 12369570 MEDLINE NLM 1 12501715 2003 01 08 2005 11 16 Print Print 0559-7765 Print 29 1 1998 Jan Sheng li ke xue jin zhan [Progress in physiology] Sheng Li Ke Xue Jin Zhan [Mechanism of bone mineral loss in microgravity]. 84-6 Y Y Cui W W chi D016428 Journal Article D016454 Review China Sheng Li Ke Xue Jin Zhan 20730140R 0559-7765 IM S D018488 N Bone Demineralization, Pathologic Q000209 Y etiology D006801 N Humans D013026 N Space Flight D014893 N Weightlessness Q000009 Y adverse effects D018474 N Weightlessness Simulation Q000009 Y adverse effects 10 Cosmos 1129 Project Cosmos 2044 Project Flight Experiment STS-51B Shuttle Project STS-54 Shuttle Project manned short duration unmanned pubmed 2002 12 28 4 0 medline 2003 1 9 4 0 entrez 2002 12 28 4 0 ppublish pubmed 12501715 MEDLINE KIE 1 12599353 2003 03 10 2007 11 15 Print Print 0025-4282 Print 53 4 1994 Maryland law review (Baltimore, Md. : 1936) MD Law Rev The new Uniform Health Care Decisions Act: paving a health care decisions superhighway? 1238-54 Y Y Sabatino C P CP American Bar Association, Commission on Legal Problems of the Elderly, USA. eng D016428 Journal Article United States MD Law Rev 100971842 0025-4282 E D016223 N Advance Directives Q000331 Y legislation & jurisprudence D003657 Y Decision Making D006801 N Humans D007883 Y Legislation, Medical D008020 N Life Support Care D026684 N Personal Autonomy D019727 N Proxy Q000331 N legislation & jurisprudence D011996 N Records as Topic D014481 N Geographic United States KIE 106309 NRCBL Special Issue KIE N Death and Euthanasia N Legal Approach N Uniform Health-Care Decisions Act Y Uniform Rights of the Terminally Ill Act KIE Sabatino, Charles P KIE 102 fn. KIE KIE Bib: advance directives pubmed 1994 1 1 0 0 medline 2003 3 11 4 0 entrez 1994 1 1 0 0 ppublish pubmed 12599353 MEDLINE NLM 1 12416895 2003 04 01 2015 11 19 Print Print 1528-9117 Print 8 5 2002 Sep-Oct Cancer journal (Sudbury, Mass.) Cancer J Radiotherapy alone for lymphocyte-predominant Hodgkin\\'s disease. 377-83 PURPOSE OBJECTIVE The purpose of the study was to analyze the results with radiotherapy alone in a select group of asymptomatic adults with nonbulky, early-stage lymphocyte-predominant Hodgkin\\'s disease. PATIENTS AND METHODS METHODS Between 1963 and 1995, 36 patients with nonbulky stage IA (N = 27) or IIA (N = 9) supradiaphragmatic (N = 27) or subdiaphragmatic (N = 9) lymphocyte-predominant Hodgkin\\'s disease were treated with radiotherapy alone. Eleven of the patients underwent laparotomy. Limited-field radiotherapy involving only one side of the diaphragm and extended-field radiotherapy encompassing both sides of the diaphragm were used in 28 and 8 cases, respectively. Median dose to involved areas was 40.0 Gy given daily in 20 2.0-Gy fractions. Salvage treatmentconsisted of MOPP (mechlorethamine, vincristine, prednisone, procarbazine), CVPP/ABDIC (cyclophosphamide, vinblastine, procarbazine and prednisone/doxorubicin, bleomycin, dacarbazine, lomustine, and prednisone), or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and/or involved-field radiotherapy. RESULTS RESULTS Median follow-up was 8.8 years (range, 3.0-34.4 years). None of the 15 patients with supradiaphragmatic disease who received limited-field radiotherapy to regions that did not include the mediastinal or hilar nodes subsequently experienced relapse there. Only one of 20 patients who received supradiaphragmatic limited-field radiotherapy alone experienced relapse in the paraaortic nodes or spleen. The 5-year relapse-free and overall survival rates for the 20 patients with stage IA lymphocyte-predominant Hodgkin\\'s disease treated with involved-field or regional radiotherapy were 95% and 100%, respectively. There were no cases of severe or life-threatening cardiac toxicity. No solid tumors have been observed in-field in patients treated with limited-field radiotherapy, even though they have been followed up longer than those treated with extended-field radiotherapy (median follow-up, 11.6 vs 5.5 years); two solid tumors have developed in-field in patients who received extended-field radiotherapy. DISCUSSION CONCLUSIONS Involved-field or regional radiotherapy alone may be adequate in stage IA lymphocyte-predominant Hodgkin\\'s disease patients. Longer follow-up will help to more clearly define the risks of cardiac toxicity and solid tumors that result from involved-field or regional radiotherapy, which appear to be low based on follow-up to date. Y Y Schlembach Pamela J PJ Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA. Y Wilder Richard B RB Y Jones Dan D Y Ha Chul S CS Y Fayad Luis E LE Y Younes Anas A Y Hagemeister Fredrick F Y Hess Mark M Y Cabanillas Fernando F Y Cox James D JD eng Y CA 16672 CA NCI NIH HHS United States CA 6294 CA NCI NIH HHS United States D016428 Journal Article D013487 Research Support, U.S. Gov\\'t, P.H.S. United States Cancer J 100931981 1528-9117 11056-06-7 D001761 Bleomycin 35S93Y190K D011344 Procarbazine 50D9XSG0VR D008466 Mechlorethamine 5J49Q6B70F D014750 Vincristine 5V9KLZ54CY D014747 Vinblastine 7BRF0Z81KG D008130 Lomustine 7GR28W0FJI D003606 Dacarbazine 80168379AG D004317 Doxorubicin VB0R961HZT D011241 Prednisone Protocol C040721 ABDIC protocol Protocol C034632 ABVD protocol Protocol C034078 CVPP protocol Protocol C014553 MOPP protocol IM CommentIn Cancer J. 2002 Sep-Oct;8(5):367-8 1 12416892 D000293 N Adolescent D000328 N Adult D000971 N Antineoplastic Combined Chemotherapy Protocols Q000008 N administration & dosage Q000627 N therapeutic use D001761 N Bleomycin Q000008 N administration & dosage D003131 N Combined Modality Therapy D003606 N Dacarbazine Q000008 N administration & dosage D004317 N Doxorubicin Q000008 N administration & dosage D005260 N Female D006689 N Hodgkin Disease Q000188 N drug therapy Q000532 Y radiotherapy D006801 N Humans D008130 N Lomustine Q000008 N administration & dosage D008297 N Male D008466 N Mechlorethamine Q000008 N administration & dosage D008875 N Middle Aged D011241 N Prednisone Q000008 N administration & dosage D011344 N Procarbazine Q000008 N administration & dosage D011879 N Radiotherapy Dosage D012189 N Retrospective Studies D016879 N Salvage Therapy Q000379 N methods D016019 N Survival Analysis D016896 N Treatment Outcome D014747 N Vinblastine Q000008 N administration & dosage D014750 N Vincristine Q000008 N administration & dosage pubmed 2002 11 6 4 0 medline 2003 4 2 5 0 entrez 2002 11 6 4 0 ppublish pubmed 12416895 MEDLINE KIE 1 12599354 2003 03 10 2004 11 17 Print Print 0025-4282 Print 53 4 1994 Maryland law review (Baltimore, Md. : 1936) MD Law Rev The right to refuse life-sustaining medical treatment: national trend and recent changes in Maryland law. 1306-43 Y Y Goldmeier K E KE eng D016428 Journal Article United States MD Law Rev 100971842 0025-4282 E D003657 Y Decision Making D005066 N Euthanasia, Passive Q000331 Y legislation & jurisprudence D005190 N Family Q000523 N psychology D006801 N Humans D007872 N Legal Guardians Q000331 Y legislation & jurisprudence D008020 Y Life Support Care D008396 N Geographic Maryland D018458 N Persistent Vegetative State D012297 N Right to Die Q000331 Y legislation & jurisprudence D016312 N Treatment Refusal Q000331 Y legislation & jurisprudence D014481 N Geographic United States KIE 106310 NRCBL Special Issue KIE N Death and Euthanasia N Legal Approach N Mack v. Mack KIE Goldmeier, Karen E KIE 235 fn. KIE KIE Bib: allowing to die/legal aspects; treatment refusal pubmed 1994 1 1 0 0 medline 2003 3 11 4 0 entrez 1994 1 1 0 0 ppublish pubmed 12599354 PubMed-not-MEDLINE NLM 1 11909345 2002 05 16 2003 11 03 Print-Electronic Print 0031-9007 Print 88 10 2002 Mar 11 Physical review letters Phys. Rev. Lett. Measurement of B --> K*gamma branching fractions and charge asymmetries. 101805 The branching fractions of the exclusive decays B0-->K(*0)gamma and B+-->K(*+)gamma are measured from a sample of (22.74+/-0.36)x10(6) BB decays collected with the BABAR detector at the PEP-II asymmetric e(+)e(-) collider. We find B (B0-->K(*0)gamma) = [4.23+/-0.40(stat)+/-0.22(syst)]x10(-5), B(B+-->K(*+)gamma) = [3.83+/-0.62(stat)+/-0.22(syst)]x10(-5) and constrain the CP-violating charge asymmetry to be -0.170<A(CP)(B-->K(*)gamma)<0.082 at 90% C.L. Y Y Aubert B B Laboratoire de Physique des Particules, F-74941 Annecy-le-Vieux, France. Y Boutigny D D Y Gaillard J-M JM Y Hicheur A A Y Karyotakis Y Y Y Lees J P JP Y Robbe P P Y Tisserand V V Y Palano A A Y Chen G P GP Y Chen J C JC Y Qi N D ND Y Rong G G Y Wang P P Y Zhu Y S YS Y Eigen G G Y Reinertsen P L PL Y Stugu B B Y Abbott B B Y Abrams G S GS Y Borgland A W AW Y Breon A B AB Y Brown D N DN Y Button-Shafer J J Y Cahn R N RN Y Clark A R AR Y Gill M S MS Y Gritsan A V AV Y Groysman Y Y Y Jacobsen R G RG Y Kadel R W RW Y Kadyk J J Y Kerth L T LT Y Kluth S S Y Kolomensky Yu G YG Y Kral J F JF Y LeClerc C C Y Levi M E ME Y Liu T T Y Lynch G G Y Meyer A B AB Y Momayezi M M Y Oddone P J PJ Y Perazzo A A Y Pripstein M M Y Roe N A NA Y Romosan A A Y Ronan M T MT Y Shelkov V G VG Y Telnov A V AV Y Wenzel W A WA Y Zisman M S MS Y Bright-Thomas P G PG Y Harrison T J TJ Y Hawkes C M CM Y Knowles D J DJ Y O\\'Neale S W SW Y Penny R C RC Y Watson A T AT Y Watson N K NK Y Deppermann T T Y Goetzen K K Y Koch H H Y Krug J J Y Kunze M M Y Lewandowski B B Y Peters K K Y Schmuecker H H Y Steinke M M Y Andress J C JC Y Barlow N R NR Y Bhimji W W Y Chevalier N N Y Clark P J PJ Y Cottingham W N WN Y De Groot N N Y Dyce N N Y Foster B B Y McFall J D JD Y Wallom D D Y Wilson F F FF Y Abe K K Y Hearty C C Y Mattison T S TS Y McKenna J A JA Y Thiessen D D Y Jolly S S Y McKemey A K AK Y Tinslay J J Y Blinov V E VE Y Bukin A D AD Y Bukin D A DA Y Buzykaev A R AR Y Golubev V B VB Y Ivanchenko V N VN Y Korol A A AA Y Kravchenko E A EA Y Onuchin A P AP Y Salnikov A A AA Y Serednyakov S I SI Y Skovpen Yu I YI Y Telnov V I VI Y Yushkov A N AN Y Best D D Y Lankford A J AJ Y Mandelkern M M Y McMahon S S Y Stoker D P DP Y Ahsan A A Y Arisaka K K Y Buchanan C C Y Chun S S Y Branson J G JG Y MacFarlane D B DB Y Prell S S Y Rahatlou Sh Sh Y Raven G G Y Sharma V V Y Campagnari C C Y Dahmes B B Y Hart P A PA Y Kuznetsova N N Y Levy S L SL Y Long O O Y Lu A A Y Richman J D JD Y Verkerke W W Y Witherell M M Y Yellin S S Y Beringer J J Y Dorfan D E DE Y Eisner A M AM Y Frey A A Y Grillo A A AA Y Grothe M M Y Heusch C A CA Y Johnson R P RP Y Kroeger W W Y Lockman W S WS Y Pulliam T T Y Sadrozinski H H Y Schalk T T Y Schmitz R E RE Y Schumm B A BA Y Seiden A A Y Turri M M Y Walkowiak W W Y Williams D C DC Y Wilson M G MG Y Chen E E Y Dubois-Felsmann G P GP Y Dvoretskii A A Y Hitlin D G DG Y Metzler S S Y Oyang J J Y Porter F C FC Y Ryd A A Y Samuel A A Y Weaver M M Y Yang S S Y Zhu R Y RY Y Devmal S S Y Geld T L TL Y Jayatilleke S S Y Mancinelli G G Y Meadows B T BT Y Sokoloff M D MD Y Barillari T T Y Bloom P P Y Dima M O MO Y Fahey S S Y Ford W T WT Y Johnson D R DR Y Nauenberg U U Y Olivas A A Y Park H H Y Rankin P P Y Roy J J Y Sen S S Y Smith J G JG Y van Hoek W C WC Y Wagner D L DL Y Blouw J J Y Harton J L JL Y Krishnamurthy M M Y Soffer A A Y Toki W H WH Y Wilson R J RJ Y Zhang J J Y Brandt T T Y Brose J J Y Colberg T T Y Dahlinger G G Y Dickopp M M Y Dubitzky R S RS Y Hauke A A Y Maly E E Y Mller-Pfefferkorn R R Y Otto S S Y Schubert K R KR Y Schwierz R R Y Spaan B B Y Wilden L L Y Behr L L Y Bernard D D Y Bonneaud G R GR Y Brochard F F Y Cohen-Tanugi J J Y Ferrag S S Y Roussot E E Y T\\'Jampens S S Y Thiebaux Ch Ch Y Vasileiadis G G Y Verderi M M Y Anjomshoaa A A Y Bernet R R Y Khan A A Y Lavin D D Y Muheim F F Y Playfer S S Y Swain J E JE Y Falbo M M Y Borean C C Y Bozzi C C Y Dittongo S S Y Folegani M M Y Piemontese L L Y Treadwell E E Y Anulli F F Y Baldini-Ferroli R R Y Calcaterra A A Y de Sangro R R Y Falciai D D Y Finocchiaro G G Y Patteri P P Y Peruzzi I M IM Y Piccolo M M Y Xie Y Y Y Zallo A A Y Bagnasco S S Y Buzzo A A Y Contri R R Y Crosetti G G Y Fabbricatore P P Y Farinon S S Y Lo Vetere M M Y Macri M M Y Monge M R MR Y Musenich R R Y Pallavicini M M Y Parodi R R Y Passaggio S S Y Pastore F C FC Y Patrignani C C Y Pia M G MG Y Priano C C Y Robutti E E Y Santroni A A Y Morii M M Y Bartoldus R R Y Dignan T T Y Hamilton R R Y Mallik U U Y Cochran J J Y Crawley H B HB Y Fischer P-A PA Y Lamsa J J Y Meyer W T WT Y Rosenberg E I EI Y Benkebil M M Y Grosdidier G G Y Hast C C Y Hcker A A Y Lacker H M HM Y Laplace S S Y Lepeltier V V Y Lutz A M AM Y Plaszczynski S S Y Schune M H MH Y Trincaz-Duvoid S S Y Valassi A A Y Wormser G G Y Bionta R M RM Y Brigljevi V V VV Y Lange D J DJ Y Mugge M M Y Shi X X Y van Bibber K K Y Wenaus T J TJ Y Wright D M DM Y Wuest C R CR Y Carroll M M Y Fry J R JR Y Gabathuler E E Y Gamet R R Y George M M Y Kay M M Y Payne D J DJ Y Sloane R J RJ Y Touramanis C C Y Aspinwall M L ML Y Bowerman D A DA Y Dauncey P D PD Y Egede U U Y Eschrich I I Y Gunawardane N J W NJ Y Nash J A JA Y Sanders P P Y Smith D D Y Azzopardi D E DE Y Back J J JJ Y Dixon P P Y Harrison P F PF Y Potter R J L RJ Y Shorthouse H W HW Y Strother P P Y Vidal P B PB Y Williams M I MI Y Cowan G G Y George S S Y Green M G MG Y Kurup A A Y Marker C E CE Y McGrath P P Y McMahon T R TR Y Ricciardi S S Y Salvatore F F Y Scott I I Y Vaitsas G G Y Brown D D Y Davis C L CL Y Allison J J Y Barlow R J RJ Y Boyd J T JT Y Forti A C AC Y Fullwood J J Y Jackson F F Y Lafferty G D GD Y Savvas N N Y Simopoulos E T ET Y Weatherall J H JH Y Farbin A A Y Jawahery A A Y Lillard V V Y Olsen J J Y Roberts D A DA Y Schieck J R JR Y Blaylock G G Y Dallapiccola C C Y Flood K T KT Y Hertzbach S S SS Y Kofler R R Y Moore T B TB Y Staengle H H Y Willocq S S Y Brau B B Y Cowan R R Y Sciolla G G Y Taylor F F Y Yamamoto R K RK Y Milek M M Y Patel P M PM Y Trischuk J J Y Lanni F F Y Palombo F F Y Bauer J M JM Y Booke M M Y Cremaldi L L Y Eschenburg V V Y Kroeger R R Y Reidy J J Y Sanders D A DA Y Summers D J DJ Y Martin J P JP Y Nief J Y JY Y Seitz R R Y Taras P P Y Zacek V V Y Nicholson H H Y Sutton C S CS Y Cartaro C C Y Cavallo N N Y De Nardo G G Y Fabozzi F F Y Gatto C C Y Lista L L Y Paolucci P P Y Piccolo D D Y Sciacca C C Y LoSecco J M JM Y Alsmiller J R G JR Y Gabriel T A TA Y Handler T T Y Brau J J Y Frey R R Y Iwasaki M M Y Sinev N B NB Y Strom D D Y Colecchia F F Y Dal Corso F F Y Dorigo A A Y Galeazzi F F Y Margoni M M Y Michelon G G Y Morandin M M Y Posocco M M Y Rotondo M M Y Simonetto F F Y Stroili R R Y Torassa E E Y Voci C C Y Benayoun M M Y Briand H H Y Chauveau J J Y David P P Y de La Vaissire Ch Ch Y Del Buono L L Y Hamon O O Y Le Diberder F F Y Leruste Ph P Y Lory J J Y Roos L L Y Stark J J Y Versill S S Y Manfredi P F PF Y Re V V Y Speziali V V Y Frank E D ED Y Gladney L L Y Guo Q H QH Y Panetta J H JH Y Angelini C C Y Batignani G G Y Bettarini S S Y Bondioli M M Y Carpinelli M M Y Forti F F Y Giorgi M A MA Y Lusiani A A Y Martinez-Vidal F F Y Morganti M M Y Neri N N Y Paoloni E E Y Rama M M Y Rizzo G G Y Sandrelli F F Y Simi G G Y Triggiani G G Y Walsh J J Y Haire M M Y Judd D D Y Paick K K Y Turnbull L L Y Wagoner D E DE Y Albert J J Y Bula C C Y Elmer P P Y Lu C C Y McDonald K T KT Y Miftakov V V Y Schaffner S F SF Y Smith A J S AJ Y Tumanov A A Y Varnes E W EW Y Cavoto G G Y del Re D D Y Faccini R R Y Ferrarotto F F Y Ferroni F F Y Fratini K K Y Lamanna E E Y Leonardi E E Y Mazzoni M A MA Y Morganti S S Y Piredda G G Y Safai Tehrani F F Y Serra M M Y Voena C C Y Christ S S Y Waldi R R Y Adye T T Y Franek B B Y Geddes N I NI Y Gopal G P GP Y Xella S M SM Y Aleksan R R Y De Domenico G G Y Emery S S Y Gaidot A A Y Ganzhur S F SF Y Giraud P-F PF Y Hamel Monchenault G G Y Kozanecki W W Y Langer M M Y London G W GW Y Mayer B B Y Serfass B B Y Vasseur G G Y Yche Ch Ch Y Zito M M Y Copty N N Y Purohit M V MV Y Singh H H Y Yumiceva F X FX Y Adam I I Y Anthony P L PL Y Aston D D Y Baird K K Y Berger J P JP Y Bloom E E Y Boyarski A M AM Y Bulos F F Y Calderini G G Y Claus R R Y Convery M R MR Y Coupal D P DP Y Coward D H DH Y Dorfan J J Y Doser M M Y Dunwoodie W W Y Field R C RC Y Glanzman T T Y Godfrey G L GL Y Gowdy S J SJ Y Grosso P P Y Himel T T Y Hryn\\'ova T T Y Huffer M E ME Y Innes W R WR Y Jessop C P CP Y Kelsey M H MH Y Kim P P Y Kocian M L ML Y Langenegger U U Y Leith D W G S DW Y Luitz S S Y Luth V V Y Lynch H L HL Y Marsiske H H Y Menke S S Y Messner R R Y Moffeit K C KC Y Mount R R Y Muller D R DR Y O\\'Grady C P CP Y Perl M M Y Petrak S S Y Quinn H H Y Ratcliff B N BN Y Robertson S H SH Y Rochester L S LS Y Roodman A A Y Schietinger T T Y Schindler R H RH Y Schwiening J J Y Seeman J T JT Y Serbo V V VV Y Snyder A A Y Soha A A Y Spanier S M SM Y Stelzer J J Y Su D D Y Sullivan M K MK Y Tanaka H A HA Y Va\\'vra J J Y Wagner S R SR Y Weinstein A J R AJ Y Wienands U U Y Wisniewski W J WJ Y Wright D H DH Y Young C C CC Y Burchat P R PR Y Cheng C H CH Y Kirkby D D Y Meyer T I TI Y Roat C C Y De Silva A A Y Henderson R R Y Bugg W W Y Cohn H H Y Weidemann A W AW Y Izen J M JM Y Kitayama I I Y Lou X C XC Y Turcotte M M Y Bianchi F F Y Bona M M Y Di Girolamo B B Y Gamba D D Y Smol A A Y Zanin D D Y Bosisio L L Y Della Ricca G G Y Lanceri L L Y Pompili A A Y Poropat P P Y Vuagnin G G Y Panvini R S RS Y Brown C M CM Y Kowalewski R R Y Roney J M JM Y Band H R HR Y Charles E E Y Dasu S S Y Di Lodovico F F Y Eichenbaum A M AM Y Hu H H Y Johnson J R JR Y Liu R R Y Nielsen J J Y Pan Y Y Y Prepost R R Y Scott I J IJ Y Sekula S J SJ Y von Wimmersperg-Toeller J H JH Y Wu S L SL Y Yu Z Z Y Zobernig H H Y Kordich T M B TM Y Neal H H Y BABAR Collaborations eng D016428 Journal Article Electronic 2002 02 26 United States Phys Rev Lett 0401141 0031-9007 received 2001 10 25 pubmed 2002 3 23 10 0 medline 2002 3 23 10 1 entrez 2002 3 23 10 0 ppublish pubmed 11909345 doi 10.1103/PhysRevLett.88.101805 MEDLINE NLM 1 12742516 2009 02 27 2013 11 21 Print Electronic 1879-0712 Internet 468 2 2003 May 09 European journal of pharmacology Eur. J. Pharmacol. S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties. 93-101 Mitochondrial Ca(2+) accumulation can induce a sudden increase in the permeability of the inner membrane. This phenomenon is due to the generation of a large nonselective ion channel, termed the permeability transition pore (PTP), which contributes to cellular injury during ischemia and reperfusion. Inhibition of PTP generation constitutes a relevant pharmacological target to protect a cell from death. In this study, we examined the effect of S-15176 ((N-[(3,5-di-tertiobutyl-4-hydroxy-1-thiophenyl)]-3-propyl-N\\'-(2,3,4-trimethoxybenzyl)piperazine), a novel anti-ischemic agent, on PTP in rat liver mitochondria. S-15176 prevented PTP opening generated by various triggering agents, as attested by the concentration-dependent inhibition of mitochondrial swelling, of mitochondrial membrane potential dissipation and of NADPH oxidation. These effects were associated with an increase in the Ca(2+) loading capacity of mitochondria. S-15176 was a strong inhibitor of lipid peroxidation, but experiments with another trimetazidine derivative devoid of antioxidant activity indicated that this activity was not essential to the inhibitory effect. Binding studies demonstrated that [3H]S-15176 bound to mitochondrial binding sites, especially those localized in the inner membrane. These sites were shared by several well-known inhibitors of PTP opening. These results demonstrate that the mechanism by which S-15176 protects mitochondria against the deleterious effects of ischemia-reperfusion involves inhibition of PTP opening and provide evidence that the drug operates through low structural specificity binding sites located in the inner mitochondrial membrane. Y Y Elimadi Aziz A Dpartement de Pharmacologie, Facult de Mdecine de Paris XII, Crteil, France Y Jullien Vincent V Y Tillement Jean Paul JP Y Morin Didier D eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Netherlands Eur J Pharmacol 1254354 0014-2999 0 D000975 Antioxidants 0 D033681 Mitochondrial Membrane Transport Proteins 0 D010879 Piperazines 0 C416838 S 15176 0 C120771 mitochondrial permeability transition pore 53-59-8 D009249 NADP SY7Q814VUP D002118 Calcium IM D000818 N Animals D000975 N Antioxidants Q000494 Y pharmacology D001665 N Binding Sites D002118 N Calcium Q000378 N metabolism D015227 N Lipid Peroxidation Q000187 N drug effects D008297 N Male D053078 N Membrane Potential, Mitochondrial Q000187 N drug effects D008930 N Mitochondria, Liver Q000187 Y drug effects Q000378 N metabolism D033681 N Mitochondrial Membrane Transport Proteins Q000187 Y drug effects Q000378 N metabolism D009249 N NADP Q000378 N metabolism D010084 N Oxidation-Reduction D010879 N Piperazines Q000494 Y pharmacology D051381 N Rats D017208 N Rats, Wistar pubmed 2003 5 14 5 0 medline 2009 2 28 9 0 entrez 2003 5 14 5 0 ppublish pubmed 12742516 pii S0014299903016716 MEDLINE NLM 1 12742519 2009 02 27 2014 11 20 Print Electronic 1879-0712 Internet 468 2 2003 May 09 European journal of pharmacology Eur. J. Pharmacol. Risperidone reduces limited access alcohol drinking in alcohol-preferring rats. 121-7 An atypical antipsychotic drug risperidone reduced ethanol drinking of ethanol-preferring Alko, Alcohol (AA) rats in a limited access paradigm. Its effect was transient at a dose known to preferentially antagonize the 5-HT(2) receptors (0.1 mg/kg, s.c.), but long-lasting when the dose was increased to 1.0 mg/kg that also blocks dopamine D(2) receptors. Risperidone also reduced dose-dependently locomotor activity and limited access saccharin intake of the AA rats, indicating that its effect on ethanol drinking was not selective. Risperidone at 0.1 mg/kg given before four successive daily ethanol-drinking sessions significantly reduced the ethanol intake. These data from an animal model of high ethanol intake suggest that risperidone should be tested in various populations of alcoholics for reducing ethanol consumption. Y Y Ingman Kimmo K Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland Y Honkanen Aapo A Y Hyyti Petri P Y Huttunen Matti O MO Y Korpi Esa R ER eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Netherlands Eur J Pharmacol 1254354 0014-2999 0 D014150 Antipsychotic Agents 0 D065127 Dopamine D2 Receptor Antagonists 0 D058830 Serotonin 5-HT2 Receptor Antagonists FST467XS7D D012439 Saccharin L6UH7ZF8HC D018967 Risperidone IM D000428 N Alcohol Drinking Q000517 Y prevention & control D000437 N Alcoholism Q000188 N drug therapy D000818 N Animals D014150 N Antipsychotic Agents Q000008 N administration & dosage Q000494 Y pharmacology D004195 N Disease Models, Animal D065127 N Dopamine D2 Receptor Antagonists D004305 N Dose-Response Relationship, Drug D008297 N Male D009043 N Motor Activity Q000187 Y drug effects D051381 N Rats D018967 N Risperidone Q000008 N administration & dosage Q000494 Y pharmacology D012439 N Saccharin D012646 N Self Administration D058830 N Serotonin 5-HT2 Receptor Antagonists pubmed 2003 5 14 5 0 medline 2009 2 28 9 0 entrez 2003 5 14 5 0 ppublish pubmed 12742519 pii S0014299903016698 MEDLINE NLM 1 12742518 2009 02 27 2014 11 20 Print Electronic 1879-0712 Internet 468 2 2003 May 09 European journal of pharmacology Eur. J. Pharmacol. Behavioral effects of rimcazole analogues alone and in combination with cocaine. 109-19 Several sigma receptor ligands have been reported to also have affinity for the dopamine transporter, among them rimcazole (9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride). However, rimcazole lacks behavioral effects like those of other dopamine uptake inhibitors, such as cocaine and GBR 12909 (1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride). Because of this profile, the interactions with cocaine of rimcazole and several of its novel analogues were assessed. The compounds studied were rimcazole, its N-methyl analogue, SH 1-73 (9-[3-(cis-3,5-dimethyl-4-methyl-1-piperazinyl)-propyl]carbazole hydrobromide), the dibrominated analogue, SH 1-76 (3,6-dibromo-9-[3-(cis-3,5-dimethyl-1-piperazinyl)-propyl]carbazole hydrochloride), and the N-propylphenyl analogues, SH 3-24 ([3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]diphenylamine hydrochloride) and SH 3-28 (9-[3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]carbazole hydrobromide). The former has a diphenyl-amine group in place of the carbazole moiety of rimcazole, giving the compound additional structural similarity to GBR 12909. The rimcazole analogues produced dose-related decreases in locomotor activity, and also decreased cocaine-stimulated activity in mice. In rats trained to discriminate 10 mg/kg cocaine (i.p.) from saline injections, cocaine and GBR 12909 each produced a dose-related increase in cocaine-appropriate responding. Cocaine also increased rates of responding. SH 3-28 decreased cocaine-appropriate responding at the cocaine training dose to about 58% (SH 3-28) with two of five subjects selecting the cocaine response key. Neither rimcazole nor SH 3-24 produced a significant attenuation of the discriminative effects of cocaine. Rimcazole and its analogs all attenuated the increases in rates of responding produced by cocaine. In contrast to effects obtained with rimcazole analogs, GBR 12909 potentiated the cocaine-induced increases in locomotor activity and operant behavior, as well as the discriminative-stimulus effects of cocaine. The present results indicate that analogues of rimcazole can attenuate the behavioral effects of cocaine, and though the mechanism for these effects is not presently clear, it is possible that this attenuation maybe mediated by actions of the rimcazole analogues at the dopamine transporter and/or sigma receptors. Y Y Katz Jonathan L JL Department of Health and Human Services, Medications Discovery Research Branch, NIDA Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA. jkatz@intra.nida.nih.gov Y Libby Therissa A TA Y Kopajtic Theresa T Y Husbands Stephen M SM Y Newman Amy Hauck AH eng D016428 Journal Article D052061 Research Support, N.I.H., Extramural Netherlands Eur J Pharmacol 1254354 0014-2999 0 D002227 Carbazoles 0 D050483 Dopamine Plasma Membrane Transport Proteins 0 D018765 Dopamine Uptake Inhibitors 0 D017480 Receptors, sigma C3N1PS8CX1 C034931 rimcazole I5Y540LHVR D003042 Cocaine IM D000818 N Animals D001522 N Behavior, Animal Q000187 Y drug effects D002227 N Carbazoles Q000008 N administration & dosage Q000819 N agonists Q000494 Y pharmacology D003042 N Cocaine Q000008 N administration & dosage Q000494 Y pharmacology D003216 N Conditioning, Operant Q000187 N drug effects D050483 N Dopamine Plasma Membrane Transport Proteins Q000187 Y drug effects Q000378 N metabolism D018765 N Dopamine Uptake Inhibitors Q000008 N administration & dosage Q000494 N pharmacology D004305 N Dose-Response Relationship, Drug D008297 N Male D051379 N Mice D009043 N Motor Activity Q000187 N drug effects D051381 N Rats D017207 N Rats, Sprague-Dawley D017480 N Receptors, sigma Q000187 N drug effects Q000378 N metabolism D013329 N Structure-Activity Relationship pubmed 2003 5 14 5 0 medline 2009 2 28 9 0 entrez 2003 5 14 5 0 ppublish pubmed 12742518 pii S0014299903016388 MEDLINE NLM 1 13072632 2003 05 01 2009 11 11 Print Print 217 2 1953 Jan 05 Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie Naunyn Schmiedebergs Arch Exp Pathol Pharmakol [Pharmacology of phosphoric acid esters; diethylthiophosphoric acid ester of ethylthioglycol]. 144-52 Y Y WIRTH W W und D016428 Journal Article Zur Pharmakologie der Phosphorsureester; diathylthiophosphorsureester des Athylthioglykol Systox-Wirkstoff. Germany Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 0054224 0 D004952 Esters 0 D007306 Insecticides 0 D010755 Organophosphates 0 D010710 Phosphates OM D004952 Y Esters D007306 Y Insecticides D010755 Y Organophosphates D010710 Y Phosphates CLML 5324:43336:331:494 NLM Y INSECTICIDES Y PHOSPHATES pubmed 1953 1 5 medline 1953 1 5 0 1 entrez 1953 1 5 0 0 ppublish pubmed 13072632 MEDLINE NLM 1 13634534 2000 07 01 2013 11 21 Print Print 0014-2565 Print 71 6 1958 Dec 31 Revista clinica espanola Rev Clin Esp [Physiopathology of phosphorus and calcium changes and of bone lesions in glomerular nephropathies]. 365-77 Y Y LICHTWITZ A A Y DE SEZE S S Y PARLIER R R Y HIOCO D D Y BORDIER P P Y STRAUSS M M Y FERGOLA-MIRAVET L L spa D016428 Journal Article Fisiopatologa de las modificaciones fosfoclcicas y de las lesiones seas en las nefropatas glomerulares. Spain Rev Clin Esp 8608576 0014-2565 27YLU75U4W D010758 Phosphorus SY7Q814VUP D002118 Calcium OM D001847 N Bone Diseases Q000502 Y physiology D002118 N Calcium Q000378 Y metabolism D005921 N Glomerulonephritis Q000502 Y physiology D006801 N Humans D007674 Y Kidney Diseases D010758 N Phosphorus Q000378 Y metabolism CLML 5936:8365:92:105:226:416 NLM Y BONE DISEASES/physiology Y CALCIUM/metabolism Y GLOMERULONEPHRITIS/physiology Y PHOSPHORUS/metabolism pubmed 1958 12 31 medline 1958 12 31 0 1 entrez 1958 12 31 0 0 ppublish pubmed 13634534 MEDLINE NLM 1 14177620 1996 12 01 2006 11 15 Print Print 0016-5662 Print 68 1963 Dec 31 Gazzetta internazionale di medicina e chirurgia Gazz Int Med Chir [JEJUNAL BIOPSY AND LIPEMIA TOLERANCE TEST IN CIRRHOTIC PATIENTS]. SUPPL:4309-22 Y Y CESAREBASILE R R Y GABBRIELLI L L Y COLAVOLPE V V Y RULLI V V ita D016428 Journal Article BIOPSIA DIGIUNALE E LIPEMIA DA CARICO DEL CIRROTICO. Italy Gazz Int Med Chir 0373000 0016-5662 0 D002914 Chylomicrons 0 D008055 Lipids 0 D008074 Lipoproteins OM D001201 Y Ascites D001706 Y Biopsy D002914 Y Chylomicrons D003920 Y Diabetes Mellitus D005745 Y Gastric Acidity Determination D005756 Y Gastritis D006505 Y Hepatitis D006506 Y Hepatitis A D006801 N Humans D006949 Y Hyperlipidemias D007565 Y Jaundice D007583 Y Jejunum D050356 Y Lipid Metabolism D008055 N Lipids Q000097 Y blood D008074 Y Lipoproteins D008103 Y Liver Cirrhosis D008288 Y Malaria D010336 Y Pathology D010998 Y Pleurisy D011488 Y Protein Deficiency NLM Y ASCITES Y BLOOD LIPIDS Y CHYLOMICRONS Y DIABETES MELLITUS Y GASTRIC ACIDITY DETERMINATION Y GASTRITIS Y HEPATITIS, INFECTIOUS Y JAUNDICE Y JEJUNUM Y LIPID METABOLISM Y LIPOPROTEINS Y LIVER CIRRHOSIS Y MALARIA Y PATHOLOGY Y PLEURISY Y PROTEIN DEFICIENCY pubmed 1963 12 31 medline 1963 12 31 0 1 entrez 1963 12 31 0 0 ppublish pubmed 14177620 MEDLINE NLM 1 14337379 1996 12 01 2017 09 08 Print Print 0002-9378 Print 93 1965 Oct 01 American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. SEROTONIN CONTENT OF HUMAN PLACENTA AND FETUS DURING PREGNANCY. 411-5 Y Y KOREN Z Z Y PFEIFER Y Y Y SULMAN F G FG eng D016428 Journal Article United States Am J Obstet Gynecol 0370476 0002-9378 333DO1RDJY D012701 Serotonin OM D000028 Y Abortion, Induced D002585 Y Cesarean Section D005260 N Female D005333 Y Fetus D006651 Y Histocytochemistry D006801 N Humans D008660 Y Metabolism D010920 Y Placenta D011247 N Pregnancy D012701 Y Serotonin NLM Y ABORTION Y CESAREAN SECTION Y FETUS Y HISTOCYTOCHEMISTRY Y METABOLISM Y PLACENTA Y PREGNANCY Y SEROTONIN pubmed 1965 10 1 medline 1965 10 1 0 1 entrez 1965 10 1 0 0 ppublish pubmed 14337379 pii 0002-9378(65)90070-0 MEDLINE NLM 1 14316043 1996 12 01 2015 11 29 Print Print 0042-0255 Print 2 1965 Dec-1966 Jan University of Toronto undergraduate dental journal Univ Toronto Undergrad Dent J THE RESPONSIBILITY OF THE DENTIST AND THE DENTAL PROFESSION WITH RESPECT TO JAW FRACTURES. 5-11 Y Y PHILLIPS H H eng D016428 Journal Article Canada Univ Toronto Undergrad Dent J 7905911 0042-0255 D OM D003815 Y Dentists D005592 Y Fracture Fixation D050723 Y Fractures, Bone D006801 N Humans D007400 Y Interprofessional Relations D007568 Y Jaw D007572 Y Jaw Fractures D008338 Y Mandibular Injuries D008446 Y Maxillofacial Injuries D011215 Y Practice Management, Dental NLM Y DENTISTS Y FRACTURE FIXATION Y FRACTURES Y INTERPROFESSIONAL RELATIONS Y JAW Y MANDIBULAR INJURIES Y MAXILLOFACIAL INJURIES Y PRACTICE MANAGEMENT, DENTAL pubmed 1965 12 1 medline 1965 12 1 0 1 entrez 1965 12 1 0 0 ppublish pubmed 14316043 MEDLINE NLM 1 14594616 2004 02 02 2004 11 17 Print Electronic 1087-2108 Internet 9 4 2003 Oct Dermatology online journal Dermatol. Online J. Epidermal nevus. 43 A 20-year-old woman presented with an asymptomatic, life-long, verrucous, hyperpigmented plaque on the face and neck that corresponded to the lines of Blaschko. Histopathologic examination shows an epidermal nevus. This nevus presents a challenge in management because of the location and extent of the lesion. Y Y Cassetty Christopher T CT Ronald O. Perelman Department of Dermatology, New York University, USA. Y Leonard Aimee L AL eng D002363 Case Reports D016428 Journal Article United States Dermatol Online J 9610776 1087-2108 IM D000328 N Adult D005153 Y Facial Neoplasms Q000473 N pathology Q000628 N therapy D005260 N Female D006801 N Humans D009506 Y Nevus Q000473 N pathology Q000628 N therapy D012878 Y Skin Neoplasms Q000473 N pathology Q000628 N therapy pubmed 2003 11 5 5 0 medline 2004 2 3 5 0 entrez 2003 11 5 5 0 ppublish pubmed 14594616 MEDLINE NLM 1 14668029 2015 02 20 2003 12 11 Print Electronic 1607-8454 Internet 8 6 2003 Dec Hematology (Amsterdam, Netherlands) Hematology Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. 359-65 Y Y Dorsam Robert T RT Y Murugappan Swaminathan S Y Ding Zhongren Z Y Kunapuli Satya P SP eng D016428 Journal Article D016454 Review England Hematology 9708388 1024-5332 0 D010975 Platelet Aggregation Inhibitors 0 D058921 Purinergic P2Y Receptor Antagonists 0 D058925 Receptors, Purinergic P2Y12 A74586SNO7 C055162 clopidogrel OM90ZUW7M1 D013988 Ticlopidine IM D000595 N Amino Acid Sequence D000818 N Animals D001792 N Blood Platelets Q000187 N drug effects Q000378 N metabolism D006801 N Humans D008969 N Molecular Sequence Data D010975 N Platelet Aggregation Inhibitors Q000737 N chemistry Q000494 Y pharmacology D058921 N Purinergic P2Y Receptor Antagonists Q000737 N chemistry Q000494 Y pharmacology D058925 N Receptors, Purinergic P2Y12 Q000097 N blood Q000737 N chemistry Q000378 Y metabolism D013988 N Ticlopidine Q000031 Y analogs & derivatives Q000737 N chemistry Q000494 N pharmacology pubmed 2003 12 12 5 0 medline 2015 2 24 6 0 entrez 2003 12 12 5 0 ppublish pubmed 14668029 doi 10.1080/10245330310001621260 pii 3FQ445E3467ML63X MEDLINE NLM 1 14668030 2015 02 20 2003 12 11 Print Electronic 1607-8454 Internet 8 6 2003 Dec Hematology (Amsterdam, Netherlands) Hematology Platelet counts and interleukin-6 (IL-6) promoter polymorphism in patients with Gaucher disease. 367-8 INTRODUCTION BACKGROUND The purpose of this study was to ascertain whether polymorphism of the IL-6 promoter gene affects platelet counts among patients with Gaucher disease since it has been shown that in healthy individuals, the CC genotype is correlated with lower platelet counts. METHODS METHODS Blood samples from all adult patients seen at a referral clinic during a 12 month period were taken for PCR analysis for the IL-6 promoter polymorphism. Platelet counts were culled from the records on date of presentation and prior to advent of enzyme replacement therapy where relevant. RESULTS RESULTS Of 138 Ashkenazi Jewish patients, 31 patients had platelet counts <60,000/mm<PRE>3</PRE> and 37 patients had normal platelet counts (>150,000/mm<PRE>3</PRE>). Of the former group, 4/31 (13%) and of the latter group, 3/37 (8%), had the CC genotype. Although all seven patients had relatively mild Gaucher disease (only one required therapy), there was no statistically significant difference in allele frequency of the IL-6 promoter polymorphism in either group relative to healthy Ashkenazi Jews. CONCLUSION CONCLUSIONS Whether comparing patients with Gaucher disease with normal platelet counts or with thrombocytopenia to healthy Ashkenazi Jews, there was no difference in frequency of the CC state. Thus, the IL-6 promoter polymorphism may not influence Gaucher disease to induce lower platelet counts as shown in other normal Caucasians. Y Y Elstein Deborah D Y Altarescu Gheona G Y Zimran Ari A eng D016428 Journal Article England Hematology 9708388 1024-5332 0 D015850 Interleukin-6 IM D000293 N Adolescent D000328 N Adult D000368 N Aged D000369 N Aged, 80 and over D016022 N Case-Control Studies D002648 N Child D002675 N Child, Preschool D005260 N Female D005776 N Gaucher Disease Q000097 Y blood Q000235 Y genetics D006801 N Humans D015850 N Interleukin-6 Q000097 Y blood Q000235 Y genetics D007585 N Jews Q000235 N genetics D008297 N Male D008875 N Middle Aged D010976 N Platelet Count D011110 N Polymorphism, Genetic D011401 N Promoter Regions, Genetic D013921 N Thrombocytopenia Q000097 N blood Q000235 N genetics D055815 N Young Adult pubmed 2003 12 12 5 0 medline 2015 2 24 6 0 entrez 2003 12 12 5 0 ppublish pubmed 14668030 doi 10.1080/10245330310001621297 pii MAT9NVAB4BEMLX27 MEDLINE NLM 1 14695699 2005 04 12 2013 11 21 Print Print 1226-0479 Print 9 4 2003 Dec Taehan Kan Hakhoe chi = The Korean journal of hepatology Taehan Kan Hakhoe Chi [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis]. 324-31 BACKGROUND/AIMS OBJECTIVE The diagnosis of refractory ascites means a poor prognosis for patients with liver cirrhosis. The definition of refractory ascites has already been established, but using the dosage of diuretics that correlates with the definition of refractory ascites in an out-patient department will lower the compliance of the patient, as well as causing serious complications, such as hepatic encephalopathy and hyponatremia, as the dosage of diuretics is increased. Due to this fact, it is very difficult to apply this definition of refractory ascites to patients in a domestic out-patient department. In this study, in situations where there are difficulties in applying the diuretics dosage according to definition of refractory ascites, we tried to find out whether measuring the value of urine sodium after the administration of intravenous furosemide can be the standard in early differentiation of the response to diuretics treatment. METHODS METHODS We reviewed 16 cases of liver cirrhosis with ascites and classified them into two groups by the response to diuretics. The diuretics-responsive ascites group was 8 cases and the diuretics-unresponsive ascites group consisted of 8 cases. After admission, we examined the patients\\' CBC, biochemical liver function test, spot urine sodium, and 24 hour creatinine clearance. After the beginning of the experiment, all diuretic therapy was stopped for 3 days. Daily we examined the patients\\' CBC, biochemical liver function test, and in the 3rd experiment day, we measured 24-hour urine volume and sodium. In the 4th experiment day, after sampling for ADH, plasma renin activity and plasma aldosterone level, we administrated the furosemide 80 mg I.V, and measured the amount of 8 hour urine volume and sodium. RESULTS RESULTS The plasma aldosterone level was significantly higher in the diuretics- unresponsive ascites group than in the diuretics-responsive ascites group. In the 4th experiment day, the amount of urine volume and sodium was very significantly lower in the diuretics-unresponsive ascites group than in the diuretics-responsive ascites group (1297.5 +/-80.9 vs 2003.7 +/-114.6 ml, p<0.005, 77.3 +/-8.2 vs 211.8 +/-12.6 mEq, p<0.001). CONCLUSIONS CONCLUSIONS In out-patient departments, the measurement of urine sodium 8 hours after administrating 80 mg of intravenous furosemide, will help in differentiating ascites patients with lower treatment response to diuretics. Y Y Cho Hyun Seok HS Research Institute of Digestive Disease, Hanyang University College of Medicine, Seoul, Korea. Y Park Geun Tae GT Y Kim Young Hoon YH Y Shim Sung Gon SG Y Kim Jin Bae JB Y Lee Oh Young OY Y Choi Ho Soon HS Y Hahm Joon Soo JS Y Lee Min Ho MH kor D004740 English Abstract D016428 Journal Article Korea (South) Taehan Kan Hakhoe Chi 9607534 1226-0479 0 D004232 Diuretics 7LXU5N7ZO5 D005665 Furosemide 9NEZ333N27 D012964 Sodium IM D000328 N Adult D000368 N Aged D001201 N Ascites Q000188 Y drug therapy Q000209 N etiology Q000652 N urine D004232 N Diuretics Q000008 Y administration & dosage D005260 N Female D005665 N Furosemide Q000008 Y administration & dosage D006801 N Humans D007262 N Infusions, Intravenous D008103 N Liver Cirrhosis Q000150 Y complications D008297 N Male D008875 N Middle Aged D012964 N Sodium Q000652 Y urine pubmed 2003 12 27 5 0 medline 2005 4 13 9 0 entrez 2003 12 27 5 0 ppublish pubmed 14695699 pii 200312324 MEDLINE NLM 1 14729922 2004 02 11 2014 06 10 Electronic-Print Electronic 1362-4962 Internet 32 1 2004 Nucleic acids research Nucleic Acids Res. Local homology recognition and distance measures in linear time using compressed amino acid alphabets. 380-5 Methods for discovery of local similarities and estimation of evolutionary distance by identifying k-mers (contiguous subsequences of length k) common to two sequences are described. Given unaligned sequences of length L, these methods have O(L) time complexity. The ability of compressed amino acid alphabets to extend these techniques to distantly related proteins was investigated. The performance of these algorithms was evaluated for different alphabets and choices of k using a test set of 1848 pairs of structurally alignable sequences selected from the FSSP database. Distance measures derived from k-mer counting were found to correlate well with percentage identity derived from sequence alignments. Compressed alphabets were seen to improve performance in local similarity discovery, but no evidence was found of improvements when applied to distance estimates. The performance of our local similarity discovery method was compared with the fast Fourier transform (FFT) used in MAFFT, which has O(L log L) time complexity. The method for achieving comparable coverage to FFT is revealed here, and is more than an order of magnitude faster. We suggest using k-mer distance for fast, approximate phylogenetic tree construction, and show that a speed improvement of more than three orders of magnitude can be achieved relative to standard distance methods, which require alignments. Y Y Edgar Robert C RC bob@drive5.com eng D016428 Journal Article Electronic 2004 01 16 England Nucleic Acids Res 0411011 0305-1048 0 D000596 Amino Acids 0 D011506 Proteins IM Cites Mol Biol Evol. 1987 Jul;4(4):406-25 1 3447015 Cites J Theor Biol. 1986 Mar 21;119(2):205-18 1 3461222 Cites J Mol Biol. 1990 Oct 5;215(3):403-10 1 2231712 Cites J Mol Biol. 1991 Jun 5;219(3):555-65 1 2051488 Cites Comput Appl Biosci. 1992 Jun;8(3):275-82 1 1633570 Cites Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10915-9 1 1438297 Cites Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 1 7984417 Cites Proc Int Conf Intell Syst Mol Biol. 1996;4:230-40 1 8877523 Cites Nucleic Acids Res. 1998 Jan 1;26(1):316-9 1 9399863 Cites Proteins. 2000 Feb 1;38(2):149-64 1 10656262 Cites Protein Eng. 2000 Mar;13(3):149-52 1 10775656 Cites J Comput Biol. 2000 Feb-Apr;7(1-2):1-46 1 10890386 Cites Mol Biol Evol. 2002 Jan;19(1):8-13 1 11752185 Cites Nucleic Acids Res. 2002 Jul 15;30(14):3059-66 1 12136088 Cites J Mol Biol. 2003 Feb 7;326(1):317-36 1 12547212 Cites Bioinformatics. 2003 Mar 1;19(4):513-23 1 12611807 Cites Protein Eng. 2003 May;16(5):323-30 1 12826723 Cites Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444-8 1 3162770 D000465 N Algorithms D000596 N Amino Acids Q000032 Y analysis D019295 N Computational Biology Q000379 Y methods D019143 Y Evolution, Molecular D008969 N Molecular Sequence Data D010802 N Phylogeny D011506 N Proteins Q000737 N chemistry D016415 N Sequence Alignment Q000379 N methods D017386 Y Sequence Homology, Amino Acid D012984 N Software D013997 N Time Factors NLM PMC373290 pubmed 2004 1 20 5 0 medline 2004 2 12 5 0 entrez 2004 1 20 5 0 epublish pubmed 14729922 doi 10.1093/nar/gkh180 pii 32/1/380 pmc PMC373290 MEDLINE NLM 1 14749521 2004 02 23 2013 11 21 Electronic Electronic 1539-6150 Internet 2004 4 2004 Jan 28 Science of aging knowledge environment : SAGE KE Sci Aging Knowledge Environ Hampering a heartbreaker. Antibiotic might stem injury from heart attack. nf13 A TV ad urges people who think they\\'re having a heart attack to pop an aspirin before rushing to the emergency room. They might be even better off taking antibiotics, according to a new study. The work shows that an antibiotic stems a previously untreatable form of heart damage not by killing bugs but by suppressing cellular enzymes. Y Y Leslie Mitch M eng D016433 News Electronic 2004 01 28 United States Sci Aging Knowledge Environ 101146039 1539-6150 0 D004791 Enzyme Inhibitors 66974FR9Q1 D002701 Chloramphenicol IM D000818 N Animals D002701 N Chloramphenicol Q000627 Y therapeutic use D004791 N Enzyme Inhibitors Q000627 N therapeutic use D006801 N Humans D009203 N Myocardial Infarction Q000201 N enzymology Q000517 Y prevention & control D017202 N Myocardial Ischemia Q000201 N enzymology Q000517 Y prevention & control D015428 N Myocardial Reperfusion Injury Q000201 N enzymology Q000517 Y prevention & control D051381 N Rats pubmed 2004 1 30 5 0 medline 2004 2 24 5 0 entrez 2004 1 30 5 0 epublish pubmed 14749521 doi 10.1126/sageke.2004.4.nf13 pii 2004/4/nf13 MEDLINE NLM 1 14744982 2004 02 02 2014 06 10 Electronic Electronic 1362-4962 Internet 32 1 2004 Jan 15 Nucleic acids research Nucleic Acids Res. Superior 5\\' homogeneity of RNA from ATP-initiated transcription under the T7 phi 2.5 promoter. e14 Transcription from the commonly used GTP- initiating T7 class III promoter phi6.5 frequently produces heterogeneous RNA at both 3\\' and 5\\' ends. We demonstrate here that RNA transcripts from the T7 class II promoter phi2.5 have superior 5\\' homogeneity over those from the phi6.5 promoter, with comparable total RNA yields. The overall homogeneity of RNA transcripts is improved to different degrees depending on RNA sequences, although transcription under phi2.5 does not affect the 3\\' heterogeneity of RNA. In combination with 3\\' RNA trimming by DNAzymes or ribozymes, this ATP- initiated transcription system based on the T7 phi2.5 promoter can provide excellent quality of RNA for applications requiring a high degree of RNA size homogeneity. Y Y Coleman Tricia M TM Department of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, MS 39406-5043, USA. Y Wang Guocan G Y Huang Faqing F eng D016428 Journal Article D013486 Research Support, U.S. Gov\\'t, Non-P.H.S. Electronic 2004 01 15 England Nucleic Acids Res 0411011 0305-1048 0 D020413 3\\' Untranslated Regions 0 D020121 5\\' Untranslated Regions 0 D012367 RNA, Viral 8L70Q75FXE D000255 Adenosine Triphosphate IM Cites Curr Opin Struct Biol. 2000 Jun;10(3):298-302 1 10851189 Cites RNA. 1999 Sep;5(9):1268-72 1 10496227 Cites Methods. 2001 Mar;23(3):201-5 1 11243833 Cites Nucleic Acids Res. 2002 Jun 15;30(12):e56 1 12060694 Cites Chem Biol. 2002 Nov;9(11):1227-36 1 12445773 Cites Nucleic Acids Res. 2003 Feb 1;31(3):e8 1 12560511 Cites Nucleic Acids Res. 2003 Aug 1;31(15):e82 1 12888534 Cites Chembiochem. 2003 Oct 6;4(10):936-62 1 14523911 Cites RNA. 2003 Dec;9(12):1562-70 1 14624011 Cites J Mol Biol. 1983 Jun 5;166(4):477-535 1 6864790 Cites Nucleic Acids Res. 1987 Nov 11;15(21):8783-98 1 3684574 Cites J Biol Chem. 1988 Dec 5;263(34):18123-7 1 3192528 Cites Nature. 1992 Jan 9;355(6356):184-6 1 1370345 Cites Nucleic Acids Res. 1992 Sep 11;20(17):4515-23 1 1383928 Cites Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3680-4 1 7682716 Cites Nature. 1994 Nov 3;372(6501):68-74 1 7969422 Cites J Mol Biol. 1995 Jun 2;249(2):398-408 1 7540213 Cites Methods Enzymol. 1995;261:300-22 1 8569501 Cites Methods Enzymol. 1995;261:350-80 1 8569503 Cites Nucleic Acids Res. 1996 Mar 1;24(5):977-8 1 8600468 Cites Science. 1996 Sep 20;273(5282):1678-85 1 8781224 Cites Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4262-6 1 9113977 Cites RNA. 1998 Oct;4(10):1313-7 1 9769105 Cites Science. 1998 Oct 9;282(5387):259-64 1 9841391 Cites RNA. 1999 May;5(5):618-21 1 10334331 Cites Biochemistry. 2000 Dec 19;39(50):15548-55 1 11112541 D020413 N 3\\' Untranslated Regions Q000235 N genetics Q000378 N metabolism D020121 N 5\\' Untranslated Regions Q000235 N genetics Q000378 N metabolism D000255 N Adenosine Triphosphate Q000378 Y metabolism Q000494 N pharmacology D017123 N Bacteriophage T7 Q000235 Y genetics D001483 N Base Sequence D015967 N Gene Expression Regulation, Viral D008969 N Molecular Sequence Data D008970 N Molecular Weight D011401 N Promoter Regions, Genetic Q000235 Y genetics D012367 N RNA, Viral Q000737 N chemistry Q000235 Y genetics Q000378 N metabolism D014158 Y Transcription, Genetic Q000187 N drug effects NLM PMC373309 pubmed 2004 1 28 5 0 medline 2004 2 3 5 0 entrez 2004 1 28 5 0 epublish pubmed 14744982 doi 10.1093/nar/gnh007 pii 32/1/e14 pmc PMC373309 MEDLINE NLM 1 14796701 2004 02 15 2015 11 19 Print Print 0028-0836 Print 166 4234 1950 Dec 23 Nature Nature Reduction by molecular hydrogen of acetoacetate to butyrate by butyric acid bacteria. 1077-8 Y Y COHEN G N GN Y COHEN-BAZIRE G G eng D016428 Journal Article England Nature 0410462 0028-0836 0 D000090 Acetoacetates 0 D002087 Butyrates 107-92-6 D020148 Butyric Acid 4ZI204Y1MC C016635 acetoacetic acid 7YNJ3PO35Z D006859 Hydrogen OM D000090 Y Acetoacetates D001419 Y Bacteria D002087 Y Butyrates D020148 Y Butyric Acid D006859 Y Hydrogen CLML 5120:27591:5:76:156 NLM Y ACETOACETIC ACID Y BACTERIA Y BUTYRIC ACID pubmed 1950 12 23 medline 1950 12 23 0 1 entrez 1950 12 23 0 0 ppublish pubmed 14796701 MEDLINE NLM 1 14817685 2004 02 15 2010 01 25 Print Print 47 52 1950 Dec 29 Svenska lakartidningen Sven Lakartidn [The beriberi heart]. 3017-23 Y Y PALMBORG G G und D016428 Journal Article Om beriberihjrta. Sweden Sven Lakartidn 0030130 0 D000891 Anti-Infective Agents, Local OM D000891 Y Anti-Infective Agents, Local D001602 Y Beriberi D006321 Y Heart D006331 Y Heart Diseases D006801 N Humans CLML 5120:49529:96:423 NLM Y BERIBERI Y HEART IN VARIOUS DISEASES pubmed 1950 12 29 medline 1950 12 29 0 1 entrez 1950 12 29 0 0 ppublish pubmed 14817685 MEDLINE NLM 1 14991249 2005 03 15 2017 09 23 Print-Electronic Print 0364-2348 Print 33 5 2004 May Skeletal radiology Skeletal Radiol. Spontaneous resolution of solitary osteochondroma in the young adult. 303-5 Spontaneous resolution of a solitary osteochondroma is rare. Such a case is presented in a patient nearing skeletal maturity. Based on a search of the English literature this is the first such report in a patient of this age. Y Y Reston S C SC Department of Orthopaedics, Queen Alexandra Hospital, Portsmouth, UK. Y Savva N N Y Richards R H RH eng D002363 Case Reports D016428 Journal Article Electronic 2004 02 26 Germany Skeletal Radiol 7701953 0364-2348 IM Cites Skeletal Radiol. 1983;10 (1):40-2 1 6879215 Cites Skeletal Radiol. 1998 Jan;27(1):53-5 1 9507614 Cites J Pediatr Orthop. 1997 Jul-Aug;17(4):455-9 1 9364382 Cites J Bone Joint Surg Br. 1961 Nov;43-B:700-16 1 14039414 Cites Orthopedics. 1989 Jun;12(6):861-3 1 2740267 Cites J Bone Joint Surg Am. 1984 Dec;66(9):1454-9 1 6238969 D000293 N Adolescent D001859 N Bone Neoplasms Q000175 Y diagnosis D005269 N Femur Q000000981 Y diagnostic imaging D005500 N Follow-Up Studies D006801 N Humans D008297 N Male D015831 N Osteochondroma Q000175 Y diagnosis D011859 N Radiography D012075 N Remission, Spontaneous received 2003 08 09 revised 2003 12 01 accepted 2003 12 06 pubmed 2004 3 3 5 0 medline 2005 3 16 9 0 entrez 2004 3 3 5 0 ppublish pubmed 14991249 doi 10.1007/s00256-003-0739-5 PubMed-not-MEDLINE NLM 1 15117668 2004 05 10 2004 04 30 Print Print 0022-2895 Print 22 3 1990 Sep Journal of motor behavior J Mot Behav The First Conference on Motor Control in Down Syndrome. 444-6 Y Y Latash M L ML eng D016428 Journal Article United States J Mot Behav 0236512 0022-2895 pubmed 1990 9 1 0 0 medline 1990 9 1 0 1 entrez 1990 9 1 0 0 ppublish pubmed 15117668 MEDLINE NLM 1 15110832 2004 12 10 2006 11 15 Print Print 0968-0896 Print 12 10 2004 May 15 Bioorganic & medicinal chemistry Bioorg. Med. Chem. Aminyl and iminyl radicals from arylhydrazones in the photo-induced DNA cleavage. 2509-15 Photolytic cleavage of the nitrogen-nitrogen single bond in benzaldehyde phenylhydrazones produced aminyl (R2N*) and iminyl (R2C=N*) radicals. This photochemical property was utilized in the development of hydrazones as photo-induced DNA-cleaving agents. Irradiation with 350 nm UV light of arylhydrazones bearing substituents of various types in a phosphate buffer solution containing the supercoiled circular phiX174 RFI DNA at pH 6.0 resulted in single-strand cleavage of DNA. Attachment of the electron-donating OMe group to arylhydrazones increased their DNA-cleaving activity. Results from systematic studies indicate that both the aminyl and the iminyl radicals possessed DNA-cleaving ability. Y Y Hwu Jih Ru JR Institute of Chemistry, Academia Sinica, Nankang, Taipei 11529, Taiwan, ROC. jrhwu@mx.nthu.edu.tw Y Lin Chun Chieh CC Y Chuang Shih Hsien SH Y King Ke Yung KY Y Su Tzu-Rong TR Y Tsay Shwu-Chen SC eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t England Bioorg Med Chem 9413298 0968-0896 0 D006835 Hydrazones IM D004249 Y DNA Damage D006835 N Hydrazones Q000138 N chemical synthesis Q000737 Y chemistry D015394 N Molecular Structure D010782 Y Photolysis received 2004 02 03 revised 2004 03 17 accepted 2004 03 18 pubmed 2004 4 28 5 0 medline 2004 12 16 9 0 entrez 2004 4 28 5 0 ppublish pubmed 15110832 doi 10.1016/j.bmc.2004.03.037 pii S096808960400224X MEDLINE NLM 1 15206831 2004 07 29 2007 11 14 Print Print 0896-4289 Print 29 3 2003 Fall Behavioral medicine (Washington, D.C.) Behav Med Warm partner contact is related to lower cardiovascular reactivity. 123-30 The authors investigated the relationship between brief warm social and physical contact among cohabitating couples and blood pressure (BP) reactivity to stress in a sample of healthy adults (66 African American, 117 Caucasian; 74 women, 109 men). Prior to stress, the warm contact group underwent a 10-minute period of handholding while viewing a romantic video. Followed by a 20-second hug with their partner, while the no contact group rested quietly for 10 minutes and 20 seconds. In response to a public speaking task, individuals receiving prestress partner contact demonstrated lower systolic BP diastolic BP, and heart rate increases compared with the no contact group. The effects of warm contact were comparable for men and women and were greater for African Americans compared with Caucasians. These findings suggest that affectionate relationships with a supportive partner may contribute to lower reactivity to stressful life events and may partially mediate the benefit of marital support on better cardiovascular health. Y Y Grewen Karen M KM Department of Psychiatry, University of North Carolina at Chapel Hill, 27599-7175, USA. karen_grewen@med.unc.edu Y Anderson Bobbi J BJ Y Girdler Susan S SS Y Light Kathleen C KC eng Y HL64927 HL NHLBI NIH HHS United States RR00046 RR NCRR NIH HHS United States D016428 Journal Article D013487 Research Support, U.S. Gov\\'t, P.H.S. United States Behav Med 8804264 0896-4289 IM D000328 N Adult D000339 N Affect D001794 N Blood Pressure Q000502 Y physiology D001831 Y Body Temperature D005260 N Female D006339 N Heart Rate Q000502 Y physiology D006801 N Humans D008016 N Life Change Events D008297 N Male D008393 N Marriage Q000523 N psychology D008875 N Middle Aged D013060 N Speech D018454 Y Spouses D014110 N Touch pubmed 2004 6 23 5 0 medline 2004 7 30 5 0 entrez 2004 6 23 5 0 ppublish pubmed 15206831 doi 10.1080/08964280309596065 MEDLINE NLM 1 15228064 2004 08 06 2013 11 21 Print Print 1080-6032 Print 15 2 2004 Summer Wilderness & environmental medicine Wilderness Environ Med Acute coronary ischemia following centipede envenomation: case report and review of the literature. 109-12 This is the first known case report of electrocardiographic (ECG) changes suggestive of coronary vasospasm following a centipede envenomation. A 60-year-old man presented to the emergency department (ED) 1 hour after being stung by a 12-cm centipede. He complained of right great toe pain that did not radiate to his leg. The patient had no known ischemic heart disease. He did not describe any exertional symptoms but admitted experiencing weakness. During the ED course, concurrent with obtaining peripheral intravenous access, the patient experienced diaphoresis, dizziness, hypotension, and bradycardia. His ECG showed new ST-T wave changes, which suggested an acute ischemic process. The patient\\'s blood pressure was 89/60 mm Hg, his pulse rate was 47 beats/min, and his respiration rate was 28 breaths/min. In the following hours, ECG findings returned to baseline. His blood pressure improved gradually with fluid resuscitation after approximately 5 hours. Cardiac markers returned to normal in the 13th hour after the event, and the patient underwent exercise stress testing, which was negative. The patient was discharged with cardiology follow-up. Adult patients with centipede envenomation should be closely monitored in anticipation of possible myocardial ischemia due to vasospasm, hypotension, and myocardial toxic effects of the venom. A child receiving the same amount of venom would be potentially at greater risk. Y Y Ozsarac Murat M Dokuz Eylul University School of Medicine, Department of Emergency Medicine, Inciralti, Izmir, Turkey. mozsarac@hotmail.com Y Karcioglu Ozgur O Y Ayrik Cuneyt C Y Somuncu Fatih F Y Gumrukcu Serhat S eng D002363 Case Reports D016428 Journal Article D016454 Review United States Wilderness Environ Med 9505185 1080-6032 IM D000818 N Animals D001181 Y Arthropods D003937 N Diagnosis, Differential D004562 N Electrocardiography D004638 N Emergency Treatment D006801 N Humans D008297 N Male D008875 N Middle Aged D017202 N Myocardial Ischemia Q000150 N complications Q000175 Y diagnosis Q000628 N therapy D001098 N Spider Bites Q000150 N complications Q000175 Y diagnosis Q000628 N therapy 18 pubmed 2004 7 2 5 0 medline 2004 8 7 5 0 entrez 2004 7 2 5 0 ppublish pubmed 15228064 PubMed-not-MEDLINE NLM 1 15278624 2005 02 07 2017 08 12 Print Print 0913-8668 Print 5 3 1991 Jul Journal of anesthesia J Anesth Hypoxic ventilatory response in cats lightly anesthetized with ketamine: effects of halothane and sevoflurane in low concentrations. 233-8 The effect of low concentration sevoflurane and halothane on the ventilatory response to isocapnic hypoxia was studied in sixteen cats. The cats were divided into two groups, sevoflurane group and halothane group, of eight subjects each. As parameters of the hypoxic ventilatory response, A value [the slope of the hyperbolic curve, V(E) = V(0) + A/(Pa(O)(2)-32)] and ratio of V(50) (the minute volume obtained from the hyperbolic equation when Pa(O)(2) = 50 mmHg) to V(0) were studied. These two parameters were examined at three states, sedative state with ketamine as the control, ketamine plus 0.1 MAC inhalation anesthetic, and ketamine plus 0.5 MAC inhalation anesthetic. In the sevoflurane group, the A values were 4789 +/- 1518, 2187 +/- 1214, 1730 +/- 880 (mean +/- SE. ml.min(-1).mmHg) at the control state, 0.1 MAC and 0.5 MAC, respectively. In the halothane group, the A values were 6411 +/- 2368, 2529 +/- 842 and 2372 +/- 545, respectively. The ratios of V(50) to V(0) were 1.32 +/- 0.09, 1.22 +/- 0.09, 1.25 +/- 0.08 in the sevoflurane group, 1.47 +/- 0.18, 1.32 +/- 0.11, 1.54 +/- 0.18 in the halothane group, respectively. The A value at 0.1 MAC of the halothane group was less than the control value significantly. This proved that even low concentration halothane depressed the hypoxic ventilatory responses. The depression of hypoxic ventilatory response could cause postanesthetic hypoventilation. On the other hand, we could not find significant depression on the hypoxic ventilatory response in the sevoflurane group, but we should notice that variances of the hypoxic ventilatory response were large. Y Y Tamura C C Department of Anesthesiology and Critical Care Medicine, Hamamatsu University School of Medicine, Japan. Y Doi M M Y Ikeda K K eng D016428 Journal Article Japan J Anesth 8905667 0913-8668 Cites Q J Exp Physiol Cogn Med Sci. 1958 Apr;43(2):214-27 1 13542754 Cites J Clin Invest. 1970 Jun;49(6):1061-72 1 5422012 Cites Anesthesiology. 1975 Dec;43(6):628-34 1 1190538 Cites Kokyu To Junkan. 1984 Apr;32(4):349-56 1 6379796 Cites Anesthesiology. 1974 Oct;41(4):350-60 1 4413139 Cites Masui. 1986 Nov;35(11):1680-4 1 3820557 Cites Am Rev Respir Dis. 1980 Dec;122(6):867-71 1 7458060 Cites Respir Physiol. 1972 Sep;16(1):109-25 1 5073532 Cites J Appl Physiol. 1975 Dec;39(6):911-5 1 1213971 Cites Anesthesiology. 1978 Oct;49(4):244-51 1 697078 Cites Respir Physiol. 1975 Mar;23(2):181-99 1 1144940 received 1990 07 19 accepted 1990 11 15 pubmed 1991 7 1 0 0 medline 1991 7 1 0 1 entrez 1991 7 1 0 0 ppublish pubmed 15278624 doi 10.1007/s0054010050233 PubMed-not-MEDLINE NLM 1 15284444 2004 09 29 2017 02 19 Print-Electronic Print 0027-8424 Print 101 32 2004 Aug 10 Proceedings of the National Academy of Sciences of the United States of America Proc. Natl. Acad. Sci. U.S.A. Tubular precipitation and redox gradients on a bubbling template. 11537-41 Tubular structures created by precipitation abound in nature, from chimneys at hydrothermal vents to soda straws in caves. Their formation is controlled by chemical gradients within which precipitation occurs, defining a surface that templates the growing structure. We report a self-organized periodic templating mechanism producing tubular structures electrochemically in iron-ammonium-sulfate solutions; iron oxides precipitate on the surface of bubbles that linger at the tube rim and then detach, leaving behind a ring of material. The acid-base and redox gradients spontaneously generated by diffusion of ammonia from the bubble into solution organize radial compositional layering within the tube wall, a mechanism studied on a larger scale by complex Liesegang patterns of iron oxides formed as ammonia diffuses through a gel containing FeSO(4). When magnetite forms within the wall, a tube may grow curved in an external magnetic field. Connections with free-boundary problems in speleothem formation are emphasized. Y Y Stone David A DA Department of Soil, Water, and Environmental Science, Program in Applied Mathematics, University of Arizona, Tucson, AZ 85721, USA. Y Goldstein Raymond E RE eng D016428 Journal Article Electronic 2004 07 29 United States Proc Natl Acad Sci U S A 7505876 0027-8424 Cites Nature. 2002 May 9;417(6885):139 1 12000951 Cites Science. 2004 Mar 12;303(5664):1656-8 1 15016997 Cites Phys Rev Lett. 1990 Jun 11;64(24):2953-2956 1 10041855 Cites Philos Trans R Soc Lond B Biol Sci. 2003 Jan 29;358(1429):59-83; discussion 83-5 1 12594918 Cites Science. 1988 Dec 23;242(4885):1585 1 17788426 Cites Science. 1979 Mar 16;203(4385):1073-83 1 17776033 Cites Science. 2003 Oct 24;302(5645):580-1 1 14576411 Cites J Geol Soc London. 1997 May;154(3):377-402 1 11541234 Cites J Am Chem Soc. 2003 Apr 9;125(14):4338-41 1 12670257 Cites Science. 1965 Feb 5;147(3658):563-75 1 17783259 NLM PMC511016 pubmed 2004 7 31 5 0 medline 2004 7 31 5 1 entrez 2004 7 31 5 0 ppublish pubmed 15284444 doi 10.1073/pnas.0404544101 pii 0404544101 pmc PMC511016 MEDLINE NLM 1 15611660 2006 03 23 2017 11 16 Print-Electronic Electronic 1551-4005 Internet 4 1 2005 Jan Cell cycle (Georgetown, Tex.) Cell Cycle Altered epigenetic patterning leading to replicative senescence and reduced longevity. A role of a novel SNF2 factor, PASG. 3-5 Understanding the biological mechanisms underlying aging and cancer predisposition remains a fundamentally important goal in biomedicine. The generation of a PASG hypomorphic mutant mouse model shows that PASG, an SNF2 family member, is essential for properly maintaining normal DNA methylation and gene expression patterns. Disruption of PASG leads to decreased incorporation of BrdU, accumulation of senescence-associated tumor suppressor genes, and increased senescence-associated beta-galactosidase as well as age-related phenotypes. These observations demonstrate that PASG plays a critical role in maintenance of tissue homeostasis, normal growth and longevity. Y Y Sun Lin-Quan LQ Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Y Arceci Robert J RJ eng D016428 Journal Article Electronic 2005 01 03 United States Cell Cycle 101137841 1551-4005 9007-49-2 D004247 DNA EC 2.1.1.- D008780 Methyltransferases EC 3.2.1.23 D001616 beta-Galactosidase EC 3.6.4.- D004265 DNA Helicases EC 5.99.- C487055 Hells protein, mouse G34N38R2N1 D001973 Bromodeoxyuridine IM D000818 N Animals D001973 N Bromodeoxyuridine Q000378 N metabolism D002453 N Cell Cycle Q000235 N genetics Q000502 N physiology D049109 N Cell Proliferation D016922 Y Cellular Senescence Q000235 N genetics D004247 N DNA Q000378 N metabolism D004265 N DNA Helicases Q000037 N antagonists & inhibitors Q000235 N genetics Q000502 Y physiology D019175 N DNA Methylation D044127 Y Epigenesis, Genetic D018507 N Gene Expression Regulation, Developmental D006706 N Homeostasis Q000235 N genetics Q000502 N physiology D008136 Y Longevity Q000235 N genetics D008780 N Methyltransferases Q000502 N physiology D051379 N Mice D008817 N Mice, Mutant Strains D009154 N Mutation D001616 N beta-Galactosidase Q000378 N metabolism pubmed 2004 12 22 9 0 medline 2006 3 24 9 0 entrez 2004 12 22 9 0 ppublish pubmed 15611660 pii 1341 doi 10.4161/cc.4.1.1341 MEDLINE NLM 1 15611661 2006 03 23 2009 11 19 Print-Electronic Electronic 1551-4005 Internet 4 1 2005 Jan Cell cycle (Georgetown, Tex.) Cell Cycle TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance. 8-9 Nerve growth factor receptor TrkA is critical for development and maturation of central and peripheral nervous systems, regulating proliferation, differentiation and apoptosis. In cancer, TrkA frequently exhibits suppressor activity in nonmutated form and oncogenic activity upon mutation. Our identification of a novel hypoxia-regulated alternative TrkAIII splice variant, expressed by neural crest-derived neuroblastic tumors, that exhibits neuroblastoma tumor promoting activity, adds significantly to our understanding of potential TrkA involvement in cancer. Our observation that hypoxia, which characterizes the tumor micro-environment, stimulates alternative TrkAIII splicing, provides a way by which TrkA tumor suppressing signals may convert to tumor promoting signals during progression and is consistent with conservation and pathological subversion by neural crest-derived neuroblastic tumors of a mechanism of potential physiological importance to normal neural stem/neural crest progenitors. Y Y Tacconelli Antonella A Department of Experimental Medicine, University of L\\'Aquila, L\\'Aquila, Italy. Y Farina Antonietta R AR Y Cappabianca Lucia L Y Gulino Alberto A Y Mackay Andrew R AR eng D016428 Journal Article Electronic 2005 01 05 United States Cell Cycle 101137841 1551-4005 0 D004273 DNA, Neoplasm EC 2.7.10.1 D020917 Receptor, trkA IM D017398 Y Alternative Splicing D002454 N Cell Differentiation Q000235 N genetics D015687 Y Cell Hypoxia D045744 N Cell Line, Tumor D049109 N Cell Proliferation D004273 N DNA, Neoplasm Q000235 N genetics D015972 N Gene Expression Regulation, Neoplastic D014644 Y Genetic Variation D006801 N Humans D014411 N Neoplastic Stem Cells Q000473 N pathology Q000502 N physiology D009432 N Neural Crest Q000166 N cytology Q000502 N physiology D009447 N Neuroblastoma Q000235 N genetics Q000473 N pathology Q000503 N physiopathology D020917 N Receptor, trkA Q000235 Y genetics Q000502 Y physiology D015398 N Signal Transduction Q000235 N genetics pubmed 2004 12 22 9 0 medline 2006 3 24 9 0 entrez 2004 12 22 9 0 ppublish pubmed 15611661 pii 1349 doi 10.4161/cc.4.1.1349 MEDLINE NLM 1 15611667 2006 03 23 2013 11 21 Print-Electronic Electronic 1551-4005 Internet 4 1 2005 Jan Cell cycle (Georgetown, Tex.) Cell Cycle Replication timing of human chromosome 6. 172-6 Genomic microarrays have been used to assess DNA replication timing in a variety of eukaryotic organisms. A replication timing map of the human genome has already been published at a 1Mb resolution. Here we describe how the same method can be used to assess the replication timing of chromosome 6 with a greater resolution using an array of overlapping tile path clones. We report the replication timing map of the whole of chromosome 6 in general, and the MHC region in particular. Positive correlations are observed between replication timing and a number of genomic features including GC content, repeat content and transcriptional activity. Y Y Woodfine Kathryn K Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. Y Beare David M DM Y Ichimura Koichi K Y Debernardi Silvana S Y Mungall Andrew J AJ Y Fiegler Heike H Y Collins V Peter VP Y Carter Nigel P NP Y Dunham Ian I eng D016428 Journal Article Electronic 2005 01 05 United States Cell Cycle 101137841 1551-4005 5Z93L87A1R D006147 Guanine 8J337D1HZY D003596 Cytosine 9007-49-2 D004247 DNA IM D002460 N Cell Line D002874 N Chromosome Mapping D002896 N Chromosomes, Human, Pair 6 Q000235 Y genetics Q000502 Y physiology D003596 N Cytosine Q000032 N analysis D004247 N DNA Q000737 N chemistry Q000235 N genetics D042622 N DNA Repeat Expansion D042522 Y DNA Replication Timing D044127 N Epigenesis, Genetic D016193 N G1 Phase Q000235 N genetics Q000502 N physiology D005786 N Gene Expression Regulation D006147 N Guanine Q000032 N analysis D006801 N Humans D008285 N Major Histocompatibility Complex Q000235 N genetics D020411 N Oligonucleotide Array Sequence Analysis Q000379 Y methods D016196 N S Phase Q000235 N genetics Q000502 N physiology D014158 N Transcription, Genetic pubmed 2004 12 22 9 0 medline 2006 3 24 9 0 entrez 2004 12 22 9 0 ppublish pubmed 15611667 pii 1350 doi 10.4161/cc.4.1.1350 MEDLINE NLM 1 15739502 2010 04 15 2016 10 18 Print Print 1000-8713 Print 15 5 1997 Sep Se pu = Chinese journal of chromatography Se Pu [The determination of olaquindox in feeds by HPLC]. 440-1 A liquid chromatographic procedure for the determination of olaquindox in feeds is described. Chromatography was performed on a PC8-10/S2504 (4.0 mm i.d. x 250 mm, 10 microm, Shimadzu Co.) column at 30 degrees C by using a mobile phase of methanol:water (20:80, V/V ) with a flow rate of 0.8 mL/min and UV detection at 260 nm. Acetanilide was used as internal standard. Olaquindox was extracted with dimethylformamide (DMF) from the feeds. The average recoveries of olaquindox were 98.58%-101.63% and the relative standard deviations were 2.67%-4.25%. The method is simple, rapid, reliable and inexpensive. Y Y Li L L Institute of Applied Chemistry, Nanchang University, Nanchang, 330047. Y Qiu S S chi D004740 English Abstract D023362 Evaluation Studies D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t China Se Pu 9424804 1000-8713 0 D005503 Food Additives 0 D011810 Quinoxalines G3LAW9U88T C013168 olaquindox IM D000821 N Animal Feed Q000032 Y analysis D002851 N Chromatography, High Pressure Liquid Q000379 Y methods D005503 N Food Additives Q000032 Y analysis D011810 N Quinoxalines Q000032 Y analysis pubmed 2005 3 3 9 0 medline 2010 4 16 6 0 entrez 2005 3 3 9 0 ppublish pubmed 15739502 PubMed-not-MEDLINE NLM 1 15810377 2010 05 21 2005 04 06 Print Print 1000-0593 Print 17 5 1997 Oct Guang pu xue yu guang pu fen xi = Guang pu Guang Pu Xue Yu Guang Pu Fen Xi [Study on cleavage mechanisms of dimer (t-Bu)2NO in several solvent phases]. 124-7 In this paper, we studied the cleavage products of dimer t-BuNO in aqueous and organic solutions using method of 1HNMR and UV-Vis, analyzed the reactive kinetics, put forward that dimer (t-Bu)2NO homolytically cleavaged in nonpolar organic solution, and that dimer (t-Bu)2NO homolytically and heterolyticall cleavaged in a competitive manner in polar aqueous solution. Y Y Ma X X Cancer Research Institute, Hunan Medical University, Changsha. Y Tang J J chi D004740 English Abstract D016428 Journal Article China Guang Pu Xue Yu Guang Pu Fen Xi 9424805 1000-0593 pubmed 2005 4 7 9 0 medline 2005 4 7 9 1 entrez 2005 4 7 9 0 ppublish pubmed 15810377 MEDLINE NLM 1 16776646 2006 08 09 2016 10 20 Print Print 0248-4900 Print 98 7 2006 Jul Biology of the cell Biol. Cell Books for free? How can this be? - A PubMed resource you may be overlooking. 439-43 The NCBI (National Center for Biotechnology Information) at the National Institutes of Health collects a wide range of molecular biological data, and develops tools and databases to analyse and disseminate this information. Many life scientists are familiar with the website maintained by the NCBI (http://www.ncbi.nlm.nih.gov), because they use it to search GenBank for homologues of their genes of interest or to search the PubMed database for scientific literature of interest. There is also a database called the Bookshelf that includes searchable popular life science textbooks, medical and research reference books and NCBI reference materials. The Bookshelf can be useful for researchers and educators to find basic biological information. This article includes a representative list of the resources currently available on the Bookshelf, as well as instructions on how to access the information in these resources. Y Y Corsi Ann K AK Department of Biology, The Catholic University of America, Washington, DC 20064, USA. corsi@cua.edu eng D016428 Journal Article England Biol Cell 8108529 0248-4900 IM D001690 Y Biological Science Disciplines D001877 Y Books D006801 N Humans D020407 Y Internet D009317 N National Library of Medicine (U.S.) D039781 Y PubMed D012013 N Reference Books D012014 Y Reference Books, Medical D013782 N Textbooks as Topic D014481 N Geographic United States pubmed 2006 6 17 9 0 medline 2006 8 10 9 0 entrez 2006 6 17 9 0 ppublish pubmed 16776646 pii BC20050093 doi 10.1042/BC20050093 MEDLINE NLM 1 15968009 2005 06 27 2014 07 29 Print Electronic 1539-3704 Internet 142 12 Pt 1 2005 Jun 21 Annals of internal medicine Ann. Intern. Med. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. 953-62 BACKGROUND BACKGROUND There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE). OBJECTIVE OBJECTIVE To evaluate the effect of hormone replacement therapy (HRT) on disease activity in postmenopausal women with SLE. DESIGN METHODS Randomized, double-blind, placebo-controlled noninferiority trial conducted from March 1996 to June 2002. SETTING METHODS 16 university-affiliated rheumatology clinics or practices in 11 U.S. states. PATIENTS METHODS 351 menopausal patients (mean age, 50 years) with inactive (81.5%) or stable-active (18.5%) SLE. INTERVENTIONS METHODS 12 months of treatment with active drug (0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month) or placebo. The 12-month follow-up rate was 82% for the HRT group and 87% for the placebo group. MEASUREMENTS METHODS The primary end point was occurrence of a severe flare as defined by Safety of Estrogens in Lupus Erythematosus, National Assessment-Systemic Lupus Erythematosus Disease Activity Index composite. RESULTS RESULTS Severe flare was rare in both treatment groups: The 12-month severe flare rate was 0.081 for the HRT group and 0.049 for the placebo group, yielding an estimated difference of 0.033 (P = 0.23). The upper limit of the 1-sided 95% CI for the treatment difference was 0.078, within the prespecified margin of 9% for noninferiority. Mild to moderate flares were significantly increased in the HRT group: 1.14 flares/person-year for HRT and 0.86 flare/person-year for placebo (relative risk, 1.34; P = 0.01). The probability of any type of flare by 12 months was 0.64 for the HRT group and 0.51 for the placebo group (P = 0.01). In the HRT group, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an arteriovenous graft; in the placebo group, 1 patient developed deep venous thrombosis. LIMITATIONS CONCLUSIONS Findings are not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis. CONCLUSIONS CONCLUSIONS Adding a short course of HRT is associated with a small risk for increasing the natural flare rate of lupus. Most of these flares are mild to moderate. The benefits of HRT can be balanced against the risk for flare because HRT did not significantly increase the risk for severe flare compared with placebo. Y Y Buyon Jill P JP Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA. jill.buyon@nyumc.org Y Petri Michelle A MA Y Kim Mimi Y MY Y Kalunian Kenneth C KC Y Grossman Jennifer J Y Hahn Bevra H BH Y Merrill Joan T JT Y Sammaritano Lisa L Y Lockshin Michael M Y Alarcn Graciela S GS Y Manzi Susan S Y Belmont H Michael HM Y Askanase Anca D AD Y Sigler Lisa L Y Dooley Mary Anne MA Y Von Feldt Joan J Y McCune W Joseph WJ Y Friedman Alan A Y Wachs Jane J Y Cronin Mary M Y Hearth-Holmes Michelene M Y Tan Mark M Y Licciardi Frederick F eng Y ClinicalTrials.gov NCT00000419 Y AR 43727 AR NIAMS NIH HHS United States M01 RR00052 RR NCRR NIH HHS United States M01 RR00096 RR NCRR NIH HHS United States U01 AR42540 AR NIAMS NIH HHS United States D016430 Clinical Trial D016428 Journal Article D016448 Multicenter Study D016449 Randomized Controlled Trial D052061 Research Support, N.I.H., Extramural D013487 Research Support, U.S. Gov\\'t, P.H.S. United States Ann Intern Med 0372351 0003-4819 0 D004966 Estrogens, Conjugated (USP) HSU1C9YRES D008525 Medroxyprogesterone AIM IM CommentIn Ann Intern Med. 2005 Jun 21;142(12 Pt 1):1014-5 1 15968016 SummaryForPatientsIn Ann Intern Med. 2005 Jun 21;142(12 Pt 1):I22 1 15968006 D000293 N Adolescent D000368 N Aged D000369 N Aged, 80 and over D004311 N Double-Blind Method D015914 N Estrogen Replacement Therapy Q000009 Y adverse effects D004966 N Estrogens, Conjugated (USP) Q000627 N therapeutic use D005260 N Female D005500 N Follow-Up Studies D006801 N Humans D008180 N Lupus Erythematosus, Systemic Q000503 Y physiopathology D008525 N Medroxyprogesterone Q000627 N therapeutic use D008875 N Middle Aged D017698 Y Postmenopause D012307 N Risk Factors pubmed 2005 6 22 9 0 medline 2005 6 28 9 0 entrez 2005 6 22 9 0 ppublish pubmed 15968009 pii 142/12_Part_1/953 MEDLINE NLM 1 16779244 2007 02 15 2016 10 25 Print Electronic 1942-597X Internet 2005 AMIA ... Annual Symposium proceedings. AMIA Symposium AMIA Annu Symp Proc MeSH Speller + askMEDLINE: auto-completes MeSH terms then searches MEDLINE/PubMed via free-text, natural language queries. 957 Medical terminology is challenging even for healthcare personnel. Spelling errors can make searching MEDLINE/PubMed ineffective. We developed a utility that provides MeSH term and Specialist Lexicon Vocabulary suggestions as it is typed on a search page. The correctly spelled term can be incorporated into a free-text, natural language search or used as a clinical queries search. Y Y Fontelo Paul P Office of High Performance Computing and Communications, National Library of Medicine, 8600 Rockville Pike, Bethesda, Maryland 20894, USA. Y Liu Fang F Y Ackerman Michael M eng Y Z99 LM999999 Intramural NIH HHS United States D016428 Journal Article United States AMIA Annu Symp Proc 101209213 1559-4076 IM Cites JAMA. 1998 Oct 21;280(15):1336-8 1 9794314 Cites J Med Internet Res. 2003 Dec 11;5(4):e31 1 14713659 D016247 N Information Storage and Retrieval Q000379 Y methods D046650 Y Medical Subject Headings D009323 Y Natural Language Processing D039781 Y PubMed NLM PMC1513542 pubmed 2006 6 17 9 0 medline 2007 2 16 9 0 entrez 2006 6 17 9 0 ppublish pubmed 16779244 pii 57378 pmc PMC1513542 MEDLINE NLM 1 16888359 2006 09 28 2014 09 09 Print Print 1064-3745 Print 338 2006 Methods in molecular biology (Clifton, N.J.) Methods Mol. Biol. Mining microarray data at NCBI\\'s Gene Expression Omnibus (GEO)*. 175-90 The Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) has emerged as the leading fully public repository for gene expression data. This chapter describes how to use Web-based interfaces, applications, and graphics to effectively explore, visualize, and interpret the hundreds of microarray studies and millions of gene expression patterns stored in GEO. Data can be examined from both experiment-centric and gene-centric perspectives using user-friendly tools that do not require specialized expertise in microarray analysis or time-consuming download of massive data sets. The GEO database is publicly accessible through the World Wide Web at http://www.ncbi.nlm.nih.gov/geo. Y Y Barrett Tanya T National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD, USA. Y Edgar Ron R eng D016428 Journal Article United States Methods Mol Biol 9214969 1064-3745 IM Cites Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W213-6 1 15215383 Cites Science. 2003 Jun 13;300(5626):1749-51 1 12805549 Cites Nucleic Acids Res. 2002 Jan 1;30(1):207-10 1 11752295 Cites Mol Cell Proteomics. 2005 May;4(5):683-92 1 15722371 Cites Nucleic Acids Res. 2005 Jan 1;33(Database issue):D562-6 1 15608262 Cites Physiol Genomics. 2004 Sep 16;19(1):131-42 1 15238619 Cites J Mol Biol. 1990 Oct 5;215(3):403-10 1 2231712 Cites Nucleic Acids Res. 2005 Jan 1;33(Database issue):D39-45 1 15608222 Cites PLoS Biol. 2004 Dec;2(12):e427 1 15562319 Cites Methods Enzymol. 1996;266:141-62 1 8743683 Cites Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13618-23 1 15353598 D000465 N Algorithms D000818 N Animals D016000 N Cluster Analysis D003627 N Data Interpretation, Statistical D030541 Y Databases, Genetic D020869 N Gene Expression Profiling Q000706 Y statistics & numerical data D006801 N Humans D016247 N Information Storage and Retrieval D020407 N Internet D009317 N National Library of Medicine (U.S.) D020411 N Oligonucleotide Array Sequence Analysis Q000706 Y statistics & numerical data D012984 N Software D014481 N Geographic United States NLM NIHMS12705 NLM PMC1619899 pubmed 2006 8 5 9 0 medline 2006 9 29 9 0 entrez 2006 8 5 9 0 ppublish pubmed 16888359 pii 1-59745-097-9:175 doi 10.1385/1-59745-097-9:175 pmc PMC1619899 mid NIHMS12705 MEDLINE NLM 1 16923641 2007 01 25 2006 08 22 Print Print 0803-9488 Print 60 4 2006 Nordic journal of psychiatry Nord J Psychiatry The use of PubMed/Medline in psychiatry. 3: Searching PubMed. 310-5 This paper is the third in a series of three, intended as a tutorial in the use of PubMed/Medline for an inexperienced user. The papers have the following contents: I--a description of NLM, Medline, PubMed and the system of Medical Subject Headings (MeSH), which form the basis for the indexing of scientific articles, books and other items at NLM. II--A description and a tutorial of the PubMed search window. III--The present article deals mainly with the searching for references in PubMed. Ways of restricting and concentrating the search are presented, and exercises are proposed. A reader may also find guidance for a search for medical books in the NLM Catalog, and in the use of tools like Related Articles, Bookshelf, and Index. With eating disorders as an example, more information is presented on the use of MeSH terms. Y Y Theander Sten S SS Division of Psychiatry, Department of Clinical Neuroscience, Lund University, Sweden. sten.theander@med.lu.se eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t England Nord J Psychiatry 100927567 0803-9488 IM D016239 N MEDLINE D046650 N Medical Subject Headings D011570 Y Psychiatry D039781 Y PubMed pubmed 2006 8 23 9 0 medline 2007 1 26 9 0 entrez 2006 8 23 9 0 ppublish pubmed 16923641 pii P37WU15215LX0170 doi 10.1080/08039480600790481 MEDLINE NLM 1 17059514 2007 05 07 2006 10 24 Print Print 0269-2813 Print 24 9 2006 Nov 01 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Effectiveness of an \\'half elemental diet\\' as maintenance therapy for Crohn\\'s disease: A randomized-controlled trial. 1333-40 BACKGROUND BACKGROUND Although thiopurines have a proven role in maintenance therapy for Crohn\\'s disease, an alternative therapy is needed for patients intolerant or resistant to thiopurines. AIM OBJECTIVE To evaluate the effectiveness of home enteral nutrition as a maintenance therapy regimen in which half of the daily calorie requirement is provided by an elemental diet and the remaining half by a free diet. We refer to this home enteral nutrition therapy as \\'half elemental diet\\'. METHODS METHODS Between 2002 and 2005, 51 patients in remission from two hospitals were randomly assigned to a half elemental diet group (n = 26) or a free diet group (n = 25). The primary outcome measure of this study was the occurrence of relapse over the 2-year period. RESULTS RESULTS The relapse rate in the half elemental diet group was significantly lower [34.6% vs. 64.0%; multivariate hazard ratio 0.40 (95% CI: 0.16-0.98)] than that in the free diet group after a mean follow-up of 11.9 months. Compliance was similar in the two groups. No adverse event occurred in any of the patients throughout the study. CONCLUSION CONCLUSIONS This randomized-controlled trial shows the effectiveness of an half elemental diet, which is a promising maintenance therapy for Crohn\\'s disease patients. Y Y Takagi S S Division of Gastroenterology, Department of Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. stakagi@int3.med.tohoku.ac.jp Y Utsunomiya K K Y Kuriyama S S Y Yokoyama H H Y Takahashi S S Y Iwabuchi M M Y Takahashi H H Y Takahashi S S Y Kinouchi Y Y Y Hiwatashi N N Y Funayama Y Y Y Sasaki I I Y Tsuji I I Y Shimosegawa T T eng D016428 Journal Article D016449 Randomized Controlled Trial England Aliment Pharmacol Ther 8707234 0269-2813 IM D000328 N Adult D003424 N Crohn Disease Q000178 Y diet therapy D004750 N Enteral Nutrition Q000379 N methods D005260 N Female D005500 N Follow-Up Studies D005526 Y Food, Formulated D006801 N Humans D008297 N Male D010288 N Parenteral Nutrition Q000379 N methods D012008 N Recurrence D016896 N Treatment Outcome pubmed 2006 10 25 9 0 medline 2007 5 8 9 0 entrez 2006 10 25 9 0 ppublish pubmed 17059514 pii APT3120 doi 10.1111/j.1365-2036.2006.03120.x MEDLINE NLM 1 16949478 2006 09 21 2006 09 04 Print Electronic 1558-3597 Internet 48 5 2006 Sep 05 Journal of the American College of Cardiology J. Am. Coll. Cardiol. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). e247-346 Y Y European Heart Rhythm Association Y Heart Rhythm Society Y Zipes Douglas P DP Y Camm A John AJ Y Borggrefe Martin M Y Buxton Alfred E AE Y Chaitman Bernard B Y Fromer Martin M Y Gregoratos Gabriel G Y Klein George G Y Moss Arthur J AJ Y Myerburg Robert J RJ Y Priori Silvia G SG Y Quinones Miguel A MA Y Roden Dan M DM Y Silka Michael J MJ Y Tracy Cynthia C Y Smith Sidney C SC Jr Y Jacobs Alice K AK Y Adams Cynthia D CD Y Antman Elliott M EM Y Anderson Jeffrey L JL Y Hunt Sharon A SA Y Halperin Jonathan L JL Y Nishimura Rick R Y Ornato Joseph P JP Y Page Richard L RL Y Riegel Barbara B Y Priori Silvia G SG Y Blanc Jean-Jacques JJ Y Budaj Andrzej A Y Camm A John AJ Y Dean Veronica V Y Deckers Jaap W JW Y Despres Catherine C Y Dickstein Kenneth K Y Lekakis John J Y McGregor Keith K Y Metra Marco M Y Morais Joao J Y Osterspey Ady A Y Tamargo Juan Luis JL Y Zamorano Jos Luis JL Y American College of Cardiology Y American Heart Association Task Force Y European Society of Cardiology Committee for Practice Guidelines eng D016428 Journal Article D017065 Practice Guideline United States J Am Coll Cardiol 8301365 0735-1097 0 D000889 Anti-Arrhythmia Agents AIM IM D000889 N Anti-Arrhythmia Agents Q000627 N therapeutic use D002303 N Cardiac Output, Low D009202 N Cardiomyopathies Q000150 N complications D017115 N Catheter Ablation D016757 N Death, Sudden, Cardiac Q000209 Y etiology Q000517 Y prevention & control D017147 N Defibrillators, Implantable D004562 N Electrocardiography D006323 N Heart Arrest Q000209 N etiology Q000628 N therapy D006334 N Heart Function Tests D006801 N Humans D017180 N Tachycardia, Ventricular Q000150 Y complications Q000188 Y drug therapy Q000503 N physiopathology D014693 N Ventricular Fibrillation Q000150 Y complications Q000188 Y drug therapy Q000503 N physiopathology pubmed 2006 9 5 9 0 medline 2006 9 22 9 0 entrez 2006 9 5 9 0 ppublish pubmed 16949478 pii S0735-1097(06)01817-1 doi 10.1016/j.jacc.2006.07.010 MEDLINE NLM 1 17712873 2007 08 22 2007 10 01 Print Electronic 1432-2218 Internet 21 6 2007 Jun Surgical endoscopy Surg Endosc Crura ultrastructural alterations in patients with hiatal hernia: a pilot study. 907-11 Y Y Fei L L Unit of Surgical Digestive Physiopathology, Second University of Naples, via Pansini 5, I-80131 Naples, Italy. landino.fei@tin.it Y del Genio G G Y Brusciano L L Y Esposito V V Y Cuttitta D D Y Pizza F F Y Rossetti G G Y Trapani V V Y Filippone G G Y Moccia F F N Francesco M M Y del Genio A A eng D016428 Journal Article Germany Surg Endosc 8806653 0930-2794 IM ErratumIn Surg Endosc. 2007 Aug;21(8):1473 Francesco, M [removed]; Moccia, F [added] D000328 N Adult D001706 N Biopsy D003238 N Connective Tissue Q000648 N ultrastructure D003964 N Diaphragm Q000002 N abnormalities Q000648 Y ultrastructure D005260 N Female D005764 N Gastroesophageal Reflux Q000209 N etiology Q000601 N surgery D006551 N Hernia, Hiatal Q000209 Y etiology Q000601 N surgery D006801 N Humans D008297 N Male D046529 N Microscopy, Electron, Transmission D008875 N Middle Aged D018482 N Muscle, Skeletal Q000648 N ultrastructure D012008 N Recurrence pubmed 2007 8 23 9 0 medline 2007 8 23 9 1 entrez 2007 8 23 9 0 ppublish pubmed 17712873 MEDLINE NLM 1 17713168 2007 10 19 2007 11 30 Print Print 1359-6535 Print 12 5 2007 Antiviral therapy Antivir. Ther. (Lond.) Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 835-9 OBJECTIVES OBJECTIVE A major barrier to successful viral suppression in HIV type 1 (HIV-1)-infected individuals is the emergence of virus resistant to antiretroviral drugs. We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort. PATIENTS AND METHODS METHODS Prevalence of major International AIDS Society-USA HIV-1 drug resistance mutations was measured over calendar years in a population with treatment failure and undergoing resistance testing. Predictors of the presence of resistance mutations were analysed by logistic regression. RESULTS RESULTS Significant reductions of the prevalence of resistance to all three drug classes examined were observed. This was accompanied by a reduction in the proportion of treatment-failing patients. Independent predictors of drug resistance were the earlier calendar year, prior use of suboptimal nucleoside analogue therapy, male sex and higher CD4 levels at testing. CONCLUSIONS CONCLUSIONS In a single clinical cohort, we observed a decrease in the prevalence of resistance to all three examined antiretroviral drug classes over time. If this finding is confirmed in multicentre cohorts it may translate into reduced transmission of drug-resistant virus from treated patients. Y Y Di Giambenedetto Simona S Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy. simona.digiambenedetto@rm.unicatt.it Y Bracciale Laura L Y Colafigli Manuela M N Colatigli Manuela M Y Cattani Paola P Y Pinnetti Carmen C N Pannetti Carmen C Y Bacarelli Alessandro A Y Prosperi Mattia M Y Fadda Giovanni G Y Cauda Roberto R Y De Luca Andrea A eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t England Antivir Ther 9815705 1359-6535 0 D019380 Anti-HIV Agents 0 D012367 RNA, Viral IM ErratumIn Antivir Ther. 2007;12(7):1145 Colatigli, Manuela [corrected to Colafigli, Manuela; Cattani, Paola [added]; Pannetti, Carmen [corrected to Pinnetti, Carmen] D000328 N Adult D019380 N Anti-HIV Agents Q000627 Y therapeutic use D023241 N Antiretroviral Therapy, Highly Active D018791 N CD4 Lymphocyte Count D015331 N Cohort Studies D024882 N Drug Resistance, Viral Q000235 Y genetics D005260 N Female D005838 N Genotype D015658 N HIV Infections Q000188 Y drug therapy Q000453 N epidemiology Q000276 N immunology Q000821 N virology D015497 N HIV-1 Q000235 Y genetics D006801 N Humans D016015 N Logistic Models D008297 N Male D008875 N Middle Aged D009154 Y Mutation D016017 N Odds Ratio D011159 N Population Surveillance D015995 N Prevalence D012367 Y RNA, Viral D018570 N Risk Assessment D012307 N Risk Factors D012737 N Sex Factors D013997 N Time Factors D017211 N Treatment Failure pubmed 2007 8 24 9 0 medline 2007 10 20 9 0 entrez 2007 8 24 9 0 ppublish pubmed 17713168 MEDLINE NLM 1 17823161 2007 09 17 2013 11 21 Print Electronic 1756-1833 Internet 335 7618 2007 Sep 08 BMJ (Clinical research ed.) BMJ Agency warns about dosing error for amphotericin after patients with cancer die. 467 Y Y Hawkes Nigel N eng D016433 News England BMJ 8900488 0959-535X 0 D000935 Antifungal Agents 7XU7A7DROE D000666 Amphotericin B AIM IM ErratumIn BMJ. 2008 Jan 12;336(7635). doi: 10.1136/bmj.39454.454676.AD D000328 N Adult D000666 N Amphotericin B Q000506 Y poisoning D000935 N Antifungal Agents Q000506 Y poisoning D004739 N Geographic England D006801 N Humans D008297 N Male D008508 Y Medication Errors D009181 N Mycoses Q000188 Y drug therapy D009369 N Neoplasms Q000150 Y complications NLM PMC1971151 pubmed 2007 9 8 9 0 medline 2007 9 18 9 0 entrez 2007 9 8 9 0 ppublish pubmed 17823161 pii 335/7618/467 doi 10.1136/bmj.39329.504757.DB pmc PMC1971151 MEDLINE NLM 1 17926191 2008 04 09 2013 11 21 Print Print 1042-8194 Print 48 11 2007 Nov Leukemia & lymphoma Leuk. Lymphoma Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. 2145-51 AML with inv(3)/t(3;3) are generally considered of having a poor prognosis. For further insight in this rare entity the outcome of 65 inv(3)/t(3;3) positive AML cases were examined with special emphasis o n patient a nd disease related factors at diagnosis. Survival data were available from 35 patients. A hematological CR was achieved in 16/35 patients (46%). Eight patients (50%) relapsed. The median duration of remission was 177 days. Probability of OS was 23% at 2 years. Advanced age and high initial WBC count were associated with shorter OS (p = 0.021 and p = 0.005, respectively). Loss of chromosome 7 was the most frequent additional aberration (n = 34; 52%), followed complex aberrant aberrations (n = 5). Cases with monosomy 7 or the presence of FLT3-length mutations (FLT3-LM)--detected in 13% of cases--were not associated with an even more inferior outcome. Allogeneic stem cell translplantation, performed in 12 cases, resulted in a probability of OS of 62% at 2 years. Our data (1) confirm that inv(3)/t(3;3) AML has a poor prognosis (2) show that age and initial WBC are risk factors for prognosis; (3) suggest that this group may benefit from allogeneic stem cell transplantation. Y Y Weisser Martin M Medical Department III, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany. martin.weisser@gmx.de Y Haferlach Claudia C Y Haferlach Torsten T Y Schnittger Susanne S eng D023362 Evaluation Studies D016428 Journal Article England Leuk Lymphoma 9007422 1026-8022 04079A1RDZ D003561 Cytarabine 094ZI81Y45 D013629 Tamoxifen 0O54ZQ14I9 D000616 Aminoglutethimide BZ114NVM5P D008942 Mitoxantrone N29QWW3BUO D003613 Danazol Protocol C435907 MAC chemotherapy protocol Protocol C035360 TAD protocol IM CommentIn Leuk Lymphoma. 2007 Nov;48(11):2096-7 1 17990175 D000328 N Adult D000367 N Age Factors D000368 Y Aged D000369 N Aged, 80 and over D000616 N Aminoglutethimide Q000627 N therapeutic use D000971 N Antineoplastic Combined Chemotherapy Protocols Q000627 N therapeutic use D007446 Y Chromosome Inversion D002893 Y Chromosomes, Human, Pair 3 D015331 N Cohort Studies D003561 N Cytarabine Q000627 N therapeutic use D003613 N Danazol Q000627 N therapeutic use D005260 N Female D005500 N Follow-Up Studies D018380 N Hematopoietic Stem Cell Transplantation D006801 N Humans D007621 N Karyotyping D015470 N Leukemia, Myeloid, Acute Q000175 Y diagnosis Q000235 Y genetics Q000401 N mortality Q000628 N therapy D007958 Y Leukocyte Count D008297 N Male D008875 N Middle Aged D008942 N Mitoxantrone Q000627 N therapeutic use D011379 N Prognosis D016019 N Survival Analysis D013629 N Tamoxifen Q000627 N therapeutic use D014178 Y Translocation, Genetic pubmed 2007 10 11 9 0 medline 2008 4 10 9 0 entrez 2007 10 11 9 0 ppublish pubmed 17926191 pii 782923449 doi 10.1080/10428190701632848 MEDLINE NLM 1 18122624 2007 12 27 1949 12 01 Print Print 0891-3633 Print 59 (1 vol.) 1947-1948 Transactions of the Southern Surgical Association. Southern Surgical Association (U.S.) Trans South Surg Assoc Mesenteric vascular occlusion. 136-55 Y Y RIVES J D JD Y STRUG L H LH Y ESSRIG I M IM eng D016428 Journal Article United States Trans South Surg Assoc 20930080R 0891-3633 OM D006801 N Humans D008641 Y Mesenteric Vascular Occlusion D008643 Y Mesentery D014652 Y Vascular Diseases CLML 4916:397a1 NLM Y MESENTERY/occlusion pubmed 1947 1 1 0 0 medline 1947 1 1 0 0 entrez 1947 1 1 0 0 ppublish pubmed 18122624 MEDLINE NLM 1 18311089 2016 04 23 2016 09 12 Print Print 1091-0220 Print 12 3 2008 Mar Mayo Clinic women\\'s healthsource Mayo Clin Womens Healthsource Cancer death rates have fallen faster since 2002. 3 eng D016428 Journal Article United States Mayo Clin Womens Healthsource 9891120 1091-0220 K D002423 Y Cause of Death D006801 N Humans D009369 N Neoplasms pubmed 2008 3 4 9 0 medline 2016 4 24 6 0 entrez 2008 3 4 9 0 ppublish pubmed 18311089 PubMed-not-MEDLINE NLM 1 18243949 2012 10 02 2008 02 04 Print Print 0278-0062 Print 4 1 1985 IEEE transactions on medical imaging IEEE Trans Med Imaging Electrophoretic recording of electronically stored radiographs. 39-43 Continuous tone hard copies of electronically stored radiographs are recorded on transparent film with a silverless conductive coating by electrophoretic deposition of toner particles. A stationary experimental print head with a row of 320 electrodes (eight electrodes per mm) was employed. The performance of the recording process with regard to the most important parameters, i.e., toner concentration, width of the gap between recording medium and electrodes, recording voltage, and speed will be described. The process exhibits continuous tone characteristics, because the optical density can be varied continuously by the recording voltage. The image resolution which can be achieved is characterized by a modulation transfer function. Y Y Hinz H D HD Y Lobl H H eng D016428 Journal Article United States IEEE Trans Med Imaging 8310780 0278-0062 pubmed 1985 1 1 0 0 medline 1985 1 1 0 1 entrez 1985 1 1 0 0 ppublish pubmed 18243949 doi 10.1109/TMI.1985.4307691 PubMed-not-MEDLINE NLM 1 18964660 2012 10 02 2008 10 30 Print Print 0039-9140 Print 35 12 1988 Dec Talanta Talanta Multiparametric curve fitting-XIII Reliability of formation constants determined by analysis of potentiometric titration data. 981-91 The formation (protonation) constants log K(i), of the acid H(j)L are determined by regression analysis of potentiometric titration data when common parameters (log K(i), i = 1,..., j) and group parameters (E(0)\\', L(0), H(T)) are refined. The influence of three kinds of error on the protonation constants has been investigated: error from the strategy of minimization, random error, and error from uncertain estimates of group parameters. An analysis of variance of the log K(i), matrix was made for 7 identical titrations and 8 computational strategies, or of 7 identical titrations and 8 different options of group parameters to be refined. The influence of the standard potential E(0) of the glass-electrode cell on the systematic error in log K is greater than that of the acid concentration (L(0)) or the concentration of titrant used (H(T)). The ill-conditioned group parameters should be refined together with the common parameters (K(i)), otherwise the estimates of log K(i), are not accurate enough. Two ways of calibrating the glass electrode cell were compared. Internal calibration (performed during titration) was more accurate than external calibration done separately. Of the programs tested ESAB and ACBA are the most powerful because they permit refinement of group parameters and internal calibration. Citric acid was chosen as model substance. Y Y Meloun M M Department of Analytical Chemistry, College of Chemical Technology, CS-532 10 Pardubice, Czechoslovakia. Y Bartos M M Y Hgfeldt E E eng D016428 Journal Article Netherlands Talanta 2984816R 0039-9140 received 1987 04 24 revised 1988 06 29 accepted 1988 08 12 pubmed 1988 12 1 0 0 medline 1988 12 1 0 1 entrez 1988 12 1 0 0 ppublish pubmed 18964660 pii 0039-9140(88)80233-9 MEDLINE NLM 1 18941263 2015 07 23 2008 10 22 Print Electronic 1833-3575 Internet 37 3 2008 The HIM journal HIM J Issues in the measurement of social determinants of health. 26-32 This article focuses on the measurement of the social determinants of health, and specifically on issues relating to two key variables relevant to the analysis of public health information: poverty and inequality. Although the paper has been written from the perspective of economics, the discipline of the two authors, it is also of relevance to researchers in other disciplines. It is argued that there is a need to ensure that, when considering measurement in this largely neglected area of research, sufficient thought is given to the relationships that are being examined or assessed. We argue further that any attempt at measurement in this area must take into account the historical backdrop and the complex nature of the relationships between these key variables. Y Y Mooney Gavin G Curtin University of Technology, Perth, Western Australia. g.mooney@curtin.edu.au Y Fohtung Nubong G NG eng D016428 Journal Article United States HIM J 101122643 1833-3583 H D001315 N Geographic Australia D006301 N Health Services Needs and Demand D006801 N Humans D011203 Y Poverty D011634 N Public Health D012923 N Social Class D064890 Y Social Determinants of Health D012959 Y Socioeconomic Factors pubmed 2008 10 23 9 0 medline 2015 7 24 6 0 entrez 2008 10 23 9 0 ppublish pubmed 18941263 PubMed-not-MEDLINE NLM 1 19771122 2009 12 11 2009 09 22 Print Print 0146-9592 Print 15 24 1990 Dec 15 Optics letters Opt Lett Ultrashort-laser-pulse amplification in a XeF[C --> A] excimer amplifier. 1461-3 Tunable blue-green subpicosecond laser pulses have been amplified in an electron-beam-pumped XeF(C --> A) excimer amplifier. Small-signal gains of 3.5% cm(-1) were measured using a 50-cm active gain length. At output energy densities as high as 170 mJ/cm(2), only a small degree of saturation occurred, resulting in a gain of 2.5% cm(-1). Y Y Sharp T E TE Department of Electrical and Computer Engineering, Rice University, P.O. Box 1892, Houston, Texas 77251, USA. Y Hofmann T T Y Dane C B CB Y Wilson W L WL Jr Y Tittel F K FK Y Wisoff P J PJ Y Szab G G eng D016428 Journal Article United States Opt Lett 7708433 0146-9592 entrez 2009 9 23 6 0 pubmed 1990 12 15 0 0 medline 1990 12 15 0 1 ppublish pubmed 19771122 pii 59797 MEDLINE NLM 1 21002435 2010 10 28 2014 08 12 Print Print 0002-9955 Print 132 12 1946 Nov 23 Journal of the American Medical Association J Am Med Assoc BRUTALITIES of Nazi physicians. 714 eng D016428 Journal Article United States J Am Med Assoc 7507176 0002-9955 OM D035843 Y Biomedical Research D006805 Y Human Experimentation D006801 N Humans D028683 Y National Socialism D010820 Y Physicians D012106 Y Research D014858 Y War Crimes CLML 4611:956w NLM Y RESEARCH, MEDICAL/human experimentation Y WAR/crimes entrez 2010 10 29 6 0 pubmed 1946 11 23 0 0 medline 2014 8 13 6 0 ppublish pubmed 21002435 PubMed-not-MEDLINE NLM 1 20405411 2011 05 04 2010 04 20 Print Electronic 1828-1427 Internet 44 1 2008 Jan-Mar Veterinaria italiana Vet. Ital. Long distance animal transport: the way forward. 43-7 Too often, the issue of animal welfare during transport is the subject of emotional debates. For farmers within the International Federation of Agricultural Producers, it is important that the economic, scientific and practical aspects be taken into account when setting international rules for animal welfare. Farmers also stress the need to combine scientific data with their practical experience. Raising awareness, adopting a risk-based approach, education, labelling, slaughterhouse capacity and animal health, as well as standards and rules, are issues of importance for developing a long distance transportation infrastructure respectful of animal welfare around the world. Y Y Osinga Klaas Johan KJ International Federation of Agricultural Producers/LTO Netherland, Drachten, The Netherlands. klaasjohan@yahoo.com eng D016428 Journal Article Italy Vet Ital 0201543 0505-401X entrez 2010 4 21 6 0 pubmed 2008 1 1 0 0 medline 2008 1 1 0 1 ppublish pubmed 20405411 MEDLINE NLM 1 21007460 2010 10 28 2015 11 19 Print Print 1944-1945 The Proceedings of the Cardiff Medical Society Proc Cardiff Med Soc Social psychiatry in the post-war world. 55-9 Y Y REES J R JR eng D016428 Journal Article Wales Proc Cardiff Med Soc 7505858 OM D003158 Y Community Psychiatry D006801 N Humans D014857 Y Warfare CLML 4610:216i1 NLM Y PSYCHIATRY/social entrez 2010 10 29 6 0 pubmed 1944 1 1 0 0 medline 2011 4 13 6 0 ppublish pubmed 21007460 MEDLINE NLM 1 18719013 2008 09 02 2017 09 22 Electronic Electronic 1756-1833 Internet 337 2008 Aug 21 BMJ (Clinical research ed.) BMJ Health related quality of life after combined hormone replacement therapy: randomised controlled trial. a1190 doi Y 10.1136/bmj.a1190 pii Y 337/aug21_2/a1190 OBJECTIVE OBJECTIVE To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life. DESIGN METHODS Randomised placebo controlled double blind trial. SETTING METHODS General practices in United Kingdom (384), Australia (94), and New Zealand (24). PARTICIPANTS METHODS Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively. INTERVENTIONS METHODS Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year. MAIN OUTCOME MEASURES METHODS Health related quality of life and psychological wellbeing as measured by the women\\'s health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiological Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively. RESULTS RESULTS After one year small but significant improvements were observed in three of nine components of the women\\'s health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P<0.001), sexual functioning (P<0.001), and sleep problems (P<0.001). Significantly fewer women in the combined HRT group reported hot flushes (P<0.001), night sweats (P<0.001), aching joints and muscles (P=0.001), insomnia (P<0.001), and vaginal dryness (P<0.001) than in the placebo group, but greater proportions reported breast tenderness (P<0.001) or vaginal discharge (P<0.001). Hot flushes were experienced in the combined HRT and placebo groups by 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year. CONCLUSIONS CONCLUSIONS Combined HRT started many years after the menopause can improve health related quality of life. TRIAL REGISTRATION BACKGROUND ISRCTN 63718836. Y Y Welton Amanda J AJ MRC General Practice Research Framework, Stephenson House, London NW1 2ND. Y Vickers Madge R MR Y Kim Joseph J Y Ford Deborah D Y Lawton Beverley A BA Y MacLennan Alastair H AH Y Meredith Sarah K SK Y Martin Jeannett J Y Meade Tom W TW Y WISDOM team eng Y ISRCTN ISRCTN63718836 Y British Heart Foundation United Kingdom Medical Research Council United Kingdom Department of Health United Kingdom MC_U122797165 Medical Research Council United Kingdom G0701113 Medical Research Council United Kingdom D016428 Journal Article D016448 Multicenter Study D016449 Randomized Controlled Trial D013485 Research Support, Non-U.S. Gov\\'t Electronic 2008 08 21 England BMJ 8900488 0959-535X 0 D004967 Estrogens 0 D011372 Progestins AIM IM CommentIn Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):136-7 1 19229231 CommentIn BMJ. 2009;338:a2597 1 19139137 CommentIn BMJ. 2008;337:a1494 1 18768558 Cites Horm Behav. 1996 Sep;30(3):244-50 1 8918680 Cites Biol Psychiatry. 2004 Feb 15;55(4):406-12 1 14960294 Cites Arch Gen Psychiatry. 2001 Jun;58(6):529-34 1 11386980 Cites N Engl J Med. 2006 Apr 6;354(14):1497-506 1 16598046 Cites Soc Sci Med. 1994 Dec;39(11):1537-44 1 7817218 Cites Annu Rev Public Health. 1994;15:535-59 1 8054098 Cites N Engl J Med. 2004 Feb 5;350(6):622 1 14762196 Cites Qual Life Res. 1996 Oct;5(5):469-80 1 8973126 Cites Decubitus. 1993 Sep;6(5):56-8 1 8286021 Cites Qual Life Res. 2004 Mar;13(2):311-20 1 15085903 Cites Am J Obstet Gynecol. 2000 Aug;183(2):414-20 1 10942479 Cites Support Care Cancer. 1995 Jan;3(1):11-22 1 7697298 Cites JAMA. 2005 Jul 13;294(2):183-93 1 16014592 Cites Am J Obstet Gynecol. 1994 Feb;170(2):618-24 1 7509570 Cites Am J Psychiatry. 1983 Jan;140(1):41-6 1 6847983 Cites BMJ. 2007 Aug 4;335(7613):239 1 17626056 Cites Arch Intern Med. 2003 Jan 27;163(2):205-9 1 12546611 Cites Med Care. 1997 Nov;35(11):1109-18 1 9366890 Cites Hypertension. 2006 May;47(5):833-9 1 16585410 Cites JAMA. 2002 Feb 6;287(5):591-7 1 11829697 Cites J Gen Intern Med. 2006 Apr;21(4):363-6 1 16686814 Cites BMJ. 1993 Oct 2;307(6908):836-40 1 8401125 Cites Horm Behav. 2006 Apr;49(4):441-9 1 16257405 Cites Menopause. 2003 Jan-Feb;10(1):4-5 1 12544670 Cites JAMA. 2002 Jul 17;288(3):321-33 1 12117397 Cites Climacteric. 2007 Jun;10(3):181-94 1 17487645 Cites BMJ. 2004 Feb 14;328(7436):371 1 14962874 Cites Fertil Steril. 2005 Mar;83(3):558-66 1 15749481 Cites Arch Intern Med. 2005 Apr 25;165(8):863-7 1 15851636 Cites Stroke. 1997 Oct;28(10):1876-82 1 9341688 Cites Health Qual Life Outcomes. 2003;1:24 1 12848895 Cites J Allergy Clin Immunol. 1998 Jul;102(1):16-7 1 9679842 Cites Climacteric. 2002 Dec;5(4):317-25 1 12626209 Cites Fertil Steril. 2001 Jun;75(6):1080-7 1 11384630 Cites N Engl J Med. 2003 May 8;348(19):1839-54 1 12642637 Cites Menopause. 2004 Sep-Oct;11(5):508-18 1 15356403 Cites Neurobiol Aging. 2006 Jan;27(1):141-9 1 16298249 Cites Neurology. 2007 Sep 25;69(13):1322-30 1 17893293 Cites J Gen Intern Med. 2004 Jul;19(7):791-804 1 15209595 Cites Br J Obstet Gynaecol. 1997 Oct;104(10):1191-5 1 9332999 Cites Arch Intern Med. 2005 Sep 26;165(17):1976-86 1 16186467 Cites Stroke. 1998 Jan;29(1):63-8 1 9445330 Cites Climacteric. 2005 Mar;8(1):49-55 1 15804731 Cites BMC Womens Health. 2007 Feb 26;7:2 1 17324282 D000368 N Aged D004311 N Double-Blind Method D004359 N Drug Therapy, Combination D004967 N Estrogens Q000008 Y administration & dosage D005260 N Female D006304 N Health Status D020249 N Hormone Replacement Therapy Q000379 Y methods D006801 N Humans D008875 N Middle Aged D017698 N Postmenopause Q000523 Y psychology D011372 N Progestins Q000008 Y administration & dosage D011379 N Prognosis D011788 Y Quality of Life D011795 N Surveys and Questionnaires D016387 N Women\\'s Health NLM PMC2518695 Y Abdalla M M Y DeStavola B L BL Y Allen P P Y Allen H H Y Bastick R R Y Brown H H Y Foulger K K Y Fox S S Y Glynn V V Y Hall A A Y Hand L L Y Hill A A Y Leathem C C Y Mackinnon W W Y Marshall E E Y Williams A A Y Collins N N N Y O\\'Conner B B Y Darbyshire J H JH Y Ghali M M Y Furness P P Y Islam M Z MZ Y Harrild K K Y Knott C C Y Taylor L L Y Walgrove M A MA Y Wilkes H C HC Y Zhu C-Q CQ Y Zuhrie S R SR Y Griffith E E Y Ryan P P Y Komesaroff P P Y Marley J J Y Paine B J BJ Y Stocks N P NP Y Dowell A A Y Rose S S pubmed 2008 8 23 9 0 medline 2008 9 3 9 0 entrez 2008 8 23 9 0 epublish pubmed 18719013 pmc PMC2518695 MEDLINE NLM 1 21024418 2010 11 12 2017 10 16 Print Print 64 1944-1945 Transactions. Ophthalmological Society of the United Kingdom Trans Ophthalmol Soc U K Preventable blindness in war. 165-78 Y Y CRUISE R R eng D016428 Journal Article England Trans Ophthalmol Soc U K 0201270 OM D001766 Y Blindness D006801 N Humans D008887 Y Military Medicine D009885 Y Ophthalmology D014857 Y Warfare CLML 4610:1030s NLM Y BLINDNESS/in war Y MILITARY MEDICINE/ophthalmology entrez 2010 10 29 6 0 pubmed 1944 1 1 0 0 medline 2014 8 13 6 0 ppublish pubmed 21024418 MEDLINE NLM 1 23674598 2013 07 16 2017 09 22 Print Electronic 1477-9129 Internet 140 11 2013 Jun Development (Cambridge, England) Development The neural crest. 2247-51 doi Y 10.1242/dev.091751 The neural crest (NC) is a highly migratory multipotent cell population that forms at the interface between the neuroepithelium and the prospective epidermis of a developing embryo. Following extensive migration throughout the embryo, NC cells eventually settle to differentiate into multiple cell types, ranging from neurons and glial cells of the peripheral nervous system to pigment cells, fibroblasts to smooth muscle cells, and odontoblasts to adipocytes. NC cells migrate in large numbers and their migration is regulated by multiple mechanisms, including chemotaxis, contact-inhibition of locomotion and cell sorting. Here, we provide an overview of NC formation, differentiation and migration, highlighting the molecular mechanisms governing NC migration. Y Y Mayor Roberto R Department of Cell and Developmental Biology, University College London, Gower Street, London WC1E 6BT, UK. r.mayor@ucl.ac.uk Y Theveneau Eric E eng Y MR/J000655/1 Medical Research Council United Kingdom Biotechnology and Biological Sciences Research Council United Kingdom Medical Research Council United Kingdom Wellcome Trust United Kingdom D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t D016454 Review England Development 8701744 0950-1991 IM D000818 N Animals D002465 Y Cell Movement D002633 N Chemotaxis D002642 N Chick Embryo D047108 N Embryonic Development Q000502 N physiology D058750 N Epithelial-Mesenchymal Transition D018507 Y Gene Expression Regulation, Developmental D006801 N Humans D051379 N Mice D009369 N Neoplasms Q000378 N metabolism D009432 N Neural Crest Q000196 N embryology Q000502 Y physiology D014981 N Xenopus D015027 N Zebrafish NOTNLM N Cancer N Cell migration N Chemotaxis N Contact-inhibition of locomotion N Epithelium-to-mesenchyme transition N Neural crest cells N Neurocristopathies entrez 2013 5 16 6 0 pubmed 2013 5 16 6 0 medline 2013 7 17 6 0 ppublish pubmed 23674598 pii 140/11/2247 doi 10.1242/dev.091751 MEDLINE NLM 1 23326248 2013 06 28 2015 02 19 Print-Electronic Electronic 1612-3174 Internet 11 2013 German medical science : GMS e-journal Ger Med Sci Transcatheter Amplatzer vascular plug-embolization of a giant postnephrectomy arteriovenous fistula combined with an aneurysm of the renal pedicle by through-and-through, arteriovenous access. Doc01 doi Y 10.3205/000169 Although endovascular transcatheter embolization of arteriovenous fistulas is minimally invasive, the torrential flow prevailing within a fistula implies the risk of migration of the deployed embolization devices into the downstream venous and pulmonary circulation. We present the endovascular treatment of a giant postnephrectomy arteriovenous fistula between the right renal pedicle and the residual renal vein in a 63-year-old man. The purpose of this case report is to demonstrate that the Amplatzer vascular plug (AVP) can be safely positioned to embolize even relatively large arteriovenous fistulas (AVFs). Secondly, we illustrate that this occluder can even be introduced to the fistula via a transvenous catheter in cases where it is initially not possible to advance the deployment-catheter through a tortuous feeder artery. Migration of the vascular plug was ruled out at follow-up 4 months subsequently to the intervention. Thus, the Amplatzer vascular plug and the arteriovenous through-and-through guide wire access with subsequent transvenous deployment should be considered in similar cases. Y Y Kayser Ole O Department of Radiology, University Hospital Schleswig-Holstein, Kiel, Germany. o.kayser@rad.uni-kiel.de Y Schfer Philipp P eng D002363 Case Reports D016428 Journal Article Electronic 2013 01 14 Germany Ger Med Sci 101227686 1612-3174 IM Cites Cardiovasc Intervent Radiol. 2008 Jul;31 Suppl 2:S92-5 1 18049835 Cites Emerg Radiol. 2008 Mar;15(2):119-22 1 17593408 Cites Cardiovasc Intervent Radiol. 2009 May;32(3):543-7 1 18574625 Cites Int J Urol. 2009 Jul;16(7):648-9 1 19659804 Cites Heart Vessels. 2010 Jul;25(4):356-8 1 20676847 Cites Urology. 2011 Oct;78(4):820-6 1 21813164 Cites J Endovasc Ther. 2011 Dec;18(6):811-8 1 22149231 Cites Vasc Endovascular Surg. 2003 Jan-Feb;37(1):47-57 1 12577139 Cites Curr Vasc Pharmacol. 2003 Oct;1(3):347-54 1 15320481 Cites J Chir (Paris). 1978 Oct;115(10):541-4 1 739047 Cites Urology. 1985 Jan;25(1):13-6 1 3966275 Cites Surgery. 1986 Jan;99(1):114-8 1 3941996 Cites Surgery. 1989 Jan;105(1):1-12 1 2643193 Cites Ann Vasc Surg. 1992 Jul;6(4):378-80 1 1390028 Cites J Cardiovasc Surg (Torino). 1998 Aug;39(4):433-6 1 9788787 Cites Br J Urol. 1962 Mar;34:15-8 1 13899592 Cites Am J Med. 1964 Oct;37:499-513 1 14215839 Cites J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):363-7 1 16517784 Cites Vascular. 2009 Jan-Feb;17(1):40-3 1 19344582 D000783 N Aneurysm Q000175 N diagnosis Q000209 N etiology Q000628 Y therapy D001027 N Aortography D001164 N Arteriovenous Fistula Q000175 N diagnosis Q000209 N etiology Q000628 Y therapy D042241 N Early Diagnosis D004621 N Embolization, Therapeutic Q000295 Y instrumentation Q000379 N methods D006801 N Humans D007668 N Kidney Q000293 N injuries D008297 N Male D008875 N Middle Aged D009392 Y Nephrectomy D011183 N Postoperative Complications Q000175 N diagnosis Q000209 N etiology Q000628 Y therapy D012077 Y Renal Artery D055989 Y Septal Occluder Device D014057 N Tomography, X-Ray Computed D018616 N Ultrasonography, Doppler, Duplex D014682 Y Vena Cava, Inferior NLM PMC3546418 Publisher ger Obwohl die endovaskulre Katheter-Embolisation von arteriovensen Fisteln minimal-invasiv ist, impliziert die, in der Fistel vorherrschende, hohe Strmungsgeschwindigkeit ein Risiko zur Migration des Embolisats in den nachgeschalteten vensen Abstrom und in den Lungenkreislauf. Wir beschreiben die endovaskulre Behandlung einer groen arteriovensen Fistel zwischen der rechten Nierenarterie und residueller Nierenvene nach Nephrektomie im Fall eines 63-jhrigen Mannes.Dieser Fallbericht demonstriert, dass der Amplatzer vascular plug sicher innerhalb sogar relativ grokalibriger AVFs platziert werden kann. Zweitens zeigen wir, dass dieser \"Occluder\" sogar ber einen transvensen Katheter in die Fistel eingebracht werden kann, falls es initial nicht mglich ist, den Freisetzungs-Katheter ber die (in unserem Fall) stark gewundene zufhrende Arterie in die Fistel einzufhren. Migration des \"vascular plug\" wurde in der Verlaufskontrolle 4 Monate postinterventionell ausgeschlossen.Der hier vorgestellte kombiniert-arteriovense Zugangsweg mittels transfistulr durchgezogenem Fhrungsdraht und nachfolgender, transvenser Freisetzung des Amplatzer vascular plugs sollte in hnlichen Fllen bercksichtigt werden. NOTNLM N AV-fistula N Amplatzer vascular plug N arteriovenous access N arteriovenous fistula N embolisation N endovascular treatment N nephrectomy N through-and-through N transvenous access received 2012 11 10 revised 2012 11 26 entrez 2013 1 18 6 0 pubmed 2013 1 18 6 0 medline 2013 7 3 6 0 ppublish pubmed 23326248 doi 10.3205/000169 pii 000169 pmc PMC3546418 PubMed-not-MEDLINE NLM 1 23807877 2013 07 01 2017 02 20 Electronic-eCollection Print 1662-4548 Print 7 2013 Frontiers in neuroscience Front Neurosci Improved blood velocity measurements with a hybrid image filtering and iterative Radon transform algorithm. 106 doi Y 10.3389/fnins.2013.00106 Neural activity leads to hemodynamic changes which can be detected by functional magnetic resonance imaging (fMRI). The determination of blood flow changes in individual vessels is an important aspect of understanding these hemodynamic signals. Blood flow can be calculated from the measurements of vessel diameter and blood velocity. When using line-scan imaging, the movement of blood in the vessel leads to streaks in space-time images, where streak angle is a function of the blood velocity. A variety of methods have been proposed to determine blood velocity from such space-time image sequences. Of these, the Radon transform is relatively easy to implement and has fast data processing. However, the precision of the velocity measurements is dependent on the number of Radon transforms performed, which creates a trade-off between the processing speed and measurement precision. In addition, factors like image contrast, imaging depth, image acquisition speed, and movement artifacts especially in large mammals, can potentially lead to data acquisition that results in erroneous velocity measurements. Here we show that pre-processing the data with a Sobel filter and iterative application of Radon transforms address these issues and provide more accurate blood velocity measurements. Improved signal quality of the image as a result of Sobel filtering increases the accuracy and the iterative Radon transform offers both increased precision and an order of magnitude faster implementation of velocity measurements. This algorithm does not use a priori knowledge of angle information and therefore is sensitive to sudden changes in blood flow. It can be applied on any set of space-time images with red blood cell (RBC) streaks, commonly acquired through line-scan imaging or reconstructed from full-frame, time-lapse images of the vasculature. Y Y Chhatbar Pratik Y PY Department of Neurosciences, Medical University of South Carolina Charleston, SC, USA. Y Kara Prakash P eng Y R01 EY017925 EY NEI NIH HHS United States D016428 Journal Article Electronic 2013 06 18 Switzerland Front Neurosci 101478481 1662-453X Cites J Biomed Opt. 2010 Sep-Oct;15(5):056014 1 21054108 Cites Neuroimage. 2012 Feb 1;59(3):2569-88 1 21925275 Cites Nat Methods. 2010 Aug;7(8):655-60 1 20581828 Cites Nature. 2005 Feb 10;433(7026):597-603 1 15660108 Cites Front Mol Neurosci. 2013 Mar 04;6:2 1 23459413 Cites IEEE Trans Med Imaging. 2011 Aug;30(8):1527-45 1 21427018 Cites J Vis Exp. 2012 Dec 12;(70):e50025 1 23271035 Cites Nat Methods. 2009 Dec;6(12):875-81 1 19898485 Cites Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7319-24 1 12777621 Cites J Neurophysiol. 2008 Feb;99(2):787-98 1 18046008 Cites Proc Natl Acad Sci U S A. 2011 May 17;108(20):8473-8 1 21536897 Cites Trends Neurosci. 1988 Oct;11(10):419-24 1 2469158 Cites PLoS One. 2012;7(6):e38590 1 22761686 Cites PLoS One. 2011;6(8):e24056 1 21887370 Cites Nature. 2012 Apr 04;484(7392):24-6 1 22481337 Cites Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13081-6 1 14569029 Cites Front Neural Circuits. 2012 Dec 13;6:101 1 23248588 Cites J Comput Neurosci. 2010 Aug;29(1-2):5-11 1 19459038 Cites Nat Methods. 2012 Jan 22;9(3):273-6 1 22266543 Cites PLoS Biol. 2006 Feb;4(2):e22 1 16379497 Cites Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15741-6 1 9861040 Cites J Neurosci. 2005 Jun 1;25(22):5333-8 1 15930381 NLM PMC3684769 NOTNLM N Sobel filtering N blood flow N line-scan N space-time images N two-photon imaging N velocity received 2013 04 01 accepted 2013 05 24 entrez 2013 6 29 6 0 pubmed 2013 6 29 6 0 medline 2013 6 29 6 1 epublish pubmed 23807877 doi 10.3389/fnins.2013.00106 pmc PMC3684769 MEDLINE NLM 1 23685357 2013 08 12 2017 09 22 Print-Electronic Electronic 1460-2075 Internet 32 12 2013 Jun 12 The EMBO journal EMBO J. Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activity. 1730-44 doi Y 10.1038/emboj.2013.107 Actin-based remodelling underlies spine structural changes occurring during synaptic plasticity, the process that constantly reshapes the circuitry of the adult brain in response to external stimuli, leading to learning and memory formation. A positive correlation exists between spine shape and synaptic strength and, consistently, abnormalities in spine number and morphology have been described in a number of neurological disorders. In the present study, we demonstrate that the actin-regulating protein, Eps8, is recruited to the spine head during chemically induced long-term potentiation in culture and that inhibition of its actin-capping activity impairs spine enlargement and plasticity. Accordingly, mice lacking Eps8 display immature spines, which are unable to undergo potentiation, and are impaired in cognitive functions. Additionally, we found that reduction in the levels of Eps8 occurs in brains of patients affected by autism compared to controls. Our data reveal the key role of Eps8 actin-capping activity in spine morphogenesis and plasticity and indicate that reductions in actin-capping proteins may characterize forms of intellectual disabilities associated with spine defects. Y Y Menna Elisabetta E CNR Institute of Neuroscience, Milano, Italy. e.menna@in.cnr.it Y Zambetti Stefania S Y Morini Raffaella R Y Donzelli Andrea A Y Disanza Andrea A Y Calvigioni Daniela D Y Braida Daniela D Y Nicolini Chiara C Y Orlando Marta M Y Fossati Giuliana G Y Cristina Regondi Maria M Y Pattini Linda L Y Frassoni Carolina C Y Francolini Maura M Y Scita Giorgio G ORCID 0000000179841889 Y Sala Mariaelvina M Y Fahnestock Margaret M Y Matteoli Michela M eng Y GGP12115 Telethon Italy D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t Electronic 2013 05 17 England EMBO J 8208664 0261-4189 0 D000199 Actins 0 D048868 Adaptor Proteins, Signal Transducing 0 C083430 Eps8 protein, mouse 0 D009419 Nerve Tissue Proteins IM Cites Nat Rev Neurosci. 2004 Jan;5(1):45-54 1 14708003 Cites J Neurosci. 2010 Nov 10;30(45):14937-42 1 21068295 Cites Curr Opin Neurobiol. 2009 Apr;19(2):231-4 1 19545994 Cites J Neuropathol Exp Neurol. 2012 Apr;71(4):289-97 1 22437340 Cites EMBO J. 1999 Oct 1;18(19):5300-9 1 10508163 Cites Mol Brain. 2009;2:27 1 19674479 Cites Neuron. 2003 May 8;38(3):447-60 1 12741991 Cites Front Mol Neurosci. 2010 Feb 09;3:1 1 20162032 Cites Science. 2008 Mar 21;319(5870):1683-7 1 18309046 Cites J Cell Biol. 1992 Jul;118(2):335-46 1 1629237 Cites Hum Mol Genet. 2009 Mar 15;18(6):1075-88 1 19153075 Cites Genes Cells. 2010 Jun;15(7):737-47 1 20545768 Cites J Neurosci. 1984 Aug;4(8):1944-53 1 6470762 Cites Nat Cell Biol. 2004 Dec;6(12):1180-8 1 15558031 Cites J Cell Biol. 1995 Jan;128(1-2):61-70 1 7822423 Cites Cell. 2008 Oct 31;135(3):401-6 1 18984149 Cites PLoS Comput Biol. 2011 Jul;7(7):e1002088 1 21814501 Cites Biol Psychiatry. 2011 May 1;69(9):875-82 1 21306704 Cites J Neurosci. 2012 Feb 8;32(6):1989-2001 1 22323713 Cites J Neurodev Disord. 2009 Sep;1(3):185-96 1 19966931 Cites PLoS Biol. 2010;8(6):e1000387 1 20532239 Cites J Neurosci. 2009 Sep 30;29(39):12167-73 1 19793974 Cites J Neurosci. 2009 Jan 14;29(2):351-8 1 19144835 Cites Cell. 1996 Dec 13;87(6):1025-35 1 8978607 Cites J Neurosci. 2008 May 28;28(22):5654-9 1 18509026 Cites Mol Cell Neurosci. 2001 Aug;18(2):210-20 1 11520181 Cites Trends Neurosci. 2006 Jan;29(1):8-20 1 16337695 Cites Mol Biol Cell. 2008 Apr;19(4):1561-74 1 18256280 Cites Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6856-61 1 10823894 Cites J Neurosci. 2011 Jul 13;31(28):10228-33 1 21752999 Cites Neuron. 2000 Jul;27(1):11-4 1 10939326 Cites Nat Genet. 2007 Jan;39(1):25-7 1 17173049 Cites PLoS One. 2010;5(3):e9468 1 20209148 Cites Science. 2000 Oct 27;290(5492):754-8 1 11052932 Cites J Neurosci. 2003 Sep 17;23(24):8498-505 1 13679418 Cites Neuron. 2002 Jul 3;35(1):121-33 1 12123613 Cites Trends Neurosci. 2003 Jul;26(7):360-8 1 12850432 Cites Annu Rev Physiol. 2009;71:261-82 1 19575680 Cites J Biol Chem. 2008 Jun 6;283(23):15912-20 1 18430734 Cites PLoS Biol. 2009 Jun 30;7(6):e1000138 1 19564905 Cites Nat Neurosci. 2004 Oct;7(10):1104-12 1 15361876 Cites J Cell Biol. 2010 May 17;189(4):619-29 1 20457765 Cites Trends Neurosci. 2008 Sep;31(9):487-94 1 18684518 Cites J Cell Biol. 2009 Apr 20;185(2):323-39 1 19380880 Cites J Autism Dev Disord. 1994 Oct;24(5):659-85 1 7814313 Cites Nat Cell Biol. 2004 Dec;6(12):1173-9 1 15558032 Cites EMBO J. 2011 Feb 16;30(4):719-30 1 21252856 Cites Nat Neurosci. 2011 Mar;14(3):285-93 1 21346746 Cites J Neurosci. 1992 Jul;12(7):2685-705 1 1613552 Cites Cell. 2008 May 30;133(5):841-51 1 18510928 Cites J Neurosci. 2007 Jan 10;27(2):355-65 1 17215396 Cites Nat Rev Neurosci. 2008 May;9(5):344-56 1 18425089 Cites J Neurosci. 1996 May 1;16(9):2983-94 1 8622128 Cites Behav Brain Res. 2004 Aug 31;153(2):423-9 1 15265638 Cites Cell. 2006 Oct 6;127(1):213-26 1 17018287 Cites Biophys J. 2005 Aug;89(2):782-95 1 15879474 Cites Curr Opin Neurobiol. 2009 Apr;19(2):146-53 1 19523814 Cites Nat Genet. 2003 May;34(1):27-9 1 12669065 Cites Dev Biol. 2006 Sep 1;297(1):214-27 1 16806147 Cites J Cell Biol. 1992 Dec;119(5):1151-62 1 1447293 Cites EMBO J. 2004 Aug 4;23(15):3010-9 1 15282541 Cites Exp Cell Res. 2010 Jul 15;316(12):1914-24 1 20184880 Cites J Neurosci. 2001 Aug 15;21(16):6105-14 1 11487634 Cites Brain Res. 1977 May 13;126(3):397-42 1 861729 Cites Cereb Cortex. 2014 Feb;24(2):364-76 1 23064108 Cites Trends Genet. 2010 Aug;26(8):363-72 1 20609491 Cites Biochem Biophys Res Commun. 2002 Feb 15;291(1):62-7 1 11829462 Cites Brain Res. 2010 Jan 14;1309:83-94 1 19896929 Cites J Neurosci. 1998 Nov 1;18(21):8900-11 1 9786995 Cites J Neurosci. 2003 Nov 19;23(33):10645-9 1 14627649 Cites Neuron. 2001 Jan;29(1):243-54 1 11182095 Cites World J Gastroenterol. 2012 Aug 7;18(29):3896-903 1 22876043 Cites Cell. 2008 Jul 11;134(1):175-87 1 18614020 Cites J Neurosci. 2010 Sep 1;30(35):11565-75 1 20810878 Cites Nat Neurosci. 2000 Jun;3(6):545-50 1 10816309 Cites J Neurosci. 2010 Mar 31;30(13):4757-66 1 20357126 Cites Nat Cell Biol. 2006 Dec;8(12):1337-47 1 17115031 Cites Curr Neurol Neurosci Rep. 2010 May;10(3):207-14 1 20425036 Cites Neuron. 2008 Mar 13;57(5):719-29 1 18341992 Cites Immunity. 2011 Sep 23;35(3):388-99 1 21835647 Cites Hippocampus. 2006;16(5):472-9 1 16502390 Cites Neuron. 1996 Jul;17(1):91-102 1 8755481 Cites Arch Gen Psychiatry. 2000 Apr;57(4):331-40 1 10768694 Cites Mol Cell Biol. 2004 Dec;24(24):10905-22 1 15572692 Cites PLoS Biol. 2009 Oct;7(10):e1000208 1 19806181 Cites J Comp Neurol. 2011 Sep 1;519(13):2522-45 1 21456011 Cites Brain Res. 2008 Jan 10;1188:241-53 1 18022143 Cites Mol Biol Cell. 2010 Jan 1;21(1):165-76 1 19889835 Cites Annu Rev Neurosci. 2001;24:1071-89 1 11520928 Cites Nature. 2010 Jul 15;466(7304):368-72 1 20531469 Cites PLoS Biol. 2011 Apr;9(4):e1001048 1 21526224 Cites Neuroscience. 2007 Mar 2;145(1):116-29 1 17223277 Cites Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13438-43 1 10557339 Cites J Neurosci. 2013 Feb 6;33(6):2661-70 1 23392693 D000199 N Actins Q000235 N genetics Q000378 Y metabolism D048868 N Adaptor Proteins, Signal Transducing Q000235 N genetics Q000378 Y metabolism D000818 N Animals D001321 N Autistic Disorder Q000235 N genetics Q000378 N metabolism D001921 N Brain Q000378 Y metabolism D003071 N Cognition Q000502 N physiology D049229 N Dendritic Spines Q000235 N genetics Q000378 Y metabolism D006801 N Humans D017774 N Long-Term Potentiation Q000502 N physiology D051379 N Mice D018345 N Mice, Knockout D009419 N Nerve Tissue Proteins Q000235 N genetics Q000378 Y metabolism D013569 N Synapses Q000235 N genetics Q000378 Y metabolism NLM PMC3680733 received 2013 01 14 accepted 2013 04 15 entrez 2013 5 21 6 0 pubmed 2013 5 21 6 0 medline 2013 8 13 6 0 ppublish pubmed 23685357 pii emboj2013107 doi 10.1038/emboj.2013.107 pmc PMC3680733 PubMed-not-MEDLINE NLM 1 23852273 2013 07 15 2017 02 20 Electronic Electronic 2157-3999 Internet 5 2013 Jul 02 PLoS currents PLoS Curr Twitter as a sentinel in emergency situations: lessons from the Boston marathon explosions. doi Y 10.1371/currents.dis.ad70cd1c8bc585e9470046cde334ee4b pii Y ecurrents.dis.ad70cd1c8bc585e9470046cde334ee4b Immediately following the Boston Marathon attacks, individuals near the scene posted a deluge of data to social media sites. Previous work has shown that these data can be leveraged to provide rapid insight during natural disasters, disease outbreaks and ongoing conflicts that can assist in the public health and medical response. Here, we examine and discuss the social media messages posted immediately after and around the Boston Marathon bombings, and find that specific keywords appear frequently prior to official public safety and news media reports. Individuals immediately adjacent to the explosions posted messages within minutes via Twitter which identify the location and specifics of events, demonstrating a role for social media in the early recognition and characterization of emergency events. *Christopher Cassa and Rumi Chunara contributed equally to this work. Y Y Cassa Christopher A CA Harvard Medical School Brigham and Women\\'s Hospital. Y Chunara Rumi R Y Mandl Kenneth K Y Brownstein John S JS eng Y K99 HG007229 HG NHGRI NIH HHS United States D016428 Journal Article Electronic 2013 07 02 United States PLoS Curr 101515638 2157-3999 Cites Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11576-81 1 22711804 Cites MMWR Suppl. 2004 Sep 24;53:130-6 1 15714642 Cites PLoS Med. 2008 Jul 8;5(7):e151 1 18613747 Cites PLoS Med. 2007 Jun;4(6):e210 1 17593895 Cites J Am Med Inform Assoc. 2007 Sep-Oct;14(5):581-8 1 17600100 Cites Proc Natl Acad Sci U S A. 2007 May 29;104(22):9404-9 1 17519338 Cites Am J Trop Med Hyg. 2012 Jan;86(1):39-45 1 22232449 NLM PMC3706072.1 entrez 2013 7 16 6 0 pubmed 2013 7 16 6 0 medline 2013 7 16 6 1 epublish pubmed 23852273 doi 10.1371/currents.dis.ad70cd1c8bc585e9470046cde334ee4b pmc PMC3706072.1 PubMed-not-MEDLINE NLM 1 25143782 2014 08 21 2014 08 25 Electronic-eCollection Print 1749-7922 Print 9 2014 World journal of emergency surgery : WJES World J Emerg Surg Reviewer acknowledgement. 24 doi Y 10.1186/1749-7922-9-24 CONTRIBUTING REVIEWERS UNASSIGNED The World Journal of Emergency Surgery-which received its first Impact Factor in 2013-is extremely grateful for the time, hard work and support of its highly-qualified peer reviewers. The editors of World Journal of Emergency Surgery and BioMed Central would like to show our appreciation by thanking the following people for their assistance reviewing manuscripts for the journal in 2013. Y Y Catena Fausto F Chief of the Emergency Surgery Department, Parma University Hospital, Parma, Italy. Y Moore Frederick F Chief of Acute Care Surgery, Department of Surgery, The University of Florida, Gainesville, Florida. eng D016428 Journal Article Electronic 2014 03 31 England World J Emerg Surg 101266603 1749-7922 NLM PMC4138712 received 2014 01 17 accepted 2014 01 17 entrez 2014 8 22 6 0 pubmed 2014 8 22 6 0 medline 2014 8 22 6 1 epublish pubmed 25143782 doi 10.1186/1749-7922-9-24 pii 1749-7922-9-24 pmc PMC4138712 MEDLINE NLM 1 24090994 2014 06 02 2013 11 01 Print-Electronic Electronic 1873-6971 Internet 91 2013 Dec Fitoterapia Fitoterapia Modulation of COX, LOX and NFB activities by Xanthium spinosum L. root extract and ziniolide. 284-9 doi Y 10.1016/j.fitote.2013.09.015 pii Y S0367-326X(13)00260-8 Xanthium spinosum L. (Asteraceae) is a medicinal weed distributed worldwide. Many of its diverse ethnopharmacological uses - namely diarrhoea, inflammation, liver disorders, snake bite and fever - are linked - at least in part - to an uncontrolled release of arachidonic acid metabolites. The crude extract of X. spinosum roots from Jordanian origin dose-dependently inhibited the 5-LOX (IC50 is approximately equal to 10 g/mL), COX-1(IC50 is approximately equal to 50 g/mL), and 12-LOX (IC50 is approximately equal to 170 g/mL) enzymatic pathways in intact pro-inflammatory cells. A direct activity at the level of PLA2 is not probable, but the extract induced the synthesis of the anti-inflammatory eicosanoid 15(S)-HETE, which may in turn inhibit this enzyme. 5-LOX bioguided fractionation of the crude extract led to the isolation of ziniolide, a known 12,8-guaianolide sesquiterpene lactone, from the hydro-alcoholic fraction of the n-hexane extract (IC50=69 M). Both the plant extract and ziniolide are in vitro inhibitors of the phorbol-induced NFB activation, a key regulator of the arachidonic pathway.  2013. Y Y Bader Ammar A Department of Pharmacognosy, Faculty of Pharmacy, Umm Al-Qura University, Makkah, 21955, Saudi Arabia. Y Giner Rosa M RM Y Martini Francesca F Y Schinella Guillermo R GR Y Ros Jos L JL Y Braca Alessandra A Y Prieto Jos M JM eng D016428 Journal Article Electronic 2013 10 01 Netherlands Fitoterapia 16930290R 0367-326X 0 D000893 Anti-Inflammatory Agents 0 D016861 Cyclooxygenase Inhibitors 0 D006893 Hydroxyeicosatetraenoic Acids 0 D016859 Lipoxygenase Inhibitors 0 D016328 NF-kappa B 0 D010704 Phorbols 0 D010936 Plant Extracts 0 D045789 Sesquiterpenes, Guaiane 0 C000588656 ziniolide 73945-47-8 C025984 15-hydroxy-5,8,11,13-eicosatetraenoic acid EC 1.13.11.- D058945 Lipoxygenases EC 1.14.99.1 D051545 Cyclooxygenase 1 XUZ76S9127 C033085 phorbol IM D000893 N Anti-Inflammatory Agents Q000302 N isolation & purification Q000494 Y pharmacology Q000627 N therapeutic use D051545 N Cyclooxygenase 1 Q000378 Y metabolism D016861 N Cyclooxygenase Inhibitors Q000302 N isolation & purification Q000494 N pharmacology Q000627 N therapeutic use D004305 N Dose-Response Relationship, Drug D006367 N HeLa Cells D006801 N Humans D006893 N Hydroxyeicosatetraenoic Acids Q000096 N biosynthesis D007249 N Inflammation Q000139 N chemically induced Q000188 N drug therapy Q000378 Y metabolism D020128 N Inhibitory Concentration 50 D016859 N Lipoxygenase Inhibitors Q000302 N isolation & purification Q000494 N pharmacology Q000627 N therapeutic use D058945 N Lipoxygenases Q000378 Y metabolism D016328 N NF-kappa B Q000037 Y antagonists & inhibitors D010704 N Phorbols D008517 N Phytotherapy D010936 N Plant Extracts Q000737 N chemistry Q000494 N pharmacology Q000627 N therapeutic use D018517 N Plant Roots Q000737 N chemistry D045789 N Sesquiterpenes, Guaiane Q000302 N isolation & purification Q000494 Y pharmacology Q000627 N therapeutic use D031210 N Xanthium Q000737 Y chemistry NOTNLM N Cyclooxygenase N Lipoxygenases N NF-B N Sesquiterpene lactones N Xanthium spinosum N Ziniolide received 2012 12 15 revised 2013 09 15 accepted 2013 09 22 entrez 2013 10 5 6 0 pubmed 2013 10 5 6 0 medline 2014 6 3 6 0 ppublish pubmed 24090994 pii S0367-326X(13)00260-8 doi 10.1016/j.fitote.2013.09.015 MEDLINE NLM 1 25031417 2014 09 05 2014 11 20 Print Electronic 1529-2401 Internet 34 29 2014 Jul 16 The Journal of neuroscience : the official journal of the Society for Neuroscience J. Neurosci. A new pathway mediating social effects on the endocrine system: female presence acting via norepinephrine release stimulates gonadotropin-inhibitory hormone in the paraventricular nucleus and suppresses luteinizing hormone in quail. 9803-11 doi Y 10.1523/JNEUROSCI.3706-13.2014 Rapid effects of social interactions on transient changes in hormonal levels are known in a wide variety of vertebrate taxa, ranging from fish to humans. Although these responses are mediated by the brain, neurochemical pathways that translate social signals into reproductive physiological changes are unclear. In this study, we analyzed how a female presence modifies synthesis and/or release of various neurochemicals, such as monoamines and neuropeptides, in the brain and downstream reproductive hormones in sexually active male Japanese quail. By viewing a female bird, sexually active males rapidly increased norepinephrine (NE) release in the paraventricular nucleus (PVN) of the hypothalamus, in which gonadotropin-inhibitory hormone (GnIH) neuronal cell bodies exist, increased GnIH precursor mRNA expression in the PVN, and decreased luteinizing hormone (LH) concentration in the plasma. GnIH is a hypothalamic neuropeptide that inhibits gonadotropin secretion from the pituitary. It was further shown that GnIH can rapidly suppress LH release after intravenous administration in this study. Centrally administered NE decreased plasma LH concentration in vivo. It was also shown that NE stimulated the release of GnIH from diencephalic tissue blocks in vitro. Fluorescence double-label immunohistochemistry indicated that GnIH neurons received noradrenergic innervations, and immunohistochemistry combined with in situ hybridization have further shown that GnIH neurons expressed 2A-adrenergic receptor mRNA. These results indicate that a female presence increases NE release in the PVN and stimulates GnIH release, resulting in the suppression of LH release in sexually active male quail. Copyright  2014 the authors 0270-6474/14/349803-09$15.00/0. Y Y Tobari Yasuko Y ORCID http://orcid.org/0000-0003-0572-4123 Laboratory of Integrative Brain Sciences, Department of Biology and Center for Medical Life Science, Waseda University, Shinjuku-ku, Tokyo 162-8480, Japan, and. Y Son You Lee YL Laboratory of Integrative Brain Sciences, Department of Biology and Center for Medical Life Science, Waseda University, Shinjuku-ku, Tokyo 162-8480, Japan, and. Y Ubuka Takayoshi T ORCID http://orcid.org/0000-0002-4731-8118 Laboratory of Integrative Brain Sciences, Department of Biology and Center for Medical Life Science, Waseda University, Shinjuku-ku, Tokyo 162-8480, Japan, and. Y Hasegawa Yoshihisa Y Experimental Animal Science, School of Veterinary Medicine and Animal Sciences, Kitasato University, Aomori 034-8628, Japan. Y Tsutsui Kazuyoshi K Laboratory of Integrative Brain Sciences, Department of Biology and Center for Medical Life Science, Waseda University, Shinjuku-ku, Tokyo 162-8480, Japan, and k-tsutsui@waseda.jp. eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States J Neurosci 8102140 0270-6474 0 D030161 Avian Proteins 0 D015306 Biogenic Monoamines 0 D007028 Hypothalamic Hormones 0 D012333 RNA, Messenger 0 D018341 Receptors, Adrenergic, alpha-2 0 C413752 gonadotropin-inhibitory hormone, Coturnix japonica 33515-09-2 D007987 Gonadotropin-Releasing Hormone 9002-67-9 D007986 Luteinizing Hormone X4W3ENH1CV D009638 Norepinephrine IM D000704 N Analysis of Variance D000818 N Animals D030161 N Avian Proteins Q000494 Y pharmacology D015306 N Biogenic Monoamines Q000378 N metabolism D004797 N Enzyme-Linked Immunosorbent Assay D005260 N Female D007987 N Gonadotropin-Releasing Hormone Q000235 N genetics Q000378 N metabolism D007028 N Hypothalamic Hormones Q000494 Y pharmacology D007398 N Interpersonal Relations D007986 N Luteinizing Hormone Q000097 Y blood D008297 N Male D017551 N Microdialysis D009638 N Norepinephrine Q000378 Y metabolism Q000494 N pharmacology D009924 N Organ Culture Techniques D010286 N Paraventricular Hypothalamic Nucleus Q000187 N drug effects Q000378 Y metabolism D011784 N Quail D012333 N RNA, Messenger Q000378 N metabolism D018341 N Receptors, Adrenergic, alpha-2 Q000235 N genetics Q000378 N metabolism D012726 Y Sexual Behavior, Animal NOTNLM N bird N monoamine N neurochemical pathway N neuropeptide N social signal N visual stimuli entrez 2014 7 18 6 0 pubmed 2014 7 18 6 0 medline 2014 9 6 6 0 ppublish pubmed 25031417 pii 34/29/9803 doi 10.1523/JNEUROSCI.3706-13.2014 In-Process NLM 1 27687974 2017 01 03 Print-Electronic Electronic 1941-0611 Internet 9 2017 Jan 03 Annual review of marine science Ann Rev Mar Sci SAR11 Bacteria: The Most Abundant Plankton in the Oceans. 231-255 doi Y 10.1146/annurev-marine-010814-015934 28 SAR11 is a group of small, carbon-oxidizing bacteria that reach a global estimated population size of 2.410 cells-approximately 25% of all plankton. They are found throughout the oceans but reach their largest numbers in stratified, oligotrophic gyres, which are an expanding habitat in the warming oceans. SAR11 likely had a Precambrian origin and, over geological time, evolved into the niche of harvesting labile, low-molecular-weight dissolved organic matter (DOM). SAR11 cells are minimal in size and complexity, a phenomenon known as streamlining that is thought to benefit them by lowering the material costs of replication and maximizing transport functions that are essential to competition at ultralow nutrient concentrations. One of the surprises in SAR11 metabolism is their ability to both oxidize and produce a variety of volatile organic compounds that can diffuse into the atmosphere. SAR11 cells divide slowly and lack many forms of regulation commonly used by bacterial cells to adjust to changing environmental conditions. As a result of genome reduction, they require an unusual range of nutrients, which leads to complex biochemical interactions with other plankton. The study of SAR11 is providing insight into the biogeochemistry of labile DOM and is affecting microbiology beyond marine science by providing a model for understanding the evolution and function of streamlined cells. Y Y Giovannoni Stephen J SJ Department of Microbiology, Oregon State University, Corvallis, Oregon 97331; email: steve.giovannoni@oregonstate.edu. eng D016428 Journal Article Electronic 2016 09 28 United States Ann Rev Mar Sci 101536246 1941-0611 NOTNLM N carbon cycle N dissolved organic matter N proteorhodopsin N streamlining pubmed 2016 10 1 6 0 medline 2016 10 1 6 0 entrez 2016 10 1 6 0 ppublish pubmed 27687974 doi 10.1146/annurev-marine-010814-015934 Publisher NLM 1 27687975 2017 02 20 Electronic Electronic 2045-2322 Internet 6 2016 Sep 30 Scientific reports Sci Rep Novel roles for the radial spoke head protein 9 in neural and neurosensory cilia. 34437 doi Y 10.1038/srep34437 Cilia are cell surface organelles with key roles in a range of cellular processes, including generation of fluid flow by motile cilia. The axonemes of motile cilia and immotile kinocilia contain 9 peripheral microtubule doublets, a central microtubule pair, and 9 connecting radial spokes. Aberrant radial spoke components RSPH1, 3, 4a and 9 have been linked with primary ciliary dyskinesia (PCD), a disorder characterized by ciliary dysmotility; yet, radial spoke functions remain unclear. Here we show that zebrafish Rsph9 is expressed in cells bearing motile cilia and kinocilia, and localizes to both 9+2 and 9+0 ciliary axonemes. Using CRISPR mutagenesis, we show that rsph9 is required for motility of presumptive 9+2 olfactory cilia and, unexpectedly, 9+0 neural cilia. rsph9 is also required for the structural integrity of 9+2 and 9+0 ciliary axonemes. rsph9 mutant larvae exhibit reduced initiation of the acoustic startle response consistent with hearing impairment, suggesting a novel role for Rsph9 in the kinocilia of the inner ear and/or lateral line neuromasts. These data identify novel roles for Rsph9 in 9+0 motile cilia and in sensory kinocilia, and establish a useful zebrafish PCD model. Y Y Sedykh Irina I Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Department of Neuroscience, University of Wisconsin, Madison, WI, 53706, USA. Y TeSlaa Jessica J JJ Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Department of Neuroscience, University of Wisconsin, Madison, WI, 53706, USA. Cellular and Molecular Biology Training Program, University of Wisconsin, Madison, WI, 53706, USA. Y Tatarsky Rose L RL Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Department of Neuroscience, University of Wisconsin, Madison, WI, 53706, USA. Y Keller Abigail N AN Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Department of Neuroscience, University of Wisconsin, Madison, WI, 53706, USA. Y Toops Kimberly A KA Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53706, USA. McPherson Eye Research Institute, University of Wisconsin, Madison, WI, 53706, USA. Y Lakkaraju Aparna A Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53706, USA. McPherson Eye Research Institute, University of Wisconsin, Madison, WI, 53706, USA. Y Nyholm Molly K MK Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Department of Neuroscience, University of Wisconsin, Madison, WI, 53706, USA. Y Wolman Marc A MA Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Y Grinblat Yevgenya Y Department of Zoology, University of Wisconsin, Madison, WI, 53706, USA. Department of Neuroscience, University of Wisconsin, Madison, WI, 53706, USA. McPherson Eye Research Institute, University of Wisconsin, Madison, WI, 53706, USA. eng Y P30 EY016665 EY NEI NIH HHS United States R01 EY022098 EY NEI NIH HHS United States D016428 Journal Article Electronic 2016 09 30 England Sci Rep 101563288 2045-2322 Cites J Exp Biol. 2005 Apr;208(Pt 7):1363-72 1 15781896 Cites Nat Cell Biol. 2010 Apr;12(4):407-12 1 20305649 Cites Neuroscience. 1982;7(12):3091-103 1 6984492 Cites J Cell Biol. 1970 Oct;47(1):159-82 1 4935335 Cites Am J Hum Genet. 2013 Oct 3;93(4):672-86 1 24094744 Cites Curr Biol. 2014 Oct 6;24(19):R973-82 1 25291643 Cites Hum Mol Genet. 2014 Jul 1;23(13):3362-74 1 24518672 Cites Hum Mutat. 2013 Mar;34(3):462-72 1 23255504 Cites J Comp Neurol. 1993 Jul 8;333(2):289-300 1 8345108 Cites Dev Cell. 2015 Mar 23;32(6):756-64 1 25752963 Cites Cells. 2015 Sep 11;4(3):500-19 1 26378583 Cites BMC Dev Biol. 2006 Jan 13;6:1 1 16412219 Cites Nat Commun. 2014 Dec 04;5:5727 1 25473808 Cites Dev Dyn. 2007 Jul;236(7):1963-9 1 17503454 Cites Am J Respir Cell Mol Biol. 2015 Oct;53(4):563-73 1 25789548 Cites Methods Cell Biol. 2010;97:415-35 1 20719283 Cites Cilia. 2015 Jan 22;4(1):2 1 25610612 Cites Dev Dyn. 2003 Nov;228(3):464-74 1 14579384 Cites J Cell Biol. 1985 Jun;100(6):2008-18 1 2860115 Cites Dev Dyn. 1995 Jul;203(3):253-310 1 8589427 Cites J Cell Biol. 1981 Dec;91(3 Pt 2):107s-124s 1 6459326 Cites J Otolaryngol. 2002 Feb;31(1):13-7 1 11881766 Cites Development. 2014 Apr;141(7):1427-41 1 24644260 Cites Am J Respir Crit Care Med. 2014 Mar 15;189(6):707-17 1 24568568 Cites PLoS One. 2013;8(3):e59436 1 23527195 Cites Nat Genet. 2000 Oct;26(2):216-20 1 11017081 Cites Development. 2012 May;139(10):1777-87 1 22461562 Cites Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18499-504 1 20937855 Cites J Neurosci. 2007 May 2;27(18):4984-94 1 17475807 Cites Nat Rev Genet. 2010 May;11(5):331-44 1 20395968 Cites Am J Hum Genet. 2013 Sep 5;93(3):561-70 1 23993197 Cites Development. 2005 Apr;132(8):1907-21 1 15790966 Cites Annu Rev Physiol. 2007;69:401-22 1 16945069 Cites Chem Senses. 1998 Feb;23(1):39-48 1 9530968 Cites PLoS One. 2012;7(3):e33667 1 22448264 Cites Dev Biol. 2008 Feb 15;314(2):261-75 1 18178183 Cites Hum Mol Genet. 2015 May 1;24(9):2482-91 1 25601850 Cites J Med Genet. 2014 Jan;51(1):61-7 1 24203976 Cites Dev Cell. 2015 Oct 26;35(2):236-46 1 26506310 Cites Nature. 2009 Jan 8;457(7226):205-9 1 19043402 Cites J Biophys Biochem Cytol. 1959 Mar 25;5(2):269-78 1 13654448 Cites Hum Mol Genet. 2002 Mar 15;11(6):715-21 1 11912187 Cites Nat Rev Drug Discov. 2014 Oct;13(10):759-80 1 25233993 Cites Hum Mol Genet. 2009 Jan 15;18(2):289-303 1 18971206 Cites Nat Biotechnol. 2013 Mar;31(3):227-9 1 23360964 Cites Nature. 2009 May 7;459(7243):98-102 1 19305393 Cites Nat Genet. 2008 Dec;40(12):1445-53 1 19011630 Cites Am J Hum Genet. 2013 Aug 8;93(2):346-56 1 23891471 Cites PLoS One. 2008 Sep 01;3(9):e3090 1 18769618 Cites Am J Respir Crit Care Med. 2013 Oct 15;188(8):913-22 1 23796196 Cites Annu Rev Physiol. 2007;69:377-400 1 17009929 Cites Development. 2009 Nov;136(22):3791-800 1 19855021 Cites Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15468-73 1 21876167 Cites Development. 2005 Mar;132(6):1247-60 1 15716348 Cites Biol Open. 2012 Aug 15;1(8):815-25 1 23213475 Cites J Cell Biol. 1974 Oct;63(1):35-63 1 4424314 Cites Bioarchitecture. 2014 Jan-Feb;4(1):6-15 1 24481178 Cites Methods Cell Biol. 2009;93:197-217 1 20409819 Cites Am J Hum Genet. 2013 Oct 3;93(4):711-20 1 24055112 Cites Am J Hum Genet. 2013 Aug 8;93(2):357-67 1 23849778 Cites Development. 2014 Sep;141(17):3410-9 1 25139857 Cites Genet Med. 2009 Jul;11(7):473-87 1 19606528 Cites PLoS One. 2011;6(5):e19713 1 21603650 Cites Development. 2004 Aug;131(16):4085-93 1 15269167 Cites J Cell Biol. 1965 Apr;25:1-8 1 14283628 Cites PLoS One. 2013 Aug 26;8(8):e72299 1 23991085 Cites Dev Dyn. 2004 Jul;230(3):403-9 1 15188426 Cites J Cell Biol. 2014 Mar 3;204(5):807-19 1 24590175 Cites Hum Mol Genet. 2004 Sep 15;13(18):2133-41 1 15269178 Cites Am J Hum Genet. 2009 Feb;84(2):197-209 1 19200523 Cites Cell. 2006 Apr 7;125(1):33-45 1 16615888 Cites Methods Enzymol. 2013;525:219-44 1 23522472 Cites Am J Hum Genet. 2015 Jul 2;97(1):153-62 1 26073779 Cites Biotechniques. 2007 Nov;43(5):610, 612, 614 1 18072590 received 2016 02 05 accepted 2016 09 14 entrez 2016 10 1 6 0 pubmed 2016 10 1 6 0 medline 2016 10 1 6 0 epublish pubmed 27687975 pmc PMC5043386 pii srep34437 doi 10.1038/srep34437 MEDLINE NLM 1 27763809 2017 10 24 2017 10 24 Print-Electronic Electronic 2164-554X Internet 13 3 2017 Mar 04 Human vaccines & immunotherapeutics Hum Vaccin Immunother Do Australian immunoglobulin products meet international measles antibody titer standards? 607-612 doi Y 10.1080/21645515.2016.1234554 rd The effectiveness of passive immunisation post-exposure to measles appears subject to a dose-response effect. New Zealand and the United Kingdom have increased the recommended dose of polyclonal human immunoglobulin for post-exposure prophylaxis within the last decade in response to concerns about decreasing levels of measles antibodies in these products. This study used the plaque-reduction neutralization test (PRNT) to measure the titer of measles-specific antibodies in Australian immunoglobulin products for post-exposure prophylaxis and compared the utility of an enzyme-linked immunosorbent assay (ELISA) to the PRNT in available Australian and international samples: Australian intramuscular (n = 10), Australian intravenous (n = 28), New Zealand intramuscular (n = 2), Hizentra (subcutaneous)(USA) (n = 3), and Privigen (intravenous)(USA) (n = 2). Measles titres in Australian IM and IV immunoglobulins ranged from 51 to 76 IU/mL and 6 to 24IU/mL respectively, as measured by PRNT calibrated to the WHO 3 international standard. ELISA titres were variable but higher than PRNT titres in all tested samples. Measles antibody titres in Australian immunoglobulin products meet consensus-prescribed international thresholds. Development of a convenient, standardized, readily accessible assay for determination of measles titres in immunoglobulin products would be useful for future studies and facilitate international comparisons. Y Y Young Megan K MK a School of Medicine and Menzies Health Institute Queensland , Griffith University , Gold Coast , Australia. Y Bertolini Joseph J b CSL Behring (Australia) Pty Ltd , Broadmeadows , Australia. Y Kotharu Pushpa P b CSL Behring (Australia) Pty Ltd , Broadmeadows , Australia. Y Maher Darryl D b CSL Behring (Australia) Pty Ltd , Broadmeadows , Australia. Y Cripps Allan W AW a School of Medicine and Menzies Health Institute Queensland , Griffith University , Gold Coast , Australia. eng D003160 Comparative Study D016428 Journal Article Electronic 2016 10 20 United States Hum Vaccin Immunother 101572652 2164-5515 0 D000914 Antibodies, Viral 0 D001688 Biological Products IM Cites CMAJ. 2014 Apr 15;186(7):E205-6 1 24638029 Cites Am J Epidemiol. 2000 Jun 1;151(11):1039-48; discussion 1049-52 1 10873127 Cites J Clin Immunol. 2010 Jul;30(4):574-82 1 20405177 Cites Hum Vaccin Immunother. 2013 Sep;9(9):1885-93 1 23783220 Cites MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34 1 23760231 Cites Cochrane Database Syst Rev. 2014 Apr 01;(4):CD010056 1 24687262 Cites Wkly Epidemiol Rec. 2012 Feb 3;87(5):45-52 1 22308581 Cites J Virol Methods. 2011 Dec;178(1-2):124-8 1 21939689 Cites Przegl Epidemiol. 2014;68(3):417-20, 527-9 1 25394302 Cites J Pediatr. 2001 Jun;138(6):926-8 1 11391343 Cites MMWR Morb Mortal Wkly Rep. 2015 Feb 20;64(6):153-4 1 25695321 Cites Euro Surveill. 2014 Dec 11;19(49):null 1 25523970 Cites Vaccine. 2007 Dec 21;26(1):59-66 1 18063236 Cites N Z Med J. 2015 Sep 25;128(1422):53-62 1 26411847 D000914 N Antibodies, Viral Q000276 Y immunology D001315 N Australia D001688 N Biological Products Q000592 Y standards D004797 N Enzyme-Linked Immunosorbent Assay D006801 N Humans D007116 N Immunization, Passive Q000379 Y methods D008457 N Measles Q000517 Y prevention & control D009500 N Neutralization Tests D056990 N Post-Exposure Prophylaxis Q000379 Y methods D010948 N Viral Plaque Assay NOTNLM N Australia N blood products N immunoglobulin N measles N prevention pubmed 2016 10 21 6 0 medline 2017 10 25 6 0 entrez 2016 10 21 6 0 ppublish pubmed 27763809 doi 10.1080/21645515.2016.1234554 pmc PMC5360119 MEDLINE NLM 1 29049350 2017 11 07 2017 11 07 Electronic-eCollection Electronic 1932-6203 Internet 12 10 2017 PloS one PLoS ONE An integrative in-silico approach for therapeutic target identification in the human pathogen Corynebacterium diphtheriae. e0186401 doi Y 10.1371/journal.pone.0186401 Corynebacterium diphtheriae (Cd) is a Gram-positive human pathogen responsible for diphtheria infection and once regarded for high mortalities worldwide. The fatality gradually decreased with improved living standards and further alleviated when many immunization programs were introduced. However, numerous drug-resistant strains emerged recently that consequently decreased the efficacy of current therapeutics and vaccines, thereby obliging the scientific community to start investigating new therapeutic targets in pathogenic microorganisms. In this study, our contributions include the prediction of modelome of 13 C. diphtheriae strains, using the MHOLline workflow. A set of 463 conserved proteins were identified by combining the results of pangenomics based core-genome and core-modelome analyses. Further, using subtractive proteomics and modelomics approaches for target identification, a set of 23 proteins was selected as essential for the bacteria. Considering human as a host, eight of these proteins (glpX, nusB, rpsH, hisE, smpB, bioB, DIP1084, and DIP0983) were considered as essential and non-host homologs, and have been subjected to virtual screening using four different compound libraries (extracted from the ZINC database, plant-derived natural compounds and Di-terpenoid Iso-steviol derivatives). The proposed ligand molecules showed favorable interactions, lowered energy values and high complementarity with the predicted targets. Our proposed approach expedites the selection of C. diphtheriae putative proteins for broad-spectrum development of novel drugs and vaccines, owing to the fact that some of these targets have already been identified and validated in other organisms. Y Y Jamal Syed Babar SB PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Y Hassan Syed Shah SS PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Chemistry, Islamia College University Peshawar, KPK, Pakistan. Y Tiwari Sandeep S PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Y Viana Marcus V MV PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Y Benevides Leandro de Jesus LJ PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Y Ullah Asad A Department of Chemistry, Islamia College University Peshawar, KPK, Pakistan. Y Turjanski Adrin G AG Departamento de Qumica Biolgica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabelln II, Buenos Aires, Argentina. Y Barh Debmalya D Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India. Y Ghosh Preetam P Department of Computer Science, Virginia Commonwealth University, Richmond, VA, United States of America. Y Costa Daniela Arruda DA PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Y Silva Artur A Institute of Biologic Sciences, Federal University of Para, Belm, PA, Brazil. Y Rttger Richard R Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark. Y Baumbach Jan J Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark. Y Azevedo Vasco A C VAC PG program in Bioinformatics (LGCM), Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of General Biology (LGCM), Institute of Biologic Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. eng D016428 Journal Article D023361 Validation Studies Electronic 2017 10 19 United States PLoS One 101285081 1932-6203 0 D000900 Anti-Bacterial Agents 0 D001426 Bacterial Proteins 0 D001428 Bacterial Vaccines 0 D008024 Ligands IM Cites Chem Biol Drug Des. 2011 Jul;78(1):73-84 1 21443692 Cites BMC Genomics. 2014;15 Suppl 7:S3 1 25573232 Cites Structure. 1996 Sep 15;4(9):1093-104 1 8805594 Cites Nat Rev Drug Discov. 2008 Nov;7(11):900-7 1 18927591 Cites PLoS One. 2013;8(3):e59126 1 23527108 Cites PLoS One. 2012;7(8):e43080 1 22912793 Cites BMC Genomics. 2011 Jan 27;12:75 1 21272313 Cites Nucleic Acids Res. 2000 Jan 1;28(1):27-30 1 10592173 Cites J Med Chem. 1998 Nov 19;41(24):4790-9 1 9822549 Cites J Periodontol. 2015 Oct;86(10 ):1176-84 1 26110450 Cites Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12989-94 1 14569030 Cites Database (Oxford). 2011 Mar 29;2011:bar009 1 21447597 Cites Mol Biol Rep. 2014 Jan;41(1):337-45 1 24234753 Cites Proteins. 2015 Aug;83(8):1539-46 1 26010010 Cites Clin Microbiol Rev. 1997 Jan;10(1):125-59 1 8993861 Cites Acta Crystallogr D Biol Crystallogr. 2008 Jun;64(Pt 6):627-35 1 18560150 Cites Integr Biol (Camb). 2013 Mar;5(3):495-509 1 23288366 Cites In Silico Biol. 2007;7(4-5):453-65 1 18391237 Cites Postgrad Med J. 1996 Oct;72(852):619-20 1 8977947 Cites Bioinformatics. 2012 Aug 1;28(15):2074-5 1 22628523 Cites Bioinformation. 2009 Oct 11;4(4):143-50 1 20198190 Cites J Comput Chem. 2004 Oct;25(13):1605-12 1 15264254 Cites Nucleic Acids Res. 2007 Jan;35(Database issue):D395-400 1 17090594 Cites In Silico Biol. 2006;6(1-2):43-7 1 16789912 Cites J Med Chem. 2002 Aug 29;45(18):3865-77 1 12190310 Cites J Med Chem. 2006 Jun 1;49(11):3315-21 1 16722650 Cites Nucleic Acids Res. 2014 Jan;42(Database issue):D222-30 1 24288371 Cites Science. 2000 Mar 10;287(5459):1816-20 1 10710308 Cites Epidemiol Infect. 2010 Nov;138(11):1519-30 1 20696088 Cites Nat Struct Biol. 2000 Jun;7(6):475-8 1 10881194 Cites In Silico Biol. 2004;4(3):355-60 1 15724285 Cites Adv Enzymol Relat Areas Mol Biol. 1975;42:193-226 1 236638 Cites Nature. 2003 Aug 7;424(6949):699-703 1 12904796 Cites In Silico Biol. 2009;9(4):225-31 1 20109152 Cites J Chem Inf Comput Sci. 2001 May-Jun;41(3):702-12 1 11410049 Cites BMC Bioinformatics. 2009 May 20;10:154 1 19457249 Cites Science. 2004 Jan 2;303(5654):76-9 1 14704425 Cites Pediatr Clin North Am. 1979 May;26(2):445-59 1 379784 Cites Proc Natl Acad Sci U S A. 1980 Apr;77(4):1837-41 1 6445562 Cites J Inorg Biochem. 2005 Mar;99(3):841-51 1 15708806 Cites J Adv Pharm Technol Res. 2012 Oct;3(4):200-1 1 23378939 Cites In Silico Biol. 2006;6(4):341-6 1 16922696 Cites Nucleic Acids Res. 2004 Jan 1;32(Database issue):D271-2 1 14681410 Cites Bioinformatics. 2001 Sep;17(9):849-50 1 11590105 Cites Nucleic Acids Res. 2002 Jan 1;30(1):276-80 1 11752314 Cites BMC Syst Biol. 2016 Nov 4;10 (1):103 1 27814699 Cites PLoS One. 2009;4(2):e4413 1 19198654 Cites Integr Biol (Camb). 2014 Nov;6(11):1088-99 1 25212181 Cites Pharm Biol. 2014 Sep;52(9):1170-8 1 24766364 Cites Chem Biol Drug Des. 2008 Jun;71(6):554-62 1 18489439 Cites CSH Protoc. 2007 Jul 01;2007:pdb.top17 1 21357135 Cites PLoS Negl Trop Dis. 2010 Aug 24;4(8):e804 1 20808766 Cites Bioinformation. 2009 Dec 31;4(6):245-8 1 20975918 Cites Protein Sci. 2004 May;13(5):1402-6 1 15096640 Cites Curr Protoc Protein Sci. 2007 Nov;Chapter 2:Unit 2.9 1 18429317 D000900 N Anti-Bacterial Agents Q000494 N pharmacology D001426 N Bacterial Proteins Q000378 N metabolism D001428 N Bacterial Vaccines Q000494 N pharmacology D003198 N Computer Simulation D003353 N Corynebacterium diphtheriae Q000187 N drug effects Q000235 N genetics Q000378 N metabolism Q000472 Y pathogenicity D016680 N Genome, Bacterial D006801 N Humans D008024 N Ligands D008954 N Models, Biological D062105 N Molecular Docking Simulation received 2016 12 06 accepted 2017 09 29 entrez 2017 10 20 6 0 pubmed 2017 10 20 6 0 medline 2017 11 8 6 0 epublish pubmed 29049350 doi 10.1371/journal.pone.0186401 pii PONE-D-16-48307 pmc PMC5648181 Publisher NLM 1 23203861 2012 12 03 Print Print 0167-9228 Print 38 1 2007 Feb Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 47 dut D016428 Journal Article Recensie. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2007 2 1 0 0 medline 2007 2 1 0 0 ppublish pubmed 23203861 doi 10.1007/BF03074826 Publisher NLM 1 23203860 2012 12 03 Print Print 0167-9228 Print 38 1 2007 Feb Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 44-46 dut D016428 Journal Article Signalementen. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2007 2 1 0 0 medline 2007 2 1 0 0 ppublish pubmed 23203860 doi 10.1007/BF03074825 In-Process NLM 1 28647898 2017 11 21 Print-Electronic Electronic 1439-0973 Internet 45 6 2017 Dec Infection Infection Respiratory diphtheria due to Corynebacterium ulcerans transmitted by a companion dog, Italy 2014. 903-905 doi Y 10.1007/s15010-017-1040-1 A serious respiratory tract infection due to Corynebacterium ulcerans was observed in a 70-year-old woman. Clinical presentation included pseudomembranes in the upper respiratory tract and lung involvement. C. ulcerans was recovered from the nose of the patient\\'s dog. Both dog\\'s and patient\\'s isolates belonged to Sequence Type 331. Y Y Monaco Monica M Istituto Superiore di Sanit, Rome, Italy. monica.monaco@iss.it. Y Sacchi Anna Rita AR Azienda Unit Sanitaria locale, Piacenza, Italy. Y Scotti Marzia M Ospedale Guglielmo da Saliceto, Piacenza, Italy. Y Mancini Fabiola F Istituto Superiore di Sanit, Rome, Italy. Y Riccio Carlo C Azienda Unit Sanitaria locale, Piacenza, Italy. Y Errico Giulia G Istituto Superiore di Sanit, Rome, Italy. Y Ratti Giovanna G Ospedale Guglielmo da Saliceto, Piacenza, Italy. Y Bondi Filippo F Ospedale Guglielmo da Saliceto, Piacenza, Italy. Y Ciervo Alessandra A Istituto Superiore di Sanit, Rome, Italy. Y Pantosti Annalisa A Istituto Superiore di Sanit, Rome, Italy. eng D016428 Journal Article Electronic 2017 06 24 Germany Infection 0365307 0300-8126 ErratumIn Infection. 2017 Aug 7;: 1 28786003 NOTNLM N Corynebacterium ulcerans N Diphtheria toxin N Dog N Molecular typing N Respiratory diphtheria received 2017 06 14 accepted 2017 06 19 pubmed 2017 6 26 6 0 medline 2017 6 26 6 0 entrez 2017 6 26 6 0 ppublish pubmed 28647898 doi 10.1007/s15010-017-1040-1 pii 10.1007/s15010-017-1040-1 In-Process NLM 1 28726616 2017 11 11 Print Electronic 1080-6059 Internet 23 8 2017 08 Emerging infectious diseases Emerging Infect. Dis. Molecular Characterization of Corynebacterium diphtheriae Outbreak Isolates, South Africa, March-June 2015. 1308-1315 doi Y 10.3201/eid2308.162039 In 2015, a cluster of respiratory diphtheria cases was reported from KwaZulu-Natal Province in South Africa. By using whole-genome analysis, we characterized 21 Corynebacterium diphtheriae isolates collected from 20 patients and contacts during the outbreak (1 patient was infected with 2 variants of C.diphtheriae). In addition, we included 1 cutaneous isolate, 2 endocarditis isolates, and 2 archived clinical isolates (ca. 1980) for comparison. Two novel lineages were identified, namely, toxigenic sequence type (ST) ST-378 (n = 17) and nontoxigenic ST-395 (n = 3). One archived isolate and the cutaneous isolate were ST-395, suggesting ongoing circulation of this lineage for >30 years. The absence of preexisting molecular sequence data limits drawing conclusions pertaining to the origin of these strains; however, these findings provide baseline genotypic data for future cases and outbreaks. Neither ST has been reported in any other country; this ST appears to be endemic only in South Africa. Y Y du Plessis Mignon M Y Wolter Nicole N Y Allam Mushal M Y de Gouveia Linda L Y Moosa Fahima F Y Ntshoe Genevie G Y Blumberg Lucille L Y Cohen Cheryl C Y Smith Marshagne M Y Mutevedzi Portia P Y Thomas Juno J Y Horne Valentino V Y Moodley Prashini P Y Archary Moherndran M Y Mahabeer Yesholata Y Y Mahomed Saajida S Y Kuhn Warren W Y Mlisana Koleka K Y McCarthy Kerrigan K Y von Gottberg Anne A eng D016428 Journal Article D013485 Research Support, Non-U.S. Gov\\'t United States Emerg Infect Dis 9508155 1080-6040 Cites Infect Immun. 2010 Sep;78(9):3791-800 1 20547743 Cites S Afr Med J. 1954 Aug 14;28(33):685-9 1 13195862 Cites Bioinformatics. 2015 Nov 15;31(22):3691-3 1 26198102 Cites Epidemiol Infect. 2017 Jul 3;:1 1 28669370 Cites J Bacteriol. 2012 Jun;194(12):3199-215 1 22505676 Cites Genome Announc. 2016 Nov 23;4(6):null 1 27881543 Cites Euro Surveill. 2010 Oct 28;15(43):null 1 21087580 Cites Euro Surveill. 2008 May 08;13(19):null 1 18761980 Cites Emerg Infect Dis. 2013 Nov;19(11):1870-2 1 24209492 Cites BMC Infect Dis. 2006 Aug 15;6:129 1 16911772 Cites J Clin Microbiol. 2010 Nov;48(11):4177-85 1 20844217 Cites Bioinformatics. 2014 May 1;30(9):1312-3 1 24451623 Cites Am J Epidemiol. 1975 Aug;102(2):179-84 1 808123 Cites Clin Microbiol Infect. 2016 Dec;22(12 ):1005.e1-1005.e7 1 27585941 Cites J Infect Dis. 2000 Feb;181 Suppl 1:S27-34 1 10657187 Cites Bioinformatics. 2009 Aug 15;25(16):2071-3 1 19515959 Cites J Bacteriol. 2004 Mar;186(5):1518-30 1 14973027 Cites S Afr Med J. 1961 Aug 26;35:711-5 1 13870743 Cites Nucleic Acids Res. 2007 Jul;35(Web Server issue):W52-7 1 17537822 Cites J Clin Microbiol. 2012 Jan;50(1):173-5 1 22090411 Cites J Clin Microbiol. 1978 Dec;8(6):767-8 1 106070 Cites J Clin Microbiol. 2005 Jan;43(1):223-8 1 15634975 Cites Nucleic Acids Res. 2003 Nov 15;31(22):6516-23 1 14602910 Cites Infect Genet Evol. 2014 Jan;21:54-7 1 24200588 Cites Genome Announc. 2017 Mar 2;5(9):null 1 28254972 Cites Nat Rev Microbiol. 2011 Jun;9(6):467-77 1 21552286 Cites Diagn Microbiol Infect Dis. 2012 Jun;73(2):111-20 1 22494559 Cites J Clin Microbiol. 2006 May;44(5):1625-9 1 16672385 Cites Emerg Infect Dis. 1998 Oct-Dec;4(4):539-50 1 9866730 Cites J Clin Microbiol. 2002 Dec;40(12):4713-9 1 12454177 Cites J Clin Microbiol. 2005 Apr;43(4):1662-8 1 15814981 NOTNLM Y CRISPR Y Corynebacterium diphtheriae Y MLST Y South Africa Y bacteria Y cutaneous diphtheria Y diphtheria Y molecular epidemiology Y outbreak Y respiratory diphtheria Y respiratory infections Y sequence type Y whole-genome sequencing entrez 2017 7 21 6 0 pubmed 2017 7 21 6 0 medline 2017 7 21 6 0 ppublish pubmed 28726616 doi 10.3201/eid2308.162039 pmc PMC5547784 Publisher NLM 1 23203892 2012 12 03 Print Print 0167-9228 Print 41 3 2010 Jun Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 151-152 dut D016428 Journal Article Recente onderzoeksliteratuur. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2010 6 1 0 0 medline 2010 6 1 0 0 ppublish pubmed 23203892 doi 10.1007/BF03096197 Publisher NLM 1 23203893 2012 12 03 Print Print 0167-9228 Print 41 3 2010 Jun Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 152-153 dut D016428 Journal Article Boekbespreking. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2010 6 1 0 0 medline 2010 6 1 0 0 ppublish pubmed 23203893 doi 10.1007/BF03096198 Publisher NLM 1 23203895 2012 12 03 Print Print 0167-9228 Print 41 3 2010 Jun Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 155 dut D016428 Journal Article In memoriam dr. EHW van Kammen-Wijnmalen, 1921-2010. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2010 6 1 0 0 medline 2010 6 1 0 0 ppublish pubmed 23203895 doi 10.1007/BF03096200 Publisher NLM 1 23203894 2012 12 03 Print Print 0167-9228 Print 41 3 2010 Jun Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 153-154 dut D016428 Journal Article Signalementen. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2010 6 1 0 0 medline 2010 6 1 0 0 ppublish pubmed 23203894 doi 10.1007/BF03096199 Publisher NLM 1 23203896 2012 12 03 Print Print 0167-9228 Print 41 3 2010 Jun Tijdschrift voor gerontologie en geriatrie Tijdschr Gerontol Geriatr 156 dut D016428 Journal Article Congresagenda. Netherlands Tijdschr Gerontol Geriatr 8210346 0167-9228 entrez 2012 12 4 6 0 pubmed 2010 6 1 0 0 medline 2010 6 1 0 0 ppublish pubmed 23203896 doi 10.1007/BF03096201 '"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_text_data[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
